{
	"hash": "460a9135ae9b46c34c1e4d39d4c3fc46",
	"cards": [
		{
			"slug": "abdominal-pain-diagnostics",
			"title": "Abdominal Pain - Diagnostic Studies",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/07/22",
			"updates": [
				"2017/02/21"
			],
			"categories": [
				"Gastroenterology",
				"Surgery",
				"EBM"
			],
			"body": "\n\n\n## Imaging\n\n**Plain abdominal radiography**\n\nWhen compared to unenhanced helical CT, 3-view xrays demonstrated:\n\n- Sensitivity = 30%, Specificity = 88%, Accuracy = 56%\n- Negative predictive value = 51%\n- **Pearl:** A 3-way acute abdominal series is too insensitive to rule-out any major acute causes of abdominal pain with confidence. No need to order routinely. If you are worried about a perforated viscus, order an upright chest x-ray instead -- more accurate and less radiation. \n\nObtain plain film if suspicious for:\n\n- Pneumoperitoneum (although upright CXR is better)\n- Small bowel obstruction (where CT not readily available) \n- Localization of foreign body ingestion or catheter\n\n**Abdominal/Pelvis CT**\n\n- Median radiation dose = 15-31 mSv (CXR has 0.1 mSv dose.)\n- Oral contrast likely does NOT provide more information in acute abdominal pain. Known 241-minute delay.\n\n**Ultrasound**\n\n- Increasing use of bedside U/S for point of care testing in EDs.\n- _Advantage_: can be used for unstable patients, no radiation exposure \n\n## Lactate\n\nLactate is useful adjunct to risk stratify for mortality ([Shapiro et al. (2005)](https://www.ncbi.nlm.nih.gov/pubmed/15855951))\n\n| Lactate | Level (mmol/L) | 28-day in-hospital mortality | Early death (≤ 3d) |\n| ------- | -------------: | ---------------------------: | -----------------: |\n| Low     |        &lt;2.5 |                         4.9% |               1.5% |\n| Medium  |       2.5-3.99 |                         9.0% |               4.5% |\n| High    |             ≥4 |                        28.4% |              22.4% |\n\n## Diseases\n\n**Appendicitis**: CT is first-line, unless pediatric or pregnant patient. Then U/S is first line. MRI is an alternative to avoid CT radiation risk.\n\n**Cholecystitis**: Normal LFTs do NOT rule it out. LFT's helpful as adjunct to determine likelihood for common bile duct stone.\n\n**Diverticular disease**: Prevalence &lt;5% (age&lt;40 yrs), 30% (age 41-60 yrs), 65% (age 61-85 yrs)\n\n**Ectopic pregnancy**: Discriminatory zone for gestational sac is B-HCG ≥6,500 (transabdominal U/S) or B-HCG ≥1,500 (transvaginal U/S).\n\n**Mesenteric ischemia** of concern because of subtleties in presentation.\n\n- **Multidetector CT angiography with reformats**: sens 96%, spec 94%\n- **MR angiography**: Sensitivity 85-90% (SMA), 75-90% (celiac artery), 25% (IMA) \n\n**Nephrolithiasis**:\n\n- **Microscopic hematuria:** sens 89%, spec 29%\n\n**Pancreatitis**: Lipase (sens 90%, spec 93%) is better than amylase (sens 79%, spec 93%). Unlike level of elevated enzymes, CT correlates with severity.\n\n**UTI**: Urine dipstick alone is adequately predictive, except for children, elderly, suspected urosepsis.\n\n- **Nitrites:** Odds Ratio (OR) = 6.36\n- **Leukocyte esterase:** OR = 4.52 \n- **Blood:** OR = 2.23\n\n**LUQ Pain:** Limited use for labs/imaging, unless elderly, immunosuppressed, or trauma patient\n\n## References\n\n- Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, Weiss JW.Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med. 2005 May;45(5):524-8. \\[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15855951)]\n- Panebianco NL, Jahnes K, Mills AM. Imaging and Laboratory Testing in Acute Abdominal Pain. Emerg Med Clin N Am. 2011;29:175-93. \\[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21515175)]\n- Ultrasonography vs. CT for suspected Nephrolithiasis. New England Journal of Medicine. 2014;371(26):2529-2531. \\[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25229916)]\n"
		},
		{
			"slug": "abg-interpretation",
			"title": "ABG Interpretation",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/04/02",
			"updates": [
				"2017/02/24"
			],
			"categories": [
				"Pulmonology"
			],
			"body": "\n\n\n## Rules of thumb\n\n**Look at pH**: Whichever side of 7.4 the pH is on, the process that caused it to shift to that side is the primary abnormality\n\n**Calculate the anion gap**. If AG &ge; 20, there is a primary metabolic acidosis regardless of the pH or serum bicarbonate concentration\n\n**Calculate the excess anion gap** = total anion gap - 12 + measured bicarb\n\n- If sum is > 30, then metabolic alkalosis\n- If sum is &lt; 23, then nongap metabolic acidosis\n\nRespiratory compensation occurs almost immediately in response to metabolic disorders.\n\nMetabolic compensation occurs over 3-5 days in response to respiratory disorders.\n\n## Primary respiratory alkalosis \n\neg. 7.50/ 29 / 80 / 22 (pH / PaCo2 / PaO2 / \\[HCO3-])\n\n**Differential**\n\n- Anxiety\n- Lung disease\n- CNS disease \n- Mechanical ventilation\n- Drug use (aspirin, catecholamines, progesterone)\n- Pregnancy\n- Hepatic encephalopathy\n- Sepsis\n- Hypoxia\n\n## Primary respiratory acidosis \n\neg. 7.25 / 60 / 80 / 26 = **ACUTE** because no bicarbonate compensation\n\neg. 7.34 / 60 / 80 / 31 = **CHRONIC** because bicarbonate conensation\n\n**Differential**\n\n- Acute airway obstruction\n- Severe pneumonia or pulm edema   |\n- CNS depression            \n- Thoracic cage injury-flail chest\n- Impaired lung motion (PTX)\n- Ventilator dysfunction          \n- Neuromuscular disorder                               \n\n## Primary metabolic alkalosis\n\neg. 7.50 / 48 / 80 / 36\n\n**Differential**\n\n- **Urine Cl = low**   \\| **Urine Cl = normal-high**        \\|\n- Diuretic use in past \n- Current diuretic use             \n- NG suction           \n- Excess alkali administration     \n- Post-hypercapnia     \n- Excess mineralocorticoid activity\n-  Vomiting            \n-  Refeeding alkalosis             \n\n## Primary metabolic acidosis \n\neg. 7.20 / 21 / 80 / 8\n\n**Nonanion gap:** CAGE\n\n- Chloride (HCL) administration \n- Acetazolamide/Addisons\n- GI Loss\n- Extras – RTA, ingestion of oral acidifying salts, recovery phase of DKA\n\n**Anion gap:** MUDPILES\n\n- Methanol\n- Uremia\n- DKA\n- Paraldehydes, paint sniffing\n- INH, iron, ibuprofen, inborn error of metabolism\n- Lactic acidosis\n- Ethanol, ethylene glycol\n- Salicylates\n\n_Pearl_: If anion gap > 20 exists, there is a primary metabolic acidosis\n\n_Pearl_: If anion gap exists, calculate the excess anion gap to determine if there is an underlying metabolic alkalosis or nongap metabolic acidosis exists.\n\n## Examples\n\n7.4 / 40 / 80 / 24, Na 145, Cl 100 --> Metab acidosis + metab alkalosis\n\n7.5 / 20 / 80 / 15, Na 145, Cl 100 --> Resp alkalosis + metab acidosis + metab alkalosis\n\n7.1 / 50 / 80 / 15, Na 145, Cl 100 --> Resp acidosis + metab acidosis + metab alkalosis \n\n7.15 / 15 / 80 / 5, Na 140, Cl 110 --> Metab acidosis, gap AND nongap\n\n## References\n\n- Haber RJ. A practical approach to acid-base disorders. West J Med 1991; 155:146-51. [[Source](http://tmedweb.tulane.edu/mu/owlclub/files/2010/06/Must-Read-Acid-Base-Article-.pdf)]\n"
		},
		{
			"slug": "acetaminophen-toxicity",
			"title": "Acetaminophen toxicity",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/11/04",
			"updates": null,
			"categories": [
				"Toxicology",
				"Pharmacology"
			],
			"body": "\n\n\n**Rumack Matthew Nomogram**\n\n![Rumack Matthew Nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/acetaminophen-toxicity/image-1.png)\n\nNote: Use for single time-point ingestion only. Does not predict toxicity in chronic ingestion.\n\n## Background\n\n**Acetaminophen**\n\n- Metabolized through cytochrome P450 system to form toxic NAPQI metabolite, which requires glutathione to detoxify.\n- Toxic ingestion dose = 150 mg/kg \n\n**Clinical Stages of Acetaminophen Overdose**\n\n- **Stage 1** (&lt; 24 hr): Abd pain, N/V, anorexia, lethargy, diaphoresis; normal labs\n- **Stage 2** (24-72 hr): RUQ abdominal pain, jaundice, rising AST/ALT/INR values \n- **Stage 3** (72-96 hr): Peak hepatotoxicity, renal insufficiency, and death vs. mild symptoms if treated\n- **Stage 4** (4 days-2 wk): 70% survive acute liver failure; resolution of symptoms\n\n## Workup and Treatment\n\n**Lab:** Draw serum acetaminophen level at 4 hours post-ingestion. \n\n### Treatment\n\n<span class=\"drug\">Activated charcoal</span>\n- Of benefit &lt; 1 hour of ingestion and possible benefit beyond 1 hour\n\n<span class=\"drug\">N-acetylcysteine</span> (PO or IV) \nStart within 8-10 hours if:\n- Above “possible hepatic toxicity” line\n- Estimated single ingestion of acetaminophen > 150 mg/kg\n- Time of ingestion unknown and serum level > 10 mcg/mL\n- Lab evidence of hepatotoxicity and history of excessive ingestion \n- Repeated ingestion and a serum level > 10 mcg/mL\n\nPO: \n- First dose **140 mg/kg** \n- Then **70 mg/kg** every 4 hours \n- Typically treat for 20 hours for uncomplicated overdose\n\nIV: \n- First dose **150 mg/kg** over 1 hour to minimize anaphylactoid reaction\n- Then **50 mg/kg** over first 4 hours\n- Then **100 mg/kg** over next 16 hours\n- Total Dose = 300 mg/kg over 20 hours\n\n## References\n\n- Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11(3):525-48 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=17723918)]\n"
		},
		{
			"slug": "acls",
			"title": "ACLS 2015 Algorithm for Cardiac Arrest",
			"authors": [
				"Michelle Lin, MD",
				"Jeremy Voros, MD"
			],
			"created": "2011/12/16",
			"updates": [
				"2017/02/24"
			],
			"categories": [
				"Cardiovascular",
				"Critical Care"
			],
			"body": "\n\n\n![2015 ACLS cardiac arrest algorithm](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/acls/image-1.png)\n\n## Tips\n\n- **2 minutes** of continuous, uninterrupted CPR is key before rechecking the rhythm.\n- Think about giving <span class=\"drug\">epinephrine</span> every **OTHER** time you check the rhythm. This puts it at roughly a q4 minute dosing (recommended q3-5 minutes).\n- Don't delay CPR when you recognize a cardiac arrest. That means do this first, and then work on giving oxygen, placing the patient on various monitors, setting up the defibrillator, and establishing IV/IO access. Hence, the C-A-B mnemonic (Circulation before Airway)\n- Chest compressions should be \"hard and fast\" -- Depth of at least 2 inches and &ge; 100 compressions with a target PCO<sub>2</sub> on the end-tidal capnography of &ge;10 mm Hg.\n- Use your mobile phone's timer to help alert you every time when 2 minutes is up.\n\n## Additional reversible causes\n\n**(not listed on ACLS AHA guidelines)**\n\n- Hypoglycemia\n- Trauma\n\n## Return of Spontaneous Circulation\n\n- Pulse and blood pressure\n- PETCO<sub>2</sub> abruptly sustained increase (typically &ge; 40 mm Hg)\n\n## Post-Cardiac Arrest Care\n\n**Ventillation & Oxygenation**: \n\n- Start at 10 breaths per minute\n- Titrate to target PCO<sub>2</sub> 30-40 mm Hg\n- Titrate FIO<sub>2</sub> to minimum necessary to achieve SpO<sub>2</sub> &ge; 94%\n\n**Treat Hypotension**\n\n- IV/IO bolus: 1-2L normal saline or lactate \n- Vasopressor infusion as needed:\n  - <span class=\"drug\">Epinepherine IV</span> 0.1-0.5 mcg/kg per minute\n  - <span class=\"drug\">Dopamine IV</span> 5-10 mcg/kg per minute\n  - <span class=\"drug\">Norepihephrine IV</span> 0.1-0.5 mcg/kg per minute\n\n**Evaluate Need for Coronary Catheterization**\n\n- 12-Lead ECG STEMI or high suspicion of acute myocardial infarction? Proceed to coronary reperfusion.\n\n**Targeted Temperature Management**\n\n- If no meaningful response to verbal stimuli, maintain a constant temperature between 32°C and 36°C \n\n## Patwari Academy video tutorials\n\n- [ACLS: Airway](https://www.aliem.com/2012/patwari-academy-videos-acls-and-airway/)\n\n## References\n\n- Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S315-67. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26472989)]\n"
		},
		{
			"slug": "acute-bronchiolitis",
			"title": "Acute Bronchiolitis Management",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2016/11/07",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Pulmonology",
				"Infectious Disease"
			],
			"body": "\n\n\n## How to Use Algorithm\n\n### Scope\n\nDoes not apply if severe or atypical presentation\n\n### Inclusion Criteria\n\nChildren, 1‐12 months of age, presenting with symptoms and signs suggestive of a clinical diagnosis of bronchiolitis, such as upper respiratory tract infection such as rhinitis and coughing, progressing to lower respiratory symptoms including wheezing, crackles, and/or tachypnea that may result in difficulty breathing and/or difficulty feeding\n\n### Exclusion Criteria\n\n- Full‐term infants that are &lt;28 days old\n- Premature infants that are &lt;48 weeks post‐conception\n- Patients with hemodynamically significant cardiac or significant pulmonary disease (such as bronchopulmonary dysplasia or asthma) or other major chronic conditions (such as immunodeficiency and neuromuscular disease)\n\n## History & Physical\n\n1. Obtain patient's medical history\n2. Complete physical exam with vital signs and pulse oximetry\n3. Assess hydration status\n\n## Assess Severity\n\nAssess severity by considering:\n\n- Any history of apnea\n- Respiratory rate\n- Work of breathing\n- Mental status\n- Pulse oximetry\n- Ability to feed/drink\n\n> Routine chest xray, viral testing, and blood or urine testing are **NOT** recommended\n> The above diagnostic testing **MAY** be considered in the case of severe or atypical presentation or if concern for congenital or acquired heart disease\n\n## First Line Therapies\n\n- May consider supplemental oxygen to maintain SpO<sub>2</sub> > 90%\n- Consider nasal suctioning (if signs of nasal congestion)\n- Maintain hydration status (if needed via IV or nasogastric feedings)\n\n## If Patient is stable and/or improving\n\nDischarge home if patient meets following criteria.\n\n### Discharge Criteria (must meet all requirements)\n\n1. O<sub>2</sub> saturation &ge; 90% while awake\n2. No more than mild/moderate respiratory distress\n3. Ability to maintain hydration\n4. Ability to obtain reliable follow-up care\n\nIf patient does not meet all criteria, continue to observe and reassess.\n\n## If Patient NOT stable or improving\n\nConsider the following adjunct therapies\n\n- High flow nasal canula\n- Nebulized epinepherine\n- Manage as appropriate to clinical findings\n\n![Acute bronchiolitis workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/acute-bronchiolitis/image-1.png)\n\n## References\n\n1. Ralston S, Lieberthal A, Meissner H, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25349312)]\n"
		},
		{
			"slug": "acute-limb-ischemia",
			"title": "Acute Limb Ischemia",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/08/13",
			"updates": [
				"2017/02/13"
			],
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\n- True vascular emergency\n- Golden Window = **6 hours**\n- Etiologies: \n\n**Most common:** Thromboembolic cause\n\n**Less common causes:**\n\n- Vascular dissection\n- Compartment syndrome\n- Thoracic outlet syndrome\n- Trauma\n- Vasospasm\n- Vasculitis\n- Low intravascular volume\n\n## Focused physical exam checklist\n\n- **Cardiac:** Check for murmur, atrial fibrillation\n- **Extremity:** Check for signs of chronic peripheral vascular disease: hair loss, foot ulcer, decreased pulse, muscle atrophy\n- **Neurological:** Check for sensory and motor loss\n- **Vascular:** Grade peripheral pulses\n\n  - 0 = No Doppler signal\n  - 1 = Reduced\n  - 2 = Normal\n  - 3 = Increased\n  - 4 = Bounding\n\n- Rutherford Classification scheme for ALI ([Rutherford et al](https://www.ncbi.nlm.nih.gov/pubmed/?term=9308598))\n\n  - **Thrombotic occlusions** usually class I or IIA because of presence of collateral vasculature\n  - **Embolic occlusions** usually class IIB or III\n\n| Class   | Category                                   | Prognosis                       | Sensory Loss        | Muscle Weakness  | Arterial Dopper Signal | Venous Doppler Signal |\n| ------- | ------------------------------------------ | ------------------------------- | ------------------- | ---------------- | ---------------------- | --------------------- |\n| **I**   | Viable, No immediate limb threat           | None                            | None                | Audible          | Audible                |                       |\n| **IIA** | Threatened: Marginal                       | Salvageable if treated promptly | Min-none            | None             | +/- Audible            | Audible               |\n| **IIB** | Threatened: Immediate                      | Salvageable if treated immed.   | More than just toes | Mild-mod         | Rarely audible         | Audible               |\n| **III** | Irreversible Limb loss or permanent damage | Profound                        | Profound            | None             | None                   |                       |\n\n- Ankle brachial index (ABI)\n- Electrocardiogram\n- CBC \n- Type and screen\n- Basic metabolic panel\n- PT/PTT\n- Creatine kinase\n- Troponin\n\n## Imaging\n\n- **First line imaging** = Digital subtraction angiography (DSA)\n- Ultrasound, CT angiography, MR angiography – not well studied in ALI and loss of time-to-intervention\n- No imaging if unstable patient --> go straight to amputation\n\n## ED treatment\n\n- <span class=\"drug\">**Aspirin**</span>\n- <span class=\"drug\">Unfractionated heparin</span> (consider no bolus and lower infusion due to risk of hemorrhage)\n- Position extremity in dependent position\n- Avoid extremes of temperature\n- Pain control\n\n## Management Plan\n\n**Interventional radiology** = Catheter-directed (intra-arterial) thrombolysis +/-mechanical thrombectomy\n\n-  If Class I or IIA ischemia; duration &lt;14 days, esp if bypass graft; high operative risk\n\n**Operating room** = Open thrombectomy, bypass\n\n-  If Class IIB or III ischemia; symptoms > 14 days\n\n**Amputation** = If class III and high risk for reperfusion injury\n\n## References\n\n- Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version.J Vasc Surg. 1997 Sep;26(3):517-38. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=9308598)]\n"
		},
		{
			"slug": "adenosine",
			"title": "Adenosine 6-12-12 Approach",
			"authors": [
				"Bryan Hayes, PharmD"
			],
			"created": "2012/12/06",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"Pharmacology",
				"Critical Care"
			],
			"body": "\n\n\nThe ACLS-recommended dosing strategy of 6 mg, 12 mg, and 12 mg for <span class=\"drug\">adenosine</span> may not be appropriate in every situation. There are a few instances when lower or higher dosing should be considered.\n\n_Caveat:_ All recommendations are data-based, but many factors affect successful conversion of paroxysmal supraventricular tachycardia (PSVT) including proper line placement and administration technique.\n\n## Option 1: Starting at higher dose\n\n**Caffeine and theophylline:** Caffeine is an <span class=\"drug\">adenosine</span> blocker and can interfere with the successful reversion of PSVT. In fact, ingestion of caffeine less than 4 hours before a 6-mg <span class=\"drug\">adenosine</span> bolus significantly reduced its effectiveness in the treatment of PSVT. An increased initial <span class=\"drug\">adenosine</span> dose may be indicated for these patients.\n\nRemember that theophylline may require higher dosing as well, because it is similar to caffeine (another methylxanthine), but is not prescribed much in the U.S. anymore.\n\n**_Recommended dosing strategy_** \\[[Cabalag, 2009](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]:\n\n- 1st dose: 12 mg (instead of 6)\n- 2nd/3rd doses: 18 mg (instead of 12)\n\n## Option 2: Starting at lower dose\n\n**Central Line:** The initial <span class=\"drug\">adenosine</span> dose should be reduced if administered through a central line. Remember a central line delivers the <span class=\"drug\">adenosine</span> right where you need it. This recommendation is supported by the 2010 ACLS guidelines. Cases of prolonged bradycardia and severe side effects have been reported after full-dose <span class=\"drug\">adenosine</span> through a central line.\n\n**Carbamazepine or Dipyridamole:** Lower dose for patients on <span class=\"drug\">carbamazepine</span> or <span class=\"drug\">dipyridamole</span> \n\n**Transplanted heart:** Lowr dose for patients with heart transplants\n\n**_Recommended dosing strategy_**\\[[Chang, 2002](http://www.ncbi.nlm.nih.gov/pubmed/11858927); [Neumar, 2010](http://www.ncbi.nlm.nih.gov/pubmed/20956256); [Mc-Intosh-Yellin, 1993](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]:\n\n- 1st dose: 3 mg (instead of 6)\n- 2nd/3rd doses: 6 mg (instead of 12)\n\n**[ALiEM Blog Post](https://www.aliem.com/2012/is-6-12-12-adenosine-approach-always/)**\n\n## References\n\n- McIntosh-Yellin NL, et al. Safety and efficacy of central intravenous bolus administration for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]\n- Cabalag MS, et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad Emerg Med 2009;17(1):44-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]\n- Chang M, et al. Adenosine dose should be less when administered through a central line. J Emerg Med 2002;22(2):195-8 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11858927)]\n- Neumar RW, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-S767. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20956256)]\n"
		},
		{
			"slug": "against-medical-advice",
			"title": "Against Medical Advice (AMA)",
			"authors": [
				"Matthew DeLaney, MD"
			],
			"created": "2014/01/13",
			"updates": null,
			"categories": [
				"Education and Policy"
			],
			"body": "\n\n\n**Take Home Points**\nPatients are going to continue to leave AMA. Providers should recognize these situations as high risk to both the patient and provider. When patients insist on leaving careful discussion with the patient and specific documentation can hopefully improve outcomes.\n\n## Risks to the Patient\n\nFrom a medical standpoint, patients who leave AMA tend to have an increased risk of having an adverse outcome. Baptist et al. found that asthma patients who left AMA had an increased risk of both relapse and subsequent ICU admissions [1]. Similarly patients with chest pain who left AMA had a higher risk of myocardial infarction than other patients with similar characteristics who stayed in the ED to complete their workup [2].\n\n## Risks to the Providers\n\nPatients who leave against medical advice are up to 10x more likely to sue the emergency physician when compared to other ED patients. Some estimate that 1 in 300 AMA cases results in a lawsuit compared to 1 in 30,000 standard ED visits [3].\n\nWhile posing a particular challenge to providers, there are several basic steps that can be taken when dealing with a patient leaving AMA that can help improve patient outcomes while providing significant medicolegal protection to the providers.\n\n## How to do it Properly\n\n_“The patient looks sober. I told them if they leave that they could die.”_\n\nWhile seen on charts in ED’s across the country, documentation like this offers essentially no legal protection and should not be used. When patients insist on leaving AMA there are eight commonly held standards that should be discussed and documented with all patients.\nBasically the provider needs to establish that the patient is able to make reasonable decisions and in this particular instance was given all the information that would be necessary to make an informed decision.\n\n## Eight Parts of the AMA Process\n\n### 1. Capacity\n\nThis term refers to the patient’s medical ability to make a decision. Documenting that the patient “understood” offers little protection, while documenting a patient’s ability to carry on a conversation and demonstrate reason provides a much more compelling example of their capacity to make decisions. Additionally patients should be noted to be clinically sober as a way to support their capacity. Example: “The patient is clinically sober, free from distracting injury, appears to have intact insight and judgment and reason and in my opinion has the capacity to make decisions.”\n\n### 2. Signs and Symptoms\n\nThe patient and provider need to agree on both the patient’s symptoms and also the providers concerns. Example: “The patient presents with abdominal pain. I have explained that I am concerned that this may represent appendicitis; they have verbalized an understanding of my concerns.”\n\n### 3. Extent and Limitation of the Exam\n\nDocument what has been done as well as the limitations that still exist. Example: “I have told the patient that while their labs were normal, they could still have appendicitis.”\n\n### 4. Current Treatment Plan\n\nExample: “I have discussed the need for a CT scan to get more information about potential causes of the patient’s pain.”\n\n### 5. Risks of Foregoing Treatment\n\nSimply documenting “you could die if you leave” is inadequate. Patient should be informed of reasonably foreseeable complications including disability and death. Specific threats such as loss of fertility for testicular/ovarian pathology or loss of vision for ocular complaints should be included when appropriate. Example: “I have told the patient that if they leave and have appendicitis, they could get much worse, could become critically ill, and could possibly become disabled or die.”\n\n### 6. Alternatives to Suggested Treatment\n\nProviders should clearly document the efforts they have made to prevent the patient from leaving AMA. In addition to alternative diagnostics and treatments, discussions with family and friends can be included. Example: “I have offered to give the patient more pain medication. I have asked them to stay in the hospital for serial abdominal exams. I have offered to have an ultrasound performed instead of a CT scan. I have discussed these concerns with the patient’s wife who is at the bedside and she is unable to convince them to stay for further evaluation.”\n\n### 7. Explicit Statement of AMA and About What the Patient Refused\n\nExample: “The patient is not willing to undergo a CT scan. He is unwilling to stay overnight for monitoring. He is refusing any further care and is leaving against medical advice.”\n\n### 8. Questions, Follow-up, Medicines, Instructions\n\nWhen patients leave AMA, providers should do whatever is possible to limit bad medical outcomes. A commonly held misconception is that providing a patient with prescriptions or paperwork somehow negates their AMA status and places the provider at risk. In reality, refusing to provide any discharge medication or instructions only increases the chance that the patient will have a bad outcome, which significantly increases the provider’s risk. For instance, if a patient with pneumonia is leaving AMA, they should be given appropriate antibiotics, and the provider should offer to set up outpatient follow-up. All questions should be answered. Example: “I am unable to convince the patient to stay, I have asked them to return as soon as possible to complete their evaluation. I have spoken with coverage for their primary care doctor in regards to their abdominal pain. I have answered all their questions.”\n\n## References\n\n1. Bitterman RA. Against medical advice: When should you take “no” for an answer? Lecture presented at ACEP Scientific Assembly. Chicago, Oct. 30, 2008.\n\n2. Monico EP, Schwartz I. Leaving against medical advice: facing the issue in the emergency department. J Healthc Risk Manag. 2009;29 (2): 6-9, 13, 15. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19908647)]\n\n3. Miller S. Obtaining a valid AMA (Against Medical Advice). JEMS. 1996;21 (2): 54-5. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=10154651)]\n"
		},
		{
			"slug": "anaphylaxis",
			"title": "Anaphylaxis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/02/24",
			"updates": [
				"2017/02/13"
			],
			"categories": [
				"Allergy-Immunology"
			],
			"body": "\n\n\n**Definition**: A serious allergic reaction that is rapid in onset and might cause death\n\n**Mechanism**: IgE-mediated immune reaction\n\n**Pearl**: Hypotension is NOT required to diagnose anaphylaxis.\n\n**Triggers**: Almost any food, allergens, or medications can be a trigger.\n\n**Common culprits**:\n\n- Antibiotics (especially beta-lactams)\n- NSAIDs\n- Peanuts\n- Shellfish\n\n**Organ involvement**: \n\n- Skin 80-90%\n- Respiratory 70%\n- Gastrointestinal 45%\n- Cardiovascular 45%\n- Central nervous system 15%\n\n**Biphasic anaphylaxis pattern**: 2nd flare may occur despite trigger removed (typically within 72 hours of onset)\n\n## Diagnostic criteria\n\n> Highly likely if **1 or 3 criteria** fulfilled per 2nd National Institute of Allergy and ID/Food Allergy and Anaphylaxis Network\n\n1. Acute onset (min-several hrs), involving skin, mucosa, or both (hives, flushing, pruritis, angioedema) AND at least 1 of the following:\n\n   - Respiratory compromise: shortness of breath, wheezing, stridor, hypoxemia, reduced PEF\n   - Reduced BP or associated sx of end-organ dysfunction: hypotonia, syncope, incontinence\n\n2. Two or more of the following that occur rapidly after exposure to likely allergen:\n\n   - Involvement of skin-mucosal tissue: hives, itching, flushing\n   - Respiratory compromise: shortness of breath, wheezing, stridor, hypoxema, reduced PEF\n   - Reduced BP or associated dx: hypotonia, syncope, incontinence\n   - Persistent GI sx: cramping, abdominal pain, vomiting\n\n3. Reduced BP after exposure to known allergen\n\n   - Infants/children: Low SBP (age specific) or > 30% decrease in SBP\n     - Age 1 mo - 1 yr: SBP &lt; 70 mmHg\n     - Age 1 yr - 10 yr: SBP &lt; 70 mmHg + [2 x age]\n\n   - Adults: SBP &lt;90 mmHg or >30% decrease in person's baseline\n\n## ED management\n\n- Supine position, ABCs\n- **IM <span class=\"drug\">epinephrine</span> STAT**. Repeat every 5-15 min if refractory\n  - 0.3-0.5 mg for adults = 0.3-0.5 mL 0f 1:1000 concentration of epinephrine\n  - 0.15 mg for patient wt &lt; 30 kg\n  - **IM injection into lateral thigh** - quickest absorption centrally\n- IV fluids 2 liters\n- H1 antagonist (eg. <span class=\"drug\">diphenhydramine</span>)\n- H2 antagonist (eg. <span class=\"drug\">ranitidine</span>)\n- Glucocorticoids (eg. <span class=\"drug\">Methylprednisolone</span>; may blunt biphasic response)\n- <span class=\"drug\">Albuterol</span> (beta-agonist) nebulizer for wheezing/lower airway obstruction\n- Consider: <span class=\"drug\">Glucagon</span> 3.5-5 mg IV if refractory to epinephrine and on beta-blockers\n- If discharging patient home after observation, **prescribe <span class=\"drug\">epinephrine pen</span>**\n\n## References\n\n- Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S161-81. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20176258)]\n- Arnold JJ, Williams PM. Anaphylaxis: recognition and management. Am Fam Physician. 2011;84(10):1111-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22085665)]\n"
		},
		{
			"slug": "angioedema",
			"title": "Angioedema",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/03/26",
			"updates": [
				"2017/2/24"
			],
			"categories": [
				"Allergy-Immunology"
			],
			"body": "\n\n\n**Definition**: self-limited, asymmetric, localized, non-pitting swelling\n\n**Background**\n\n- 15% of population\n- 50% with urticaria\n- _Common sites:_ perioribtal, lips, tongue, extremity, bowel wall\n- _Main cause of death:_ Laryngeal edema (25-40% mortality if present)\n\n## Syndromes and Specific Treatments\n\n**Idiopathic Angioedema**\n\n- 38% of patients with angioedema\n\n**Allergic or IgE Mediated Angioedema**\n\n- Type I hypersensitivity reaction\n- Commonly from food or medications\n- _Tx:_ allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema\n\n**Hereditary Angioedema**\n\n- C1q esterase inhibitor deficiency\n- _Triggers:_ trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, stress\n- _Prophylaxis tx:_ **danazol** better than tranexamic acid and aminocaproic acid\n- _Acute tx:_  **FFP**, C1 INH, icatibant, and ecallantide can all be used\n- Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n\n**ACE Inhibitor Angioedema**\n\n- 0.3-0.7% of those taking ACE-I's\n- From elevated levels of bradykinin\n- Highest incidence during 1st month of starting medication, but can occur years after \n- 5x more common in African-Americans compared to Caucasians\n- Controversial whether patient can take ARBs (doesn’t cause elevated bradykinin) as well – some with angioedema.\n- _Tx:_ Discontinue medication and supportive care\n- Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema\n\n**Treatment philosophy:** \n\n- Low threshold to protect airway by intubation\n- If initial exam does not trigger an intubation frequent re-evaluations should be made as a patients clinical picture can change rapidly\n- Once a decision for intubation has been made make sure you are prepared to perform an emergent cricothyroidotomy if necessary and consult Anesthesia or ENT. Also consider performing Fiberoptic nasopharyngoscopy to evaluate the patients airway and if needed as a primary airway technique. Finally consider NOT paralyzing these patients, and possibly using Ketamine as your induction agent\n- _Fiberoptic nasopharyngoscopy_: consider performing on all patients with voice change to look for largnyeal edema\n- **_Pearl:_** Be sure to prescribe patients Epi-pen if discharged home\n\n## Admission guidelines for angioedema\n\n([Ishoo et al., Head Neck Surg, 1999](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684))  \n\n- 93 episodes in 80 patients (1985-95) with no deaths \n- 9.7% cases required intubation/tracheostomy\n- _Causes:_ 39% from <span class=\"drug\">ACE-I</span>\n- _Disposition:_ 25% outpt, 23% floor, 53% ICU\n- ICU admissions correlated with voice change, hoarseness, dyspnea, rash \n- Airway intervention correlated with voice change, hoarseness, dyspnea, stridor\n\n**Proposed staging system:**\n\n- **Stage I:** Facial rash, facial edema, lip edema - outpatient\n- **Stage II**: Soft palate edema – outpatient or floor\n- **Stage III:** Lingual edema --> ICU (7% required airway intervention)\n- **Stage IV:** Laryngeal edema –> ICU (24% required airway intervention)\n\n## References\n\n- Ishoo E et al. Predicting airway risk in angioedema: Staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263-8. [[PubMed] [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)]\n- Temino VM, Peebles RS. Spectrum and Treatment of Angioedema. Am J Med 2008; 121: 282-6(https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)\n- Guyer AC, Banerji A. ACE inhibitor-induced angioedema. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on June 4, 2015.) [[Source](http://www.uptodate.com/)]\n- Shenvi C, Serrano K. New Treatments for Angioedema. Emergency Physicians Monthly. Sep 2016. [[Source](http://epmonthly.com/article/new-treatments-angioedema/)]\n"
		},
		{
			"slug": "ankle-fxs-lauge-hansen",
			"title": "Ankle Fractures: Lauge-Hansen Classification",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/02/18",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## Lauge-Hansen Classification\n\n- Describes position of foot and mechanism of injury\n- Fracture(s) progress from Stage 1--> 4 involving more areas\n- Each type of fracture type has classic radiographic appearance\n\n### 4 areas of injury\n\n- Anterior talofibular ligament (AFTL) tear\n- Lateral malleolus (LM) fx\n- Posterior malleolus (PM) fx, or posterior talofibular ligament (PTFL) tear\n- Medial malleolus (MM) fx, or deltoid ligament tear\n\n![Graphic displaying the 4 areas of injury](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ankle-fxs-lauge-hansen/image-1.png)\n\n\\* Often fibula fx pattern hints at classification \n\n### Supination-External Rotation (SER) \n\n40-75% of all ankle fractures \n\n- _Stage 1_: ATFL tear\n- _Stage 2:_ Spiral oblique distal fibula fx at ankle mortise level \n- _Stage 3_: PM fx or PTFL tear\n- _Stage 4_: Transverse MM fx or deltoid ligament tear\n\n![X-ray image showing Supination-External Rotation (SER)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ankle-fxs-lauge-hansen/image-2.png)\n\n### Supination-Adduction (SAD) \n\n 10-20% of all ankle fractures \n\n- _Stage 1_: Low avulsion LM fx or lateral ligament injury\n- _Stage 2_: Vertical shear fx of MM\n\n![X-ray image showing Supination-Adduction (SAD)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ankle-fxs-lauge-hansen/image-3.png)\n\n### Pronation-Abduction (PAB)\n\n 5-20% of all ankle fractures\n\n- Associated with syndesmosis instability\n- _Stage 1_: Transverse MM fx (or deltoid ligament tear) \n- _Stage 2_: ATFL or PTFL tear\n- _Stage 3_: Transverse fibula fx at or above ankle mortise\n- Typically fibula fx has butterfly segment (comminuted)\n\n![X-ray image showing Pronation-Abduction (PAB)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ankle-fxs-lauge-hansen/image-4.png)\n\n### Pronation-External Rotation (PER) \n\n7-19% of all ankle fractures \n\n- Maisonneuve fx is a type of PER injury\n- Associated with syndesmosis instability\n- Staging:\n  - _Stage 1_: Transverse MM fx (or deltoid ligament tear) \n  - _Stage 2_: ATFL tear\n  - _Stage 3_: Spiral oblique fibula fx above ankle mortise \n  - _Stage 4_: PM fx or PTFL tear\n- To diagnose deltoid ligament instability, use “gravity stress” view (lateral portion of ankle rests on xray table to increase medial mortise)\n- Operative repair depends on talar stability under tibial plafond. A 1 mm lateral talar shift causes loss of joint surface contact by 42% --> chronic arthritis complications \n\n![X-ray image showing Pronation-External Rotation (PER)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ankle-fxs-lauge-hansen/image-5.png)\n\n## References\n\n- Clare MP. A rational approach to ankle fractures. Foot Ankle Clin. 2008 Dec;13(4):593-610. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19013398)]\n"
		},
		{
			"slug": "aorta-ultrasound",
			"title": "Ultrasound: Focused Abdominal Aorta Ultrasound",
			"authors": [
				"Victoria Koskenoja, MD",
				"Heidi Kimberly, MD",
				"Mike Stone, MD"
			],
			"created": "2014/09/13",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology",
				"Cardiovascular"
			],
			"body": "\n\n\n**Goal**\n- Evaluate for abdominal aortic aneurysm (AAA)\n\n**Transducer** \n- Low-frequency curvilinear (low-frequency phased if curvilinear unavailable)\n\n**Windows** \n- The goal is to image the entire abdominal aorta from diaphragm (subxiphoid area) to bifurcation into iliac arteries (near the umbilicus). Images should be obtained in both **transverse** and **longitudinal** planes. The specific areas include:\n\n![Transducer positions for aortic scan. Proximal (A), Mid-aorta (B), Distal (C), and Longitudinal (D)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/aorta-ultrasound/image-1.png)\n\nFigure 1: Transducer positions for aortic scan. Proximal (A), Mid-aorta (B), Distal (C), and Longitudinal (D)\n\n## Normal Reference Measurements\n\n- Aorta from outer wall to outer wall &lt;3 cm\n- Iliac vessels at bifurcation, outer wall to outer wall &lt;1.5 cm\n\n**Signs of AAA:** \n- Enlarged aorta >3 cm\n- Most AAA’s are fusiform and are infrarenal.\n- The SMA is a useful landmark as it is in close proximity to the renal arteries, which are often difficult to identify. \n- AAAs often contain a mural thrombus that MUST be included in your measurement of the aneurysm.\n\n![Aortic aneurysm (aaa) measuring 6 cm wide with mural thrombus (asterisks)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/aorta-ultrasound/image-2.png)\n\nFigure 2: Aortic aneurysm (aaa) measuring 6 cm wide with mural thrombus (asterisks).\n\n## Transverse View\n\nTransducer orientation is transverse with marker towards the patient’s right\n\n1. Proximal – Midline just below the xiphoid process\n2. Mid-Aorta – Midline between xiphoid process and umbilicus\n3. Distal - Midline near level of umbilicus\n\n![Proximal aorta transverse view demonstrating the inferior vena cava (ivc), the aorta (ao), the celiac trunk (red arrows) branching into the common hepatic artery (green arrow) and splenic artery (yellow arrow). Known as “seagull sign”](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/aorta-ultrasound/image-3.png)\nFigure 3: Proximal aorta transverse view demonstrating the inferior vena cava (ivc), the aorta (ao), the celiac trunk (red arrows) branching into the common hepatic artery (green arrow) and splenic artery (yellow arrow). Known as “seagull sign”.\n\n![Proximal aorta transverse view caudal to Figure 3. Note inferior vena cava (ivc), aorta (ao), anterior cortex of vertebral body (yellow arrows) and superior mesenteric artery (green arrow) with surrounding hyperechoic fat (“clock mantle” sign)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/aorta-ultrasound/image-4.png)\nFigure 4: Proximal aorta transverse view caudal to Figure 3. Note inferior vena cava (ivc), aorta (ao), anterior cortex of vertebral body (yellow arrows) and superior mesenteric artery (green arrow) with surrounding hyperechoic fat (“clock mantle” sign).\n\n## Longitudinal View\n\nTransducer orientation is sagittal with marker towards the patient’s head \n\n![Proximal aorta longitudinal view demonstrating the abdominal aorta (red arrows), the celiac trunk (yellow arrow) and the superior mesenteric artery (green arrow). Note that the abdominal aorta becomes more superficial as it descends into the abdomen, following the natural curvature of the spinal column](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/aorta-ultrasound/image-5.png)\n\nFigure 5: Proximal aorta longitudinal view demonstrating the abdominal aorta (red arrows), the celiac trunk (yellow arrow) and the superior mesenteric artery (green arrow). Note that the abdominal aorta becomes more superficial as it descends into the abdomen, following the natural curvature of the spinal column.\n\n## Struggling with the Exam?\n\n### Can’t find the aorta?\n\n- Use plenty of compression to displace bowel gas – it’s remarkable how much pressure patients tolerate and how much it will improve your view. The vertebral shadow can be used as a landmark as the aorta should be just anterior to the vertebrae. Increase the depth setting until the vertebral shadow is seen. You can start in any segment and follow the aorta proximally or distally. You may also roll the patient on his/her left side or use the liver as a window to find the proximal aorta by using a coronal RUQ view (like a FAST view) with increased depth.\n\n### Not sure if you are scanning proximal vs mid-aortic site?\n\n- The proximal view should include the celiac trunk and/or the SMA branching from aorta. Both arise anteriorly with the celiac immediately splitting (seagull sign) and the SMA surrounded by bright echogenic fat (Fig 3-4). The mid-aorta does not have these landmarks.\n\n## Common Errors\n\n- Measuring the lumen instead of the entire vessel.  Abdominal aortic aneurysms often have mural thrombus so be careful to measure outer wall to outer wall to avoid incorrect measurements. \n\n- Mistaking IVC for aorta. The aorta is on the patient’s left (screen right), has a thicker more echogenic wall, and is round in a transverse view while the IVC is often teardrop shaped.\n\n- Failing to visualize the entire aorta – you must see it from diaphragm to bifurcation to exclude the presence of an aneurysm.  \n\n- Relying on ultrasound for the diagnosis of aortic dissection. While a dissection flap can be visualized and should prompt immediate action, failure to visualize a flap by ultrasound does not exclude aortic dissection.\n\n## References\n\n- Tayal VS, Graf CD, Gibbs MA. Prospective study of accuracy and outcome of emergency ultrasound for abdominal aortic aneurysm over two years. Acad Emerg Med. 2003;10(8):867-71. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12896888)]\n- Kuhn M, Bonnin RL, Davey MJ, Rowland JL, Langlois SL. Emergency department ultrasound scanning for abdominal aortic aneurysm: accessible, accurate, and advantageous. Ann Emerg Med. 2000;36(3):219-23. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10969223)]\n- Taylor RA, Oliva I, Van tonder R, Elefteriades J, Dziura J, Moore CL. Point-of-care focused cardiac ultrasound for the assessment of thoracic aortic dimensions, dilation, and aneurysmal disease. Acad Emerg Med. 2012;19(2):244-7. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22288871)]\n"
		},
		{
			"slug": "aortic-dissection",
			"title": "Aortic Dissection",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/05/20",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"Critical Care"
			],
			"body": "\n\n\nInternational Registry for Aortic Dissection (IRAD):\n\n- Descriptive case study by [Hagan et al](http://www.ncbi.nlm.nih.gov/pubmed/?term=10685714) of 464 patients with aortic dissection from 12 international centers \n\n## Patient History\n\n| Factor                  | Incidence   |\n| ----------------------- | ----------: |\n| Marfan syndrome         |        4.9% |\n| Hypertension            |       72.1% |\n| Atherosclerosis         |       31.0% |\n| Known aortic aneurysm   |       16.1% |\n| Prior aortic dissection |        6.4% |\n| Diabetes mellitus       |        5.1% |\n\n## Iatrogenic\n\n| Factor               | Incidence   |\n| -------------------- | ----------: |\n| Catheterization/PTCA |        2.2% |\n| Cardiac surgery      |        2.2% |\n\n## Presenting Symptoms\n\n| Factor                       | Incidence % |\n| ---------------------------- | ----------: |\n| Pain,                        |             |\n| - Any                        |       95.5% |\n| - Abrupt onset               |       84.8% |\n| - Chest                      |       72.7% |\n| - Anterior chest             |       60.9% |\n| - Posterior chest            |       35.9% |\n| - Back                       |       53.2% |\n| - Abdomen                    |       29.6% |\n| - Severe or worst ever       |       90.6% |\n| - Tearing or ripping quality |       50.6% |\n| - Radiating                  |       28.3% |\n| - Migrating                  |       16.6% |\n| Syncope                      |        9.4% |\n\n## Physical Exam\n\n| Factor                        | Incidence   |\n| ----------------------------- | ----------: |\n| SBP ≥150 mmHg                 |       49.0% |\n| SBP 100-149 mmHg              |       34.6% |\n| SBP &lt;100 mmHg              |        8.0% |\n| SBP ≤ 80 mmHg                 |        8.4% |\n| Mumur of aortic insufficiency |       31.6% |\n| Pulse deficit                 |       15.1% |\n| CVA                           |        4.7% |\n| CHF                           |        6.8% |\n\n## Chest X-Ray Findings\n\n| Factor                                          | Incidence   |\n| ----------------------------------------------- | ----------: |\n| Normal                                          |       12.4% |\n| Widening mediastinum or abnormal aortic contour |       78.7% |\n| Pleural effusion                                |       19.2% |\n\n## ECG Findings\n\n| Factor                        | Incidence   |\n| ----------------------------- | ----------: |\n| Normal                        |       31.3% |\n| Nonspecific ST-T wave changes |       41.4% |\n| Left ventricular hypertrophy  |       26.1% |\n| Ischemia                      |       15.1% |\n\n## Overall hospital mortality: 26.4%\n\n### Abbrevations\n- **CHF** = _congestive heart failure_\n- **CVA** = _cerebrovascular accident_\n- **PTCA** = _percutaneous transluminal coronary angioplasty_\n\n## References\n\n- Hagan PG. et. al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=10685714)]\n"
		},
		{
			"slug": "appendicitis-acep",
			"title": "Appendicitis ACEP Clinical Policy",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/06/18",
			"updates": null,
			"categories": [
				"Surgery",
				"EBM"
			],
			"body": "\n\n\n## How predictive is WBC in appendicitis?\n\nWBC count > 10K and likelihood of having appendicitis:\n\n- Positive LR 1.59, Negative LR 0.46 ([Cardall et al, Acad Emerg Med 2004](http://onlinelibrary.wiley.com/doi/10.1197/j.aem.2004.04.011/abstract))\n- Positive LR 2.47, Negative LR 0.25 ([Andersson, Br J Surg 2004](http://onlinelibrary.wiley.com/doi/10.1002/bjs.4464/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false))\n\n## Alvarado Score\n\n**Alvarado score in predicting appendicitis** (Max 10 points)\n\n| Symptom or sign           | Point(s) |\n| ------------------------- | :------: |\n| Pain migration            |     1    |\n| Anorexia-acetone in urine |     1    |\n| Nausea/vomiting           |     1    |\n| RLQ tenderness            |     2    |\n| Rebound pain              |     1    |\n| Temperature > 37.3C oral  |     1    |\n| WBC > 10K                 |     2    |\n| Left shift WBC (>75% PMN) |     1    |\n\n**_Score:_** \n\n- 1-4 (appendicitis unlikely)\n- 5-6 (possible)\n- 7-8 (probable)\n- 9-10 (very probable)\n\nHowever, 0-8% of patients with Score &lt; 5 had appendicitis\n\nBeware of patients &lt;10 yr and >60 yr old for atypical presentations\n\n## CT imaging\n\n**IV contrast improves ability to detect appendicitis** ([Jacobs, Radiology 2001](http://radiology.rsna.org/content/220/3/683.long)) \n\n| CT with...       | Sensitivity  |\n| ---------------- | :----------: |\n| PO/IV contrast   |      91%     |\n| PO contrast only |      76%     |\n\n**Addition of oral contrast to CT Abd-pelvis (IV contrast) study is unnecessary** ([Anderson, Am J Surg 2005](https://secure.muhealth.org/~ed/students/articles/ajs_190_p0474.pdf))\n\n| CT Technique    | Sens | Spec |\n| --------------- | ---- | ---- |\n| Noncontrast     | 93%  | 98%  |\n| PO/IV contrast  | 93%  | 93%  |\n| Rectal contrast | 97%  | 97%  |\n\n## Imaging in Pediatric Appendicitis\n\n**_Ultrasound_**: Appendix >6 mm in diameter, non-compressible appendix, appendiceal tenderness \n\n- Positive LR 17.2-49.5\n- Negative LR 0.01-0.14\n\n**_CT_**: Unclear about additional benefit of PO/IV contrast. Many give PO/IV because ofless intraperitoneal fat in children (less obvious stranding on noncontrast study)\n\n[Kharbanda, Pediatrics 2005:](http://pediatrics.aappublications.org/content/116/3/709.short) In kids, if 0/5 of the following criteria, then the patient is very unlikely to have appendicitis (negative LR=0.058): \n\n1. Nausea\n2. Right lower quadrant pain\n3. Difficulty walking\n4. Rebound tenderness\n5. Absolute PMN>6,750 (\\* see Fagan nomogram)\n\n## Fagan nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/appendicitis-acep/image-1.png)\n\nDraw a connecting your pre-test probability and your likelihood ratio. This provides you with your post-test probability.\n\n## References\n\n- Howell JM, Eddy OL, Lukens TW, Thiessen ME, Weingart SD, Decker WW; American College of Emergency Physicians.Clinical policy: Critical issues in the evaluation and management of emergency department patients with suspected appendicitis. Ann Emerg Med. 2010 Jan;55(1):71-116. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20116016)]\n"
		},
		{
			"slug": "atls",
			"title": "ATLS - Palpable Pulses are Inaccurate",
			"authors": [
				"Salim Rezaie, MD"
			],
			"created": "2013/03/13",
			"updates": null,
			"categories": [
				"Surgery",
				"Trauma"
			],
			"body": "\n\n\n**Take Home Points**\n\nIn Advanced Trauma Life Support (ATLS), we learned that a carotid, femoral, and radial pulse correlates to a certain systolic blood pressure (SBP) in hypotensive trauma patients.  Specifically ATLS stated:\n\n-  Carotid pulse only = SBP 60–70 mmHg\n-  Carotid & Femoral pulse only = SBP 70–80 mmHg\n-  Radial pulse present = SBP >80 mmHg\n\nThere were two studies \\[[Poulton, 1988](http://www.ncbi.nlm.nih.gov/pubmed/3337405); [Deakin, 2000](http://www.ncbi.nlm.nih.gov/pubmed/10987771)] that evaluated this paradigm.  Although very small studies, they were done by two different authors, using different methods (BP cuff vs arterial line).  Both came to the same conclusion: \n\n- **ATLS overestimates SBP based on palpation of radial, femoral, & carotid pulses.** \n\nAnother way to state this is, if using ATLS guidelines to guestimate BP, we are grossly underestimating the degree of hypovolemia our patients have.\n\n## Poulton, 1988\n\n\"ATLS Paradigm Fails\" \\[[Poulton, 1988](http://www.ncbi.nlm.nih.gov/pubmed/3337405)] \n\n **What they did:** Manually measured SBP with sphygmomanometer in 20 hypovolemic trauma patients and compared with ATLS\n\n- 5/20 (25%) pts were correctly predicted by ATLS guidelines\n- 10/20 (50%) pts had false overestimation of BP by ATLS guidelines\n- False overestimation of BP was greatest in pts with lowest BPs\n- Mean difference of actual and estimated BP using ATLS was 34 mmHg\n\n**Conclusion:**  Radial pulses are often present in severely hypotensive hypovolemic patients, meaning the ATLS paradigm is invalid.\n\n## Deakin, 2000\n\n\"Accuracy of ATLS guidelines for predicting SBP\" \\[[Deakin, 2000](http://www.ncbi.nlm.nih.gov/pubmed/10987771)] \n\n**What they did:** Measured SBP with arterial line in 20 patient with hypovolemic shock and compared to pulses palpated by an observer blinded to BP readings.\n\n**What they found:** The disappearance of pulse always occurred in the following order radial > femoral > carotid pulse. There were 4 subgroups:\n\n- Group 1: Radial, femoral, and carotid pulses present\n  - 10/12 (83%) had SBP &lt;80 mmHg\n- Group 2: Femoral and carotid pulses only\n  - 10/12 (83%) had SBP &lt;70 mmHg\n- Group 3: Carotid pulse only\n  - 0/4 (0%) had SBP >60 mmHg\n- Group 4: Radial, femoral, and carotid pulses absent\n  - 2/3 (67%) had SBP &lt;60 mmHg\n\n**Conclusion:** ATLS guidelines for assessing SBP are inaccurate and generally overestimate the patient’s SBP. \n\n**Click [here](https://www.aliem.com/2013/is-atls-wrong-about-palpable-blood-pressure/) for full ALiEM blog post**\n\n## References\n\n- Poulton TJ. ATLS paradigm fails. Ann Emerg Med. 1988;17(1):107. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/3337405)]\n- Deakin CD, Low JL. Accuracy of the advanced trauma life support guidelines for predicting systolic blood pressure using carotid, femoral, and radial pulses: observational study. BMJ. 2000;321(7262):673-4. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10987771)]\n"
		},
		{
			"slug": "atrial-fibrillation",
			"title": "Atrial Fibrillation and Anticoagulation",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/04/09",
			"updates": [
				"2017/02/13"
			],
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\n## Background\n\n**Atrial Fibrillation** (AF) = **5x** risk for CVA and increases with age \n\n- Patients with persistent and paroxysmal atrial fibrillation should be treated the same when it comes to deciding about anticoagulation. They have an equivalent risk of stroke.\n\n**Stroke risk factors for patients with AF:**\n\n- Prior CVA or TIA\n- HTN\n- Age &ge;75\n- CHF\n- Poor LV function\n- DM\n\n## CHADS2 stroke risk stratification scheme \n\n- **C** = Congestive heart failure (1 pt)\n- **H** = Hypertension (1 pt)\n- **A** = Age &ge; 75 (1 pt)\n- **D** = DM (1 pt)\n- **S2** = prior Stroke or TIA (2 pts)\n\n![Bar chart showing stroke rate as CHADS2 score increases](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/atrial-fibrillation/image-1.png)\n\n([Gage et al., JAMA, 2001](https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607))\n\n## Deciding on whether to anticoagulate with aspirin or warfarin: ([AHA/ACC/ESC 2006 guidelines](http://circ.ahajournals.org/content/114/7/e257.full))\n\n### Weak Risk Factors\n\n- Female gender    \n- Age 65-74 years        \n- Coronary artery disease               \n- Thyrotoxicosis\n\n**Treatment**\n\n- <span class=\"drug\">Aspirin</span> or <span class=\"drug\">warfarin</span>\n\n### Moderate Risk Factors\n\n- Age >75 years          \n- Hypertension                     \n- Heart failure           \n- LV ejection fracture &le;35%              \n- Diabetes mellitus \n\n**Treatment**\n\n- 1 risk factor: <span class=\"drug\">aspirin</span> or <span class=\"drug\">warfarin</span>\n- &gt;1 risk factor: <span class=\"drug\">warfarin</span>\n\n### High Risk Factors\n\n- Prior CVA        \n- Prior TIA         \n- Embolism          \n- Mitral stenosis   \n- Mechanical heart valve\n\n**Treatment**\n\n- <span class=\"drug\">Warfarin</span>\n\n## Notes\n\n- Anticoagulation goal with <span class=\"drug\">warfarin</span>: INR 2-3\n- If age &lt;60 years AND zero risk factors: No anticoagulation because low risk for CVA \n\n## References\n\n- Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-354. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16908781)]\n- Waldo AL. Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. Cardiol Clin 2009; 27:125-35. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19111769)]\n- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607)]\n"
		},
		{
			"slug": "bells-palsy-treatment",
			"title": "Bell's Palsy Treatment",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/02/21",
			"updates": [
				"2017/02/13"
			],
			"categories": [
				"Neurology"
			],
			"body": "\n\n\n## Treatment\n\n- Corticosteroids, if onset within 72 hours\n- 1 in 11 were helped (to complete recovery) - [NNT.com](http://www.thennt.com/nnt/steroids-for-bells-palsy/)\n- **<span class=\"drug\">Prednisone</span>:** 60 mg daily x 1 week. May consider taper for days #8-10\n- <span class=\"drug\">Artificial tears</span> in daytime and lubricating eye ointment at night to prevent corneal drying and exposure\n- Tape eyelid shut while asleep.\n\nControversial benefit of antivirals (at most risk difference of 7%):\n\n- American Academy of Neurology (2012), JAMA (2009), and UpToDate suggest giving for severe cases such as for Grade IV and higher\n- Cochrane review (2009): No antivirals indicated. \n- **<span class=\"drug\">Valacylovir**</span> 1000 mg TID or **<span class=\"drug\">Acyclovir**</span> 400 mg 5x daily x 1 week\n- Also prescribe <span class=\"drug\">corticosteroids</span>, if antivirals given.\n\n## House-Brackmann grading for severity of facial nerve weakness\n\n|  Grade |    Dysfunction    | Gross weakness                                                                                                     | At rest                  |  Motion                                                                                 |\n| :----: | :---------------: | ------------------------------------------------------------------------------------------------------------------ | ------------------------ | --------------------------------------------------------------------------------------- |\n|    I   |        None       | No weakness                                                                                                        | No weakness              | Normal function all groups                                                              |\n|   II   |        Mild       | Slight weakness noticeable on close inspection. May have very slight synkinesis                                    | Normal symmetry and tone | **Forehead**: Moderate-to-good function  **Mouth**: Slight asymmetry                    |\n|   III  |      Moderate     | Obvious but not disfiguring difference; noticeable but not severe synkinesis, contracture, and/or hemifacial spasm | Normal symmetry and tone | **Forehead**: Slight-to-moderate movement  **Mouth**: Slightly weak with maximum effort |\n|   IV   | Moderately severe | Obvious weakness and/or disfiguring asymmetry                                                                      | Normal symmetry and tone | **Forehead**: None  **Mouth**: Asymmetric with maximum effort                           |\n|    V   |       Severe      | Only barely perceptible motion                                                                                     | Asymmetry                | **Forehead**: None      **Mouth**: Slight movement                                      |\n|   VI   |  Total paralysis  | No movement                                                                                                        | Asymmetry                | None for all groups                                                                     |\n\n## References\n\n- Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012 Nov 27;79(22):2209-13. doi: 10.1212/WNL.0b013e318275978c. Epub 2012 Nov 7. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23136264)]\n- de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, Chen JM. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA. 2009 Sep 2;302(9):985-93. doi: 10.1001/jama.2009.1243. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19724046)]\n- Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009 Oct 7;(4):CD001869. doi: 10.1002/14651858.CD001869.pub4. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19821283)]\n"
		},
		{
			"slug": "benzo-metabolism",
			"title": "Benzodiazepines Metabolism by the Liver",
			"authors": [
				"Bryan Hayes, PharmD"
			],
			"created": "2013/11/13",
			"updates": [
				"2017/05/10"
			],
			"categories": [
				"Pharmacology",
				"Toxicology"
			],
			"body": "\n\n\n## Take Home Points\n\n- **ALL benzodiazepines are metabolized by the liver.** Some are just metabolized by different pathways that are less dependent on global liver function.\n- **The ‘LOT’ drugs are those metabolized mostly by conjugation.**\n\n  - L – <span class=\"drug\">Lorazepam</span>\n  - O – <span class=\"drug\">Oxazepam</span>\n  - T – <span class=\"drug\">Temazepam</span>\n\n- The ‘LOT’ drugs do not have active metabolites after hepatic conjugation, and therefore have minimally affected half-lives in patients with liver disease. \n\n## Non-LOT Benzodiazepine Medications\nThese benzodiazepines may have prolonged effects in patients with market liver disease.\n- Primarily metabolized via hepatic CYP-mediated oxidation. \n- Examples: Drugs with active metabolites include - \n  - <span class=\"drug\">Diazepam</span>\n  - <span class=\"drug\">Clonazepam</span>\n  - <span class=\"drug\">Midazolam</span>\n\nSome practitioners like to take advantage of the longer duration of action and active metabolites.\n\n**Click [here](https://www.aliem.com/2013/all-benzodiazepines-are-metabolized-by-the-liver/) for full ALiEM blog post**\n\n## References\n\n- Mihic SJ, Harris RA. Chapter 17. Hypnotics and Sedatives. In: Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12nd ed. New York: McGraw-Hill; 2011. Accessed November 7, 2013. \n- Lee DC, Ferguson KL. Chapter 74. Sedative-Hypnotics. In: Lee DC, Ferguson KL, eds.Goldfrank’s Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011. Accessed November 7, 2013.\n"
		},
		{
			"slug": "blood-cultures",
			"title": "Blood Culture Indications",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/08/17",
			"updates": null,
			"categories": [
				"Infectious Disease"
			],
			"body": "\n\n\nBacteremia = true-positive bacterial presence in bloodstream\n\n- Approximately 50% (+) blood cultures are false (+) from contaminants\n- Overall 4.1-7.3% incidence of true (+) blood cultures\n\n| Condition                                       | Pretest probability of bacteremia |\n| ----------------------------------------------- | --------------------------------: |\n| Cellulitis                                      |                                2% |\n| Ambulatory outpatient                           |                                2% |\n| Community acquired pneumonia                    |                                7% |\n| Community-onset fever requiring hospitalization |                               13% |\n| Pyelonephritis                                  |                            19-25% |\n| Severe sepsis                                   |                               38% |\n| Acute bacterial meningitis                      |                               53% |\n| Septic shock                                    |                               69% |\n\n## Risk stratifying for bacteremia (excludes immunocompromised/endocarditis)\n\n|  Finding                                                                              | Positive LR                                                                                                 |  Negative LR                                                                                            |\n| ------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------- |\n| Chills                                                                                | 1.6 (1.3-1.8)                                                                                               | 0.84 (0.77-0.90)                                                                                        |\n| Chills + febrile patient                                                              | 2.2 (1.4-3.3)                                                                                               | 0.56 (0.41-0.76)                                                                                        |\n| _**Severity of chills**_<li>Shaking</li><li>Moderate</li><li>Mild</li><li>None</li>   | <br><li>**4.7** (3.0-7.2) </li><li>1.7 (1.0-2.8)</li><li>0.61 (0.26-1.4)</li><li>0.24 (0.11-0.55)</li></ul> |                                                                                                         |\n| _**Temperature**_<li>≥ 40.0 C</li><li>≥ 39.0 C</li><li>≥ 38.5 C</li><li>≥ 38.0 C</li> | <br><li>0.3 (0.13-1.0)</li><li>1.1 (0.79-1.6)</li><li>1.4 (1.1-2.0)</li><li>1.9 (1.4-2.4)</li></ul>         | <br><ul><li>1.1 (1.0-1.2)</li><li>0.95 (0.83-1.1)</li><li>0.50 (0.3-0.82)</li><li>0.54 (0.38-0.78)</li> |\n| Elevated WBC (cutoffs at 10K-15K)                                                     | ≥ 1.7                                                                                                       | ≥ 0.60                                                                                                  |\n| Platelet count &lt; 150,000                                                           | 2.0-2.1                                                                                                     | 0.68-0.91                                                                                               |\n| Presence of SIRS (inpatient study)                                                    | 1.8 (1.6-2.0)                                                                                               | **0.09** (0.03-0.26)                                                                                    |\n| Shapiro prediction rule (ED study)                                                    | 1.3 (1.2-1.4)                                                                                               | **0.08** (0.04-0.17)                                                                                    |\n\n## Systemic inflammatory response syndrome (SIRS)\n\n_At least 2 of following:_\n\n- Temperature &lt;36°C or >38°C\n- Heart rate >90 bpm\n- Respiratory rate > 22 / min, or pCO2 &lt;32 mmHg on ABG\n- WBC &lt;4K or >12K, or >10% bands\n\n## Shapiro clinical prediction rule for bacteremia\n\n_If suspect infection, blood cultures indicated if 1 major OR 2 minor criteria:_\n\n### Major\n\n- Endocarditis suspicion\n- Temperature >39.4°C\n- Indwelling vascular catheter\n\n### Minor\n\n- Temperature 38.3°C - 39.3°C\n- Age > 65 years\n- Chills\n- Vomiting\n- SBP &lt;90 mmHg\n- WBC >18K\n- Creatinine >2 mg/dL\n\n## References\n\n- Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? JAMA. 2012 Aug 1;308(5):502-11. doi: 10.1001/jama.2012.8262. \\[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22851117)]\n"
		},
		{
			"slug": "blunt-abdominal-trauma",
			"title": "Blunt Intra-Abdominal Injury",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/04/20",
			"updates": null,
			"categories": [
				"Trauma",
				"EBM"
			],
			"body": "\n\n\n## History and Physical\n\n|                                   | Positive LR    | Negative LR       |\n| --------------------------------- | -------------- | ----------------- |\n| Coastal margin tenderness         | 1.4 \\[1.3-1.7] | 0.74 \\[0.66-0.84] |\n| Abdominal tenderness on exam      | 1.4 \\[1.3-1.5] | 0.61 \\[0.46-0.80] |\n| Abdominal pain complaint          | 1.6 \\[1.3-2.0] | 0.52 \\[0.34-0.79] |\n| Abdominal guarding                | 3.7 \\[2.3-5.9] | 0.80 \\[0.70-0.91] |\n| Abdominal distention              | 3.8 \\[1.9-7.6] | 0.90 \\[0.83-0.98] |\n| Abdominal \"seat belt sign\" in MVC | 5.6-9.9        | 0.53-0.55         |\n| Glasgow coma scale &lt; 14        | 1.8-2.0        | 0.86-0.87         |\n| Presence of femur fracture        | 2.9 \\[2.1-4.1] | 0.92 \\[0.88-0.96] |\n\n## Lab Tests\n\n|                            | Positive LR      | Negative LR       |\n| -------------------------- | ---------------- | ----------------- |\n| Hematocrit change > 5%     | 0.91 \\[0.44-1.9] | 1.0 \\[0.79-1.4]   |\n| Serum lactate > 2.2 mmol/L | 1.3 \\[1.1-1.5]   | 0.61 \\[0.41-0.90] |\n| Serum WBC > 10K            | 1.7 \\[1.5-2.0]   | 0.35 \\[0.23-0.55] |\n| Hematocrit &lt; 36%        | 2.2 \\[1.6-3.1]   | 0.76 \\[0.64-0.90] |\n| Hematocrit &lt; 30%        | 3.3 \\[2.4-4.5]   | 0.79 \\[0.71-0.88] |\n| AST > 50 U/L               | 2.5 \\[2.0-3.0]   | 0.38 \\[0.26-0.56] |\n| AST or ALT > 130 U/L       | 5.2 \\[3.5-7.9]   | 0.46 \\[0.33-0.65] |\n| Hematuria > 50 RBC/hpf     | 3.7 \\[2.4-5.8]   | 0.44 \\[0.35-0.77] |\n| Hematuria                  | 4.1 \\[3.4-4.9]   | 0.66 \\[0.60-0.24] |\n| Base deficit &lt; -6 mEq/L | 18 \\[11-30]      | 0.12 \\[0.06-0.24] |\n\n## Imaging\n\n|                       | Positive LR     | Negative LR       |\n| --------------------- | --------------- | ----------------- |\n| Abdominal pelvic Xray | 1.6 \\[0.78-3.4] | 0.96 \\[0.90-1.0]  |\n| Abdominal pelvic Xray | 2.5-3.8         | 0.70-0.96         |\n| FAST ultrasound       | 30 \\[20-46]     | 0.26 \\[0.19-0.34] |\n\n## References\n\n- Nishijima DK et al. Does this adult patient have a blunt intra-abdominal injury? JAMA 2012;307(14):1517-27 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22496266)]\n"
		},
		{
			"slug": "blunt-cardiac-injury",
			"title": "Blunt Cardiac Injury",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/06/29",
			"updates": null,
			"categories": [
				"Trauma",
				"Cardiovascular"
			],
			"body": "\n\n\n_Definition:_ Encompasses wide spectrum of clinical injuries, ranging from asymptomatic myocardial bruise to cardiac rupture/death \n\nNo gold standard \n\n**Pearls:**\n\n- Causes 20% of all deaths due to motor vehicle collisions\n- Most commonly injured chamber: Right ventricle (most anterior in chest) \n\n**Clinical tips:**\n\n- Suspect in anyone with significant blunt, deceleration, or crush trauma to chest\n- Consider BCI in hemodynamically unstable patients without alternative cause\n- Troponin I and T lack adequate sensitivity as screening test  \n\n## Suggested algorithm, based on available evidence\n\n![Blunt cardiac injury algorithm](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/blunt-cardiac-injury/image-1.png)\n\n## References\n\n- Bernardin B, Troquet JM. Initial management and resuscitation of severe chest trauma. EM Clinics of North Am. 2012;30:377-400. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=22487111)]\n"
		},
		{
			"slug": "blunt-cerebrovascular-injury",
			"title": "Blunt Cerebrovascular Injuries",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/07/01",
			"updates": null,
			"categories": [
				"Trauma",
				"Neurology"
			],
			"body": "\n\n\n## Classic mechanisms of injury\n\n- **Carotid artery injury (CAI)**: Hyperextension of neck resulting in stretching of carotid artery over lateral processes of C1-C3\n- **Vertebral artery injury (VAI)**: Fracture through transverse process of C-spine, or hyperextension-stretch injury\n\n## Treatment\n\n- Antithrombotic agent (<span class=\"drug\">heparin</span> vs <span class=\"drug\">aspirin</span>)\n\n## Denver Screening Criteria for BCVI \n\n### Signs / symptoms of BCVI\n\n- Arterial hemorrhage from neck, nose, or mouth\n- Cervical bruit in patients &lt;50 years old\n- Expanding cervical hematoma\n- Focal neurologic deficit (TIA, hemiparesis, vertebrobasilar symptoms, Horner’s) \n- Neurologic exam incongruous with head CT findings\n- CVA on CT or MRI \n\n### Risk factors for BCVI\n\n- LeFort II or III facial fracture\n- C-spine fracture patterns: subluxation, fx extending into transverse foramen, fracture involving C1-C3\n- Basilar skull fracture with carotid canal involvement\n- Petrous bone fracture\n- Diffuse axonal injury with GCS &lt;6\n- Near-hanging with anoxic brain injury\n- Clothesline type injury or seat belt abrasion with significant swelling, pain, or altered mental status\n\n## Imaging Choice\n\n- **Gold standard**: Digital subtraction angiography\n- **Accepted first-line imaging**: CT angiography (at least 16-slice scanner)\n- **Alternative**: MRI (does not need contrast), may be less sensitive and less specific than CT\n- **NOTE:** A simple seat-belt sign along the neck does not warrant a CT angiogram. Patients with higher risk findings such as significant pain, tenderness, swelling, and/or a bruit may need imaging.\n\n## BCVI Grading and Incidence of CVA complication\n\n| Grade | Definition                                                                                                                | CVA Rate Carotid | CVA Rate Vertebral |\n| ----: | ------------------------------------------------------------------------------------------------------------------------- | ---------------: | -----------------: |\n| **1** | Irregularity of vessel wall, or dissection/intramural hematoma with <25% luminal stenosis                                 |               3% |                 6% |\n| **2** | Intraluminal thrombus or raised intimal flap is visualized, or dissection/intramural hematoma with ≥25% luminal narrowing |              14% |                38% |\n| **3** | Pseudoaneurysm                                                                                                            |              26% |                27% |\n| **4** | Vessel occlusion                                                                                                          |              50% |                28% |\n| **5** | Vessel transection                                                                                                        |             100% |               100% |\n\nRisk of undiagnosed BVCI: Delayed CVA\n\n- May occur hours to 14 years later \n- Majority develop CVA symptoms in 10-72 hours\n\n## References\n\n- Burlew CC, Biffl WL. Imaging for blunt carotid and vertebral artery injuries. Surg Clin N Amer. 2011, 91(1), 217-31 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21184911)]\n"
		},
		{
			"slug": "brugada",
			"title": "Brugada Syndrome",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/05/06",
			"updates": [
				"2017/05/10"
			],
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\n- Genetically linked, cardiac sodium channelopathy\n- High risk for sudden death in young, healthy adults because VTach/VFib \n- Mean age of sudden death = 41 ± 15 years\n- Higher prevalence in males and Asian descent\n- Atrial fibrillation associated in 10-20% cases\n\n## ECG findings\n\n- 3 types\n- Type 1 – Most specific for Brugada Syndrome\n- Highest risk for symptoms of syncope and sudden death\n\n![Examples of type 1, type 2, and type 3 Brugada ECG patterns](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/brugada/image-1.png)\n\n## Differential diagnosis\n\n|                                       |                                       |\n| ------------------------------------- | ------------------------------------- |\n| After electrical cardioversion        | Friedreich ataxia                     |\n| Arrhythmogenic RV dysplasia           | Early repolarization, esp in athletes |\n| Atypical right BBB                    | Hypothermia                           |\n| Acute MI, especiall RV infarct        | Pericardial effusion                  |\n| Acute myopericarditis                 | Pulmonary embolism                    |\n| Compression of RV outflow tract       | Left ventricular hypertrophy          |\n| Disorder of central/auton nerv system | Mediastinal tumor                     |\n| Dissecting aortic aneurysm            | Pectus excavatum                      |\n| Duchenne muscular dystrophy           |                                       |\n\n## Treatment\n\n### Indications for implantable cardiac defibrillator\n\n**Brugada Type 1 PLUS one of following:**\n\n- Aborted sudden cardiac death\n- Syncope, seizure, or noctural agonal respirations without alternative cause\n- Family history of sudden cardiac death (likely from Brugada) AND positive electrophysiology (EPS) study \n- A positive EPS study\n\nOtherwise, close followup with cardiologist.\n\n## References\n\n- Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.Circulation. 2005 Feb 8;111(5):659-70. Epub 2005 Jan 17. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15655131)]\n"
		},
		{
			"slug": "brugada-vs-svt",
			"title": "Brugada Criteria for SVT with Aberrancy vs VT",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/02/27",
			"updates": null,
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\nUse this sequential 4-question approach to determine if the ECG reveals SVT with aberrancy vs ventricular tachycardia\n\n**If you answer YES to any of these questions, it is ventricular tachycardia.**\n\n1. Is there an ABSENCE of RS complex in all precordial leads (V1-V6?)\n2. Is the R to S interval >100 msec (2.5 boxes) in one precordial lead?\n3. Is there atrioventricular (AV) dissociation?\n4. Is there morphology criteria for VT?\n\n## 1. Is there an ABSENCE of RS complex in all precordial leads (V1-V6?)\n\n- **YES:** VT diagnosis (Sensitivity 21%, Specificity 100%)\n- **NO:** Move to Question 2\n\n![Example of an RS complex](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/brugada-vs-svt/image-1.png)\n\n## 2. Is the R to S interval > 100 msec (2.5 boxes) in one precordial lead?\n\n- **YES:** VT diagnosis (Sensitivity 66%, Specificity 98%)\n- **NO:** Move to Question 3\n\n![Example of how to measure the R-S interval](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/brugada-vs-svt/image-2.png)\n\n## 3. Is there Atrioventricular (AV) dissociation?\n\n- **YES:** VT diagnosis (Sensitivity 82%, Specificity 98%)\n- **NO: **Move to Question 4\n\n![Example of AV dissociation](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/brugada-vs-svt/image-3.png)\n\n## 4. Is there morphology criteria for VT?\n\nDetermine if you have a LBBB morphology (dominant S wave in V1) or a RBBB morphology (dominant R wave in V1) then use the appropriate section below to help differentiate. Is there morphology criteria for VT?\n\n- **YES:** VT diagnosis (Sensitivity 98.7%, Specificity 96.5%)\n- **NO:** SVT with aberrance (Sensitivity 96.5%, Specificity 98.7%)\n\n![Examples of LBBB and RBBB morphologies](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/brugada-vs-svt/image-4.png)\n\n## Dr. Stephen Smith's Expert Review\n\nValidations of the Brugada method have not had very good results.\n\nHere is a [paper by Isenhour et al](https://www.ncbi.nlm.nih.gov/pubmed/10917326) that had, for Emergency Physician (EP) #1, a sensitivity of 83% (95% CI = 78% to 91%) and a specificity of 43% (95% CI = 25% to 59%), while EP #2 attained 79% (95% CI = 73% to 87%) and 70% (95% CI = 51% to 84%). \n\nVerekei has subsequently published 2 criteria which are much easier to apply and performed better than the Brugada criteria: \n\n1. [Heart Journal 2007](https://academic.oup.com/eurheartj/article/28/5/589/2887583/Application-of-a-new-algorithm-in-the-differential): Still a bit complex\n2. [Heart Rhythm 2008](https://www.ncbi.nlm.nih.gov/pubmed/18180024): Uses aVR only\n\nI have a [post on differentiating VT and SVT with aberrancy using the Sasaki rule](http://hqmeded-ecg.blogspot.com/2011/10/wide-complex-tachycardia-ventricular.html), which has not been validated either, but is even simpler than either Vereckei rule. I use it as a final step if I don’t have the diagnosis from 6 earlier steps. Of course, the diagnosis is not nearly as important as the management, which is easily accomplished by electrical cardioversion.\n\n## References\n\n- Brugada P et al. Circulation. 1991 May;83(5): 1649-59. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2022022)]\n"
		},
		{
			"slug": "burn-wounds",
			"title": "Burn Wounds",
			"authors": [
				"Michelle Lin, MD",
				"Christian Rose, MD"
			],
			"created": "2010/07/02",
			"updates": [
				"2016/04/22"
			],
			"categories": [
				"Trauma"
			],
			"body": "\n\n\n## American Burn Association Classification (2009)\n\n**Superficial**: EPIDERMIS depth only; painful\n\n**Partial-Thickness:** Involves dermis\n\n- **Superficial**\n  - EPIDERMIS + SHALLOW DERMIS\n  - Moist, blistering; skin blanches, very painful\n  - Heals within 3 weeks\n- **Deep**\n  - EPIDERMIS + DEEP DERMIS\n  - Looks between superficial partial-thickness and 3<sup>rd</sup> degree burn\n  - May need skin graft\n  - Heals in >3 weeks\n\n**Full-Thickness:** \n\n- EPIDERMIS + ENTIRE DERMIS\n- Dark brown, charred, skin does not blanch\n- Site insensate because burned nerve fibers\n- Needs skin graft\n\n![Epidermis, dermis, and subcutaneous layers of skin](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/burn-wounds/image-1.png)\n\n## Total body surface area (TBSA)\n\n- Rule of 9’s\n- Patient’s palm and fingers = 1% TBSA\n- In calculating TBSA % burn, do not include 1<sup>st</sup> degree burns\n\n![Body surface area chart for an adult and child](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/burn-wounds/image-2.png)\n\n## Burn unit referral\n\n- Partial thickness >10% TBSA\n- Burns of face, hands, feet, genitalia, perineum, major joints\n- Full thickness burn\n- Electrical or chemical burn\n- Inhalational injury\n- Patient with co-morbidities\n- Special considerations: Social, emotional, or long-term rehab intervention\n\n**Fluid resuscitation** = 4 cc/kg/% TBSA of Lactated Ringers over 24 hrs with half given in first 8 hrs\n\n- Titrate to urine output\n\n| Age           | Target urine output |\n| ------------- | ------------------- |\n| Adults        | 30-50 cc/hr         |\n| Age > 2 yr    | 0.5-1 cc/kg/hr      |\n| Age &lt; 2 yr | 1-2 cc/kg/hr        |\n\n- Start if &gt;20% TBSA involvement\n\n## Burn Management\n\n**Minor burns**\n\n- Tetanus update\n- Pain medications\n- Debride dead skin, +/- unroof blisters >2 cm diameter\n- Apply topical antimicrobial/dressing\n- 24 hr follow-up\n\n**Large burns**\n\n- Apply topical antimicrobial agent such as **bacitracin**, **neomycin**, **mupirocin**, or **honey**. Membrane-based dressings can be used alternatively.\n\n**Practice Change:** **Silver sulfadiazine** has fallen out favor for burn prophylaxis in partial-thickness burns. May slow wound healing, increases frequency of dressing changes, and more painful\n\n**What is high voltage injury?** &gt;1000 volts\n\n## References\n\n- Gomez R et. al. Management of burn wounds in the emergency department.Emerg Med Clin North Am. 2007 Feb;25(1):135-46. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gomez+Cancio+Emerg+Med+Clin+of+N+Am+2007)]\n- Int Wound J. 2010 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20649832)]\n- Cochrane Database Syst Rev 2015 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25742878)] \n"
		},
		{
			"slug": "c1-c2-fractures",
			"title": "C1 and C2 Spine Fractures",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/09/24",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## Atlanto-occipital dislocation\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | No     |\n\n- Often instantly fatal\n- More common in children because small horizontally-oriented occipital condyles\n- Dislocation can be anterior (most common), superiorly distracted, or posterior\n\n## Anterior atlantoaxial dislocation\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | No     |\n\n- Associated with transverse ligament rupture\n- Most commonly occurs in patients with rheumatoid arthritis and ankylosing spondylitis from ligament laxity\n- Widening of predental space seen on lateral plain film\n\n## Jefferson fracture = C1 burst fracture\n\n| Mechanism         | Stable |\n| ----------------- | ------ |\n| Axial Compression | No     |\n\n- 33% with associated C2 fracture\n- Low incidence of neurologic injury because of wide C1 spinal canal\n- Usually involves fractures of both the anterior and posterior C1 arches, often with 3 or 4 fracture fragments\n- Complication: transverse ligament rupture, especially if C1 lateral masses are &ge;7 mm wider than expected (MRI recommended)\n- Complication: vertebral artery injury (CT angiography recommended)\n\n## C1 posterior arch fracture\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Extension | Yes    |\n\n- An associated C2 fracture (occurs 50% of time) makes the posterior arch fracture unstable\n- On plain films, no displacement of lateral masses on the odontoid view and no prevertebral soft tissue swelling, unlike Jefferson burst fracture\n\n## C2 dens fracture\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | +/-    |\n\n- _Type I_ (stable): Avulsion of dens with intact transverse ligament\n- _Type II_ (unstable): Fracture at base of dens; 10% have an associated rupture of the transverse ligament-- MRI provides definitive diagnosis of ligament rupture\n- _Type III_ (stable): Fracture of dens extending into vertebral body\n\n## Hangman's fracture = C2 spondylolisthesis\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Extension | No     |\n\n- Bilateral C2 pedicle fractures\n- At risk for disruption of the posterior longitudinal ligament (PLL), C2 anterior subuxation, and C2-C3 disk rupture\n- Low risk for spinal cord injury because of C2 anterior subluxation, which widens spinal canal\n\n## Extension teardrop fracture\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Extension | No     |\n\n- Small triangular avulsion of anteroinferior vertebral body, at insertion point of anterior longitudinal ligament\n- Occurs most frequently at C2 level, but can occur in lower cervical spine\n- Complication: Central cord syndrome due to ligamentum flavum buckling during hyperextension\n- Requires CT differentiation from very unstable flexion teardrop fracture\n\n![C1-C2 fracture diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/c1-c2-fractures/image-1.png)\n\n(ALL = Anterior Longitudinal Ligament)\n\n## References\n\n- Lin M and Mahadevan S. \"Spine and Spinal Cord Injuries\" in Adams J et al (eds), Emergency Medicine. New York: Elsevier, 2007. [[Source](http://books.google.com/books/about/Emergency_Medicine.html?id=Q2Ag9OKC7awC)]\n"
		},
		{
			"slug": "c3-c7-fractures",
			"title": "C3-C7 Spine Fractures",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/10/01",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## Articular mass fractures\n\n| Mechanism        | Stable |\n| ---------------- | ------ |\n| Flexion-rotation | Yes    |\n\n- Associated with transverse process and vertebral body fractures\n- Uncommon\n\n## Burst fractures\n\n| Mechanism         | Stable |\n| ----------------- | ------ |\n| Axial compression | Yes/No |\n\n- Compressive fracture of the anterior and posterior vertebral body\n- _Complication_: Spinal cord injury because of retropulsed vertebral body fragment (especially anterior cord syndrome)\n\n## Spinous process fracture (“Clay Shoveler’s\" fracture)\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | Yes    |\n\n- Spinous process fracture from forceful neck flexion\n- Most commonly occurs in lower cervical levels (C7)\n- Not associated with neurologic injury\n\n## Extension teardrop fracture\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Extension | No     |\n\n- See Fracture, C1 and C2 spine topic\n- Most commonly occurs at C2\n\n## Facet dislocation, bilateral\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | No     |\n\n- Significant anterior displacement (>50%) of spine when bilateral inferior facets displace anterior to the superior facets below\n- At risk for injuring anterior and posterior longitudinal ligament, disk, vertebral arteries, and spinal cord\n\n## Flexion dislocation, unilateral\n\n| Mechanism        | Stable |\n| ---------------- | ------ |\n| Flexion-rotation | Yes    |\n\n- Usually causes 25-50% anterior displacement of spine\n- Complication: Vertebral artery injury (CT angiography recommended)\n\n## Flexion teardrop Fracture\n\n| Mechanism              | Stable |\n| ---------------------- | ------ |\n| Flexion and axial load | No     |\n\n- Fracture and anterior displacement of anteroinferior vertebral body (appears similar to extension teardrop fracture, except much more unstable)\n- Rupture of both anterior & posteior ligamentous complexes \n- Unique findings for flexion (versus extension) teardrop fx: Same-level fxs, displacement of posterior structures\n- Regarded as ONE OF THE MOST UNSTABLE FX's in the lower cervical spine, because involves both columns \n- Usually occurs at C5 or C6\n\n## Subluxation, anterior\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | No     |\n\n- Ruptured posterior ligamentous complex, such that anterior and posterior vertebral lines are disrupted\n- Complication: vertebral artery dissection (CT angiography recommended)\n- May only be evident during flexion views by conventional xray; the interspinous distance widens and the vertebral body subluxes anteriorly\n\n## Transverse Process Fracture\n\n| Mechanism       | Stable |\n| --------------- | ------ |\n| Lateral flexion | Yes    |\n\n- _Complication_: Vertebral artery injury, because travels within the transverse foramina (CT angio recommended)\n- _Complication_: Cervical radiculopathy and brachial plexus injuries associated in 10% of cases\n\n## Wedge Fracture\n\n| Mechanism | Stable |\n| --------- | ------ |\n| Flexion   | Yes    |\n\n- Compression fracture of only the anterosuperior vertebral body endplate\n- Disruption of anterior vertebral line\n\n| **Injury (Mechanism)**                          | **Stable** |\n| ----------------------------------------------- | ---------- |\n| Articular mass fx (Flexion-rotation)            | Yes        |\n| Burst fx (Axial compression)                    | Yes/No     |\n| Spinous process fx (Flexion)                    | Yes        |\n| Extension teardrop fx (Extension)               | No         |\n| Facet dislocation, bilateral (Flexion)          | No         |\n| Flex dislocation, unilateral (Flexion-rotation) | Yes        |\n| Flexion teardrop fx (Flexion and axial load)    | No         |\n| Subluxation, anterior (Flexion)                 | No         |\n| Transverse process fx (Lateral flexion)         | Yes        |\n| Wedge fx (Flexion)                              | Yes        |\n\n![C3-C7 fracture diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/c3-c7-fractures/image-1.png)\n\n## References\n\n- Lin M and Mahadevan S. “Spine and Spinal Cord Injuries” in Adams J et al (eds), Emergency Medicine Clinical Essentials. New York: Elsevier, 2007\n"
		},
		{
			"slug": "cancer-neutropenic-fever",
			"title": "Neutropenic Fever and Cancer",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/10/07",
			"updates": [
				"2017/05/10"
			],
			"categories": [
				"Hematology and Oncology"
			],
			"body": "\n\n\nChemotherapy causes neutropenia in 10-50% of patients with solid tumors and > 80% of patients with hematologic malignancies during chemotherapy cycle\n\n**Fever:** &ge; 38.3 C (101 F) or ≥ 38.0 C (100.4 F) over 1-hour period\n\n**Neutropenia:** Absolute neutrophil count &lt; 500 cells/mm3\n\n## MASCC score\n\n**Multinational Association for Supportive Care in Cancer (MASCC) Score**\n\n| Criteria                                                                                          |                         Points |\n| ------------------------------------------------------------------------------------------------- | -----------------------------: |\n| Burden of febrile neutropenia                                                                     | 5 (if mild) or 3 (if moderate) |\n| No hypotension (SBP ≥ 90 mmHg)                                                                    |                              5 |\n| No COPD                                                                                           |                              4 |\n| Solid tumor or hematologic malignancy <span class=\"drug\">with</span> no previous fungal infection |                              4 |\n| No dehydration requiring parenteral fluids                                                        |                              3 |\n| Outpatient status                                                                                 |                              3 |\n| Age &lt;60 years                                                                                  |                              2 |\n\n### High Risk Patients (require admission)\n\n- MASCC score &lt;21 **OR**\n- Any of clinical findings:\n  - Prolonged (>7 days duration) and profound neutropenia (ANC ≤100 cells/mm3)\n  - Hypotension\n  - Pneumonia\n  - New abdominal pain\n  - Neurologic changes\n\n### Low Risk Patients (may be eligible for outpatient tx)\n\n- MASCC score &ge;21\n- Brief (&le;7 days duration) neutropenic periods and few co-morbidities\n\n## Workup\n\n- CBC, BUN/creatinine, electrolytes, AST/ALT, bilirubin\n- Chest xray, if respiratory signs or symptoms\n- 2 blood cultures (1 central line lumen if present + 1 peripheral vein, or 2 peripheral veins)\n\n## Antibiotic Treatment\n\n### Monotherapy\n\n- Antipseudomonal beta-lactam (eg. <span class=\"drug\">cefipime</span>, <span class=\"drug\">carbapenem</span>, <span class=\"drug\">pip-tazo</span>)\n- <span class=\"drug\">Vancomycin</span> is not always indicated in cancer patients with a neutropenic fever.\n- Add **vancomycin** only if suspect catheter-related infection, skin/soft tissue infection, pneumonia, hemodynamic instability, colonization with MRSA/VRE/PCN-resistant _Strep pneumoniae_\n- _For penicillin allergy_: <span class=\"drug\">Ciprofloxacin</span> + <span class=\"drug\">clindamycin</span>, or <span class=\"drug\">aztremonam</span> + <span class=\"drug\">vancomycin</span>\n- _Oral medication options for outpatient_: <span class=\"drug\">Ciprofloxacin</span> + <span class=\"drug\">amoxicillin-clavulanate</span>\n\n## Central line-associated blood stream infection (CLABSI)\n\n**Remove catheter:** Consider removal if any of following: \n\n- Caused by _S. aureus_, _P. aeruginosa_, fungi, mycobacteria\n- Tunnel infection\n- Pocket site infection\n- Septic thrombosis\n- Endocarditis\n- Sepsis with hemodynamic instability\n- Bacteremia despite ≥72 hours of antibiotics\n\n**Keep catheter** and treat with antiobitics: If coagulase-negative staph\n\n## References\n\n- Fairefield AG et. al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. 2010 update by the IDSA. Clinical Infectious Disease 2011; 52 (4): e56-93. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21205990)]\n"
		},
		{
			"slug": "cardiac-tamponade",
			"title": "Cardiac Tamponade",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/07/08",
			"updates": null,
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\n**Definition:** Clinical state where pericardial fluid compresses the heart and compromises cardiac output.\n\nNormal pericardial fluid volume: 15-30 mL\n\n## Echocardiography findings\n\n- RA systolic collapse\n- RV diastolic collapse\n- IVC plethora\n- Exaggeration of respirophasic changes in flow velocities across TV and MV\n\n## Systematic review of 8 studies with a total of 300 patients\n\n| Finding                   | Sensitivity | Specificity | (+) Likelihood Ratio | (-) Likelihood Ratio |\n| ------------------------- | ----------: | ----------: | -------------------: | -------------------: |\n| **Clinical history**      |             |             |                      |                      |\n| - Dyspnea                 |      87-88% |             |                      |                      |\n| **Physical exam**         |             |             |                      |                      |\n| - Tachycardia             |         77% |             |                      |                      |\n| - Hypotension             |         26% |             |                      |                      |\n| - Diminished heart sounds |         28% |             |                      |                      |\n| - Elevated JVP            |         76% |             |                      |                      |\n| **ECG**                   |             |             |                      |                      |\n| - Low voltage             |         42% |             |                      |                      |\n| - Electrical alternans    |      16-21% |             |                      |                      |\n| - ST elevation            |      18-30% |             |                      |                      |\n| - PR depression           |         18% |             |                      |                      |\n| **Chest xray**            |             |             |                      |                      |\n| - Cardiomegaly            |         89% |             |                      |                      |\n| **Pulsus paradoxus**      |             |             |                      |                      |\n| - >12 mmHg                |         98% |         83% |                  5.9 |                 0.03 |\n| - >10 mmHg                |         98% |         70% |                  3.3 |                 0.03 |\n\nUse below Fagan nomogram\n\n## Fagan Nomogram\n\n![Fagan Nonogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/cardiac-tamponade/image-1.png)\n\n- Draw a connecting your pre-test probability and your likelihood ratio. \n- This provides you with your post-test probability.\n\n## References\n\n- Roy CL et al. Does This Patient With a Pericardial Effusion Have Cardiac Tamponade? JAMA. 2007;297:1810-8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=17456823)]\n"
		},
		{
			"slug": "cdiff",
			"title": "Clostridium Difficile Infection",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/06/24",
			"updates": null,
			"categories": [
				"Infectious Disease"
			],
			"body": "\n\n\n## Treatment\n\n| Clinical Category                   | Presentation                                 | Treatment                                                                                                                                             |\n| ----------------------------------- | -------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1st episode, mild-moderate severity |                                              | <span class=\"drug\">Metronidazole</span> 500 mg PO TID x 10-14 days                                                                                    |\n| 1st episode, severe                 | Serum WBC ≥15k or creatinine > 1.5x baseline | <span class=\"drug\">Vancomycin</span> 125 mg PO QID x 10-14 days                                                                                       |\n| 1st episode, severe,complicated     | Hypotension, shock ileus, or megacolon       | <span class=\"drug\">Vancomycin</span> 500 mg QID PO/NG (PR if ileus) PLUS <span class=\"drug\">Metronidazole</span> 500 mg IV q8h</span>                 |\n| First recurrence                    |                                              | Same as for 1st episode (because minimal resistance)                                                                                                  |\n| Second and more recurrences         |                                              | <span class=\"drug\">Vancomycin</span> PO in tapered or pulsed regimen. Avoid <span class=\"drug\">metronidazole</span> overuse because of neurotoxicity. |\n\n## Background\n\n### Definition of _Clostridium difficile_ infection (CDI)\n\n- Presence of diarrhea (3 unformed stools in ≤24 hours)\n- Stool test positive for _C. difficile_ or its toxins, or colonoscopic findings of pseudomembranous colitis\n\n### Epidemiology\n\n- Accounts for 20-30% of all antibiotic-associated diarrhea\n- Most common cause of infectious diarrhea in healthcare settings\n\n### Transmission\n\n- Fecal-oral route\n- Median time from exposure to C. difficile to diarrhea symptoms = 2-3 days\n\n### Risk factors to develop CDI\n\n- Age &ge; 65 years\n- Duration of hospitalization\n- Exposure to antibiotics (almost every Abx has been assoc with CDI – not just <span class=\"drug\">clindamycin</span>)\n  - 96% have received abx within 14 days before diarrhea onset \n- Cancer chemotherapy\n- HIV\n- GI surgery or manipulation of GI tract (i.e. tube feeding)\n\n### Clinical presentation\n\n- Diarrhea may have mucous or occult blood\n\n### Recurrence rates\n\n- 20% (typically within 4 weeks), despite <span class=\"drug\">metronidazole</span> or <span class=\"drug\">vancomycin</span> treatment ([Kelly et al., NEJM, 2008](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494))\n\n## Complications\n\n- Bowel perforation\n- Dehydration\n- Electrolyte imbalance \n- Hypoalbuminemia\n- Hypotension\n- Renal failure\n- SIRS, sepsis\n- Toxic megacolon\n- Death\n\n## References\n\n- Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010; 31(5):431-55. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20307191)]\n- Kelly CP, LaMont JT.Clostridium difficile--more difficult than ever.N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18971494)]\n"
		},
		{
			"slug": "chemical-sedation",
			"title": "Chemical Sedation - Haldoperidol vs. Lorazepam vs. Midazolam",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/03/25",
			"updates": null,
			"categories": [
				"Pharmacology"
			],
			"body": "\n\n\n## Question\n\nWhat single agent best manages violent, agitated patients in the ED, as measured by shortest time to sedation and shortest time to arousal?\n\n## Methodology\n\n- Prospective, randomized, double-blinded study of 111 violent and agitated patients\n- <span class=\"drug\">Haloperidol<span> (5 mg IM), <span class=\"drug\">Lorazepam</span> (2 mg IM), or <span class=\"drug\">Midazolam</span> (5 mg IM)\n- <span class=\"drug\">Midazolam</span> is a water-soluble benzodiazepine – excellent IM absorption profile\n- Patients were agitated because of recreational drug use, alcohol use, and prior psychiatric history and divided equally in each of the 3 arms of treatment.\n\n## Results\n\n|                        | Haloperidol (n=42) | Lorazepam (n=27) | Midazolam (n=42) |\n| ---------------------- | :----------------: | :--------------: | :--------------: |\n| Time to sedation (min) |      28.3 ± 25     |     32.3 ± 20    |     18.3 ± 14    |\n| Time to arousal (min)  |     126.5 ± 85     |    217.2 ± 107   |     81.9 ± 66    |\n\nThere were **no significant differences in vital signs** between groups.\n\nLorazepam was stopped after the first 95 patients at interim analysis because of prolonged sedation times.\n\nPatients required “rescue drugs”, which were additional sedation medications at the discretion of attending physician: \n\n- 8 <span class=\"drug\">haloperidol</span> patients (19%)\n- 7 <span class=\"drug\">lorazepam</span> patients (26%) \n- 7 <span class=\"drug\">midazolam</span> patients (17%)\n\n**Complications:** 2 patients who received haloperidol\n\n- 1 had hypotension\n- 1 had transient apnea\n\n## Other IM medication options\n\n- _HAC:_ <span class=\"drug\">Haloperidol</span> 5 mg, <span class=\"drug\">Ativan (lorazepam)</span> 2 mg, <span class=\"drug\">Cogentin</span> 1 mg IM all in 1 syringe\n- _B52:_ <span class=\"drug\">Haloperidol</span> 5 mg, <span class=\"drug\">Lorazepam</span> 2 mg, <span class=\"drug\">Benedryl (diphenhydramine)</span> 50 mg IM\n\n## BOTTOM LINE\n\n- Use **<span class=\"drug\">midazolam</span> 5 mg IM** to chemically sedation a severely agitated patients because of its **shorter time to sedation** (18 min) and **arousal** (82 min).\n\n## References\n\n- Nobay F et al. A Prospective, Double-blind, Randomized Trial of Midazolam versus Haloperidol versus Lorazepam in the Chemical Restraint of Violent and Severely Agitated Patients . Acad Emerg Med. 2004; 11:747-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15231461)]\n"
		},
		{
			"slug": "chest-pain-history",
			"title": "Chest Pain History",
			"authors": [
				"Salim Rezaie, MD"
			],
			"created": "2013/03/28",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"EBM"
			],
			"body": "\n\n\n## Take Home Points\n\n**Clinical factors that INCREASE likelihood of ACS/AMI:**\n\n1. CP radiating bilaterally > right > left\n2. Diaphoresis associated with CP\n3. N/V associated with CP\n4. Pain with exertion\n\n**Clinical factors that DECREASE likelihood of ACS/AMI:**\nChest pain that is:\n\n1. Pleuritic\n2. Positional\n3. Sharp, stabbing\n4. Reproducible with palpation\n\n## Severity of pain is not related to likelihood of AMI at presentation, or composite end points (death, revascularization, or AMI) at 30 days\n\n[Edwards et al., 2011]((http://www.ncbi.nlm.nih.gov/pubmed/21802776))\n\n**Objective:** \n\n- Determine any correlation between severity of CP and the risk of AMI at presentation, or composite end points (death, revascularization, or acute myocardial infarction) at 30 days\n- Severe CP was defined as 9–10 on a 10-point pain scale. \n\n**Results:** (n=3,306)\n\n- Risk of AMI with Pain Score of 1–8 (82% of patients) = 3.0%\n- Risk of AMI with Pain Score of 9–10 (18% of patients) = 3.9%\n- Not statistically significant different\n\n## Many “atypical” symptoms are more likely to render the diagnosis of ACS than traditional “typical” symptoms \n\n[Body et al., 2010](http://www.ncbi.nlm.nih.gov/pubmed/20036454)\n\n**Objective:** \n\n- Assess the value of individual symptoms for predicting a diagnosis of AMI or the occurrence of adverse events (death, AMI, revascularization via PCI or CABG) within 6 months\n\n**Results:** (n=796)\n\n- Strongest positive predictor of AMI: \n- Diaphoresis with CP\n- Other positive predictors of AMI and adverse events\n- Nausea and vomiting with CP\n- CP with radiation to both shoulders > right shoulder > left shoulder\n- Central chest pain\n- Strongest negative predictor of AMI\n- Pain located in the left anterior chest\n- Other negative predictors of AMI and adverse events\n- CP described as pain being the same as previous AMI\n- Presence of CP at rest\n\n## No characteristics of CP alone, or in combination, identify a group of patients that can be safely discharge home without further diagnostic testing\n\n[Swap et al., 2006](%20http://www.ncbi.nlm.nih.gov/pubmed/16304077)\n\n**Objective:** In a literature review (1970-2005), identify the elements of a CP history that might be most helpful to the clinician in identifying ACS.\n\n**CP characteristics that INCREASE likelihood of ACS/MI:**\n\n| Characteristic                   | # of Patients  |  LR |\n| -------------------------------- | -------------: | --: |\n| Radiating to both shoulders/arms |            893 | 4.1 |\n| Radiating to right shoulder      |            770 | 4.7 |\n| Pain precipitated with exertion  |            893 | 2.4 |\n| Pain associated with diaphoresis |          8,426 | 2.0 |\n\n**CP characteristics that DECREASE likelihood of ACS/MI:**\n\n|  Characteristic                | # of Patients   | LR  |\n| ------------------------------ | --------------: | --: |\n| Pain that is sharp/stabbing    |           1,088 | 0.3 |\n| Pleuritic pain                 |           8,822 | 0.2 |\n| Positional pain                |           8,330 | 0.3 |\n| Pain reproducible by palpation |           8,822 | 0.3 |\n\n**NOTE:** Beware the chest pain which radiates to the RIGHT shoulder (LR = 4.7).\n\n## Clinical features have a limited role in triage decision-making for ACS/AMI\n\n[Goodacre et al., 2002](http://www.ncbi.nlm.nih.gov/pubmed/11874776)\n\n**Study Design:** Prospective, observation cohort study \n\n**Objective:** Assess the performance of clinical features used in the diagnosis of CP, specifically in patients who were clinically stable and had a non-diagnostic ECG.\n\n**Results:** (n=893)\n\n-  Predictive of ACS/AMI:\n  - Exertional pain\n  - Pain radiating to both arms > right arm\n-  NOT predictive of ACS/AMI: \n  - Presence of chest wall tenderness\n  - Nausea or vomiting\n  - Diaphoresis\n\n## History alone can help, but can NOT rule out ACS/AMI! \n\n[Panju et al., 1998](http://www.ncbi.nlm.nih.gov/pubmed/9786377)\n\n**Objective:** To identify clinical features that would increase or decrease the probability of an AMI, presenting with acute CP through a literature review (1980-1991).\n\n**Features that INCREASE the probability of an AMI**\n\n|  Clinical Feature                          | LR  |\n| ------------------------------------------ | --: |\n| Chest pain that radiates to both arms      | 7.1 |\n| Chest pain that radiates to right shoulder | 2.9 |\n\n**Features that DECREASE the probability of an AMI**\n\n|  Clinical Feature                    |  LR |\n| ------------------------------------ | --: |\n| Pleuritic chest pain                 | 0.2 |\n| Chest pain that is sharp or stabbing | 0.3 |\n| Positional chest pain                | 0.3 |\n| Chest pain reproduced by palpation   | 0.3 |\n\n## References\n\n- M. Edwards, A.M. Chang, A.C. Matsuura, M. Green, J.M. Robey, and J.E. Hollander, \"Relationship between pain severity and outcomes in patients presenting with potential acute coronary syndromes.\", Annals of emergency medicine, 2011. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21802776)]\n- R. Body, S. Carley, C. Wibberley, G. McDowell, J. Ferguson, and K. Mackway-Jones, \"The value of symptoms and signs in the emergent diagnosis of acute coronary syndromes.\", Resuscitation, 2009 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20036454)]\n- C.J. Swap, and J.T. Nagurney, \"Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes.\", JAMA : the journal of the American Medical Association, 2005.(%20http://www.ncbi.nlm.nih.gov/pubmed/16304077)\n- S. Goodacre, T. Locker, F. Morris, and S. Campbell, \"How useful are clinical features in the diagnosis of acute, undifferentiated chest pain?\", Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2002. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11874776)]\n- A.A. Panju, B.R. Hemmelgarn, G.H. Guyatt, and D.L. Simel, \"The rational clinical examination. Is this patient having a myocardial infarction?\", JAMA : the journal of the American Medical Association, 1998. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9786377)]\n- S.R. Pitts, R.W. Niska, J. Xu, and C.W. Burt, \"National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary.\", National health statistics reports, 2008. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18958996)]\n- C.V. Pollack, F.D. Sites, F.S. Shofer, K.L. Sease, and J.E. Hollander, \"Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population.\", Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2005. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16365321)]\n"
		},
		{
			"slug": "cholecystitis-diagnosis",
			"title": "Cholecystitis Diagnostic Test",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/03/18",
			"updates": null,
			"categories": [
				"Gastroenterology",
				"EBM"
			],
			"body": "\n\n\n**JAMA Clinical Rational Examination Series:**\nMeta-analysis of 17 studies which evaluated role of history, physical, and lab tests in working up cholecystitis\n\n## History and Physical Exam\n\n| **Finding**          | **(+) LR** | **(-) LR** |\n| -------------------- | ---------: | ---------: |\n| Anorexia             |    1.1-1.7 |    0.5-0.9 |\n| Emesis               |    1.1-2.1 |    0.3-0.9 |\n| Fever (&gt;35C)      |    1.0-2.3 |    0.8-1.0 |\n| Guarding             |    1.1-2.8 |    0.5-1.0 |\n| Murphy sign          |    0.8-8.6 |    0.2-1.0 |\n| Nausea               |    1.0-1.2 |    0.6-1.0 |\n| Rebound              |    0.6-1.7 |    0.8-1.4 |\n| Rectal tenderness    |    0.5-2.3 |    1.0-1.3 |\n| Rigidity             |    0.3-0.7 |    1.0-1.2 |\n| RUQ mass             |    0.5-1.2 |    0.9-1.1 |\n| RUQ pain             |    0.9-2.5 |    0.3-1.6 |\n| RUQ tenderness       |    1.0-2.5 |    0.2-1.1 |\n\n## Laboratory tests\n\n| **Finding**                                   | **(+) LR** | **(-) LR** |\n| --------------------------------------------- | ---------: | ---------: |\n| Alkaline phosphatase (AP) &gt;120 U/L         |    0.4-1.6 |    0.6-2.0 |\n| ALT &gt;40 U/L or AST &gt;48 U/L              |    0.5-2.0 |    0.8-1.4 |\n| Total bilirubin &gt;2 mg/dL                   |    0.7-2.3 |    0.7-1.2 |\n| All 3 elevated: Total bili, AST, AP           |    1.0-2.8 |    0.8-0.9 |\n| Any 1 elevated: Total bili, AST, AP           |    1.0-1.5 |    0.6-0.9 |\n| WBC &gt;10K                                   |    1.2-1.9 |    0.5-1.8 |\n| WBC &gt;10K and fever (&gt;35&deg;C)          |    0.9-2.8 |    0.8-1.0 |\n| WBC &le;10K and no fever (&le;35&deg;C)       |    0.4-0.7 |    1.4-1.8 |\n\nUse the Fagan nomogram\n\n**Note:**\n\n- All likelihood ratios (LR) cross or almost cross 1.0.\n- This is no history, physical exam, or lab test that would comfortably allow you to rule- out or rule-in cholecystitis.\n- Murphy’s sign is perhaps the most useful sign because the +LR has been shown to be as high as 8.6.\n\n## Bottom line\n\nHave a **low threshold** to perform a RUQ abdominal bedside ultrasonography for patients with upper abdominal pain or a fever from an unclear source (especially elder patients). Look for **indirect signs** of cholecystitis:\n\n- Murphy sign\n- Distended gallbladder\n- Pericholecystic fluid\n- Thickened gallbladder wall \n- Gallstones\n\n## Fagan nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/cholecystitis-diagnosis/image-1.png)\n\nDraw a connecting your pre-test probability and your likelihood ratio. This provides you with your post-test probability.\n\n## References\n\n- Trowbridge RL et al. Does this patient have acute cholecystitis? JAMA. 2003, 289(1): 80-6. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12503981)]\n"
		},
		{
			"slug": "condyle-fracture-lateral",
			"title": "Elbow Injuries  Epicondyle Fracture (Lateral)",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Milch 1 vs Milch 2 fractures](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/condyle-fracture-lateral/image-1.png)\n\n## Xray Views\n\nElbow XR: AP, lateral, internal oblique\n\n## Acute Management\n\n- Long-arm posterior splint with elbow at 90&deg; flexion and forearm supination\n- Consider a long arm cast instead\n\n## Operative Indications\n\n- \\\\&gt;2 mm displacement\n- Any joint incongruity\n- Fracture non-union\n\n## Follow-up Timing\n\n- Non-operative: Follow up in 5-7 days\n- Operative: Follow up in 2-3 days\n\n## Notes\n\nMilch Classification\n\n- Type I: Fx line is lateral to trochlear grove\n- Type II: Fx line into trochlear groove\n\nComplications: Ulnar nerve injury and avascular necrosis\n\n- Usually in children 5-10 years old\n- Majority will require operative stabilization\n\n## References\n\n- Wheeless&rsquo; Textbook of Orthopaedics.  \\[[Source](http://Wheelessonline.com)]\n- Orthobullets  \\[[Source](http://OrthoBullets.com)]\n- Radiopaedia  \\[[Source](http://Radiopaedia.org)]\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children&rsquo;s Hospital, Dept of Orthopedics\n"
		},
		{
			"slug": "croup",
			"title": "Croup",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/08/20",
			"updates": null,
			"categories": [
				"Pediatrics",
				"ENT"
			],
			"body": "\n\n\n- Laryngotracheobronchitis\n- Viral inflammatory condition of the subglottic airway\n- **Typical age:** 6 months-5 years\n- **Cause:** Parainfluenza in 80% cases\n- **Presentation:** hoarse voice, “barky” cough, low-grade fever, stridor, resp distress \n- **Differential diagnosis:** epiglottitis (which does not usually have URI sx and usually more toxic)\n- [Video of child with croup](https://www.youtube.com/watch?v=0lepci-YheI)\n\n## Westley croup scoring system\n\n(Scoring systems not extensively evaluated)\n\n| Finding                             | Points |\n| ----------------------------------- | -----: |\n| **STRIDOR**                         |        |\n| • None                              |      0 |\n| • Only with agitation or excitement |      1 |\n| • At rest with stethoscope          |      2 |\n| • At rest without stethoscope       |      3 |\n| **RETRACTION**                      |        |\n| • None                              |      0 |\n| • Mild                              |      1 |\n| • Moderate                          |      2 |\n| • Severe                            |      3 |\n| **AIR ENTRY**                       |        |\n| • Normal                            |      0 |\n| • Decreased                         |      1 |\n| • Severely decreased                |      2 |\n| **CYANOSIS**                        |        |\n| • None                              |      0 |\n| • With agitation                    |      4 |\n| • At rest                           |      5 |\n| **LEVEL OF CONSCIOUSNESS**          |        |\n| • Normal                            |      0 |\n| • Altered mental status             |      5 |\n\n**Severity:**\n\n- Mild (0-2)\n- Moderate (3-6)\n- Severe (>6)\n\n**Pearl:**\nCheck for cutaneous hemangiomas, because may be subglottic hemangioma (esp in age &lt;6 mo)\n\n**CXR (AP view)**: \n\n- Not helpful to look for “steeple” sign. \n- Poor specificity and sensitivity\n\n## Treatment \n\n1. Keep child calm.\n2. Give supplemental oxygen\n3. <span class=\"drug\">**Racemic epinephrine:**</span> Reduces airway edema. Use for moderate-severe respiratory distress. Observe 3-4 hours for rebound symptoms. Dose: 0.5 mL/kg (onset &lt;30 minutes, duration 2 hours)\n4. <span class=\"drug\">**Dexamethasone:**</span> Reduces severity and duration of croup, even in mild cases ([Bjornson et al., NEJM, 2004](https://www.ncbi.nlm.nih.gov/pubmed/?term=15385657))\n\n- Dose 0.6 mg/kg po\n\n## NO longer part of treatment\n\n1. **Cool mist:** NO added benefit in moderate-severe croup ([Scholnik, JAMA 2006](https://www.ncbi.nlm.nih.gov/pubmed/?term=16537737))\n2. **Humidified air:** NO added benefit ([Moore et al., Cochrane, 2006](https://www.ncbi.nlm.nih.gov/pubmed/?term=16855994))\n\n## References\n\n- Sobol SE, Zapata S. Epiglottitis and Croup. Otolaryn Clin N Am. 2008, 41:551-66 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18435998)]\n- Scolnik D, Coates AL, Stephens D, Da Silva Z, Lavine E, Schuh S.Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. JAMA. 2006 Mar 15;295(11):1274-80. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16537737)]\n- Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002870. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16855994)]\n- Everard ML. Acute Bronchiolitis and Croup. Pediatr Clin N Am. 2009, 56:1 19-33 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19135584)]\n- Bjornson CL, Klassen TP, Williamson J, Brant R, Mitton C, Plint A, Bulloch B, Evered L, Johnson DW; Pediatric Emergency Research Canada Network.A randomized trial of a single dose of oral dexamethasone for mild croup.N Engl J Med. 2004 Sep 23;351(13):1306-13. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15385657)]\n"
		},
		{
			"slug": "cspine-distracting-injuries",
			"title": "Cervical Spine Distracting Injuries",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/09/11",
			"updates": null,
			"categories": [
				"Trauma",
				"Orthopedics"
			],
			"body": "\n\n\n## The **NEXUS definition of \"distracting injury\"** is vague  \n\n([Hoffman et al., NEJM, 2000)](https://www.ncbi.nlm.nih.gov/pubmed/?term=10891516)\n\nDefined as “a condition thought by the clinician to be producing pain sufficient to distract the patients from a second (neck) injury. Examples may include, but are not limited to the following:\n\n- A long bone fracture\n- A visceral injury requiring surgical consultation\n- A large laceration, degloving injury, or crush injury\n- Large burns\n- Any other injury producing acute functional impairment\n\nPhysicians may also classify any injury as distracting if it is thought to have the potential to impair the patient’s ability to appreciate other injuries\"\n\nDistracting injury alone accounted for 30% of all radiographic studies ordered for the 818 NEXUS patients\n\n## Injuries to the upper torso may be considered distracting injuries \n\n([Heffernan et al., J Trauma, 2005](https://www.ncbi.nlm.nih.gov/pubmed/?term=16394912))\n\n**Study design:**\n\n- Prospective study of blunt trauma patients\n- Exclusion criteria: patient age &lt;18 years, prolonged ICU care, non-English speaking \n\n**Results:** (n=40 patients with cervical spine injury out of 406 patients)\n\n-  7 of 40 patients (18%) had no neck pain or tenderness\n-  All 7 patients had upper torso injuries.\n\n## Severe pain or injuries in the chest may be considered distracting injuries\n\n([Konstantinidis et al, J Trauma, 2011](https://www.ncbi.nlm.nih.gov/pubmed/?term=21248650)) \n\n**Study design:**\n\n- Prospective study of blunt trauma patients\n- Exclusion criteria: GCS &lt;13, intoxication, patient age &le;16 years\n\n**Results:**  (n =101 patients with a cervical spine injury out of 9,103 blunt trauma patients)\n\n- 4 of 101 (4%) patients had no neck pain or tenderness\n- All 4 patients had rib fractures or severe chest tenderness.\n\n## References\n\n- Konstantinidis A, Plurad D, Barmparas G, Inaba K, Lam L, Bukur M, Branco BC, Demetriades D.The presence of nonthoracic distracting injuries does not affect the initial clinical examination of the cervical spine in evaluable blunt trauma patients: a prospective observational study.J Trauma. 2011 Sep;71(3):528-32. doi: 10.1097/TA.0b013e3181f8a8e0. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21248650)]\n- Hoffman JR, Mower WR, Wolfson AB, Todd KH, Zucker MI. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group.N Engl J Med. 2000 Jul 13;343(2):94-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=10891516)]\n- Heffernan DS, Schermer CR, Lu SW. What defines a distracting injury in cervical spine assessment? J Trauma. 2005 Dec;59(6):1396-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16394912)]\n"
		},
		{
			"slug": "cspine-rules",
			"title": "Cervical Spine Rules",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/12/10",
			"updates": null,
			"categories": [
				"Trauma",
				"Orthopedics"
			],
			"body": "\n\n\nThe National Emergency X-radiography Utilization Study (NEXUS) and Canadian C-spine Rules (CCR) are both validated studies which both quote a high sensitivity (over 99%) in detecting clinically significant cervical spine fractures. Both studies primarily used plain films in evaluating their patients.\n\n| Study                      | Sensitivity | Specificity |\n| -------------------------- | :---------: | :---------: |\n| **NEXUS**                  |    99.6%    |    12.6%    |\n| **Canadian C-spine Rules** |    99.4%    |    45.1%    |\n\n## NEXUS study \n\nA patient's neck can be clinically cleared safely without radiographic imaging if all five low-risk conditions are met:\n\n1. No posterior midline neck pain or tenderness \n2. No focal neurologic deficit\n3. Normal level of alertness\n4. No evidence of intoxication\n5. No clinically apparent, painful distracting injury\n\n## Canadian C-spine Rules (CCR)\n\nThe basic approach in the flowchart: \n\n1. Make sure that the patient meets the eligibility requirements as in the CCR study. \n2. Determine if there are high-risk findings. If so, go directly to imaging.\n3. If there are no high-risk findings, check to see if the patient qualifies as a low-risk candidate where you might be able to clinically clear the c-spine without imaging.\n4. If the patient is neither high or low risk, then the patient is moderate risk and requires imaging.\n\n![Canadian C-spine Rule flowchart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/cspine-rules/image-2.png)\n\n## References\n\n- Stiell IG et al. The Canadian C-spine rule for radiography in alert and stable trauma patients. JAMA. 2001 Oct 17;286(15):1841-8. [[Source](http://jama.jamanetwork.com/data/Journals/JAMA/4804/JOC10637.pdf)]\n- Hoffman JR, et al.Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. NEJM 2000; 343: 94-9; [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10891516)]\n- Stiell IG et al. The Canadian C-Spine Rule versus the NEXUS Low-Risk Criteria in Patients with Trauma. N Engl J Med 2003;349:2510-8 [[Source](http://www.nejm.org/doi/pdf/10.1056/NEJMoa031375)]\n"
		},
		{
			"slug": "ct-cancer-risk",
			"title": "Cancer Risk from CT",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/06/10",
			"updates": null,
			"categories": [
				"Radiology"
			],
			"body": "\n\n\nThe lifetime attributable risk of 1 cancer from CT by age, gender, scanned area is:\n\n![CT-cancer risk chart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ct-cancer-risk/image-1.png)\n\n## References\n\n- Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, Berrington de González A, Miglioretti DL. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009 Dec 14;169(22):2078-86. doi: 10.1001/archinternmed.2009.427. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20008690)]\n- Pearce MS et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012 Aug 4;380(9840):499-505. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=22681860)]\n"
		},
		{
			"slug": "cystitis-pyelonephritis-women",
			"title": "Cystitis and Pyelonephritis in Women",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/09/02",
			"updates": null,
			"categories": [
				"Infectious Disease",
				"Genitourinary"
			],
			"body": "\n\n\n_2010 Infectious Disease Society of America (IDSA) and European Society for Microbiology and Infectious Diseases (ESMID) guidelines_\n\n**Target population**\n\n- Acute, uncomplicated cystitis and pyelonephritis in women \n- Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)\n\n## Acute uncomplicated cystitis\n\n1. <span class=\"drug\">Nitrofurantoin</span> (100 mg PO BID x 5 days)\n2. **<span class=\"drug\">Trimethoprim</span>-sulfamethoxazole** (1 DS tab PO BID x 3 days)\n   - Rising resistance rates\n   - Only give if local antibiogram shows &lt;20% resistance\n3. <span class=\"drug\">Fosfomycin</span>(3 gm PO x 1) \n   - Slightly less efficiacy compared to standard short-course regimens \n4. <span class=\"drug\">Pivmecillinam</span> (400 mg PO BID x 3-7 days) \n   - Only available in Europe\n5. **Fluoroquinolones** (3-day course of <span class=\"drug\">ofloxacin</span>, <span class=\"drug\">ciprofloxacin</span>, or <span class=\"drug\">levofloxacin</span>) \n   - Avoid if possible to minimize selection of drug-resistant organisms\n\n**Beta-lactams** (3-7 day course of <span class=\"drug\">amoxicillin-clavulanate</span>, <span class=\"drug\">cefdinir</span>, <span class=\"drug\">cefaclor</span>, <span class=\"drug\">cefpodoxime-proxetil)</span>\n\n- Avoid if possible to minimize selection of drug-resistant organisms\n- Inferior efficacy compared with standard regimens\n- <span class=\"drug\">Cephalexin</span> less well studied\n\n## Acute Pyelonephritis\n\nUrine analysis and urine culture should always be performed \n\n<span class=\"drug\">Ciprofloxacin</span> (500 mg po BID x 7 days) +/- <span class=\"drug\">ciprofloxacin</span> 400 mg IV x 1 dose\nIf **>10% resistance to fluoroquinolones**, give 1-time IV dose:\n\n- <span class=\"drug\">Ceftriaxone</span> 1 gm IV, or \n- An aminoglycoside \n\nIf **&lt;10% resistance rate,** alternative oral fluoroquinolone outpatient dosing options:\n\n- <span class=\"drug\">Ciprofloxacin</span> XR 1000 mg po daily x 7 days, or\n- <span class=\"drug\">Levofloxacin</span> 750 mg po daily x 5 days \n\n<span class=\"drug\">Trimethoprim-sulfamethoxazole</span> (1 tab DS PO BID x 14 days)\n1\\.  If resistance rate unknown, give 1-time dose of <span class=\"drug\">ceftriaxone</span> 1 gm IV or aminoglycoside first\n\n**Beta-lactams** (10-14 day course)\n1\\.  Because of less efficacy, give 1-time dose of <span class=\"drug\">ceftriaxone</span> 1 gm IV or aminoglycoside first \n\n## References\n\n- Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5). [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10589881)]\n"
		},
		{
			"slug": "delayed-sequence-intubation",
			"title": "Delayed Sequence Intubation",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/08/31",
			"updates": [
				"2017/03/02"
			],
			"categories": [
				"Critical Care",
				"Procedures"
			],
			"body": "\n\n\n**General Concepts**\n\n- DSI is procedural sedation/dissociation where the procedure is preoxygenation\n- Breaks up the sequence of RSI to preoxygenate prior to paralysis—prolongs safe apnea duration and decreases risk of gastric insufflation or aspiration\n- Maintains patient’s spontaneous respirations and reflexes\n\n## Candidates for DSI\n\n- Agitated due to EtOH, head injury, or psychosis, but with normal lungs\n- Agitated, but with lungs capable of being oxygenated on non-rebreather (NRB) mask: hypoxic due to COPD, pneumonia, ARDS\n- Agitated, but require non-invasive positive pressure ventilation (NIPPV) to preoxygenate\n- Unobtainable or unacceptable vital signs due to any of the above\n- Need to perform a procedure that the patient is not tolerating prior to intubation (e.g. NGT placement prior to intubation of GI bleeder)\n\n## Ketamine\n\n- **Dose:** 1 mg/kg IV push (may need to re-dose 0.5 mg/kg to maintain dissociation)\n- **Pros:** 30 sec onset, achieves dissociative state, maintains spontaneous respirations and airway reflexes, maintains hemodynamic stability\n- **Cons**: May increase intracranial pressure in patients with high MAP, may cause laryngospasm, use with caution in patients with CAD, HTN, or tachycardia\n\n## Equipment and Troubleshooting\n\n- Respiratory therapist\n- Nasal cannula (NC)\n- Non-rebreather (NRB) mask\n- Bag valve mask (BVM) with PEEP valve\n- 2 O2 flow meters (NRB or BVM, NC)\n- Ventilator with NIPPV settings\n- Non-vented mask with straps for CPAP\n- End tidal CO2 monitor\n\n## Pearls: DSI ≠ NIV \n\n- Preoxygenation may be achieved with NC, NRB mask, **OR** NIPPV, depending on the patient’s needs\n- If your patient is not agitated, NIV may be sufficient without the need for sedation/dissociation\n- Intubation may be avoided if adequate dissociation and oxygenation is attained\n\n## Delayed Sequence Intubation (DSI) algorithm\n\n![Delayed Sequence Intubation (DSI) algorithm](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/delayed-sequence-intubation/image-1.png)\n\n**Note:** During CPAP or BMV, it may take several minutes (may be as long as 10 minutes) to bring the oxygen saturation > 95%, while increasing PEEP up to 15 cm H2O.\n\n## References\n\n- Weingart SD. Preoxygenation, reoxygenation, and delayed sequence intubation in the emergency department.J Emerg Med. 2011 Jun;40(6):661-7. doi: 10.1016/j.jemermed.2010.02.014. Epub 2010 Apr 8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20378297)]\n- Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med. 2012 Mar;59(3):165-75.e1. doi: 10.1016/j.annemergmed.2011.10.002. Epub 2011 Nov 3 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22050948)]\n- Sehdev RS, Symmons DA, Kindl K. Ketamine for rapid sequence induction in patients with head injury in the emergency department. Emerg Med Australas. 2006 Feb;18(1):37-44. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16454773)]\n- Bourgoin A, Albanèse J, Wereszczynski N, Charbit M, Vialet R, Martin C.Safety of sedation with ketamine in severe head injury patients: comparison with sufentanil.Crit Care Med. 2003 Mar;31(3):711-7. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12626974)]\n- Weingart SD, Trueger NS, Wong N, Scofi J, Singh N, Rudolph SS. Delayed Sequence Intubation: A Prospective Observational Study. Ann Emerg Med. 2015 Apr;65(4):349-55. doi: 10.1016/j.annemergmed.2014.09.025. Epub 2014 Oct 23. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25447559)] \n"
		},
		{
			"slug": "dental-infections",
			"title": "Dental Infections",
			"authors": [
				"Hans Rosenberg, MD"
			],
			"created": "2011/04/22",
			"updates": null,
			"categories": [
				"ENT"
			],
			"body": "\n\n\n- **Dental caries** - demineralization of protective enamel and subsequent tooth decay\n- **Pulpitis** - inflammation of pulp secondary to caries\n- **Periodontitis** - loss of supportive bone structure caused by chronic gingivitis\n\n![Cellulitis, necrotic pulp, and periapical abscess diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dental-infections/image-1.png)\n\n![Impaction of food and bacteria diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dental-infections/image-2.png)\n\n## Periapical Abscess\n\nCollection of purulent material at apex of tooth\n\n- Secondary to bacterial invasion from carious destruction of enamel\n- History: Progressive pain, thermal sensitivity\n- Exam: Caries, decayed tooth, pain with percussion, palpation of apex, gingival swelling, erythema, parulis present, mobile tooth\n- Treatment:\n\n- Antibiotics\n\n  - Uncomplicated: <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n  - Complicated: <span class=\"drug\">Penicillin</span> + <span class=\"drug\">Metronidazole</span>, Piperacillin/Tazobactam, **or** <span class=\"drug\">Clindamycin</span> + <span class=\"drug\">Ceftriaxone</span>\n\n- Pain control\n- I+D if abscess present: probe with 18g needle → purulent → 11 blade stab incision → hemostat blunt dissection +/- packing\n- <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h if I & D\n- Surgical referral, if complicated infection (Ludwig's, Lemierre's Syndrome)\n\n- Dentist followup:\n\n- Uncomplicated: Generalist in 1-2 days\n- Complicated: Oral Surgery as soon as possible\n\n## Periodontal Abscess\n\n- Localized purulent infection within the gingival wall of the periodontal pocket\n- History: Swelling, pain, loose tooth\n- Exam: Purulent discharge, erythema, fluctuant mass, dental extrusion\n- Treatment:\n\n- Pain Control: Dental block, NSAID’s +/- opioids\n- I & D abscess as needed: 11 blade stab incision → hemostat blunt dissection +/- packing\n- Antibiotics:\n\n  - <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n  - <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h\n\n- Dentist followup\n- Generalist in 1-2 days\n\n## Pericoronitis\n\n- Inflammation +/- infection surrounding impacted or partially erupted tooth\n- History: Usually 3rd molar (wisdom tooth), erupting teeth, pain, swelling, halitosis\n- Exam: Erythema, swelling, +/- abscess\n- Treatment: Same as for Periodontal Abscess\n\n  - Pain Control: Dental block, NSAID’s +/- opioids\n  - I & D abscess as needed: 11 blade stab incision → hemostat blunt dissection +/- packing\n  - Antibiotics:\n\n    - <span class=\"drug\">Penicillin</span> or <span class=\"drug\">Clindamycin</span>\n    - <span class=\"drug\">Chlorhexidine</span> 0.1% rinses q2-3h\n\n- Dentist followup: \n- Generalist in 1-2 days\n\n- Definitive treatment: Oral Surgery\n\n## References\n\n- Nguyen DH, Martin JT. Common dental infections in the primary care setting. Am Fam Physician. 2008 Mar 15;77(6):797-802. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18386594)]\n"
		},
		{
			"slug": "dental-trauma",
			"title": "Dental Trauma",
			"authors": [
				"Hans Rosenberg, MD"
			],
			"created": "2011/04/15",
			"updates": null,
			"categories": [
				"ENT"
			],
			"body": "\n\n\n**DENTITION**\n\n- 32 teeth (each quadrant: 2 incisors, 1 canine, 2 premolars, 3 molars)\n- Numbering: 1 to 32 starting in R maxilla and ending in R mandible\n\n## Tooth Anatomy\n\n- _Pulp_: Central portion, neurovascular supply\n- _Dentin_: Surrounds pulp, majority of tooth\n- _Enamel_: White visible portion of tooth\n- _Periodontium_: Attachment apparatus (gingiva, periodontal ligament, alveolar bone)\n\n## General Approach to Dental Trauma\n\n**Airway:** \n\n- Assess risk of aspiration\n- If loose/displaced tooth, do not manipulate the tooth\n\n**Hemorrhage control:** \n\n- Apply gauze and direct pressure\n\n**Avulsed tooth**\n1.  Handle by crown only to avoid damage of periodontal ligament.\n2.  Gently rise tooth with saline, but do not wipe root and ligament.\n3.  Replace tooth and ask patient to bite on gauze (if not at aspiration risk)\n4.  If unable to place in transport medium: Hank's balance solution, saline, milk\n\n**Identify all fracture fragments:** \n\n- May have been aspirated, lodged in mucosal tissue, intruded into alveolar bone\n\n**Consider radiographs:** CXR and panorex\n\n**Medications:**\n\n- Complicated fractures/avulsions may require Td and antibiotics (**<span drug=\"class\">penicillin V</span>**, **<span drug=\"class\">clindamycin</span>**)\n\nProcedural videos from [thedentalbox.com](http://thedentalbox.com/videos.html)\n\n## Fractures\n\n**Ellis Class I**\n\n- Through enamel\n- Pulp necrosis risk = 0-3%\n- Treatment: Smooth sharp edges with emery board if causing pain \n- F/U with dentist PRN\n\n**Ellis Class II**\n\n- Through enamel and dentin (yellow/pink appearance) \n- Pulp necrosis risk = 1-7%\n- Painful and temperature sensitive\n- Treatment:  \n- Cover tooth with CaOH (eg. Dycal®) after drying tooth with gauze \n- Soft food diet\n- F/U with dentist 24-48 hrs\n\n**Ellis Class III** \n\n- Involving pulp (pink appearance, blood often visible) \n- Pulp necrosis risk = 10-30%\n- Severe pain, temperature sensitive\n- Treatment: Dental emergency - contact on call dentist (If not immediatelyavailable, same treatment as Ellis II except liquid diet)\n\n**Alveolar Fracture**\n\n- Fx of underlying alveolar bone with tooth involvement\n- Associated with high impact trauma\n- Emergency Department goal: Diagnose and preserve tissue, repair mucosal tissue \n- Treatment: Dental emergency - contact on call dentist/oral surgeon \n\n## Avulsion\n\nTooth is complete displaced from periodontal ligament\nTreatment: Dental emergency - contact on call dentist\nIf PRIMAY DENTITION, do not replace because of risk of ankylosis. F/U with dentist in 1-2 weeks.\nIf ADULT DENTITION, \"time is tooth\" - Periodontal ligament necrosis in 60-90 minutes if not in transport medium, loss of viability\n\n- Suction socket with Frasier tip suction\n- Irrigate with saline\n- Implant tooth using firm pressure\n- Apply splint (eg. Coe-Pak): Apply as a bridge to teeth and gingiva\n\n## References\n\n- Benko, K. Acute Dental Emergencies in EM. EM Practice. 2003, 5(5) [[Source](http://www.ebmedicine.net/topics.php?paction=showTopicSeg&topic_id=32&seg_id=566)]\n"
		},
		{
			"slug": "dermatomes",
			"title": "Dermatomes and Myotomal Maps",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/05/26",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Dermatome map diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dermatomes/image-1.png)\n\n## Testing Motor Function by Level\n\n\\| Nerve Level \\|  Motor Function \\|\n\\| _---_ \\| --- \\|\n| C1-C4 | Spontaneous breathing |\n| C5 | Shoulder abduction (deltoid) |\n| C6 | Wrist extension (carpi radialis longus and brevis) |\n| C7 | Elbow extension (triceps) |\n| C8 | Finger flexion (flexor digitorum superficialis/profundis, lumbricals) |\n| T1 |  Finger adduction & abduction (dorsal/palmar interossei, abductor digiti quinti) |\n| T1-T12 | Intercostal and abdominal muscles |\n| T12-L3 | Hip flexion (iliopsoas) |\n| L2-L4 | Hip flexion, knee extension (quadriceps), hip adduction\n| L4 | Ankle dorsiflexion and inversion (anterior tibialis) |\n| L5 | Big toe extension (ext hallucis longus), heel walk (ext digitorum), hip abduction (gluteus medius) |\n| S1 | Ankle plantarflexion and eversion (peroneus longus), toe walk (peroneus brevis), hip extension (gluteus maximus) |\n| S2-S4 | Rectal sphincter tone |\n\n## References\n\n1. \"Dermatomes Anatomy: Overview, Gross Anatomy, Natural Variants\". Emedicine.medscape.com. N.p., 2017. Web. 24 Mar. 2017. [[Source](http://emedicine.medscape.com/article/1878388-overview)]\n"
		},
		{
			"slug": "diabetic-ulcer",
			"title": "Diabetic Leg Ulcer and Osteomyelitis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/05/26",
			"updates": null,
			"categories": [
				"Orthopedics",
				"EBM"
			],
			"body": "\n\n\n- Most common cause of nontraumatic amputations = diabetic foot problems\n\n**Osteomyelitis:**\n\n- Diagnostic gold standard for osteomyelitis = Bone biopsy and culture\n- If inadequately treated, increases risk of amputation\n- Starting pretest probability for osteomyelitis in DM patient with leg ulcer = 15%\n\n## Physical Exam of DM leg ulcer\n\n**Ulcer type:** Difficult to distinguish ulcer secondary to diabetic vs vascular insufficiency\n\n**Classic ulcer location and appearance**:\n\n- **Venous ulcer**: Above medial/lateral malleoli, irregular borders\n- **Arterial ulcer**: Affects toes or shins, pale/punched out borders, painful\n- **Diabetic ulcer**: Areas of increased pressure (plantar foot, shoe friction areas)\n\n**Probe-to-Bone test:** Using a sterile, blunt, stainless steel probe, push against ulcerbase to see if can contact hard, gritty structure (bone)\n\n**Measure ulcer area**: Multiply greatest width by greatest length of ulcer\n\n**Wagner grading scale of ulcers**\n\n- Grade 0 – No open lesions; may have evidence of healed lesions/deformitities\n- Grade 1 – Superficial ulcer\n- Grade 2 – Deeper ulcer to tendon, bone, or joint capsule\n- Grade 3 – Deeper tissues involved, with abscess, osteomyelitis, or tendonitis \n- Grade 4 – Localized gangrene of toe or forefoot\n- Grade 5 – Gangrene of foot (partial or total)\n\n**Xray findings** = loss of trabecular pattern, periosteal reaction, frank bone destruction \n\n## Bottom Line\n\n**Best positive predictors of osteomyelitis of diabetic leg ulcer are:** \n\n1. Probe-to-bone test\n2. Ulcer area >2 cm2\n3. ESR >70 mm/hr\n\n**Best negative predictor is MRI foot**\n\n- Sensitivity 90%\n- Specificity 83%\n\n| **Finding**                          | **(+) LR** | **(-) LR** |\n| ------------------------------------ | :--------: | :--------: |\n| Erythema, swelling, purulence        |     1.5    |    0.84    |\n| Positive probe-to-bone test          |   **6.4**  |    0.39    |\n| Ulcer area (LxW) >2 cm2              |   **7.2**  |    0.48    |\n| Clinical gestalt+/- Wagner grade     |     5.5    |    0.54    |\n| ESR >70 mm/h                         |   **11**   |    0.34    |\n| Plain film evidence of osteomyelitis |     2.3    |    0.63    |\n| MRI foot                             |     3.8    |  **0.14**  |\n\n**Note:**\n\n- Serum WBC and soft tissue swab culture = not diagnostic\n- Soft tissue culture: Identified same pathogens as bone culture only 19-36% isolates. Not reliably predictive. \n\n## Fagan Nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/diabetic-ulcer/image-1.png)\n\nDraw a connecting your pre-test probability and your likelihood ratio. This provides you with your post-test probability.\n\n## References\n\n- Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA. 2008 Feb 20;299(7):806-13. doi: 10.1001/jama.299.7.806. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18285592)]\n"
		},
		{
			"slug": "difficult-airway",
			"title": "Predictors of a Difficult Airway",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/10/19",
			"updates": null,
			"categories": [
				"Critical Care"
			],
			"body": "\n\n\n## Difficult bag mask ventilation (MOANS)\n\n| Criteria                        | Finding                                                                             |\n| ------------------------------- | ----------------------------------------------------------------------------------- |\n| **M**ask seal                   | Bushy beards, crusted blood on the face, or disruption of lower facial continuity   |\n| **O**besity, **O**bstruction    | Obesity, pregnancy, angioedema, Ludwig’s angina, upper airway abscess, epiglottitis |\n| **A**ge                         | Age >55 years                                                                       |\n| **N**o teeth                    | Consider leaving dentures in for edentulous patients                                |\n| **S**leep apnea, **S**tiff lung | COPD, asthma, ARDS                                                                  |\n\n## Difficult laryngoscopy and intubation (LEMON)\n\n| Criteria                     | Finding                                                                                                                                                             |\n| ---------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| **L**ook externally          | Use clinical gestalt, evidence of lower facialdisruption, bleeding, small mouth, agitated patient                                                                   |\n| **E**valuate                 | Use the 3-3-2 rule: Mouth opening (3 fingers), mandibular space of chin to hyoid (3 fingers), glottic space of hyoid to thyroid notch (2 fingers)                   |\n| **M**allampati score         | In order of increasing difficulty (Class I-IV)                                                                                                                      |\n| **O**besity, **O**bstruction | Obesity = poor glottic views. Note the 4 cardinal signs of upper airway obstruction: Stridor, muffled voice, difficulty swallowing secretions, sensation of dyspnea |\n| **N**eck immobility          | Consider using video laryngoscopy (e.g. trauma, arthritis, ankylosing spondylitis)                                                                                  |\n\n## Difficult extraglottic device (RODS)\n\n| Finding | \n\\|---\\|\n\\| **R**estricted mouth opening          |\n\\| **O**bstruction                       |\n\\| **D**isrupted or **D**istorted airway |\n\\| **S**tiff lung, cervical **S**pine    |\n\n## Difficult cricothyrotomy (SHORT)\n\n| Finding |\n\\| --- \\| \n\\| **S**urgery or other airway obstruction        |\n\\| **H**ematoma (includes infection & abscess)    |\n\\| **O**besity                                    |\n\\| **R**adiation distortion (and other deformity) |\n\\| **T**umor                                      |\n\n## References\n\n- Walls R, Murphy M. 3rd ed. Emergency Airway Management, 2008.\n"
		},
		{
			"slug": "diverticulitis-outpatient",
			"title": "Diverticulitis Outpatient Treatment",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/05/26",
			"updates": null,
			"categories": [
				"Gastroenterology",
				"EBM"
			],
			"body": "\n\n\nThe **classic teaching** for the treatment ofdiverticulitis has included:\n\n- Hospital admission\n- Bowel rest (NPO)\n- IV fluids\n- Broad spectrum IV antibiotics\n\nEarly literature suggests that there is a small sub-population who fare well with outpatient treatment. ([Friend et al., Ann Emerg Med, 2011](https://www.ncbi.nlm.nih.gov/pubmed/?term=21770056))\n\n## Outpatient treatment\n\n**BOTTOM LINE:** Uncomplicated diverticulitis might be treated as outpatient if:\n\n- Can tolerate POs\n- No significant comorbidities\n- Able to obtain antibiotics\n- Have adequate pain control\n- Access to followup and social support \n\n[Mizuki study](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼15801924):\n\n- Prospective observational study of outpatient abx treatment for diverticulitis in Japan \n- _Diverticulitis diagnosis_: Based on exam, blood tests, and ultrasound (no CT) \n- _Inclusion criteria_: Age &lt; 80 years, diverticulitis\n- _Exclusion criteria_: “Severe” diverticulitis on ultrasound, uncontrolled DM, heart failure, renal dz, end-stage cancer, antibiotics within past 24 hrs. \n- _Study group_: n=70 during 1997-2002 period\n- _Method_: Day 4 and Day 7 followup\n- _Result_: 68 of 70 (97%) were successfully treated as outpatient \n\n[Ridgway study](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼19016815):\n\n- Randomized controlled trial of IV vs PO antibiotics (cipro/metronidazole combo) fordiverticulitis in Ireland. All patients admitted to hospital.\n- _Diverticulitis diagnosis_: Purely based on clinical exam (no imaging test).\n- _Inclusion criteria_: Left iliac fossa pain and LLQ abdominal tenderness\n- _Exclusion criteria:_ Generalized abdominal tenderness or evidence of perforation \n- _Study group_: n=79 (41 with PO abx, 38 with IV abx)\n- _Result_: No difference in tenderness and days-to-resolution between groups. \n\n[Alonso study](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼19906059):\n\n- Cohort study with outpatient treatment using PO antibiotics (amox/clavulanic +metronidazole combo). All patients admitted to hospital.\n- _Inclusion criteria_: Diverticulitis diagnosis by clinical exam, labs, and CT imaging \n- _Exclusion criteria_: Unable to tolerate POs, comorbidities (DM, renal insufficiency,heart failure, COPD, no family support)\n- _Study group_: n=70\n- _Methods_: Follow-up 4-7 days after initial ED visit.\n- _Result_: 68 (97%) were successfully treated as outpatient. 2 (3%) failed outpatient tx because for increased abdominal pain (1) and vomiting (1). \n\n[Etzioni study](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼19906059):\n\n- Retrospective study of outpatient diverticulitis patients\n- _Diverticulitis diagnosis:_ By clinical exam, labs, and CT\n- _Inclusion criteria_: Outpatient diverticulitis patients\n- _Exclusion criteria_: Prior dx of diverticulitis, colorectal cancer, inflammatory bowel dzStudy group: n=693 outpatient diverticulitis patients\n- _Result_: 554 (94%) were successfully treated as outpatient.\n- _Predictors of treatment failure_:\n  - Female: OR = 3.08 [1.31-7.28]\n  - Free fluid on CT: OR = 3.19 [1.45-7.05]\n  - WBC, perforation, abscess, phlegmon were not predictive (OR crossed 1.0)\n\n**Words of caution:** \n\n- This only provides guidelines, based on the limited evidence out there. \n- Still use your **common sense**. \n- Still consider admitting patients who are elderly (>80 years old) or have evidence of any perforation on CT. \n- If on the fence,admit the patient.\n\n## References\n\n- Alonso S, Pera M, Parés D, Pascual M, Gil MJ, Courtier R, Grande L. Outpatient treatment of patients with uncomplicated acute diverticulitis. Colorectal Dis. 2010 Oct;12(10 Online):e278-82. doi: 10.1111/j.1463-1318.2009.02122.x. [[PubMed] [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼19906059)]\n- Etzioni DA, Chiu VY, Cannom RR, Burchette RJ, Haigh PI, Abbas MA. Outpatient treatment of acute diverticulitis: rates and predictors of failure. Dis Colon Rectum. 2010 Jun;53(6):861-5. doi: 10.1007/DCR.0b013e3181cdb243.(https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼19906059)\n- Friend K, Mills AM. Is outpatient oral antibiotic therapy safe and effective for the treatment of acute uncomplicated diverticulitis? Ann Emerg Med. 2011 Jun;57(6):600-2. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21770056)]\n- Mizuki A, Nagata H, Tatemichi M, Kaneda S, Tsukada N, Ishii H, Hibi T. The out-patient management of patients with acute mild-to-moderate colonic diverticulitis. Aliment Pharmacol Ther. 2005 Apr 1;21(7):889-97. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼￼15801924)]\n- Ridgway PF, Latif A, Shabbir J, Ofriokuma F, Hurley MJ, Evoy D, O'Mahony JB, Mealy K. Randomized controlled trial of oral vs intravenous therapy for the clinically diagnosed acute uncomplicated diverticulitis. Colorectal Dis. 2009 Nov;11(9):941-6. doi: 10.1111/j.1463-1318.2008.01737.x. Epub 2008 Nov 7. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=￼19016815)]\n"
		},
		{
			"slug": "does-your-pt-have-chf",
			"title": "Does Your Dyspneic Patient Have CHF?",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/08/24",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"EBM"
			],
			"body": "\n\n\n[McCullough et al: ED patients WITH a history of asthma or COPD](https://www.ncbi.nlm.nih.gov/pubmed/?term=12615582)\n\n## Population: Emergency Department patients\n\n| Finding                              |              (+) LR |            (-) LR |\n| ------------------------------------ | ------------------: | ----------------: |\n| Initial clinical judgment            |    **4.4** (1.8-10) |  0.45 (0.28-0.73) |\n| **HISTORY**                          |                     |                   |\n| • Heart failure                      |   **5.8** (4.1-8.0) |  0.45 (0.38-0.53) |\n| • Myocardial infarctio               |   **3.1** (1.3-5.8) |  0.69 (0.58-0.82) |\n| • Coronary artery disease            |       1.8 (1.1-2.8) |  0.68 (0.48-0.96) |\n| • Dyslipidemia                       |      1.7 (0.43-6.9) |   0.89 (0.69-1.1) |\n| • Diabetes mellitus                  |       1.7 (1.0-2.7) |   0.86 (0.73-1.0) |\n| • Hypertension                       |       1.4 (1.1-1.7) |  0.71 (0.55-0.93) |\n| • Smoking                            |     0.84 (0.58-1.2) |    1.4 (0.58-3.6) |\n| • COPD                               |     0.81 (0.60-1.1) |    1.1 (0.95-1.4) |\n| **SYMPTOMS**                         |                     |                   |\n| • Paroxysmal noctural dyspnea        |       2.6 (1.5-4.5) |  0.70 (0.54-0.91) |\n| • Orthopnea                          |       2.2 (1.2-3.9) |  0.65 (0.45-0.92) |\n| • Edema                              |      2.1 (0.92-5.0) |   0.64 (0.39-1.1) |\n| • Dyspnea on exertion                |       1.3 (1.2-1.4) |  0.48 (0.35-0.67) |\n| • Fatigue and weight gain            |      1.0 (0.74-1.4) |   0.99 (0.85-1.1) |\n| • Cough                              |     0.93 (0.70-1.2) |    1.0 (0.87-1.3) |\n| **PHYSICAL EXAM**                    |                     |                   |\n| • S3 (ventricular filling gallop)    |   **11** (4.9-25.0) |  0.88 (0.83-0.94) |\n| • Abdominal jugular reflex           | **6.4** (0.81-51.0) |   0.79 (0.62-1.0) |\n| • Jugular venous distension          |   **5.1** (3.2-7.9) |  0.66 (0.57-0.77) |\n| • Rales                              |       2.8 (1.9-4.1) |  0.51 (0.37-0.70) |\n| • Any murmur                         |       2.6 (1.7-4.1) | 0.81 (0.73--0.90) |\n| • Lower extremity edema              |       2.3 (1.5-3.7) |  0.64 (0.47-0.87) |\n| • Valsalva maneuver                  |       2.1 (1.0-4.2) |   0.41 (0.17-1.0) |\n| • SBP &lt;100 mmHg                   |      2.0 (0.60-6.6) |   0.97 (0.91-1.0) |\n| • S4 (atrial gallop)                 |      1.6 (0.47-5.5) |   0.98 (0.93-1.0) |\n| • SBP &ge;150 mmHg                   |      1.0 (0.69-1.6) |   0.99 (0.84-1.2) |\n| • Wheezing                           |    0.52 (0.38-0.71) |     1.3 (1.1-1.7) |\n| • Ascites                            |     0.33 (0.04-2.9) |    1.0 (0.99-1.1) |\n| **CHEST RADIOGRAPH**                 |                     |                   |\n| • Pulmonary venous congestion        | **12.0** (6.8-21.0) |  0.48 (0.28-0.83) |\n| • Interstitial edema                 | **12.0** (5.2-27.0) |  0.68 (0.54-0.85) |\n| • Alveolar edema                     |  **6.0** (2.2-16.0) |  0.95 (0.93-0.97) |\n| • Cardiomegaly                       |   **3.3** (2.4-4.7) |  0.33 (0.23-0.48) |\n| • Pleural effusion                   |   **3.2** (2.4-4.3) |  0.81 (0.77-0.85) |\n| • Any edema                          | **3.1** (0.60-16.0) |   0.38 (0.11-1.3) |\n| • Pneumonia                          |    0.50 (0.29-0.87) |     1.0 (1.0-1.1) |\n| • Hyperinflation                     |    0.38 (0.20-0.69) |     1.1 (1.0-1.1) |\n| **ECG**                              |                     |                   |\n| • Atrial fibrillation                |   **3.8** (1.7-8.8) |  0.79 (0.66-0.96) |\n| • New T-wave changes                 |   **3.0** (1.7-5.3) |  0.83 (0.74-0.93) |\n| • Any abnormal finding               |   **2.2** (1.6-3.1) |  0.64 (0.47-0.88) |\n| • ST elevation                       |      1.8 (0.80-4.0) |   0.98 (0.94-1.0) |\n| • ST depression                      |      1.7 (0.97-2.9) |   0.95 (0.90-1.0) |\n\n(NS = not significant because LR crosses 1.0)\n\n## Subset population: ED patient WITH a history of asthma or COPD\n\n| Finding                              |                         (+) LR |               (-) LR |\n| ------------------------------------ | -----------------------------: | -------------------: |\n| Initial clinical judgment            |               **9.5** (5.3-18) |     0.65 (0.55-0.77) |\n| **HISTORY**                          |                                |                      |\n| • Atrial fibrillation                |              **4.1** (2.5-6.6) |      0.74 (0.63-0.85 |\n| • CABG                               |                  2.8 (1.3-5.8) |     0.92 (0.84-0.99) |\n| • Diabetes mellitus                  |                  2.0 (1.3-3.2) |     0.85 (0.74-0.97) |\n| • Coronary artery disease            |                  2.0 (1.5-2.6) |     0.67 (0.54-0.84) |\n| • Hypertension                       |                             NS |                   NS |\n| **SYMPTOMS**                         |                                |                      |\n| • Orthopnea                          |                  1.3 (1.1-1.5) |     0.68 (0.48-0.95) |\n| • Noctural cough                     |                             NS |                   NS |\n| **PHYSICAL EXAM**                    |                                |                      |\n| • S3 (ventricular filling gallup)    |             **57.0** (7.6-425) |     0.83 (0.75-0.91) |\n| • Jugular venous distension          |              **4.3** (2.8-6.5) |     0.65 (0.54-0.78) |\n| • Leg edema                          | 2.7 (2.2-3.5) 0.41 (0.30-0.57) |                      |\n| • Rales                              |                  2.6 (1.2-4.7) |     0.39 (0.28-0.55) |\n| • Hepatic congestion                 |                  2.4 (1.2-4.7) |      0.91 (0.84-1.0) |\n| • Cardiomegaly                       |                             NS |                   NS |\n| • Wheezing                           |                             NS |                   NS |\n| **ECG**                              |                                |                      |\n| • Atrial fibrillation                |             **6.0** (3.4-10.0) |     0.74 (0.63-0.84) |\n| • Ischemic ST-T waves                |              **4.6** (2.4-8.7) |     0.83 (0.74-0.93) |\n| • Q waves                            |              **3.1** (1.8-5.5) |     0.84 (0.75-0.94) |\n| Serum BNP &ge;100 pg/mL              |              **4.1** (3.5-5.0) | **0.09** (0.04-0.19) |\n\n## BNP test characteristics to predict CHF in ED patients +/- asthma or COPD \n\n[Wang et al. (2005)](https://www.ncbi.nlm.nih.gov/pubmed/?term=16234501)\n\n| BNP level (pg/mL)     |        (+) LR |           (-) LR |\n| --------------------: | ------------: | ---------------: |\n|              &ge; 250 | 4.6 (2.6-8.0) | 0.14 (0.06-0.33) |\n|              &ge; 200 | 3.7 (2.6-5.4) | 0.11 (0.07-0.18) |\n|              &ge; 150 | 3.1 (2.1-4.5) | 0.15 (0.11-0.21) |\n|              &ge; 100 | 2.7 (2.0-3.9) | 0.11 (0.07-0.16) |\n|               &ge; 80 | 3.3 (1.8-6.3) | 0.06 (0.03-0.13) |\n|               &ge; 50 | 1.7 (1.2-2.6) | 0.06 (0.03-0.12) |\n\n## References\n\n- McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS; BNP Multinational Study Investigators. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003 Mar;10(3):198-204. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12615582)]\n- Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005 Oct 19;294(15):1944-56. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16234501)]\n"
		},
		{
			"slug": "dummy",
			"title": "Abdominal Pain - Diagnostic Studies",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/07/22",
			"updates": [
				"2017/02/21"
			],
			"categories": [
				"Gastroenterology",
				"Surgery",
				"EBM"
			],
			"body": "\n\n\nBreak\n* linter\n* should\n* alert\n\n# Some Markdown #\n\n_emphasis_\n\nA list:\n  * one\n  * two\n  * three\n\n\n\n_testing travis aftersuccess script._\n\n| table | fences |\n|----|----|\n|a|b|\n\n## References \n\n- here is a reference"
		},
		{
			"slug": "dvt-ultrasound",
			"title": "Ultrasound DVT Assessment",
			"authors": [
				"Margaret Greenwood-Ericksen, MD",
				"Joshua Rempell, MD",
				"Mike Stone, MD"
			],
			"created": "2015/02/18",
			"updates": null,
			"categories": [
				"Radiology",
				"Ultrasound",
				"Cardiovascular"
			],
			"body": "\n\n\n**Goals: **Evaluate for DVT using the 2-point compression technique, focusing on the highest probability areas: femoral and popliteal veins\n\n**Transducer: **High frequency linear transducer. Directional indicator to patient’s right in transverse position\n\n**Pt position: **Externally rotated hip, flexed knee, +/- reverse Trendelenburg\n\n## 1. Femoral Vein\n\n1. Place linear transducer in transverse position at level of inguinal ligament\n2. Identify the confluence of femoral vein and greater saphenous vein (saphenofemoral junction \\[SFJ]), and apply direct pressure to assess for compressibility\n3. To fully evaluate the common femoral vein, slide 5 cm distal to the confluence, compressing at 0.5-1 cm intervals. This allows for visualization of the proximal portion of the deep and superficial femoral veins. Assess for compressibility in both.\n\n![Transducer location to evaluate the femoral vein and normal ultrasound images showing common femoral artery and fully compressible vein](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dvt-ultrasound/image-1.png)\n\nFigure 1: Transducer location to evaluate the femoral vein and normal ultrasound images showing common femoral artery **(A)** and fully compressible vein **(V).**\n\n## 2. Popliteal Vein\n\n1. Place linear transducer in transverse position in popliteal fossa.\n2. Locate the popliteal artery and vein, and assess for compressibility of vein.\n3. To fully evaluate the popliteal region, slide distally following the popliteal vein to allow for visualization of the proximal portion of the anterior and posterior tibial veins, and the peroneal vein. At this trifurcation, assess for compressibility of all three veins.\n\n![Transducer location to evaluate the popliteal vein and normal ultrasound images showing popliteal artery and fully compressible vein](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dvt-ultrasound/image-2.png)\n\nFigure 2: Transducer location to evaluate the popliteal vein and normal ultrasound images showing popliteal artery **(A)** and fully compressible vein **(V)**.\n\n## Positive (Abnormal) DVT Study\n\n**A non-compressible vein indicates a positive study for thrombosis.**\n\nNormally, there should be complete coaptation of the venous walls – a.k.a. the walls collapse against one another. If the vein does not full compress, one assumes there is an intraluminal thrombus.\n\nNote: While the thrombus is frequently visualized as a discrete echogenic structure, it may not always be seen.\n\n![Positive DVT study showing thrombus in the femoral vein](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dvt-ultrasound/image-3.png)\n\nFigure 3: Positive DVT study showing **thrombus** in the femoral vein **(v),** adjacent to the femoral artery **(a)** and involving the greater saphenous vein **(s)**. The image on the right demonstrates that the **vein does not collapse with compression**.\n\n## Struggling with the Exam?\n\n**Larger or edematous patients?** Use the curvilinear probe if you can’t visualize the deep veins.\n\n**Can’t compress vein, but can’t visualize clot?** Assume that there is a DVT, as clots can be isoechoic with the surrounding blood and may not be directly visualized. Direct visualization of the thrombus is not required for a positive study.\n\n**Difficulty finding the popliteal vein?** The popliteal vein can be difficult to identify. Try having the patient hang the legs over the edge of the bed to distend the vessels or position the patient in the prone position while passively flexing the knee with the foot in the air. Color Doppler may also help identify the vessels.\n\n**Not sure if the vein is fully compressing?** A normal vein will completely disappear when compressed. Make sure to center the vein on the screen and apply pressure evenly. If pressure is not applied directly perpendicular to the skin, the vessel may appear not to collapse due to unevenly distributed pressure.\n\n**How much pressure is enough?** An appropriate amount of pressure gives complete collapse of the vein as well as some (but not full) compression of the adjacent artery.\n\n## Common Errors\n\n- Other structures, such as lymph nodes, may mimic a thrombus. Be sure to scan through the entire structure as a lymph node will appear discrete and separate from the vessels.\n- To fully evaluate the common femoral vein, make sure to visualize the proximal region at the confluence of the greater saphenous and common femoral veins.\n\n## References\n\n- Kline JA, O'malley PM, Tayal VS, Snead GR, Mitchell AM. Emergency clinician-performed compression ultrasonography for deep venous thrombosis of the lower extremity. Ann Emerg Med. 2008;52(4):437-45.[[PubMed]((www.ncbi.nlm.nih.gov/pubmed/18562044)]\n\n- Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008;300(14):1653-9.[[PubMed](www.ncbi.nlm.nih.gov/pubmed/18840838)]\n"
		},
		{
			"slug": "dysphagia",
			"title": "Dysphagia",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/02/03",
			"updates": null,
			"categories": [
				"Gastroenterology"
			],
			"body": "\n\n\n## Oropharyngeal Dysphagia\n\n**Symptoms:**\n\n- Difficulty initiating swallowing\n- May include coughing, choking or nasal regurgitation\n\n**Mechanical obstruction**\n\n- Tumor, inflammatory masses\n- Trauma/ surgical resection\n- Zenker's diverticulum\n- Esophageal webs\n- Extrinsic structural lesions\n- Anterior mediastinal masses\n- Cervical spondylosis\n\n**Neuromuscular disorder**\n\n- CVA (common cause)\n- Parkinson's disease\n- Brain stem tumors \n- Degenerative disease (ALS, multiple sclerosis, Hungtington's)\n- Post-infectious (polio, syphilis) \n- Peripheral neuropathy\n- Myasthenia gravis\n- Myopathies\n- Cricopharyngeal disease \n- Achalasia\n\n## Esophageal dysphagia\n\n![Esophageal dysphagia workup flowchart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/dysphagia/image-1.png)\n\n## Approach to dysphagia\n\n1. Determine first if patienthas oropharyngeal versus esophageal dysphagia. \n2. Determine ifmechanical (problem issolid foods only) versus neuromuscular(problem with liquids and solids) is more likely.\n\n**Tip:**\n\n-  Medications can causedysphagia fromesophageal mucosalinjury or reduced lower esophageal sphinctertone.\n-  CVA is most commoncause of oropharyngealdysphagia\n\n## Workup for dysphagia\n\n- Endoscopy\n- Barium swallow\n- Consider esophageal pH probe, manometry \n\n## References\n\n- Spieker MR.Evaluating dysphagia. Am Fam Physician. 2000 Jun 15;61(12):3639-48. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=10892635)]\n"
		},
		{
			"slug": "ecg-electrolytes",
			"title": "ECG Electrolyte Imbalance",
			"authors": [
				"Steve Field, MD"
			],
			"created": "2012/09/21",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"ECG",
				"Endocrinology"
			],
			"body": "\n\n\n![Normal ECG with overlay showing all the measurable intervals](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-electrolytes/image-1.png)\n\nImage courtesy of [Life in the Fast Lane](https://lifeinthefastlane.com)\n\n**PR Interval**\n\n| Short                                      | Prolonged      |\n| ------------------------------------------ | -------------- |\n| Pre-excitation, e.g. Wolff-Parkinson-White | High K, Low Ca |\n\n**QRS Duration**\n\n| Narrow                | Wide            |\n| --------------------- | --------------- |\n| Low K, Low Ca, Normal | High K, High Ca |\n\n**QTc Interval**\n\n| Short   | Prolonged     |\n| ------- | ------------- |\n| High Ca | Low K, Low Ca |\n\n**ST Segment**\n\n| Depressed      | Elevated |\n| -------------- | -------- |\n| Low K, High Ca | High K   |\n\n**T Wave**   \n\n| Peak/Tall | Flattened |\n| --------- | --------- |\n| High K    | Low K     |\n\n**U Wave**   \n\n| Absent | Present       |\n| ------ | ------------- |\n| Normal | Low K, Low Ca |\n\n**Heart Rate**   \n\n| Slow            | Fast          |\n| --------------- | ------------- |\n| High K, High Ca | Low K, Low Ca |\n\n## Electrolyte Imbalances\n\n<table>\n<colgroup>\n<col width=\"33%\" />\n<col width=\"33%\" />\n<col width=\"33%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th> </th>\n<th><strong>Low</strong></th>\n<th><strong>High</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td><br />\n<br />\n<strong>Ca</strong></td>\n<td><ul>\n<li>QTc prolonged</li>\n<li>U wave</li>\n<li>Heart blocks</li>\n<li>Dysrhythmias (heart block, torsades, ventricular)</li>\n</ul></td>\n<td><ul>\n<li>QTc shortened</li>\n<li>ST depression and shortening</li>\n<li>QRS widening</li>\n<li>Dysrhythmias (bradydysrhthmias, bundle branch block, high degree AV block)</li>\n</ul></td>\n</tr>\n<tr class=\"even\">\n<td><br />\n<br />\n<br />\n<strong>K</strong></td>\n<td><em>Early to late findings:</em>\n<ol>\n<li>T wave: decr. amplitude</li>\n<li>T wave: flat or inverted</li>\n<li>ST depression</li>\n<li>U wave</li>\n<li>QTc prolonged</li>\n</ol></td>\n<td><em>Early to late findings:</em>\n<ol>\n<li>T wave: tall, then &quot;peaked&quot;, symmetrical</li>\n<li>P wave flattening</li>\n<li>PR prolonged</li>\n<li>QRS widening</li>\n<li>Nodal blocks, escape beats</li>\n<li>Sine wave → VF or asystole</li>\n</ol></td>\n</tr>\n</tbody>\n</table>\n\n**Magnesium Derangements:**\n\n- Nonspecific ECG findings\n- Often co-exists with Ca derangements\n- Classic teaching: Low Mg level → QTc prolongation → Torsades de pointes\n\n## References\n\n- Goldberger A., Clinical Electrocardiography: A Simplified Approach, 8th Edition, 2006\n- Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004 Aug;27(2):153-60. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15261358)]\n- Marx J, Hockberger R., Walls R., Rosen’s Emergency Medicine: Concepts and Clinical Practice, 7th ed, 2010\n"
		},
		{
			"slug": "ecg-lead-avr",
			"title": "Lead aVR",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/11/18",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"ECG"
			],
			"body": "\n\n\n**Lead avR can provide some unique insight into 5 different conditions:**\n\n1. Acute MI\n2. Pericarditis\n3. Tricyclic antidepressants (TCA) and TCA-like overdose\n4. AVRT in narrow complex tachycardias\n5. Differentiating VT from SVT with aberrancy in wide complex tachycardias\n\n## Acute myocardial infarction\n\n**ST Elevation >1.5 mm in aVR**\n\n![Example of ST elevation](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-lead-avr/image-1.png)\n\n- Suggests left main coronary artery (LMCA), left anterior descending (LAD), or 3-vessel coronary disease\n- LMCA occlusion has a high mortality and often refractory to thrombolytics.\n- **aVR ST elevation in ACS patients:** Independent predictor of recurrent ischemic events in-hospital, heart failure, and death \n\n## Pericarditis\n\n**PR elevation in aVR**\n\n![Example of PR elevation](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-lead-avr/image-2.png)\n\nSuggests subepicardial atrial injury from pericardial inflammation\n\n**Multilead ST elevation:** \n\n- Differential diagnosis includes ACS vs pericarditis \n- Concurrent PR elevation in aVR suggests pericarditis instead of ACS. \n\n## Tricyclic antidepressant (TCA) & TCA-like overdose\n\n**Prominent R wave in aVR**\n\n![Example of a prominent R wave](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-lead-avr/image-3.png)\n\n- Classic ECG findings of TCA overdose:\n  - Sinus tachycardia\n  - Widened QRS and QTc interval\n  - Right axis deviation 130-170 degrees\n  - Prominent terminal R wave in aVR\n- Predictor of arrhythmia ([Buckley et al. Crit Care, 2003](http://www.ncbi.nlm.nih.gov/pubmed/12974977)):\n  - R/S ratio in aVR >0.7 (PPV 46%, NPV 95%)\n\n## AVRT in Wolff-Parkinson-White (WPW)\n\n**Atroventricular reentry tachycardia**\n\n- ST elevation in aVR in narrow complex tachycardia\n- Narrow complex tachycardia ddx:\n  - AV node reentry tachycardia \n  - AV reentry tachycardia\n  - Atrial tachycardia\n- ST elevation in aVR suggestive more of AVRT in WPW (sensitivity 71%, specificity 70%)\n\n## Vereckei criteria: VT versus SVT in wide complex tachycardia\n\n**Vereckei criteria:** \n\n- Asks 4 questions. \n- More sensitive and specific to detect ventricular tachycardia (VT) than Brugada criteria.\n- **Criteria looks ONLY at lead aVR** (if answer is yes, then VT):\n\n1. Is there an initial R wave?\n2. Is there a r or q wave >40 msec? (>1 small box width)\n3. Is there a notch on the descending limb of a negative QRS complex?\n4. Measure the voltage change in the first (vi) and last 40 msec (vt). Is vi / vt &lt;1?\n\n![Example of VT vs SVT](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-lead-avr/image-4.png)\n\n| Criteria | Sensitivity | Specificity | PPV | NPV |\n| -------- | :---------: | :---------: | :-: | :-: |\n| Brugada  |     89%     |     73%     | 92% | 67% |\n| Verecki  |     97%     |     75%     | 93% | 87% |\n\n([Vereckei et al, Heart Rhythm 2008](http://www.ncbi.nlm.nih.gov/pubmed/18180024))\n\n## References\n\n- Kireyev D et al.Clinical utility of aVR-The neglected electrocardiographic lead. Ann Noninvasive Electrocardiol. 2010;15(2):175-80. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20522059)]\n- Riera AR et al.Clinical value of lead aVR. Ann Noninvasive Electrocardiol. 2011 Jul;16(3):295-302. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21762258)]\n- Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008 Jan;5(1):89-98. doi: 10.1016/j.hrthm.2007.09.020. Epub 2007 Sep 20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18180024)]\n- Buckley NA et. al.The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose.Crit Care. 2003 Oct;7(5):R101-7. Epub 2003 Aug 18. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12974977)]\n- Williamson K et al. Electrocardiographic applications of lead aVR. Am J Emerg Med. 2006 Nov;24(7):864-74. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17098112)]\n"
		},
		{
			"slug": "ecg-right-posterior-leads",
			"title": "ECG Right and Posterior Leads",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/03/11",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"ECG"
			],
			"body": "\n\n\n## Right Sided ECG Leads\n\n![Right sided ECG lead placement diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-right-posterior-leads/image-1.png)\n\nRight sided ECG leads (V1R-V6R) are positioned in a mirror image fashion to the standard 12-lead precordial leads.\n\n- **Purpose:** To detect right ventricular (RV) infarcts\n- RV infarcts usually associated with inferior wall AMI\n- **Indications**: 2004 ACC/AHA guidelines state to get a **right-sided ECG** in setting of **inferior AMI** (ST elevation in II, III, AVF)\n\n![Example ECG showing an inferior wall MI](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-right-posterior-leads/image-2.png)\n\nHints of an associated RV infarct:\n\n1. Hypotension (RV infarcts are extremely preload dependent) \n2. STE in III is taller than ST elevation in II\n3. STE in V1\n4. ST depression (STD) in V2 or V3 relative to V1 \n\n## Posterior ECG leads\n\n![Posterior ECG lead placement diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-right-posterior-leads/image-3.png)\n\n**Posterior ECG leads (V7-V9)** are applied by moving V4-V6 to under the left scapula.\n\n**Purpose:** To detect posterior infarcts, which are often associated with inferior or lateral wall AMI\n\n**Indications:** \n\n- STD in V1-V3, or \n- R/S amplitude ratio in V1 or V2 is >1 \n\n![ST depression in leads V1-V3](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-right-posterior-leads/image-4.png)\n\nHints of an associated posterior infarct:\n\n1. Deep T wave inversion in V1 or V2 (in hyperacute stage) \n2. Upright T wave waves (in later stage)\n\n## References\n\n- Edhouse J, Brady WJ, Morris F. ABC of clinical electrocardiography: Acute myocardial infarction-Part II. BMJ. 2002; 324: 963-6. [[Source](https://doi.org/10.1136/bmj.324.7343.963)]\n- Van Gorselen EO, Verheugt FW, Meursing BT, Oude Ophuis AJ. Posterior myocardial infarction: the dark side of the moon. Neth Heart J. 2007; 15: 16-21. [[PubMed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1847720/)]\n"
		},
		{
			"slug": "ecg-sgarbossa",
			"title": "Sgarbossa Criteria for LBBB and AMI",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/11/05",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"ECG"
			],
			"body": "\n\n\nIt is difficult to determine if a patient with a left bundle branch block (LBBB) has an acute myocardial infarction (AMI) because ST segments are \"appropriately discordant\" with the terminal portion of the QRS. \n\n- The major, terminal portion of the QRS complex will normally be “appropriately discordant” with the ST segment.\n\n## Sgarbossa criteria\n\n- For detecting an AMI in the setting of a LBBB\n- Derived from the [GUSTO-1 trial](http://www.nejm.org/doi/full/10.1056/NEJM199602223340801)\n- Sgarbossa criteria are NOT perfect in screening for AMI\n- Use as another data point in risk-stratifying these complex patients with LBBB\n- Sgarbossa criteria applies also for LBBB pattern seen in pacemaker patients\n\n## 1. ST elevation &ge; 1 mm concordant with QRS complex\n\n- Most predictive of AMI\n- \\+ LR: 9.54 (3.1-17.3)\n- \\- LR: 0.3 (0.22-0.39)\n\n![ST elevation example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-sgarbossa/image-1.png)\n\n## 2. ST depression &ge; 1 mm in lead V1, V2, V3\n\n- \\+ LR: 6.58 (2.6-16.1)\n- \\- LR: 0.78 (0.7-0.87)\n\n![ST depression example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-sgarbossa/image-2.png)\n\n## 3. ST elevation &ge; 5 mm where discordant with QRS complex\n\n- May not be significant as the +LR crosses 1.0\n- \\+ LR: 3.42 (0.18-6.5)\n- \\- LR: 0.8 (0.72-0.9)\n\n![ST elevation greater than 5 millimeters example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-sgarbossa/image-3.png)\n\n_ECG tracings courtesy of [ems12lead.blogpost.com](http://ems12lead.blogpost.com)_\n\n## Modified Sgarbossa Rule (updated 01/01/2013)\n\n[Smith SW et al. Ann Emerg Med 2012](http://www.ncbi.nlm.nih.gov/pubmed?term=22939607) \n\n**Rule:**\n\n- **Ratio of ST-elevation / S-wave &lt; -0.25 is indicative of acute MI**\n- The modified Sgarbossa Rule uses proportions to identify acute AMI in the setting of ST-elevations in LBBB (helpful in low-voltage EKG)\n\n|                         | **Sensitivity** | **Specificity** | **(+) LR** | **(-) LR** |\n| ----------------------- | :-------------: | :-------------: | :--------: | :--------: |\n| Modified Sgarbossa rule |       91%       |       90%       |     9.0    |     0.1    |\n\n![Old Sgarbossa rule juxtaposed against new Sgarbossa rule](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-sgarbossa/image-4.png)\n\n## Fagan nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ecg-sgarbossa/image-5.png)\n\n## References\n\n- Sgarbossa EB et al, for GUSTO-1 investigators. ECG diagnosis of evolving AMI in the presence of LBBB, New Engl J Med 1996; 334:481-7. [[Source](http://www.nejm.org/doi/full/10.1056/NEJM199602223340801)]\n- Smith SW et al. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. Ann Emerg Med. 2012 Dec;60(6):766-76 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22939607)]\n"
		},
		{
			"slug": "echocardiography",
			"title": "Focused Echocardiography",
			"authors": [
				"Jimmy Fair, MD",
				"Mike Mallon, MD",
				"Mike Stone, MD"
			],
			"created": "2015/02/11",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"Ultrasound"
			],
			"body": "\n\n\n**Goals:** Evaluate for pericardial effusion, general cardiac function, and evidence of right heart strain.\n\n**Transducer:** Low frequency phased array transducer\n\n**Windows:** Can be performed in any order. Try alternative windows if initial choice is unsuccessful. Standard cardiac imaging places the screen indicator on the right side of the screen. Using abdominal or other machine presets where the screen indicator is on the left side of the screen will require a 180-degree flip of the transducer from the description below.\n\n![Parasternal, apical, and subxiphoid windows](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/echocardiography/image-1.png)\n\nFigure 1: Standard transducer placement for the basic transthoracic echocardiography examination\n\n## 1. Parasternal Long-Axis (PSLA)\n\n- **Anatomic landmarks**: Just left of sternum, 4th or 5th intercostal space\n- **Initial transducer orientation:** Place directional indicator towards right shoulder. Align image to include both aortic and mitral valve. Place mitral valve in center of screen.\n\n![Parasternal long-axis view example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/echocardiography/image-2.png)\n\nFigure 2: Parasternal Long Axis view with measurement. Note the right ventricle **(RV)**, interventricular septum **(S)**, left ventricle **(LV)**, left atrium **(LA)**, anterior mitral valve leaflet **(\\*)**, and aorta **(Ao)** seen at its root adjacent to the aortic valve and again descending deep to the heart. EPSS is measured in M-mode (right panel) as the distance from the interventricular septum to the first upstroke of the anterior mitral valve leaflet in diastole – used to help determine LV ejection fraction.\n\n## 2. Parasternal Short-Axis (PSSA)\n\n- **Anatomic landmarks**: Same location as PSLX. Rotate transducer 90<sup>o</sup> clockwise.\n- **Initial transducer orientation:** Directional indicator towards left shoulder. Fan transducer towards right shoulder for image of aortic valve. Fan transducer towards left hip for image of mid LV cavity.\n\n![Parasternal Short-Axis view example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/echocardiography/image-3.png)\n\nFigure 3: PSSA view with right ventricle **(RV),** circular left ventricle **(LV)**, and **papillary muscles**\n\n## 3. Apical 4-chamber (A4)\n\n- **Anatomic landmarks**: Point of Maximal Impulse (usually 2 cm below nipple).\n- **Initial transducer orientation:** Directional indicator towards left axilla with transducer angled towards right shoulder. Try to locate over the true apex of the heart and align both tricuspid and mitral valves. Septum should be vertical in image.\n\n![Apical 4-chamber example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/echocardiography/image-4.png)\n\nFigure 4: Apical 4 Chamber view demonstrating the right ventricle **(RV)**, right atrium **(RA)**, left ventricle **(LV)** and left atrium **(LA)**. Note the vertical orientation of the septum.\n\n## 4. Subxiphoid\n\n- **Anatomic landmarks**: Transducer just below xiphoid process. Slightly to patient’s right.\n- **Initial transducer orientation:** Transducer marker towards patient’s **_left_** with transducer angled towards left shoulder. (Transducer is flipped from FAST view due to flipped screen indicator in cardiac imaging). Flatten transducer on abdomen.\n\n![Subxiphoid view example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/echocardiography/image-5.png)\n\nFigure 5: Subxiphoid 4-chamber view showing right ventricle **(RV)**, right atrium **(RA)**, left ventricle **(LV)** and left atrium **(LA)**. Note the small **pericardial effusion**.\n\n## Signs of Important Pathology\n\n**Pericardial effusion**: \n\nAnechoic (black) stripe encircling the heart. Pericardial effusion on PSLA will track between descending thoracic aorta and left atrium. Pleural effusion will not.\n\n**Pericardial tamponade:** \n\nPericardial effusion with RV free wall collapse in diastole. IVC should be dilated without respiratory variation in tamponade. RA systolic collapse is an early finding. **_Tip:_** Use M-Mode through mitral valve to help with timing of RV collapse.\n\n**Hypovolemia:** \n\nHyperdynamic heart with left ventricular walls almost touching in systole as seen in the parasternal long axis view.\n\n**Right heart strain:** \n\nRV size greater than LV (normal ratio is 0.6:1) when seen in the apical 4-chamber view. Flattened septum in parasternal short axis with a D-shaped LV. Poor RV function (size doesn’t change much from systole to diastole).\n\n**Systolic heart failure:** \n\nPoor ventricular squeeze. Mitral valve does not open widely as seen in parasternal long-axis. **_EPSS_**: Using the PSLA measured distance between mitral valve and septum in diastole. Abnormal EPSS >7 mm = poor LV ejection fraction.\n\n## Struggling with the Exam?\n\n**Can’t find the heart?**\n\nPlace the patient in the left lateral decubitus position, which brings the heart closest to the chest wall. Lung artifact is common and asking the patient to exhale can improve your image. Try rib interspaces above and below standard locations.\n\n**Rib shadows obstructing view?** Try moving the transducer up or down to get between the ribs, then angle the transducer towards the heart once you have a good acoustic window.\n\n## Common Errors\n\nPleural effusion can be mistaken for pericardial effusion. To differentiate, locate the descending thoracic aorta in the parasternal long-axis view. Pericardial effusions will track superficial to the descending thoracic aorta. Pleural effusions will track deep.\n\nNon-orthogonal planes can be mistaken for an enlarged right heart or D-sign. Make sure the LV looks round in the PSSA and that the apex is at the top of the screen in the apical windows.\n\nAnterior fat pad can be mistaken for pericardial effusion, but will have internal echos (not anechoic) and will not spread all the way around the circumference of the heart when imaged in different views.\n\n## References\n\n- Randazzo MR, Snoey ER, Levitt MA, Binder K. Accuracy of emergency physician assessment of left ventricular ejection fraction and central venous pressure using echocardiography. Acad Emerg Med. 2003;10(9):973-7. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Randazzo+Acad+Emerg+Med%2C+2003.)]\n\n- Nagdev A, Stone MB. Point-of-care ultrasound evaluation of pericardial effusions: does this patient have cardiac tamponade?. Resuscitation. 2011;82(6):671-3. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nagdev%2C+A.%2C+%26+Stone%2C+M.+B.+Resuscitation%2C+2011.)]\n"
		},
		{
			"slug": "ectopic-diagnosis",
			"title": "Ectopic Pregnancy - Making the Diagnosis",
			"authors": [
				"Javier Benitez, MD"
			],
			"created": "2013/05/09",
			"updates": null,
			"categories": [
				"OBGYN"
			],
			"body": "\n\n\n[JAMA Rational Clinical Examination Series](https://www.ncbi.nlm.nih.gov/pubmed/?term=23613077)\n\nSystematic review based on 14 studies (n=12,101) with a summary prevalence of ectopic pregnancy of 15% (95% CI, 10-22%) in women presenting with abdominal pain or vaginal bleeding. \n\n## Background\n\n- Leading cause of maternal death in the first trimester of pregnancy\n- Incidence as high as 2.6%\n- **Heterotopic pregnancy**: Incidence = 0.3-0.8% (1-3% if assisted reproduction)\n- \\#1 cause of 1<sup>st</sup> trimesterpregnancy-related death\n- 8-31% initially diagnosed as “pregnancy of unknown location” (PUL), despite beta-hCG and ultrasonography\n- More than half of patients with ectopic pregnancy will have ZERO risk factors\n\n**Discriminatory zone:** Serum beta-HCG level cutoff above which intrauterine pregnancy is likely visible on ultrasound.\n\n- Variable definition of cutoff with range of 1,500-3,000 mIU/mL\n- No single serum beta-hCG value is predictive of an ectopic pregnancy\n- If beta-HCG &ge;3,000 mIU/mL and an “empty uterus” on ultrasound, suggestive of ectopic pregnancy\n\n## Diagnostic Tools to Risk Stratify\n\n| **Finding**                  |  **Sensitivity** |  **Specificity** |     **(+) LR**    |      **(-) LR**      |\n| ---------------------------- | :--------------: | :--------------: | :---------------: | :------------------: |\n| **PHYSICAL EXAM**            |                  |                  |                   |                      |\n| • Cervical motion tenderness | 0.45 (0.33-0.57) | 0.91 (0.80-0.96) |  **4.9** (1.7-14) |   0.62 (0.47-0.83)   |\n| • Peritoneal findings        |     0.23-0.27    |     0.94-0.95    |    **4.2-4.5**    |       0.78-0.81      |\n| • Adnexal mass               | 0.09 (0.02-0.27) | 0.96 (0.92-0.98) | **2.4** (1.6-3.7) |    0.94 (0.87-1.0)   |\n| • Adnexal tenderness         | 0.61 (0.52-0.69) |  0.65 (0.42-0.83 |   1.9 (1.0-3.5)   |   0.57 (0.48-0.67)   |\n| **IMAGING**                  |                  |                  |                   |                      |\n| • Transvaginal ultrasound    | 0.88 (0.52-0.98) |  0.99 (0.96-1.0) | **111** (12-1028) | **0.12** (0.03-0.55) |\n\n**Ultrasound:**\n\n- Findings of an intrauterine pregnancy (IUP) such as gestational sac or fetal pole ruled out ectopic pregnancy, except in rare cases of heterotropic prengnacy.\n- Bedside ultrasound is the single most useful diagnostic test (positive LR = 111). \n\n**Beta hCG:**\n\n- The \"discriminatory zone\" continues to be debated - no consensus on the number\n- A one-time hCG level does not rule out ectopic pregnancy\n\n**CONCLUSIONS: **\n\n1. **Transvaginal ultrasound** is the single-best test to assess for ectopic pregnancy.\n2. Patient symptoms have limited risk-stratification value.\n3. Most predictive exam findings for ectopic pregnancy: \n\n- Cervical motion tenderness (positive LR = 4.9)\n- Peritoneal findings (positive LR = 4.2-4.5)\n- Adnexal mass (positive LR = 2.4)\n\n## Fagan Nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ectopic-diagnosis/image-2.png)\n\n## References\n\n- Crochet et al. Does this woman have an ectopic pregnancy? 2013; 309(16): 1722-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23613077)]\n"
		},
		{
			"slug": "ectopic-methotrexate",
			"title": "Ectopic Pregnancy and Methotrexate",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/11/11",
			"updates": null,
			"categories": [
				"OBGYN"
			],
			"body": "\n\n\n## Methotrexate (MTX)\n\n**Background**\n\n- Dihydrofolate reductase inhibitor\n- Overall success rate for treating ectopic pregnancy = 71-94%\n- Success rate of single-dose MTX for beta-hCG >5,000 mIU/mL = 85.7% \n\n**Side Effects**\n\n- Abdominal pain\n- Nausea/vomiting\n- Stomatitis    \n\n## Eligibility / Contraindications for MTX in Ectopic Pregnancy\n\n**Eligibility Criteria: (Need to fulfill all criteria)**\n\n- High clinical suspicion or confirmed ectopic pregnancy\n- Hemodynamically stable\n- Unruptured mass\n- Able to comply with close follow-up\n- Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts \n\n**Contraindications:**\n\n- Breastfeeding\n- Overt or lab evidence of immunodeficiency\n- Alcoholism, alcoholic or chronic liver disease\n- Preexisting blood dyscrasias or significant anemia \n- Known sensitivity to MTX\n- Active pulmonary disease\n- Peptic ulcer disease\n- Hepatic, renal, or hematologic dysfunction\n- Gestational sac >3.5 cm on U/S (relative contraindication) \n- Embryonic cardiac motion on U/S (relative contraindication) \n\n## Single-Dose Regimen\n\n- Day 1: <span class=\"drug\">Methotrexate</span> 50 mg/m2 IM\n\n**Follow up with obstetrician:**\n\n- Days 4 and 7: Measure beta-hCG\n- Between Days 4 and 7: Check for 15% beta-hCG decrease\n- Measure beta-hCG weekly until non-pregnant level\n- If beta-hCG dose not decrease by >15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. \n\n## Alternative Regimens\n\n- **Two-Dose** and **Fixed Multidose** regimens available as proposed by ACOG guidelines - Consider for beta-hCG level >5,000 mIU/mL\n\n## References\n\n- ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18515537)]\n"
		},
		{
			"slug": "elbow-dislocations",
			"title": "Elbow Injuries - Elbow Dislocations",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Anterior vs posterior elbow dislocation drawing. 90% are posterior](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/elbow-dislocations/image-1.png)\n\n## X-ray views\n\n- AP Elbow\n- Lateral\n\n## Acute Management\n\nIf Simple Posterior Dislocation\n- Closed reduction\n- Observe post reduction for delayed signs of vascular or compartment syndrome\n- Long arm posterior splint with elbow in 90 degree flexion\n\n## Follow Up Timing\n\nAdmission\n- Vascular Injury\n- Open Dislocation\n- Unable to successfully close reduce the elbow\n\nUrgent (<3 days)\n- Especially for complex dislocation, anterior dislocation or peripheral nerve injury\n\nLess Urgent (< 7 days)\n- For simple posterior dislocations without neurovascular compromise\n- 1 week of immobilization with early range of motion exercises\n\n## Notes\n\nClassification:\n- Simple: No associated fracture\n- Complex: Associated with elbow fracture (1/3 of elbow dislocations)\n\nTerrible Triad:\n- Elbow Dislocation\n- Coronoid process fracture\n- Radial head fracture\n\nComplications:\n- Ulnar nerve neuropraxia (14%)\n- Median nerve and brachial artery injuries (more common with anterior and open dislocations)\n- Compartment syndrome\n\n## References\n\n- Available at: http://www.wheelessonline.com/ortho/dislocations_of_the_elbow. Accessed August 1, 2017. [[Source](http://wheelessonline.com/)]\n"
		},
		{
			"slug": "emergency-drug-card-adult",
			"title": "Emergency Drug Card - Adult",
			"authors": [
				"Rob Bryant, MD",
				"Amie Hatch, PharmD, BCPS",
				"Jeremy Bair, PharmD"
			],
			"created": "2013/09/11",
			"updates": null,
			"categories": [
				"Pharmacology",
				"Critical Care"
			],
			"body": "\n\n\n## Rapid Sequence Intubation\n\n| Drug                                      | Dose                                                                                                                   |\n| ----------------------------------------- | ---------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Etomidate</span>       | 0.3mg/kg (~20mg) IV push over 30-60 sec; onset 10-20 sec                                                               |\n| <span class=\"drug\">Lidocaine 2%</span>    | 1-2mg/kg (~100mg) IV push over 1min (20mg=1mL)                                                                         |\n| <span class=\"drug\">Rocuronium</span>      | 0.6-1.2 mg/kg (~70mg) IV push; onset 1-2 min                                                                           |\n| <span class=\"drug\">Succinylcholine</span> | **IV:** 1-1.5 mg/kg (~100 mg) IV push over 10-30 sec; onset 30-60 sec<br>**IM:** 3-4 mg/kg (max 150 mg); onset 1-4 min |\n| <span class=\"drug\">Vecuronium</span>      | 0.08-0.1 mg/kg (~10mg) IV push; onset 2-3 min                                                                          |\n\n## Cardiac\n\n| Drug                                   | Dose                                                                                                                                                                                                                                |\n| -------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Amiodarone</span>   | **Cardiac Arrest (pulseless):**300 mg IV push, may repeat 150 mg IV push in 3-5 min<br>**Wide complex tachycardia (stable):** 150 mg IV over 10 min, then 1 mg/min infusion x 6 hours, then 0.5 mg/min infusion x 18 hrs            |                                                                                                                                                        |\n| <span class=\"drug\">Diltiazem</span>    | **Bolus:** 0.25 mg/kg (~20mg) IV bolus over 2 min, may repeat in 15 min, 0.35 mg/kg (~25mg) IV over 2 min<br>**Infusion:** 5-15 mg/hr IV                                                                                            |\n| <span class=\"drug\">Esmolol</span>      | **Bolus:** 500 mcg/kg IV push over 1 min<br>**Infusion:** 50-300 mcg/kg/min IV                                                                                                                                                      |\n| <span class=\"drug\">Labetalol</span>    | **Bolus:** 20 mg IV push over 2 min; may administer 40-80 mg at 10 min intervals; MAX 300mg cumulative<br>**Infusion:** 2 mg/min IV, titrate to response; usual effective dose 50-200 mg; MAX 300 mg cumulative                     |\n| <span class=\"drug\">Nicardipine</span>  | **Infusion:** 2.5-15 mg/hr IV, increase by 2.5 mg/hr every 5-15 min                                                                                                                                                                 |\n| <span class=\"drug\">Procainamide</span> | **ACLS:** 20-50 mg/min IV until arrhythmia resolved, hypotension occurs, or QRS prolonged by 50% or total cumulative dose of 17mg/kg is given<br>**Loading Dose:** 1 gm (or 17 mg/kg) IV over 30 min<br>**Infusion:** 1-4 mg/min IV |\n\n## Sedation & Analgesia\n\n| Drug                               | Dose                                                                                                                                                                                                                   |\n| ---------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Fentanyl</span> | **Bolus:** 1 mcg/kg IV<br>**Infusion:** 25-150 mcg/hr IV, titrate to goal                                                                                                                                              |\n| <span class=\"drug\">Ketamine</span> | **IV:** 0.5-2 mg/kg IV push over 1 min, may repeat with half dose every 5-10 min PRN<br>**IM:** 3-8 mg/kg IM<br>**PO:** 6-10 mg/kg (mix with cola, give 30 min prior to procedure)<br>**Infusion:** 2-80 mcg/kg/min IV |\n| <span class=\"drug\">Propofol</span> | **Bolus:** (Procedural sedation) 0.5-1 mg/kg IV push, may repeat with 0.5 mg/kg every 3-5 min PRN<br>**Infusion:** (Sedation) 10-80 mcg/kg/min IV                                                                      |\n\n## Electrolytes\n\n| Drug                                        | Indication / Dose                                                                                                                                                                                                                 |\n| ------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Calcium Gluconate</span> | **Hyperkalemia:** 1-3 grams IV push over 3-5 minutes                                                                                                                                                                              |\n| <span class=\"drug\">Magnesium Sulfate</span> | **Asthma:** 2 grams IV over 15-30 min<br>**Pre-eclampsia:** 4-6 gm IV over 15-20 min, followed by infusion of 1-2 gm/hr IV<br>**ACLS/torsades de pointes:** Pulseless 1-2 gm IV push over 1 min, with pulse give dose over 15 min |\n\n## Vasopressors & Inotropes\n\n| Drug                                     | Dose                                                                                                                     |\n| ---------------------------------------- | ------------------------------------------------------------------------------------------------------------------------ |\n| <span class=\"drug\">Dobutamine</span>     | 5-20 mcg/kg/min IV infusion                                                                                              |\n| <span class=\"drug\">Dopamine</span>       | 5-20 mcg/kg/min IV infusion                                                                                              |\n| <span class=\"drug\">Epinephrine</span>    | **ACLS:** 1 mg IV push every 3-5 min<br>**ETT:** 2-2.5 mg diluted in 10 ml of NS<br>**Infusion**: 0.02-0.5 mcg/kg/min IV |\n| <span class=\"drug\">Norepinephrine</span> | 0.01-0.3 mcg/kg/min IV infusion                                                                                          |\n| <span class=\"drug\">Phenylephrine</span>  | 10-200 mcg/min IV infusion                                                                                               |\n| <span class=\"drug\">Vasopressin</span>    | **ACLS:** 40 Units IV push x1<br>**Infusion:** sepsis 0.01-0.04 units/min IV (0.6-2.4 units/hr)                          |\n\n## Push Dose Pressors\n\n| Drug                                    | Dose                                                                                                                                                                                                                                                                                                                                         |\n| --------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Epinephrine</span>   | <ol><li>Take a 10 ml syringe</li><li>Draw up 9 ml NS</li><li>Draw up 1 ml of epinephrine 1:10,000 (0.1mg/ml) - this is the syringe used in ACLS</li><li>Label the syringe 10 mcg/ml Dose: 5-20 mcg (0.5-2 ml) IV every 5-10 min Duration: 5-10 min</li></ol>                                                                                 |\n| <span class=\"drug\">Phenylephrine</span> | <ol><li>Take a 10 ml syringe</li><li>Draw up 1 ml phenylephrine (10 mg/ml)</li><li>Inject into a 100 ml bag NS - this bag now contains phenylephrine 100 mcg/ml</li><li>Draw up into a 10 ml syringe and label 100 mcg/ml</li><li>THROW away the 100 ml NS bag</li></ol>**Dose:** 50-200 mcg (0.5-2ml) every 2-5 min<br>**Duration:** 2-5min |\n\n## Overdose / Unresponsive\n\n| Drug                                         | Dose                                                                                                                                                                                                                                                                                                                                                                      |\n| -------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">N-acetylcysteine</span>   | **1st dose:** 150 mg/kg IV over 1 hour<br>**2nd dose:** 50 mg/kg IV over 4 hours<br>**3rd dose:** 100 mg/kg IV over 16 hours                                                                                                                                                                                                                                              |\n| <span class=\"drug\">Dextrose</span>           | 25-50 g slow IV push (Dextrose 50%)                                                                                                                                                                                                                                                                                                                                       |\n| <span class=\"drug\">Fomepizole</span>         | **Loading dose:** 15 mg/kg IV over 30 min                                                                                                                                                                                                                                                                                                                                 |\n| <span class=\"drug\">Lipid Emulsion</span>     | **Bolus**: 1.5 ml/kg IV push over 1 min (may be repeated 1 to 2 times if persistent asystole)<br>**Infusion**: 0.25-0.5 ml/kg/min IV for 30-60 min                                                                                                                                                                                                                        |\n| <span class=\"drug\">Naloxone</span>           | **Bolus**: 0.04-2 mg IV/IO/IM/SC/IN every 2 minutes to effect<br>**Infusion**: 2/3 effective bolus dose per hour                                                                                                                                                                                                                                                          |\n| <span class=\"drug\">Digoxin Immune Fab</span> | **Cardiac glycoside overdose:** (life threatening arrhythmias or hyperkalemia)<ul><li>Empiric dosing (unknown level and severe toxicity): 10-20 vials</li><li>Acute ingestion, known quantity: vials = (0.8) x mg of digoxin ingested / (0.5)</li><li>Known digoxin level: vials = digoxin level (ng/ml) x weight (kg) / 100</li><li>Chronic toxicity: ~6 vials</li></ul> |\n\n## Vasodilators\n\n| Drug                                    | Dose                                                          |\n| --------------------------------------- | ------------------------------------------------------------- |\n| <span class=\"drug\">Nitroglycerin</span> | 10-300 mcg/min IV, increase by 5-10 mcg/min every 3-5 min     |\n| <span class=\"drug\">Nitroprusside</span> | 0.2-8 mcg/kg/min IV, increase by 0.5 mcg/kg/min every 3-5 min |\n\n## OBSTETRICS\n\n| Drug                                  | Indication / Dose                                                                                                                                                              |\n| ------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| <span class=\"drug\">Methergine</span>  | **Post abortal hemorrhage due to uterine atony:** 0.2 mg IM                                                                                                                    |\n| <span class=\"drug\">Misoprostol</span> | **Post abortal hemorrhage due to uterine atony:** routes include PO, SL, buccal, vaginal, and rectal. Dose varies ~200-800 mcg. Consult OB/GYN for institution specific dosing |\n| <span class=\"drug\">RhoGAM</span>      | **Threatened termination of pregnancy:**<br>**>13 weeks gestation:** 300 mcg IM<br>**&lt;13 weeks gestation:** 50 mcg IM (300 mcg ok if 50 mcg not available)                  |\n\n## Psychiatric\n\n| Drug                                  | Dose                                                                                  |\n| ------------------------------------- | ------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Haloperidol</span> | 2-10 mg IV/IM every 30 min                                                            |\n| <span class=\"drug\">Olanzapine</span>  | 5-10 mg IM may repeat in 2 hours x 2 doses (max 30 mg/day)                            |\n| <span class=\"drug\">Ziprasidone</span> | 10-20 mg IM may repeat 10 mg dose in 2 hours or 20 mg dose in 4 hours (max 40 mg/day) |\n\n## Miscellaneous\n\n| Drug                                             | Dose                                                                                                                                                                                                                                                                                                 |\n| ------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Alteplase (rtPA)</span>       | **Stroke:** 0.9 mg/kg (not to exceed 90 mg), give 10% of dose as IV bolus followed by 90% over 1 hour<br>**PE (acute massive with pulses):** 100 mg IV infusion over 2 hours<br>**PE (cardiac arrest only):** 50 mg IV push, repeat with 50 mg IV push in 15 minutes if no ROSC                      |\n| <span class=\"drug\">Desmopressin (DDAVP)</span>   | **Reversal of platelet dysfunction in patients on aspirin:** 0.3 mcg/kg IV<br>Dilute in 50 ml NS and give over 15-30 minutes                                                                                                                                                                         |\n| <span class=\"drug\">Factor VII</span>             | 20-80 mcg/kg IV push over 3-5 min (use ideal body weight, dose depends on indication)                                                                                                                                                                                                                |\n| <span class=\"drug\">Unfractionated Heparin</span> | **Venous thromboembolism:** Bolus 80 U/kg IV, infusion 18 U/kg/h IV<br>**ACS:** Bolus 60 U/kg IV (max 4000 U), infusion 12 U/kg/h (max 1000 U/h)                                                                                                                                                     |\n| <span class=\"drug\">Octreotide</span>             | **Bolus:** 25-50 mcg IV push over 3 min<br>**Infusion:** 25-50 mcg/hr IV                                                                                                                                                                                                                             |\n| <span class=\"drug\">Tenecteplase</span>           | Single weight based bolus dose for STEMI<ul><li>&lt;60 kg = 30 mg IV bolus over 5seconds</li><li>60-69 kg = 35 mg IV bolus over 5 seconds</li><li>70-79 kg = 40 mg IV bolus over 5 seconds</li><li>80-89 kg = 45 mg IV bolus over 5 seconds</li><li>≥90 kg = 50 mg IV bolus over 5 seconds</li></ul> |\n| <span class=\"drug\">Tranexamic Acid (TXA)</span>  | **Trauma hemorrhage:** 1 gram IV load over 10 mins followed by 1 gram IV infusion over the next 8 hours                                                                                                                                                                                              |\n\n## Acknowledgements\n\n_Prepared by: Amie Hatch, PharmD, BCPS and Jeremy Bair, PharmD,BCPS. Updated AUG2013._\n\n_This document presents an evidence-based approach that is appropriate for most patients. It should be adapted to meet the needs of individual patients and situations, and should not replace clinical judgment._\n\n## References\n"
		},
		{
			"slug": "emergency-drug-card-peds",
			"title": "Emergency Drug Card - Pediatric",
			"authors": [
				"Rob Bryant, MD",
				"Amie Hatch, PharmD, BCPS",
				"Jeremy Bair, PharmD"
			],
			"created": "2013/09/11",
			"updates": null,
			"categories": [
				"Pharmacology",
				"Critical Care",
				"Pediatrics"
			],
			"body": "\n\n\n## PALS\n\n| Drug                                           | Indication / Dose                                                                                                                                                                                                           |\n| ---------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Adenosine</span>            | **Pediatric tachycardia with a pulse and poor perfusion**: 0.1 mg/kg IV rapid bolus (max 6 mg), second dose 0.2 mg/kg (max 12 mg)                                                                                           |\n| <span class=\"drug\">Amiodarone</span>           | **Cardiac Arrest (pulseless):** 5 mg/kg IV/IO (max 300 mg), repeat twice to a max of 15 mg/kg/day<br>**Wide complex tachycardia (stable):** 5 mg/kg IV over 20-60 minutes (max 300 mg), may repeat to a max of 15 mg/kg/day |\n| <span class=\"drug\">Atropine</span>             | **Pediatric bradycardia with pulse and poor perfusion:** 0.02 mg/kg (max dose 0.5 mg); May repeat once.                                                                                                                     |\n| <span class=\"drug\">Calcium Chloride 10%</span> | 20 mg/kg IV/IO (0.2 ml/kg) (max dose 2 g)<br>For non-cardiac arrest, use calcium gluconate, push slowly                                                                                                                     |\n| <span class=\"drug\">Dextrose 25%</span>         | 0.5-1 g/kg (2-4 ml/kg) slow IV/IO push (for newborns, use dextrose 10% 5-10 ml/kg)                                                                                                                                          |\n| <span class=\"drug\">Epinephrine 1:10,000</span> | **Cardiac Arrest (pulseless)**: 0.01 mg/kg (0.1 ml/kg of 1:10,000 concentration) IV/IO every 3-5 min (max 1 mg)                                                                                                             |\n| <span class=\"drug\">Magnesium Sulfate</span>    | **Pulseless VT with torsades de pointes:** 25-50 mg/kg (max 2 g) IV/IO<br>Torsades de pointes with a pulse: 25-50 mg/kg IV, push slowly<br>Asthma: 25-50 mg/kg IV over 10-20 minutes (max single dose 2 g)                  |\n| <span class=\"drug\">Procainamide</span>         | **Pediatric tachycardia with a pulse and poor perfusion:** 15 mg/kg IV/IO over 30-60 minutes<br> Infusion: 20-80 mcg/kg/min                                                                                                 |\n| <span class=\"drug\">Sodium Bicarbonate</span>   | 1 mEq/kg slow IV/IO (Use 4.2% concentration if &lt;5 kg)                                                                                                                                                                    |\n\n## Rapid Sequence Intubation\n\n| Drug                                      | Dose                                                                                                                                                                                                                                                          |\n| ----------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Etomidate</span>       | 0.3 mg/kg IV push over 30-60 sec; onset 10-20 sec                                                                                                                                                                                                             |\n| <span class=\"drug\">Lidoocaine 2%</span>   | 1-2 mg/kg IV push over 1 min (20 mg = 1 mL)                                                                                                                                                                                                                   |\n| <span class=\"drug\">Rocuronium</span>      | 0.6-1.2 mg/kg IV push; onset 1-2 min                                                                                                                                                                                                                          |\n| <span class=\"drug\">Succinylcholine</span> | **Infants:** 2 mg/kg IV push over 10-30 sec; onset 30-60 sec (Consider <span class=\"drug\">atropine</span>)<br>**Children:** 1-1.5 mg/kg IV push over 10-30 sec (Consider <span class=\"drug\">atropine</span>)<br>**IM:** 3-4 mg/kg (max 150 mg); onset 1-4 min |\n| <span class=\"drug\">Vecuronium</span>      | 0.1 mg/kg IV push; onset 2-3 min                                                                                                                                                                                                                              |\n\n## Psychiatric\n\n| Drug                                  | Dose                            |\n| ------------------------------------- | ------------------------------- |\n| <span class=\"drug\">Haloperidol</span> | 0.025-0.05 mg/kg per dose IV/IM |\n\n## Vasopressors & Inotropes\n\n| Drug                                     | Dose                                                                                  |\n| ---------------------------------------- | ------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Dobutamine</span>     | 5-20 mcg/kg/min IV                                                                    |\n| <span class=\"drug\">Dopamine</span>       | 5-20 mcg/kg/min IV                                                                    |\n| <span class=\"drug\">Epinephrine</span>    | 0.05-1 mcg/kg/min IV                                                                  |\n| <span class=\"drug\">Norepinephrine</span> | 0.1-2 mcg/kg/min IV                                                                   |\n| <span class=\"drug\">Phenylephrine</span>  | **Bolus:** 5-20 mcg/kg/dose IV every 10-15 min<br>**Infusion:** 0.1-0.5 mcg/kg/min IV |\n| <span class=\"drug\">Vasopressin</span>    | Limited Data                                                                          |\n\n## Seizure\n\n| Drug                                    | Dose                                                                                              |\n| --------------------------------------- | ------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Diazepam</span>      | 0.2-0.5 mg/kg PR                                                                                  |\n| <span class=\"drug\">Fosphenytoin</span>  | 20 mg/kg IV over 20 minutes                                                                       |\n| <span class=\"drug\">Levetiracetam</span> | 20 mg/kg IV over 20 minutes                                                                       |\n| <span class=\"drug\">Lorazepam</span>     | 0.1 mg/kg IV                                                                                      |\n| <span class=\"drug\">Midazolam</span>     | 0.2 mg/kg IN using the 5 mg/ml concentration                                                      |\n| <span class=\"drug\">Phenobarbital</span> | 10-20 mg/kg IV (max dose 800 mg) IV over 20-60 min, (see pharmacist for dilution recommendations) |\n\n## Vasodilators\n\n| Drug                                    | Dose                                                                           |\n| --------------------------------------- | ------------------------------------------------------------------------------ |\n| <span class=\"drug\">Nitroglycerin</span> | 0.25-0.5 mcg/kg/min, increase by 0.5-1 mcg/kg/min q3-5 min (max 20 mcg/kg/min) |\n| <span class=\"drug\">Nitroprusside</span> | 0.2-8 mcg/kg/min                                                               |\n\n## Allergic Reactions\n\n| Drug                                         | Dose                                                                                                                    |\n| -------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Dexamethasone</span>      | **IV or oral:** 0.6 mg/kg (max 12 mg) (may use IV solution PO)                                                          |\n| <span class=\"drug\">Diphenhydramine</span>    | **IV:** 1-1.25 mg/kg                                                                                                    |\n| <span class=\"drug\">Epinephrine</span>        | **IM:** 0.01 mg/kg every 5-15 minutes as needed (1:1,000 concentration)<br>**Continuous infusion:** 0.1-1 mcg/kg/min IV |\n| <span class=\"drug\">Famotidine</span>         | **IV:** 0.25 mg/kg                                                                                                      |\n| <span class=\"drug\">Methylprednisolone</span> | **IV:** 1-2 mg/kg IV (max 125 mg)                                                                                       |\n| <span class=\"drug\">Ranitidine</span>         | **Oral:** 2 mg/kg PO (max 150 mg)<br>**IV:** 0.5-1 mg/kg IV (max 50 mg)                                                 |\n\n## Sedation & Analgesia\n\n| Drug                                | Dose                                                                                                                                                                                                 |\n| ----------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Fentanyl</span>  | **IV:** 1 mcg/kg IV <br>**Intranasal:** 1-2 mcg/kg (max 100 mcg) using the 50 mcg/ml concentration (no more than 1 ml/nare)                                                                          |\n| <span class=\"drug\">Ketamine</span>  | **Procedural sedation:** 0.5-2 mg/kg IV push over 1 min, may repeat with half dose every 5-10 min PRN<br>**IM:** 3-8 mg/kg IM<br>**PO:** 6-10 mg/kg (mix with cola, give 30 min. prior to procedure) |\n| <span class=\"drug\">Lorazepam</span> | **IV:** 0.05-0.1 mg/kg IV                                                                                                                                                                            |\n| <span class=\"drug\">Midazolam</span> | **IV:** 0.1 mg/kg IV<br>**Intranasal:** 0.4 mg/kg (max 10 mg) using the 5 mg/ml concentration                                                                                                        |\n| <span class=\"drug\">Morphine</span>  | **IV:** 0.1 mg/kg IV                                                                                                                                                                                 |\n| <span class=\"drug\">Propofol</span>  | **Bolus (procedural sedation):** 0.5-1 mg/kg IV push, may repeat with 0.5 mg/kg every 3-5 min PRN                                                                                                    |\n\n## Overdose & Unresponsive\n\n| Drug                                       | Dose                                                                                                                                                                                                               |\n| ------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| <span class=\"drug\">N-acetylcysteine</span> | **1st dose:** 150 mg/kg IV over 1 hour<br>**2nd dose:** 50 mg/kg IV over 4 hour<br>**3rd dose:** 100 mg/kg IV over 16 hour                                                                                         |\n| <span class=\"drug\">Dextrose</span>         | **Infants &le; 6 months:** 0.25-0.5 g/kg/dose slow IV push (1-2 ml/kg/dose of D25 or 2.5-5ml/kg/dose of D10)<br>**Children > 6 months:** 0.5-1 g/kg/dose slow IV push (2-4 ml/kg/dose of D25, 5-10 ml/kg/dose D10) |\n| <span class=\"drug\">Flumazenil</span>       | **Benzodiazepine reversal:** 0.01 mg/kg (up to 0.2 mg) IV over 15 seconds.<br>May repeat 0.01 mg/kg (up to 0.2 mg) every min to max cumulative dose of 0.05 mg/kg or 1 mg.                                         |\n| <span class=\"drug\">Fomepizole</span>       | **Loading dose:** 15 mg/kg IV over 30 min                                                                                                                                                                          |\n| <span class=\"drug\">Morphine</span>         | **Total reversal required:** 0.1 mg/kg IV/IO/IM/SC/IN every 2 min PRN (max 2 mg)<br>**Infusion:** 0.002-0.16 mg/kg/hr IV                                                                                           |\n\n## Miscellaneous\n\n| Drug                                                     | Dose                                                                                                                                                                               |\n| -------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| <span class=\"drug\">Alprostadil (prostaglandin E1)</span> | **Patent ductus arteriosus:** 0.05-0.1 mcg/kg/min;<br>once therapeutic response is achieved reduce rate to lowest effective dose.                                                  |\n| <span class=\"drug\">Factor VIII</span>                    | **Minor bleeding:** 10-15 IU/kg IV push over 3-5 min<br>**Moderate bleeding:** 10-30 IU/kg IV push over 3-5 min<br>**Life-threatening bleeding:** 30-50 IU/kg IV push over 3-5 min |\n| <span class=\"drug\">Unfractionated Heparin</span>         | **VTE:** Bolus 75 U/kg given over 10 min, infusion 15-20 U/kg/hr                                                                                                                   |\n| <span class=\"drug\">Ondansetron</span>                    | **IV or oral:** 0.15 mg/kg (max 4 mg)                                                                                                                                              |\n\n## Acknowledgements\n\n_Prepared by: Amie Hatch, PharmD, BCPS and Jeremy Bair, PharmD, BCPS. Updated AUG 2013._\n\n_This document presents an evidence-based approach that is appropriate for most patients. It should be adapted to meet the needs of individual patients and situations, and should not replace clinical judgment._\n\n## References\n"
		},
		{
			"slug": "emtala-rules",
			"title": "EMTALA Transfer Rules",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/09/14",
			"updates": null,
			"categories": [
				"EMS"
			],
			"body": "\n\n\nThe Emergency Medical Treatment and Labor Act (EMTALA) is a federal law that requires anyone coming to an ED be stabilized and treated, regardless of their insurance status or ability to pay\n\n- Known as “anti-dumping law”\n- Goal: Ensure “adequate first response to a medical crisis for all patients”\n\n## Rules for the transferring ED\n\nMedically screen patients to determine whether a medical emergency exists (regardless of insurance). This goes beyond a triage assessment.\nStabilize patients with medical emergencies to reasonably ensure that no deterioration will result from patient's transfer.\nRestrict transfer of non-stabilized patients to 2 circumstances:\n\n1. Patient requests a transfer in writing after being informed of the risks involved and the hospital’s duty to treat under EMTALA, or\n2. A physician certifies that the medical benefits expected from transfer outweigh the risks involved in the transfer (e.g. need higher level of care)\n\n**Pregnancy:** When having contractions, an emergency medical condition exists when:\n\n- Inadequate time for safe transfer to another hospital before delivery, or\n- Transfer may pose a threat to the health/safety of patient or unborn child\n\n## Steps when transferring a patient\n\n1. Provide medical treatment to minimize the risk of transfer\n2. Obtain patient’s written consent for transfer\n3. Provide signed certificate of transfer\n4. Assure that the transfer takes place with qualified personnel and equipment\n5. Send copies of medical records related to the emergency condition\n\n## Obligation of receiving ED\n\nIf have available space and qualified personnel for treating the patient:\n\n1. Agree to accept transfer of the patient and to provide appropriate medical tx\n2. Regional referral centers and hospitals with specialized capabilities cannot refuse to accept an appropriate transfer if they have the capacity\n\n## Fines under EMTALA\n\nA physician can be fined for:\n\n- Failing to respond to an emergency while on-call\n- Failing to perform a screening exam\n- Failing to inform emergency patients of the risks and benefits of transfer\n- Signing a transfer certification when he or she can reasonably be expected to know that the risks outweigh the benefits\n\nFine = $25,000 or $50,000 per violation (hospital with &lt;100 beds vs &ge;100 beds)\n\n## References\n\n- EMTALA. Available at: http://www.acep.org/content.aspx?id=25936. Accessed August 1, 2017.\n- AMA Ethics Resource Center. Available at: http://www.ama-assn.org/delivering-care/medical-ethics. Accessed August 1, 2017.\n"
		},
		{
			"slug": "end-of-shift-feedback",
			"title": "End-of-Shift Feedback",
			"authors": [
				"David Thompson, MD"
			],
			"created": "2011/12/09",
			"updates": null,
			"categories": [
				"Education and Policy"
			],
			"body": "\n\n\n## For the learner to answer\n\n- What went well on today’s shift?\n- What’s something you can work on for your next shift?\n- What was something you learned today? \n\n## For the educator to answer\n\n- I noticed you did a great job with...\n- Something I noticed that I think you could work on... \n- A teaching point to remember from this shift is... \n\n## Feedback Ideas\n\n**Presentations**\n\n- History and physical exam: Was it complete? EM-focused?\n- Logically presented?\n- Differential diagnoses\n- Management plan\n\n**Procedures**\n\n- Knowledge of risks/benefits and skill competency\n- Ability to read xrays and EKGs\n- Bedside ultrasound skills\n\n**Work style**\n\n- Efficiency and multitasking skills\n- Attitude and motivation\n- Patient advocacy\n- Knowledge and/or pursuit of evidence-based medicine\n\n**Professionalism**\n\n- Documentation\n- Dealing with nurses, residents, consultants, admission teams \n\n**ACGME Core Competencies**\n\n- Patient care\n- Medical knowledge\n- Professionalism\n- Interpersonal/communication skills \n- Practice-based learning/improve \n- Systems-based practice\n\n## References\n"
		},
		{
			"slug": "epicondyle-fracture-medial",
			"title": "Elbow Injuries - Epicondyle Fracture (Medial)",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Medial epicondyle fracture drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/epicondyle-fracture-medial/image-1.png)\n\n## Xray Views\n\nElbow XR: AP, lateral, external oblique\n\n## Acute Management\n\n- Long-arm posterior splint with elbow at 90° flexion\n- Consider a long arm cast instead\n\n## Operative Indications\n\n- \\>5 mm displacement\n- Ulnar nerve dysfunction\n- Entrapment of avulsed fracture fragment in joint\n- Displacement in high level athletes\n\n## Follow-up Timing\n\n- Non-operative: Follow up in 5-7 days\n- Operative: Follow up in 2-3 days\n\n## Notes\n\nComplications: Ulnar nerve entrapment & injury\n\n- Usually in children 9-14 years old\n- May be mistaken for medial epicondyle ossification center\n- Associated with elbow dislocations\n- Most can be managed non-operatively\n\n## References\n\n- Wheeless. Available at: http://www.wheelessonline.com/ortho/medial_epicondyle_frx_of_the_humerus. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/pediatrics/4008/medial-epicondylar-fractures--pediatric. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/medial-epicondyle-fracture-1. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Department of Orthopedics\n"
		},
		{
			"slug": "epicondylitis-lateral-or-medial",
			"title": "Elbow Injuries - Epicondylitis, Lateral or Medial",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Epicondylitis drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/epicondylitis-lateral-or-medial/image-1.png)\n\n## Xray Views\n\n**No XRs:** A clinical diagnosis.\n**Lateral:** Focal epicondyle tenderness, decreased grip strength, pain with resisted wrist extension.\n**Medial:** Focal epicondyle tenderness, pain with resisted wrist flexion and forearm pronation.\n\n## Acute Management\n\n- Elbow rest.\n- Ice.\n- Daily NSAIDs.\n- Counter-force strap brace.\n- Wrist stretching and strengthening exercises.\n\n## Follow-up Timing\n\nRoutine follow up with primary care physician.\n\n## Notes\n\n### Lateral\n\n- Overuse of forearm extensor and supinator muscles\n- Associated with radial tunnel syndrome\n\n### Medial\n\n- Overuse of forearm flexor and pronator muscles\n- Associated with ulnar neuropathy and ulnar collateral ligament insufficiency\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/adult_lateral_condyle_fracure. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/sports/3082/lateral-epicondylitis-tennis-elbow. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Dept of Orthopedics.\n"
		},
		{
			"slug": "ethylene-glycol",
			"title": "Toxic Alcohol Ingestion - Ethylene Glycol",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/06/08",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\nGeneral concepts for all 3 toxic alcohols\n\n-  Parent compounds (not metabolites) cause high osmolal gap\n-  When NAD depleted, pyruvate converts to lactate, which then causes lactic acidosis\n-  See metabolism diagram below\n\n## Ethylene Glycol (EG): Factoids\n\nFound in antifreeze, coolants, deicing solutions, ink in stamp pads and ballpoint pens\n\n**Pharmacology**:\n\n- Peak serum concentration 1-4 hours, elimination half-life 3 hours\n- Minimum lethal dose 1-1.5 mL/kg \n- Metabolites (eg. oxalate acid) cause toxicity, but do NOT cause osmolal gap\n\n**Labs:** \n\n- High anion gap metabolic acidosis and high osmolal gap (early in patient course)\n\n## Classic Presentation \n\n1. Altered mental status\n2. Hypocalcemia\n3. Oxalate crystals in urine\n\n**Common Signs and Symptoms**\n\n- **Neurologic** – Nausea and vomiting, inebriation with euphoria, nystagmus, ataxia, myoclonic jerks… then CNS depression, hypotonia, seizures, coma\n- **Cardiopulmonary** – Hyperventilation from respiratory compensation of acidosis, hypoxia from heart failure, multiorgan failure, ARDS\n-  **Renal** – Flank pain, acute tubular necrosis, renal failure\n\n## Management\n\n- **Goal**: Prevent further formation of (<span class=\"drug\">fomipezole</span>) & eliminate toxic metabolites (dialysis)\n- **Antidote**: <span class=\"drug\">Fomipezole</span> inhibits alcohol dehydrogenase (alternative antidote= ethanol)\n- **Loading dose**: 15 mg/kg IV\n- **Maintenance dose**: 10 mg/kg IV every 12 hours x 2 days \n\n## American Academy of Clinical Toxicology guidelines\n\n**Indications for treatment of EG poisoning with FOMIPEZOLE: (any of following)**\n- Documented plasma ethylene glycol >20 mg/dL\n- Documented recent hx of ingesting toxic EG amounts and osmolal gap >10 mOsm/L\n- Strong suspicion of EG poisoning and at least 2 criteria:\n\n  1. Arterial pH &lt;7.3\n  2. Serum bicarbonate &lt;20 mEq/L\n  3. Osmolal gap >10 mOsm/L\n  4. Urine oxalate crystal present\n\n**Indications for treatment of EG toxicity with HEMODIALYSIS: (any of following)**\n\n1. Deteriorating clinical status despite supportive tx PLUS metabolic acidosis (arterial pH &lt; 7.25-7.3)\n2. Acute kidney injury with serum Cr > 3 mg/dL or increase in serum Cr by 1 mg/dL\n3. Acid-base/electrolyte abnormalities unresponsive to standard tx\n4. Old recommendation: EG level > 50 mg/dL\n\n_Note:_ <span class=\"drug\">Fomipezole</span> without hemodialysis is an option if normal renal function AND no metabolic acidosis\n\n## Metabolism of Alcohols\n\n![Metabolism of alcohols drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ethylene-glycol/image-1.png)\n\n## References\n\n- Marraffa JM, Cohen V, Howland MA. Antidotes for toxicological emergencies: a practical review. Am J Health Syst Pharm. 2012 Feb 1;69(3):199-212. doi: 10.2146/ajhp110014. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22261941)]\n- Kraut JF, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008 Jan;3(1):208-25. Epub 2007 Nov 28. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18045860)]\n- Jammalamadaka D, Raissi S. Ethylene glycol, methanol and isopropyl alcohol intoxication. Am J Med Sci. 2010 Mar;339(3):276-81. doi: 10.1097/MAJ.0b013e3181c94601. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20090509)]\n"
		},
		{
			"slug": "eye-ddx",
			"title": "Eye Anatomy and Key Diagnoses Rule of 2s",
			"authors": [
				"Puja Gopal, MD"
			],
			"created": "2017/04/14",
			"updates": null,
			"categories": [
				"Ophthalmology"
			],
			"body": "\r\n\r\n\r\nThe rule of 2s, as illustrated below, is a simple method with an anatomical approach to the major ocular diagnoses and is meant to provide a general framework to guide the physical exam and include or eliminate certain conditions. The rule of 2s is easy to remember as it contains the number 2 in the context of eyes and proceeds from layer to layer of the eye in an anterior to posterior direction highlighting the 2 major associated diagnoses of that layer.  \r\n\r\nThere is significant overlap among conditions that cause a red, painful or red and painful eye. Here are additional cards that may help in your evaluation:\r\n\r\n- [Painful Eye](/cards/eye-painful)\r\n- [Red Eye](/cards/red-eye)\r\n\r\n## Anterior Eye – Utilize slit lamp exam\r\n![anterior eye picture - conjunctiva (conjunctivitis and subconjunctival hemorrhage), cornea (corneal abrasion, corneal ulcer/infiltrate/keratitis, anterior chamber (cell/flare (uveitis, iritis), fluid (hyphema (blood), hypopyon (pus))), lens (cataract or swelling (as in hyperglycemia), dislocation)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/eye-ddx/image-1.png)\r\n\r\n## Posterior Eye – Use fundoscopy and ultrasound\r\n![posterior eye picture - vitreous (vitreous hemorrhage, posterior vitreous detachment), retina (retinal detachment, retinal vascular occlusion (central retinal artery or vein occlusion), optic nerve (optic neuritis (inflammation), temporal arteritis (ischemia)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/eye-ddx/image-2.png)\r\n\r\n## References\r\n\r\n- Nawar, E.W., Niska, R.W., Xu, J. National Hospital Ambulatory Medical Care Survey: 2005 Emergency Department Summary: Advance Data from Vital and Health Statistics; No. 386. National Center for Health Statistics, Hyattsville, MD; 2007. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17703794)]\r\n- Sharma R, Brunette DD. Ophthalmology. In: Marx JA, Hockberger RS, Walls RM. eds. Rosen's Emergency Medicine - Concepts and Clinical Practice. 8th ed. Philadelphia, PA: Elsevier/Saunders, 2014.\r\n- Walker RA, Adhikari S. Eye Emergencies. In: Tintinalli JE et al, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York: McGraw-Hill, 2011.\r\n"
		},
		{
			"slug": "eye-painful",
			"title": "Painful Eye",
			"authors": [
				"Puja Gopal, MD"
			],
			"created": "2017/07/14",
			"updates": null,
			"categories": [
				"Ophthalmology"
			],
			"body": "\n\nThere is significant overlap among conditions that cause a red, painful or red and painful eye. Here are additional cards that may help in your evaluation:\n\n- [Eye Differential Diagnoses](/cards/eye-ddx)\n- [Red Eye](/cards/red-eye)\n\n## Orbital Cellulitis\n\n- Infectious inflammation that occurs posterior to the orbital septum, within the bony orbit\n- Commonly a secondary infection extending from infections of the paranasal sinuses or upper respiratory tract\n- **Symptoms**: Erythema and edema of the eyelids, vision loss, fever, headache, and diplopia\n- **Physical exam**: Proptosis, chemosis, discharge, pain with eye movement, afferent pupillary defect\n- **Diagnosis**: CT imaging is indicated in patients with periorbital inflammation, proptosis, ophthalmoplegia, and worsening visual acuity. MRI can be used when CT is inconclusive.\n- **Treatment**: \n\t- Emergent ophthalmology consultation\n\t- Broad-spectrum IV antibiotics\n\t- Surgery may be required to drain orbital abscesses or remove inciting foreign bodies\n\n## Optic Neuritis\n\n![normal optic disc in optic neuritis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/eye-painful/image-1.png)\n\n- A clinical diagnosis\n- Inflammatory demyelination of the optic nerve\n- **Symptoms**: Unilateral visual loss, change in color perception or visual field defects over hours to days; pain worse with eye movements\n- **Physical exam**: Visual field defect and afferent pupillary defect, 2/3 of patients will have normal appearing optic disk \n- **Diagnostic**: Consider MRI brain/orbits for prognosis due to association with multiple sclerosis or when the diagnosis is unclear\n- **Treatment**: IV methylprednisolone (250 mg every 6 hours for 3 days followed by an oral prednisone taper)\n\n## Keratitis\n\n![keratitis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/eye-painful/image-2.png)\n\n- Inflammation may be superficial and involve only the corneal epithelium or deep with ulceration through the epithelium or the epithelium may remain intact and the stroma becomes inflamed (aka stromal keratitis)\n- **Symptoms**: photophobia, foreign body sensation, tearing, severe pain, decreased visual acuity\n- **Physical exam**: conjunctival injection, corneal infiltrate/round opacity (typically seen as a white spot) that will stain with flourescin, may see cell and flare in anterior chamber\n\t- In stromal keratitis, the corneal opacity will not stain with fluorescein dye.\n- Complications: Corneal ulcer and perforation, scarring with partial or complete visual loss, glaucoma, uveitis\n\n### Noninfectious Causes\n\n- Superficial Punctate Keratitis (SPK): Multiple causes including blepharoconjunctivitis, UV light exposure (e.g. welders), dry eye syndrome, topical drug toxicity (e.g. tobramycin, eye drop preservatives)\n\t- **Physical exam**: Characterized by pinpoint areas of flourescin uptake\n\t- **Treatment**: Address the underlying cause\n- Ulcerative Keratitis: Can be seen in association with a wide range of collagen vascular diseases (e.g. rheumatoid arthritis, sarcoidosis), DM (neurotrophic keratitis), vitamin A deficiency or allergic disease (atopic keratoconjunctivitis), among others \n  - **Treatment**: Determine and treat underlying cause\n\n### Infectious Causes\n- BACTERIAL: Commonly occurs due to _Streptococcus pneumoniae_ and in contact lens wearers _Pseudomonas_, _Staphylococcus aureus_ and _Serratia_\n\t- **Treatment**: Cephalosporin (e.g. cefazolin) + aminoglycoside or floroquinolone\n- VIRAL\n\t- HSV: dentritic corneal defects on exam\n  - **Treatment**: Topical trifluridine, oral acyclovir as alternative or adjunct \n\t- VZV: forehead and upper eyelid vesicular lesions; dendritic lesions don't have well stained terminal bulbs and ulceration is uncommon compared to HSV\n  - **Treatment**: Oral acyclovir or oral valacyclovir\n\t- Adenovirus: often bilateral diffuse punctate lesions on exam, palpable preauricular lymph node; \n  - **Treatment**: Resolves without treatment in 7-10 days\n- FUNGAL: Often due to _Fusarium_ and _Aspergillus_ due to traumatic injury from vegetable matter; are often initially treated as bacterial until corneal culture results are available\n  - **Treatment**: Admit to hospital\n  - Mild cases - Topical antifungals\n  - Severe cases - Add systemic antifungals; topical steroids are contraindicated\n- AMOEBIC: Commonly _Acanthamoeba_; suspect in contact lens wearers with dentritiform lesions (thus often be confused with HSV); send corneal epithelium cultures if suspect; consult ophthalmologist\n  - **Treatment** typically involves topical amoebicidal agents\n\n## Corneal Abrasion\n- **Symptoms**: Pain, photophobia, excessive tearing\n- **Physical exam**: Visual acuity is normal unless the abrasion involves the visual axis or there is significant corneal edema; ciliary spasm may cause miosis; conjunctival injection\n- **Diagnosis**: green flourescence at damaged area/s of cornea under Wood's lamp or cobalt blue light on slit lamp\n- **Treatment**: \n  - Topical antibiotic such as erythromycin, or in contact lens wearers gentamicin or ciprofloxacin for Pseudomonal coverage\n  - Pain control options: Topical NSAIDs, cycloplegics, oral analgesics (e.g. acetaminophen)\n  - Do not patch\n  - Discontinue contact lens use until defect heals and symptoms resolve\n- **Followup**: Small abrasions heal quickly and generally require only a single 24 hour followup exam; if contact lens related, should be reexamined daily to ensure healing\n- _Indications for referral to opthalmologist_: Large abrasions, defects over visual axis, abrasions that become larger or more symptomatic the next day, or development of ulcer\n\n## References\n\n- Dargin J, Lowenstein R. The painful eye. Emerg Med Clin North Am. 2008 Feb;26(1):199-216. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18249263)]\n- Tsirouki T, Dastiridou AI, Ibánez flores N, et al. Orbital Cellulitis. Surv Ophthalmol. 2017; [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29248536)]\n"
		},
		{
			"slug": "fagan-nomogram",
			"title": "Fagan Nomogram",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/05/17",
			"updates": [
				"2017/02/13"
			],
			"categories": [
				"EBM"
			],
			"body": "\n\n\nDraw a line connecting your pre-test probability and your likelihood ratio. This provides you with your post-test probability.\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/fagan-nomogram/image-1.png)\n\n## References\n\n- Caraguel CGB, Vanderstichel R The two-step Fagan's nomogram: ad hoc interpretation of a diagnostic test result without calculation Evidence-Based Medicine 2013;18:125-128. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23468201)]\n"
		},
		{
			"slug": "fast-ultrasound",
			"title": "Ultrasound - Focused Assessment with Sonography in Trauma (FAST)",
			"authors": [
				"Wilma Chan, MD",
				"John Eicken, MD",
				"Mike Stone, MD"
			],
			"created": "2014/09/14",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology",
				"Trauma"
			],
			"body": "\n\n\n**Goals**: Evaluate for free fluid (i.e. blood) in the abdomen, pelvis, thorax, and pericardium in the setting of trauma.\n\n**Transducer**: Low-frequency curvilinear or phased-array\n\n**Windows**:4 windows are obtained to perform a complete FAST exam (Fig 1)\n\n![Transducer positions and directional indicator orientation for the abdominal and cardiac views in the FAST exam](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/fast-ultrasound/image-1.png)\n\nFigure 1: Transducer positions and directional indicator orientation (white dot) for the abdominal and cardiac views in the FAST exam\n\n## Normal Reference Measurements\n\nThe FAST exam is dichotomous, yielding either a negative or positive result.  A negative FAST exam is defined by the absence of fluid in all four imaging windows.  A positive FAST exam is defined by the presence, no matter how small, of any amount of fluid in any of the four windows.\n\nA meta-analysis of 62 studies including FAST exams of >18,000 patients revealed a sensitivity of 78.9% and specificity of 99.2% for the identification of intra-peritoneal free fluid (Stengel et al, 2005).\n\n## Right Upper Quadrant (RUQ) View\n\n**Anatomic landmarks:** Right mid-axillary line at the level of the xiphoid process\n\n- **Initial transducer orientation:** Longitudinal (parallel to exam bed) with directional indicator towards the patient’s axilla.\n- Include the diaphragm, the liver, and the entire right kidney\n- Fan through entire hepatorenal recess (Morison’s pouch), as well as the entire depth and length of the kidney including the inferior pole. \n- FAST is **POSITIVE** if anechoic free fluid identified in the hepatorenal recess—the potential space between liver and kidney (Fig 2).\n- Fluid cephalad to the diaphragm is in the thoracic cavity, and should raise concern for hemothorax in trauma.\n\n![Positive FAST in the RUQ view demonstrating echogenic clot in Morison’s pouch with adjacent anechoic free fluid](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/fast-ultrasound/image-2.png)\n\nFigure 2: Positive FAST in the RUQ view demonstrating echogenic clot in Morison’s pouch with adjacent anechoic free fluid (\\*).\n\n## Left Upper Quadrant (LUQ) View\n\n- **Anatomic landmarks:** Left posterior axillary line at the level of the xiphoid process.\n- **Initial transducer orientation:** Longitudinal (parallel to exam bed) with directional indicator towards the patient’s axilla.\n- Include the diaphragm, spleen, and entire left kidney\n- Fan through entire LUQ including kidney, spleen tip, and subdiaphragmatic space.\n- FAST is **POSITIVE** if free fluid identified in either the splenorenal recess OR in the subdiaphragmatic space between the spleen and diaphragm\n- Fluid cephalad to the diaphragm is in the thoracic cavity, and should raise concern for hemothorax in trauma.\n\n![Positive FAST in LUQ view demonstrating large amount of complex free fluid below the diaphragm, despite a lack of fluid in the splenorenal recess](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/fast-ultrasound/image-3.png)\n\nFigure 3: Positive FAST in LUQ view demonstrating large amount of complex free fluid (\\*) below the diaphragm (yellow arrows), despite a lack of fluid in the splenorenal recess (green arrows).\n\n## Pelvic View\n\n- **Anatomic landmarks**: Suprapubic region at the level of the symphysis pubis.\n- **Initial transducer orientations** (TWO views required):\n- Transverse with the directional indicator oriented to the patient’s right\n- Longitudinal with the directional indicator oriented to the patient’s head\n- Include entire depth of bladder in both views\n- FAST is **POSITIVE** if free fluid is identified posterior to the bladder and/or uterus.\n\n## Cardiac View\n\n- **Anatomic landmarks**: Subxiphoid space\n- **Initial transducer orientation**: Place the transducer nearly flat below the xyphoid process with the directional indicator oriented to the patient’s right and the probe face directed towards the patient’s left shoulder. Use an overhand grasp on the probe to apply steady downward pressure.\n- Include views of the entire heart with all 4 chambers and surrounding pericardium\n- FAST is **POSITIVE** if free fluid is identified between the heart and pericardial sac. \n\n## Struggling with the Exam?\n\n### Can’t find the spleen or left kidney?\n\n- The left kidney is often located more superior and posterior compared to the right kidney. Try placing the probe more posterior towards the left flank.\n\n### Can’t find the bladder?\n\n- Make sure you’re as close to the symphysis pubis as possible (don’t be shy!), and aiming the transducer towards the patient’s feet. Visualization of the bladder is improved prior to emptying of the bladder. Try FAST prior to insertion of a foley catheter or prior to the patient emptying their bladder.\n\n### Rib shadows obstructing view in RUQ and LUQ views?\n\n- Try rotating the transducer obliquely parallel to the ribs in order to fit between an intercostal space. A phased array transducer’s smaller footprint can reduce or eliminate rib shadows.\n\n### Can’t see the entire heart on the subxiphoid view?\n\n- Try moving the probe more to the patient’s right to use the liver as an acoustic window. You can also try increasing the depth of the image.\n\n## Common Errors: Failure to…\n\n- Fan through entire depth and length of target organs\n- Perform serial FAST exams in patients who develop changes in their vitals or exam\n- Appreciate that the FAST exam is not sensitive for the detection of a retroperitoneal hemorrhage or for the identification of solid organ injury\n- Appreciate that the FAST exam is not sensitive for the detection of small amounts (&lt;400-500 cc) of intra-peritoneal fluid\n- Appreciate that intra-peritoneal blood will not appear anechoic in patients presenting with delayed trauma. Blood clots typically exhibit mixed echogenicity.\n- Appreciate that the FAST exam cannot reliably differentiate between ascites and blood in patients with a history of ascites.\n\n## References\n\n- Rozycki GS, Ballard RB, Feliciano DV, Schmidt JA, Pennington SD. Surgeon-performed ultrasound for the assessment of truncal injuries: lessons learned from 1540 patients. Ann Surg. 1998;228(4):557-67. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9790345)]\n- Stengel D, Bauwens K, Sehouli J, et al. Systematic review and meta-analysis of emergency ultrasonography for blunt abdominal trauma. Br J Surg. 2001;88(7):901-12. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11442520)]\n- Stengel D, Bauwens K, Rademacher G, Mutze S, Ekkernkamp A. Association between compliance with methodological standards of diagnostic research and reported test accuracy: meta-analysis of focused assessment of US for trauma. Radiology. 2005;236(1):102-11. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15983072)]\n"
		},
		{
			"slug": "first-trimester-transvaginal-ultrasound",
			"title": "Ultrasound - Focused 1st Trimester Pregnancy, Transvaginal Exam",
			"authors": [
				"Matt Lipton, MD",
				"Mike Mallin, MD",
				"Mike Stone, MD"
			],
			"created": "2015/03/04",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology",
				"OBGYN"
			],
			"body": "\n\n\n**Goals:**\n\n1. Confirm intrauterine pregnancy (IUP) and estimating its viability\n2. Look for signs of ectopic pregnancy\n\n**Transducer:** High-frequency endocavitary transducer\n\n**Windows:** Transvaginal view using cervix as window\n\n## 1. Coronal / transverse view\n\n**Directional indicator:** Pointed to patient’s right side\n\n![Appropriate transducer orientation for the coronal transvaginal exam](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-transvaginal-ultrasound/image-1.png)\n\nFigure 1: Appropriate transducer orientation for the coronal transvaginal exam\n\n![Ectopic pregnancy on transvaginal ultrasound, coronal view. Shown is a yolk sac within an extra-uterine gestational sac (black arrow) adjacent to an empty endometrium, outside of the uterus](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-transvaginal-ultrasound/image-2.png)\n\nFigure 2: Ectopic pregnancy on transvaginal ultrasound, coronal view. Shown is a **yolk sac within an extra-uterine gestational sac** (black arrow) adjacent to an empty **endometrium (e)**, outside of the **uterus**.\n\n## 2.  Sagittal / longitudinal view\n\n**Directional indicator**: Pointed to anterior of patient (towards the ceiling)\n\n![Appropriate transducer orientation for the sagittal transvaginal exam](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-transvaginal-ultrasound/image-3.png)\n\nFigure 3: Appropriate transducer orientation for the sagittal transvaginal exam\n\n![Intrauterine pregnancy on transvaginal ultrasound, sagittal view. Shown is a gestational sac containing a yolk sac and within the endometrium](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-transvaginal-ultrasound/image-4.png)\n\nFigure 4: Intrauterine pregnancy on transvaginal ultrasound, sagittal view. Shown is a **gestational sac** containing a **yolk sac** and within the **endometrium.**\n\nBoth of these windows include a complete sweep through the uterus in each direction looking for a gestational sac and yolk sac or fetal pole within the endometrium.\n\n## Interpretation and Tips\n\nAn IUP for point-of-care purposes is defined as a **yolk sac or fetal pole within a gestational sac within the endometrium**. This indirectly excludes an ectopic pregnancy in an appropriate clinical setting.\n\nConsider measuring the distance between the gestational sac and the edge of uterus. If this endomyometrial mantle thickness is &lt;8 mm, then consider the possibility of an interstitial ectopic pregnancy.\n\nAn ectopic pregnancy will occasionally be seen as an extrauterine mass. However, free fluid in a pregnant patient without an IUP should also be considered an ectopic pregnancy until proven otherwise.\n\n## Pitfalls\n\n**Inserting the transducer too deeply.** \n\n- The transducer should be inserted to the cervix, using it as a window. If you continue to push once at the cervix, the transducer will frequently slide into the posterior fornix and only bowel/rectum will be seen.\n\n**Scanning with a full bladder.** \n\n- While the transabdominal approach is enhanced by a full bladder, the patient should empty their bladder prior to transvaginal scanning to improve visualization.\n\n**Calling a gestational sac an IUP.** \n\n- At least a yolk sac is needed. A pseudogestational sac with an ectopic pregnancy is possible.\n\n**Relying on the quantitative beta-HCG and “discriminatory zone” for decision-making.** \n\n- Over 40% of ectopic pregnancies will have beta-HCG levels below the discriminatory zone.\n\n**Considering an “inconclusive scan” negative for ectopic**. \n\n- Ectopic pregnancies are almost always ruled-out by finding an IUP. Absence of an extrauterine mass does not exclude ectopic pregnancy.\n\n**Failure to recognize specific high-risk populations.** \n\n- Patients undergoing assisted reproductive therapy have a much higher (1-3%) incidence of heterotopic pregnancy. Identification of an IUP does not exclude a co-existing ectopic in this group.\n\n## References\n\n- Wang R, Reynolds TA, West HH, et al. Use of a β-hCG discriminatory zone with bedside pelvic ultrasonography. Ann Emerg Med. 2011;58(1):12-20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Use+of+a+%CE%B2-hCG+discriminatory+zone+with+bedside+pelvic+ultrasonography.)]\n- Tayal VS, Cohen H, Norton HJ. Outcome of patients with an indeterminate emergency department first-trimester pelvic ultrasound to rule out ectopic pregnancy. Acad Emerg Med. 2004;11(9):912-7. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15347539)]\n"
		},
		{
			"slug": "first-trimester-ultrasound",
			"title": "Ultrasound - Focused 1st Trimester Pregnancy, Transabdominal Exam",
			"authors": [
				"Matt Lipton, MD",
				"Mike Mallin, MD",
				"Mike Stone, MD"
			],
			"created": "2015/02/25",
			"updates": null,
			"categories": [
				"Radiology",
				"Ultrasound",
				"OBGYN"
			],
			"body": "\n\n\n**Goals:**\n\n1. Confirm intrauterine pregnancy (IUP) and estimating its viability\n2. Look for signs of ectopic pregnancy\n\n**Transducer:** Low frequency curvilinear transducer\n\n**Windows:** Suprapubic view with a full bladder (improves ability to visualize the uterus) in longitudinal (sagittal) and transverse (axial) planes\n\n## Normal IUP Findings\n\n1. **Yolk sac:** Round fluid-filled structure within the gestational sac, located in the endometrium\n2. **Fetal pole:** Small mass located near the yolk sac\n\n![Normal early IUP showing yolk sac and fetal pole](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-ultrasound/image-1.png)\n\nFigure 1: Normal early IUP showing **yolk sac** and **fetal pole**\n\n![Close-up image of a normal early IUP showing a yolk sac within a gestational sac](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-ultrasound/image-2.png)\n\nFigure 2: Close-up image of a normal early IUP showing a **yolk sac** within a gestational sac\n\n## Normal Reference Measurements\n\n1. Fetal heart rate (FHR) between 120-160 bpm (can be as low as 100 bpm in early gestation)\n2. Myometrium surrounding the IUP should be &ge; 8mm (endomyometrial mantle)\n\n**How to use the serum quantitative beta-HCG**\n\n- Do not to use a single beta-HCG data point alone in ED patient management.\n- There is no cutoff value that has been shown to adequately identify those patients for which an IUP should be visualized.\n- Order the test if you are unable to find an IUP because Ob/Gyn consultants will want to trend the value. \n- **DO NOT** use a quantitative beta-HCG as a reason not to perform a bedside ultrasound. Many patients with ectopic pregnancy have values below the traditional cutoff of 2,000-2,500 mIU/mL.\n\n## Signs of Ectopic Pregnancy\n\n- **Failure to identify an IUP** is the first indication that an ectopic may be present.\n- Other signs include: Free fluid in the pelvis and/or masses in the adnexa\n- An ectopic pregnancy in the tube or ovary often has a “ring of fire” with color Doppler imaging. However, most ectopic pregnancies are not visible with transabdominal ultrasound.\n- **Free intraperitoneal fluid** in Morison’s pouch is a **sign of a ruptured ectopic** that will likely require operative intervention.\n\n![Empty fluid-filled sac within the endometrium. Given the absence of contents, you cannot differentiate gestational vs pseudogestational sac. This is not diagnostic of an IUP](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/first-trimester-ultrasound/image-3.png)\n\nFigure 3: **Empty fluid-filled sac** within the endometrium. Given the absence of contents, you cannot differentiate gestational vs pseudogestational sac. This is **not** diagnostic of an IUP.\n\n## Struggling with the Exam?\n\n**Can’t visualize the uterus?**\n\n- Perform the ultrasound before the patient urinates. If unable to visualize key structures, proceed to a transvaginal ultrasound.\n\n**Can’t find a yolk sac or fetal pole?**\n\n1. **There may not be an IUP**. The patient may have an ectopic pregnancy or a OOcompleted abortion.\n2. **It may be too early** to visualize an IUP with transabdominal scanning. IUPs are difficult to visualize before 6-6.5 weeks gestational age. This may require a transvaginal ultrasound instead, which can visualize earlier IUPs.\n\n## Common Errors\n\n- Only using close-up, zoomed view to evaluate for intrauterine pregnancy. Be sure to get a “big picture” view of the pelvis to identify all relevant structures prior to using the zoom function.\n\n**Mistaking a pseudogestational sac for an IUP**: \n\n- A pseudogestational sac is a small fluid collection from an endometrial reaction to hormones produced by the ectopic pregnancy. This will appear within the endometrial cavity and can be seen in up to 20% of ectopic pregnancies. You **MUST** visualize at least a yolk sac within a gestational sac (located in the endometrium) before an IUP can be confirmed.\n\n**Interstitial (cornual) pregnancy**: \n\n- Although most ectopic pregnancies occur in the fallopian tubes, 3% of ectopic pregnancies implant on the edge of the uterus. This form of ectopic pregnancy can be identified by noting an eccentric location of the gestational sac within the endometrium, often with &lt;8 mm of surrounding myometrium.\n\n**Assuming an IUP rules-out an ectopic pregnancy for those undergoing assisted reproductive therapies (ART) such as in-vitro fertilization.** \n\n- The risk of a heterotopic pregnancy is too high.\n\n**Using pulsed wave or color Doppler on the fetus to confirm fetal heart rate or viability.** \n\n- Both pulse wave and color Doppler inflict unnecessary thermal energy to the developing fetus. M-Mode is sufficient for measuring fetal heart rate.\n\n## References\n\n- Wang R, Reynolds TA, West HH, et al. Use of a β-hCG discriminatory zone with bedside pelvic ultrasonography. Ann Emerg Med. 2011;58(1):12-20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Use+of+a+%CE%B2-hCG+discriminatory+zone+with+bedside+pelvic+ultrasonography.)]\n- Tayal VS, Cohen H, Norton HJ. Outcome of patients with an indeterminate emergency department first-trimester pelvic ultrasound to rule out ectopic pregnancy. Acad Emerg Med. 2004;11(9):912-7. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15347539)]\n"
		},
		{
			"slug": "gallbladder-ultrasound",
			"title": "Ultrasound - Focused Biliary Assessment",
			"authors": [
				"John Eicken, MD",
				"Mike Stone, MD"
			],
			"created": "2015/01/01",
			"updates": null,
			"categories": [
				"Radiology",
				"Ultrasound",
				"Gastroenterology"
			],
			"body": "\n\n\n**Goals:** Evaluate for gallstones, signs of cholecystitis, dilation of common bile duct (CBD)\n\n**Transducer:** Low-frequency curvilinear or phased-array\n\n**Windows:** 3 windows, can be preformed in any order. Try alternative windows if initial choice unsuccessful.\n\n![Transducer positions for gallbladder scan. A: Intercostal, B: Subcostal, C: Lateral. Green line = costal margin. X = xiphoid process](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/gallbladder-ultrasound/image-1.png)\n\nFigure 1: Transducer positions for gallbladder scan. A: Intercostal, B: Subcostal, C: Lateral. Green line = costal margin. X = xiphoid process.\n\n**1. Intercostal View** \n\n- Anatomic landmarks: Right midclavicular line at the level of the xiphoid process\n- Initial transducer orientation: Transverse with marker towards the patient’s right\n\n**2. Subcostal View** \n\n- Anatomic landmarks: Right midclavicular line just below the costal margin\n- Initial transducer orientation: Sagittal with marker towards the patient’s head\n\n**3. Lateral View** \n\n- Anatomic landmarks: Right mid or anterior axillary line at the level of the xiphoid process\n- Initial transducer orientation: Sagittal with marker towards the patient’s head\n\n_All examinations should include evaluation of the key structures in 2 orthogonal (perpendicular) planes_\n\n## Normal Reference Measurements\n\n**1. Gallbladder wall &le;3 mm** (measure at near-field/superficial wall in longitudinal view)\n\n- **Differential Diagnosis if >3 mm**: \n  - Cholecystitis, heart failure, nephrotic syndrome, hypoalbuminemia, HIV/AIDS, tuberculosis, renal failure, ascites, acute hepatitis, adenomyomatosis, multiple myeloma\n\n**2. Common bile duct &le;5 mm** (can dilate after cholecystectomy & with advanced age) \n\n- Should be measured from inner wall to inner wall\n\n## Cholelithiasis\n\nTransducer orientation is transverse with marker towards the patient’s right\n\n![Cholelithiasis example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/gallbladder-ultrasound/image-2.png)\n\nFigure 2: Cholelithiasis. Note the gallstones with shadowing and normal gallbladder wall thickness\n\n## Acute Cholecystitis\n\n**Signs of cholecystitis:** \n\n- Gallstones\n- Thickened gallbladder wall\n- Pericholecystic fluid\n- Sonographic Murphy’s sign\n\nTransducer orientation is sagittal with marker towards the patient’s head\n\n![Acute cholecystitis example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/gallbladder-ultrasound/image-3.png)\n\nFigure 3: Acute cholecystitis. Note the gallstones with shadowing, pericholecystic fluid, and thickened gallbladder wall.\n\n## Struggling with the Exam?\n\n### Can’t find the gallbladder?\n\n- Have the patient sit up and roll onto their left side to improve visualization. Try having the patient take a deep breath and hold it.\n\n### Can’t find the common bile duct (CBD)?\n\n- From the intercostal window, identify the gallbladder in a short axis. Slowly angle the ultrasound beam towards the patient’s head, passing all the way through the gallbladder and continuing upwards. The CBD will be seen in a long axis, just superficial to the portal vein. Use color Doppler to distinguish the CBD from the hepatic artery and portal vein.\n\n### Rib shadows obstructing view?\n\n- Try rotating the probe obliquely to mirror the angle of the intercostal space. If unsuccessful, you can ask the patient to take and hold a deep breath to bring the gallbladder below the ribs.\n\n## Common Errors: Failure to…\n\n- Bowel gas can cause indistinct “dirty” shadowing. Be sure shadows originate from discrete hyperechoic foci (stones) within the gallbladder lumen.\n- Edge artifact can cause shadows from the sides of the gallbladder due to refraction.\n- Scan all the way through the gallbladder to avoid missing stones in the gallbladder neck or cystic duct, common causes of acute biliary colic and cholecystitis. Be thorough!\n- Smaller stones can be missed with some portable ultrasound systems. A comprehensive study may be warranted in cases of moderate/high pre-test probability with a normal point-of-care study.\n- Polyps within the gallbladder can often be differentiated from gallstones by changing the patient’s position and assessing for movement. Polyps should remain stationary and gallstones should move with gravity (unless impacted in the neck). Additionally, polyps should not create posterior shadowing as is seen with gallstones.\n- Biliary sludge appears as an echogenic layer of fluid without associated posterior shadowing within the gallbladder.\n\n## References\n\n- Summers SM, Scruggs W, Menchine MD, et al. A prospective evaluation of emergency department bedside ultrasonography for the detection of acute cholecystitis. Ann Emerg Med. 2010;56(2):114-22. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20138397)]\n- Blaivas M, Harwood RA, Lambert MJ. Decreasing length of stay with emergency ultrasound examination of the gallbladder. Acad Emerg Med. 1999;6(10):1020-3. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10530660)]\n"
		},
		{
			"slug": "genital-ulcers",
			"title": "Genital Ulcers",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/05/04",
			"updates": null,
			"categories": [
				"Infectious Disease",
				"Genitourinary"
			],
			"body": "\n\n\n- Leading causes in the US: HSV types 1 and 2 (most common) > syphilis > chancroid\n- Note: 10% of chancroid are coinfected with syphilis or HSV\n\n## Differential diagnosis of genital ulcers\n\n| **Infectious (more common)**      | **Non-infectious (less common)** |\n| --------------------------------- | -------------------------------- |\n| Genital herpes simple virus (HSV) | Behcet syndrome                  |\n| Syphilis                          | Fixed drug eruption              |\n| Chancroid                         | Psoriasis                        |\n| Lymphogranuloma venereum          | Sexual trauma                    |\n| Granuloma inguinale (donovanosis) | Wegener granulomatosis           |\n| Fungal infection (eg. candida)    |                                  |\n| Secondary bacterial infection     |                                  |\n\n[National Coalition of STD Director Fact Sheets](http://www.ncsddc.org/publications)\nFrom “The Practitioner’s Handbook for the Management of STDs” (4th ed, 2007):\n\n<table>\n  <tr>\n    <th></th>\n    <th>Primary HSV</th>\n    <th>Recurrent HSV</th>\n    <th>Syphilis</th>\n    <th>Chancroid</th>\n    <th>LGV</th>\n  </tr>\n  <tr>\n    <td><b>Primary lesion</b></td>\n    <td>Vesicle, papule,ulcers, typically bilateral</td>\n    <td>Grouped vesicles, papules, ulcers, typically unilateral  </td>\n    <td>Ulcer, papule</td>\n    <td>Ulcer, papule</td>\n    <td>Papule, pustule, ulcer</td>\n  </tr>\n  <tr>\n    <td><b>Border</b></td>\n    <td>Erythematous,\"punched out\"  </td>\n    <td>Erythematous,\"punched out\"</td>\n    <td>Sharply demarcated </td>\n    <td>Violaceous, undermined</td>\n    <td>Variable</td>\n  </tr>\n  <tr>\n    <td><b>Depth</b></td>\n    <td>Superficial</td>\n    <td>Superficial</td>\n    <td>Superficial</td>\n    <td>Excavated</td>\n    <td>Superficial</td>\n  </tr>\n  <tr>\n    <td><b>Base</b></td>\n    <td>Red and smooth</td>\n    <td>Red and smooth</td>\n    <td>Red and smooth</td>\n    <td>Yellow to gray exudate</td>\n    <td>Variable</td>\n  </tr>\n  <tr>\n    <td><b>Secretion</b></td>\n    <td>Serous</td>\n    <td>Serous</td>\n    <td>Serous</td>\n    <td>Purulent to hemorrhagic</td>\n    <td>Variable</td>\n  </tr>\n  <tr>\n    <td><b>Number of Lesions</b></td>\n    <td>Bilateral, multiple, extensive lesion may coalesce</td>\n    <td>Usually unilateral; labia, penis, scrotum, buttocks, perianal</td>\n    <td>Vulva, penis, anal perianal, oral</td>\n    <td>Penis, vulva</td>\n    <td>Urethra, cervix, rectum</td>\n  </tr>\n  <tr>\n    <td><b>Induration</b></td>\n    <td>None</td>\n    <td>None</td>\n    <td>Firm</td>\n    <td>Rare, usually soft</td>\n    <td>None</td>\n  </tr>\n  <tr>\n    <td><b>Pain</b></td>\n    <td>Common</td>\n    <td>Common, less severe</td>\n    <td>Rare</td>\n    <td>Often</td>\n    <td>Variable</td>\n  </tr>\n  <tr>\n    <td><b>Itching</b></td>\n    <td>Common</td>\n    <td>Common</td>\n    <td>Rare</td>\n    <td>Rare</td>\n    <td>Rare</td>\n  </tr>\n  <tr>\n    <td><b>Lymph Nodes</b></td>\n    <td>Tender, firm, bilateral inguinal adenopathy</td>\n    <td>Lymphadenopathy, uncommon, unilateral</td>\n    <td>Nontender, firm, enlarged</td>\n    <td>Tender, enlarged, may suppurate</td>\n    <td>Inguinal and femoral lymphadenopathy: tender, may suppurate</td>\n  </tr>\n  <tr>\n    <td><b>Incubation Period</b></td>\n    <td>2-14 days</td>\n    <td>Recurrence within 6-9 months of primary infection </td>\n    <td>10-90 days</td>\n    <td>1-14 days</td>\n    <td>3-21 days</td>\n  </tr>\n  <tr>\n    <td><b>Time Course</b></td>\n    <td>21 days</td>\n    <td>7-10 days</td>\n    <td>2-3 weeks</td>\n    <td>2-3 weeks</td>\n    <td>1-2 weeks</td>\n  </tr>\n  <tr>\n    <td><b>Diagnostic Test</b></td>\n    <td>Viral culture</td>\n    <td>Viral culture is most sensitive, especially once vesicles rupture and ulcerate. If lesions are granulating, HSV cultures may be negative and HSV serology is useful to confirm etiology.</td>\n    <td>Darkfield microscopy, FTA-ABS, VDRL, RPR and DFA-TP</td>\n    <td>Culture of <i>Haemophilus ducreyi</i>; Gram stain of pus aspirate from lymph node</td>\n    <td>Isolation of <i>Chlamydia trachomatis</i> from urethra, cervix, rectum or lymph node aspirate; complement fixation serology &ge; 1/64</td>\n  </tr>\n</table>\n\n## References\n\n- Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. Am Fam Physician. 2012 Feb 1;85(3):254-62. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22335265)]\n"
		},
		{
			"slug": "head-ct-and-lp",
			"title": "Head CT Before LP for Meningitis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/04/23",
			"updates": null,
			"categories": [
				"Neurology",
				"Procedures",
				"EBM",
				"Radiology"
			],
			"body": "\n\n\n**Caveat**: This review only applies to those patients in whom you suspect meningitis. This does not apply to those being worked up for subarachnoid hemorrhage.\n\nIf **ZERO** of the following high risk features, it is safe to do LP without a Head CT.\n\n| **High Risk Features Associated With An Abnormal CT**      |\n|------------------------------------------------------------|\n| Age &ge;60 yr                                              |\n| Immunocompromise (HIV, transplant, immunosuppression)      |\n| History of CNS disease (mass lesion, CVA, focal infection) |\n| Seizure &lt; 1 week prior to arrival                       |\n| Altered level of consciousness                             |\n| Unable to answer 2 questions correctly                     |\n| Unable to follow 2 commands correctly                      |\n| Gaze palsy                                                 |\n| Abnormal visual fields                                     |\n| Facial palsy                                               |\n| Arm or leg drift                                           |\n| Abnormal language / speech                                 |\n\n## Study: [Hasbun et al. NEMJ, 2001](https://www.ncbi.nlm.nih.gov/pubmed/?term=11742046)\n\n**Design:** Prospective observational single-site study (n = 301)\n\n**Observed results**: \n\n- 235/301 underwent head CT\n  - 56/235 (24%) had abnormal CT\n    - 11/56 had mass effect\n\n**Validation arm: Applying the “high risk” criteria back to the enrollment group:**\n\n- 235/301 underwent head  \n  - 96/235 (41%) had no “high risk” features \n    - 93/96 (97%) had a normal CT\n      - 3/96 (3%) had 2 non-herniations and 1 mild herniation on CT\n      - All 3 patients underwent LP without complications.\n\n**Results: Time savings for who did not undergo CT imaging (CT-)**\n\n- Time to antibiotics (3.8 hr for CT+ vs 2.9 hr for CT-) \n- Time to LP (5.3 hr for CT+ vs 3.0 hr for CT-)\n\n**Limitations**\n\n- Study requires validation on a separate population, different from the derivation group \n\n**Conclusion**\n\n- If there are no abnormal “high risk” clinical features, you can safely perform a LP without a CT to assess for meningitis (NPV = 97%) \n- Skipping the head CT prior to LP decreases time-to-antibiotics and time-to-LP \n\n## References\n\n- Hasbun et al. CT of head before LP in adults with suspected meningitis. NEJM. 2001;345(24): 1727-33. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=11742046)]\n"
		},
		{
			"slug": "head-ct-in-trauma",
			"title": "Head CT in Trauma",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/05/13",
			"updates": null,
			"categories": [
				"Radiology",
				"EBM",
				"Trauma"
			],
			"body": "\n\n\n## Canadian CT Head Rules (CCHR)\n([Stiell IG eg. al Ann Emerg Med, 2001](http://www.mcgill.ca/files/emergency/CCHR.pdf))\n\n**Inclusion criteria:** \n- GCS 13-15\n- Age &ge; 16 years\n- No coagulopathy\n- No obvious open skull fracture\n\n**CT indicated if any of following:**\n\n- **High risk features** predictive for neurosurgical intervention:\n  - GCS &lt;15 at 2 hours after injury\n  - Suspected open or depressed skull fracture\n  - Signs of basal skull fracture\n  - At least 2 episodes of vomiting\n  - Age &ge;65 years old\n- **Medium risk features** for brain injury detection on CT:\n  - Amnesia before impact of &ge; 30 minutes\n  - Dangerous mechanism (pedestrian vs. auto, an occupant ejected from motor vehicle, or a fall from an elevation of &ge; 3 feet or 5 stairs)\n\n## New Orleans Criteria (NOC)\n([Haydel et. al. NEJM, July 2000](http://www.ncbi.nlm.nih.gov/pubmed/10891517))\n\n**Inclusion criteria:** GCS 15 and loss of consciousness in the setting of trauma\n\n**CT indicated if any of the following**: \n\n- Headache\n- Vomiting\n- Age >60 years\n- Drugs or alcohol\n- Short term memory deficit\n- Visible trauma above clavicles\n- Seizure  \n\n## NEXUS-II Criteria\n**CT indicated if any of following**:    \n\n([Mower et al. J Trauma, 2005](http://www.ncbi.nlm.nih.gov/pubmed/?term=Developing+a+decision+instrument+to+guide+computed+tomographic+imaging+of+blunt+head+injury+patients.))\n- Age &ge;65 years old\n- Evidence of significant skull fracture \n- Scalp hematoma\n- Neurologic deficit\n- Altered level of alertness\n- Abnormal behavior\n- Coagulopathy\n- Recurrent or forceful vomiting \n\n## Comparing Decision Rules\n\n- **CCHR vs NOC**  ([Stiell et al. JAMA, 2005](http://www.ncbi.nlm.nih.gov/pubmed/16189364))\n\n  - Validation subgroup analysis of 1,822 patients with GCS 15\n  - CCHR: Sensitivity 100%, Specificity 50.6% for clinically important intracranial injury \n  - NOC: Sensitivity 100%, Specificity 12.7% for clinically important intracranial injury \n\n- **CCHR vs NOC** ([Smits et al. JAMA, 2005](http://www.ncbi.nlm.nih.gov/pubmed/16189365))\n\n  - Validation group of 3,181 patients with GCS 13-15\n  - CCHR: Sensitivity 87.2%, Specificity 39.7% for clinically important findings \n  - NOC: Sensitivity 99.4%, Specificity 5.6% for clinically important findings\n  - The NOC had higher sensitivity (99.4%) but a much lower specificity (5.6%). \n\n- **CCHR vs NOC vs NEXUS II** ([Stein et al. Ann Emerg Med, 2009](http://138.5.157.71/emergency_medicine/documents/head_ct_decision_rules.pdf))\n\n  - Validation group of 7,955 patients with GCS 14-15\n  - CCHR: Sensitivity 99%, Specificity 47% for clinically important findings\n  - NOC: Sensitivity 99%, Specificity 33% for clinically important findings\n  - NEXUS II: Sensitivity 97%, Specificity 47% for clinically important findings \n\n## References\n\n- Mower WR, Hoffman JR, Herbert M, Wolfson AB, Pollack CV Jr, Zucker MI; NEXUS II Investigators.Developing a decision instrument to guide computed tomographic imaging of blunt head injury patients. J Trauma. 2005 Oct;59(4):954-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=Developing+a+decision+instrument+to+guide+computed+tomographic+imaging+of+blunt+head+injury+patients.)]\n- Stiell IG, Clement CM, Rowe BH, Schull MJ, Brison R, Cass D, Eisenhauer MA, McKnight RD, Bandiera G, Holroyd B, Lee JS, Dreyer J, Worthington JR, Reardon M, Greenberg G, Lesiuk H, MacPhail I, Wells GA.Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA. 2005 Sep 28;294(12):1511-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16189364)]\n- Smits M, Dippel DW, de Haan GG, Dekker HM, Vos PE, Kool DR, Nederkoorn PJ, Hofman PA, Twijnstra A, Tanghe HL, Hunink MG.External validation of the Canadian CT Head Rule and the New Orleans Criteria for CT scanning in patients with minor head injury. JAMA. 2005 Sep 28;294(12):1519-25. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16189365)]\n- Stein et al. A Critical Comparison of Clinical Decision Instruments for Computed Tomographic Scanning in Mild Closed Traumatic Brain Injury in Adolescents and Adults. Ann Emerg Med, 2009 [[Source](http://138.5.157.71/emergency_medicine/documents/head_ct_decision_rules.pdf)]\n- Haydel MJ, Preston CA, Mills TJ, Luber S, Blaudeau E, DeBlieux PM. Indications for computed tomography in patients with minor head injury. N Engl J Med. 2000 Jul 13;343(2):100-5. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10891517)]\n- Stiell IG et al. The Canadian CT Head Rule for patients with minor head injury. Ann Emerg Med, 2001 [[Source](http://www.mcgill.ca/files/emergency/CCHR.pdf)]\n"
		},
		{
			"slug": "heart-murmurs",
			"title": "Murmurs Needing Echocardiography Evaluation",
			"authors": [
				"Amy Kinard, RN"
			],
			"created": "2010/09/17",
			"updates": null,
			"categories": [
				"Cardiovascular"
			],
			"body": "\n\n\n[ACC/AHA 2008 Guidelines](http://www.ncbi.nlm.nih.gov/pubmed/?term=18848134)\n\n![Cardiac murmur workup flowchart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/heart-murmurs/image-1.png)\n\n## Grading of a Murmur\n\n| **Grade** | **Quality and Volume of Murmur**                             |\n| :-------: | ------------------------------------------------------------ |\n|     I     | Faintest murmur that can be heard (with difficulty)          |\n|     II    | Murmur also a faint murmur but can be identified immediately |\n|    III    | Murmur moderately loud                                       |\n|     IV    | Murmur loud and associated with a palpable thrill            |\n|     V     | Murmur very loud but cannot be heard without the stethoscope |\n|     VI    | Murmur loudest and can be heard without a stethoscope        |\n\n## Class I (Benefit >>> Risk)\n\nEcho is recommended for:\n\n1. Asymptomatic patients with diastolic murmurs, continuous murmurs, holosystolic murmurs, late systolic murmurs, murmurs associated with ejection clicks, or murmurs that radiate to the neck or back\n2. Patients with heart murmurs and symptoms or signs of heart failure, myocardial ischemia/infarction, syncope, thromboembolism, infective endocarditis, or other clinical evidence of structural heart disease\n3. Asymptomatic patients with grade 3 or louder mid-peaking systolic murmurs\n\n## Class IIa (Benefit >> Risk)\n\nEcho can be useful for:\n\n1. The evaluation of asymptomatic patients with (murmurs + other abnormal cardiac physical findings) or (murmurs + abnormal EKG or CXR)\n2. Patients whose symptoms and/or signs are likely non-cardiac in origin but in whom a cardiac basis cannot be excluded by standard evaluation\n\n## Class III (Benefit &ge; Risk)\n\nEcho is NOT recommended for:\n\n1. Patients who have a grade 2 or softer mid-systolic murmur identified as innocent or functional by an experienced observer\n\n## References\n\n- Bonow RO et. al.2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.J Am Coll Cardiol. 2008 Sep 23;52(13):e1-142. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18848134)]\n"
		},
		{
			"slug": "hip-injuries",
			"title": "Hip Injuries",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/14",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## [Hip Dislocation](/cards/hip-injuries-hip-dislocation)\n\n## [Femoral Head Fracture](/cards/hip-injuries-femoral-head-fracture)\n\n## [Femoral Neck Fracture](/cards/hip-injuries-femoral-neck-fracture)\n\n## [Femoral Shaft Fracture](/cards/hip-injuries-femoral-shaft-fracture)\n\n## References\n\n1. Gill SK, Smith J, Fox R, Chesser TJ. Investigation of occult hip fractures: the use of CT and MRI. Scientific World Journal. 2013;2013:830319. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)]\n\n2. Rodriguez-Merchan EC, Moraleda L, Gomez-Cardero P. Injuries associated with femoral shaft fractures with special emphasis on occult injuries. Arch Bone Jt Surg. 2013 Dec;1(2):59-63. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n"
		},
		{
			"slug": "hip-injuries-femoral-head-fracture",
			"title": "Hip Injuries - Femoral Head Fracture",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/14",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Types 1 to 4 femoral head fracture drawings](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/hip-injuries-femoral-head-fracture/image-1.png)\n\n## Xray Views\n\n- AP pelvis\n- Lateral hip\n- ± Judet view of hip (45-degree oblique)\n\n## Acute Management\n\nSurgery\n\n## Follow-up Timing\n\nAdmit and consult an orthopedic surgeon\n\n## Notes\n\n**Pipkin Classification**\n\n- **I**: Fracture below fovea/ligamentum (small); Does not involve the weight bearing portion of the femoral head\n- **II**: Fracture above fovea/ligamentum (larger); Involves the weight bearing portion of the femoral head \n- **III**: Type I or II with associated femoral neck fracture\n- **IV**: Type I or II with associated acetabular fracture\n\n## References\n\n1. Gill SK, Smith J, Fox R, Chesser TJ. Investigation of occult hip fractures: the use of CT and MRI. _Scientific World Journal_. 2013;2013:830319. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)]\n\n2. Rodriguez-Merchan EC, Moraleda L, Gomez-Cardero P. Injuries associated with femoral shaft fractures with special emphasis on occult injuries. _Arch Bone Jt Surg_. 2013 Dec;1(2):59-63. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n"
		},
		{
			"slug": "hip-injuries-femoral-neck-fracture",
			"title": "Hip Injuries - Femoral Neck Fracture",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/14",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Femoral neck fracture drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/hip-injuries-femoral-neck-fracture/image-1.png)\n\n## Xray Views\n\n- AP pelvis\n- Cross-table lateral of hip\n- AP/lateral of entire femur\n\n## Acute Management\n\nSurgery\n\n## Follow-up Timing\n\nAdmit and consult an orthopedic surgeon.\n\n## Notes\n\nHigh risk for missed occult fracture:\n\n- Up to 10% are radiographically occult (XR negative) [[Gill et al.](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)]\n- At risk: Older osteoporotic patient\n- MRI is definitive, subsequent imaging modality\n\n## References\n\n- Gill SK, Smith J, Fox R, Chesser TJ. Investigation of occult hip fractures: the use of CT and MRI. Scientific World Journal. 2013;2013:830319. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)]\n- Rodriguez-Merchan EC, Moraleda L, Gomez-Cardero P. Injuries associated with femoral shaft fractures with special emphasis on occult injuries. Arch Bone Jt Surg. 2013 Dec;1(2):59-63. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n"
		},
		{
			"slug": "hip-injuries-femoral-shaft-fracture",
			"title": "Hip Injuries - Femoral Shaft Fracture",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/14",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## Xray Views\n\n- AP/lateral of femur \n- AP/lateral of ipsilateral femoral hip\n\n## Acute Management\n\nSurgery\n\n## Follow-up Timing\n\nAdmit and consult an orthopedic surgeon.\n\n## Notes\n\n**Complications:**\n\n- Femoral artery and nerve injury\n- Pudendal nerve injury\n- Ipsilateral femoral neck fracture missed in 19-31% [[Rodriguez-Merchan et al.](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n\n## References\n- Rodriguez-Merchan EC, Moraleda L, Gomez-Cardero P. Injuries associated with femoral shaft fractures with special emphasis on occult injuries. _Arch Bone Jt Surg_. 2013 Dec;1(2):59-63. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n- Gill SK, Smith J, Fox R, Chesser TJ. Investigation of occult hip fractures: the use of CT and MRI. _Scientific World Journal_. 2013;2013:830319. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)] \n"
		},
		{
			"slug": "hip-injuries-hip-dislocation",
			"title": "Hip Injuries - Hip Dislocation",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/14",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Posterior vs anterior hip dislocation drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/hip-injuries-hip-dislocation/image-1.png)\n\n## Xray Views\n\n- AP pelvis\n- CT to look for acetabular fracture, loose bodies, or femoral head fracture\n\n## Acute Management\n\n**Reduction immediately within 6 hours** (because of avascular necrosis risk)\n\n## Follow-up Timing\n\nAdmit and consult orthopedic surgeon.\n\n## Notes\n\n**Posterior dislocation (90%):** Typically presents with hip flexed and adducted; 5-15% of posterior hip dislocations are associated with a femoral head fracture\n\n**Anterior dislocation:** Typically presents with hip abducted and externally rotated\n\n## References\n\n- Gill SK, Smith J, Fox R, Chesser TJ. Investigation of occult hip fractures: the use of CT and MRI. Scientific World Journal. 2013;2013:830319. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23476147)]\n- Rodriguez-Merchan EC, Moraleda L, Gomez-Cardero P. Injuries associated with femoral shaft fractures with special emphasis on occult injuries. Arch Bone Jt Surg. 2013 Dec;1(2):59-63. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25207289)]\n"
		},
		{
			"slug": "hyperkalemia",
			"title": "Hyperkalemia",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/03/12",
			"updates": null,
			"categories": [
				"Endocrinology",
				"Metabolic",
				"Critical Care"
			],
			"body": "\n\n\n## Potassium regulation\n\n- **Internal K shift:** modulated by insulin, catecholamines, acid-base status\n- **Total body K elimination:** By kidney (95%) and gut (5%)\n\n## Adverse effects of hyperkalemia\n\n- **Cardiac:** Peaked T, wide QRS, loss of P wave, sine wave; although ventricular fibrillation may be first cardiac manifestation\n- **Neuromuscular:** Paresthesias,weakness\n- **Metabolic:** Mild hyperchloremic metabolic acidosis\n\n## Treatment of hyperkalemia\n\n**Mechanism: Cardiac membrane stabilization**\n\n- **Calcium:** Reduces threshold potential in myocytes; check to be sure not on digoxin\n- **Hypertonic saline:** Only for severe hyponatremia in setting of hyperkalemia\n\n**Mechanism: K redistribution**\n\n- **Insulin:** Drives K intracellularly and drops serum K level by 0.6 mmol/L\n- **Beta-agonist:** Drives K intracellularly and 10 mg albuterol drops serum K level by 0.6 mmol/L (20 mg --> K drops by 1 mmol/L); effective in only 60% of patients\n\n**Mechanism: K elimination via kidney/gut**\n\n- **Bicarbonate:** drives K out at distal nephron; best as infusion x 4-6 hrs\n- **Loop diuretic**\n- **Exchange resin** (sodium polystyrene sulfonate): Of minimal to no benefit. \n  - Case reports of colonic necrosis \n\n<table>\n  <tr>\n    <th>Agent</th>\n    <th>Dose</th>\n    <th>Onset</th>\n    <th>Duration</th>\n    <th>Complication</th>\n  </tr>\n  <tr>\n    <td colspan=\"5\"><b>MEMBRANE STABILIZATION</b></td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Ca gluconate 10%</span></td>\n    <td>10 mL over 10 min</td>\n    <td>Immediate</td>\n    <td>30-60 min</td>\n    <td>Hypercalcemia</td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Hypertonic 3% NaCl</span></td>\n    <td>50 mL IV push</td>\n    <td>Immediate</td>\n    <td>Unknown</td>\n    <td>Volume overload, hypertonicity</td>\n  </tr>\n  <tr>\n  <td colspan=\"5\"><b>REDISTRIBUTION</b></td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Insulin</span></td>\n    <td>10 units IVP with D50W</td>\n    <td>20 min</td>\n    <td>4-6 hr</td>\n    <td>Hypoglycemia</td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Albuterol nebulized</span></td>\n    <td>20 mg/4 cc over 10 min</td>\n    <td>30 min</td>\n    <td>2 hrs</td>\n    <td>Tachycardia</td>\n  </tr>\n  <tr>\n  <td colspan=\"5\"><b>ELIMINATION</b></td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Loop diuretic</span></td>\n    <td>Furosemide 40-80 mg IV</td>\n    <td>15 min</td>\n    <td>2-3 hr</td>\n    <td>Volume depletion</td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Sodium bicarbonate</span></td>\n    <td>150 mmol/L IV</td>\n    <td>Hours</td>\n    <td>Infusion</td>\n    <td>Metabolic alkalosis, volume overload</td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Kayexalate</span></td>\n    <td>15-30 g</td>\n    <td>>2 hrs</td>\n    <td>4-6 hr</td>\n    <td>Variable efficacy</td>\n  </tr>\n  <tr>\n    <td><span class=\"drug\">Hemodialysis</span></td>\n    <td></td>\n    <td>Immediate</td>\n    <td>3 hrs</td>\n    <td>Arrhythmias</td>\n  </tr>\n</table>\n\n## References\n\n- Weisberg LS. Management of severe hyperkalemia. _Crit Care Med_. 2008; 36:3246-51. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18936701)]\n"
		},
		{
			"slug": "hypothermia",
			"title": "Hypothermia, Accidental",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/02/04",
			"updates": null,
			"categories": [
				"Environmental"
			],
			"body": "\n\n\n## Stages of Hypothermia\n\n### MILD HYPOTHERMIA \n32.2-35&deg;C (90-95&deg;F) \n\n| Early Stage      | Decompensated Stage                               |\n| :--------------- | :------------------------------------------------ |\n| Hypertenstion    | Apathy/Impaired Judgment                          |\n| Tachycardia      | Ataxia                                            |\n| Shivering        | Cold diuresis-kidneys unable to concentrate urine |\n| Vasoconstriction | Hypovolemia                                       |\n\n### MODERATE HYPOTHERMIA \n28-32.2&deg;C (82.4-90&deg;F)\n\n| Clinical Findings         |\n| :------------------------ |\n| Atrial dysrhythmias       |\n| J wave on ECG             |\n| Hypotension, bradycardia  | \n| Lethargy                  |\n| Mydriasis                 |\n| Diminished gag reflex     |\n| Loss of shivering         |\n| Hyporeflexia              |\n\n![J-wave example](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/hypothermia/image-1.png)\n\n### SEVERE HYPOTHERMIA \n&lt;28&deg;C (&lt;82.4&deg;F)\n\n| Clinical Findings         |\n| :------------------------ |\n| Apnea                     |\n| Coma                      |\n| No activity on EEG        |\n| Fixed pupils              |\n| Oliguria                  |\n| Pulmonary edema           |\n| Ventricular dysrhythmias  |\n| Asystole                  |\n\n**Tip**\n\n- Many thermometers do not measure below 34.4°C (94°F). Need special low-tempsensing rectal or bladder thermometers.\n- Avoid jostling the hypothermic patient too much because of myocardial irritability and consequent arrhythmias.\n\n## Direct complications from hypothermia and rewarming\n\n- Rhabdomyolysis\n- Acute tubular necrosis and renal failure\n- Electrolyte shifts, especially K+ because of acid-base changes during rewarming\n- Hypoglycemia from depleted glycogen stores\n- Functional coagulapathy: May have normal coag studies because have to be rewarmed to run the assay\n\n## Rewarming approaches\n\n1. **Passive Rewarming:** Remove cold, damp clothes. Wrap with blankets.\n2. **Active External Rewarming:** Apply heat to skin\n\n   - Heating blanket or radiant heat\n   - Hot water bottles or heating pads to truncal surfaces. Caution-- do not burn skin.\n   - Risk of “Core Temperature Afterdrop”, vasodilation with active external rewarming causes cold peripheral blood to return to heart. Give warm IV fluid beforehand.\n   - Risk of “Rewarming Acidosis”. Lactate from periphery returns to core circulation. May cause transient shock during rewarming.\n\n3. **Active Core Rewarming**\n\n   - Humidified air, 40°C (104°F) – increases core temp by 1-2.5°C (1.8-4.5°F) per hr\n   - Warm IV fluids at 40-45°C\n   - Cardiopulmonary bypass or hemodialysis, Increases core temp by 1-2°C (1.8-3.6°F) every 3-5 minutes\n   - Warm fluid lavage of stomach, colon, bladder, pleural space\n   - Peritoneal dialysis. Normal saline at 40-45°C at 6-10 L/hr increases core temp by 1-3°C (1.8-5.4°F) per hour when combined with heated oxygen.\n   - Mediastinal lavage via open thoracotomy\n\n## Choosing a rewarming approach\n\n### General approach\n\n- Check glucose.    \n- Consider thiamine 100 mg IV, esp if chronic EtOH at risk for Wernicke’s    \n- Treat underlying etiology for hypothermia \n- Give antibiotics +/- steroids, as appropriate   \n\n### If patient in cardiopulmonary arrest\n\n- Intubate, CPR, ACLS protocol\n- Warm IVF\n- Heated humidified oxygen\n- Extracorporeal rewarming (i.e. cardiopulmonary bypass), if not immediately available, do active core rewarming measures\n- Rewarm to target temperature >30°C (86°F)\n\n### If NOT in cardiopulmonary arrest AND temperature &lt;32°C (89.6°F)\n\n- Active External Rewarming (i.e. Bair Hugger, warm blankets), and\n- Minimally invasive Active Core Rewarming (warm IVF, warm air)\n\n### If NOT in cardiopulmonary arrest AND temp &ge;32°C (89.6°F)\n\n- Passive external rewarming measures    \n\n## References\n\n- McCullough L, Arora S. Diagnosis and treatment of hypothermia. _Am Fam Physician_. 2004 Dec 15;70(12):2325-32. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=15617296)]\n"
		},
		{
			"slug": "increased-osmolar-gap",
			"title": "Approach to Increased Osmolar Gap",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/06/01",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n## Background and Calculations\n\n**Serum osmolality:** Contributed by ions and low-molecular-weight solutes\n\n![Serum osmolality = (2Na) + (BUN/2.8) + (Glucose/18) + (Ethanol/4.6)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/increased-osmolar-gap/image-1.png)\n\n**Osmolal gap = Calculated osmolality – Measured osmolality**\n\n- Normal OG = -10 to +10 mOsm/kg of H2O\n\n## Osmolal gap\n\n- Most common cause: Ethanol \n- Osmolal gap calculation includes ethanol correction factor (4.6)\n- Osmoloal gap screens for toxic alcohols with decreasing sensitivity: \n  - Methanol\n  - Ethanol\n  - Isopropanol\n  - Ethylene glycol\n  - Propylene glycol\n  - Diethylene glycol\n- A gap &ge; 20 suggests ethanol or toxic alcohol exposure\n  - Although case reports of diabetic ketoacidosis causing osmolal gap &ge; 20\n\n**Toxic alcohols**\n\n- Parent unmetabolized alcohols --> Contributes to osmolal gap\n- Metabolites of alcohols --> Contributes to toxic effects (except isopropanol)\n\n<table>\n<colgroup>\n<col width=\"100%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th> <b>Causes for High anion gap metabolic acidosis + High osmolal gap</b></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td>Acute kidney injury<br />\nIntoxication, salicylates<br />\nIntoxication, toxic alcohol<br />\n<ul>\n<li>Methanol</li>\n<li>Ethylene glycol</li>\n<li>Diethylene glycol</li>\n<li>Propylene glycol</li>\n<li>Isopropanol glycol</li></ul>\nKetoacidosis, alcoholic or diabetic<br />\nLactic acidosis<br />\n</td>\n</tr>\n</tbody>\n</table>\n\n## Caution\n\nToxic alcohols may not cause significant osmolal gap because:\n\n1. High molecular weight toxic alcohols (eg. propylene glycol, diethylene glycol) do not affect the osmolality as much\n2. Wide range of normal osmolal gap (can be as low as -10)\n3. Only the parent alcohol (not the metabolites) causes osmolal gap\n\n**Tip:** Consider toxic alcohols for cases of high anion gap metabolic acidosis even with normal osmolal gap.\n\n## References\n\n- Kraut JA, Xing SX. Approach to the evaluation of a patient with an increased serum osmolal gap and high-anion-gap metabolic acidosis. _Am J Kidney Dis_. 2011 Sep;58(3):480-4. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21794966)]\n"
		},
		{
			"slug": "infusions",
			"title": "Continuous Medication Infusions",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/03/09",
			"updates": null,
			"categories": [
				"Pharmacology",
				"Critical Care"
			],
			"body": "\n\n\n## Usual dose range for adults\n\n| **Medication**  |  **Dose** | **Units (comments)**                                  |\n| --------------- | :-------: | ----------------------------------------------------- |\n| Amiodarone      |   0.5-1   | mg/min (loading dose: 150 mg over 10 min)             |\n| Diltiazem       |    5-15   | mg/hr, or indication dependent dose                   |\n| Dobutamine      |   0.5-20  | mcg/kg/min                                            |\n| Dopamine        |   0.5-20  | mcg/kg/min                                            |\n| Epinephrine     |  0.05-0.5 | mcg/kg/min                                            |\n| Esmolol         |   50-300  | mcg/kg/min                                            |\n| Fentanyl        |   25-200  | mcg/hr, or higher if tolerance                        |\n| Furosemide      |    1-10   | mg/hr                                                 |\n| Isoproterenol   |    1-10   | mcg/min                                               |\n| Ketamine        |    2-10   | mcg/kg/min                                            |\n| Lidocaine       |    1-4    | mg/min                                                |\n| Lorazepam       |   0.5-4   | mg/hr, or higher if tolerance                         |\n| Midazolam       |   0.5-2   | mg/hr or higher if tolerance                          |\n| Naloxone        |   0.25-6  | mg/hr                                                 |\n| Nicardipine     |    5-15   | mg/hr                                                 |\n| Nitroglycerin   |   10-300  | mcg/min                                               |\n| Nitroprusside   |    1-10   | mcg/kg/min                                            |\n| Norepinephrine  |   0.5-20  | mcg/min                                               |\n| Octreotide      |   25-100  | mcg/hr                                                |\n| Phenylephrine   |   10-200  | mcg/min or higher if indicated                        |\n| Propofol        |   0-100   | mcg/kg/min                                            |\n| Vasopressin     | 0.02-0.04 | units/min, or higher if indicated (max 0.2 units/min) |\n| Vecuronium      |    1-5    | mg/hr or higher if indicated                          |\n\n## References\n\n- Based on 2012 card on Continuous Infusions from the UCSF Critical Care Units as part of a campaign for Safe Medication Prescriptions\n"
		},
		{
			"slug": "intimate-partner-violence",
			"title": "Intimate Partner Violence",
			"authors": [
				"Trevor Wilson, MD",
				"Beth Kaplan, MD"
			],
			"created": "2013/07/31",
			"updates": null,
			"categories": [
				"Trauma"
			],
			"body": "\n\n\n**Definition:** Physical, sexual, or psychological harm by a current or former partner or spouse; occurs among heterosexual and same-sex couples\n\n**Epidemiology:** Lifetime estimates for IPV in women= 22-39%\n\n**Sequelae:** Untreated IPV results in many physical and psychological morbidities. \n\n**Pearl:** Physicians should screen, document,intervene, and provide resources.\n\n## Screening\n\n- U.S. Preventive Services Task Force: Level B recommendation for screening women of child-bearing age\n  - High certainty that the net benefit is moderate. \n  - Costs and potential harms of screening appear to be outweighed by potential for early intervention with screening.\n- Interview patient alone. Frame: “_Because violence is so common, we’re routinely asking our patients about their safety in their relationships_.”\n- Increase suspicion of abuse when overly protective partner, history inconsistent with injury, vague complaints, or pregnancy.\n\n**SAFE Questions**\n\n| Topic              |    Question                                                                        |\n| ------------------ | ---------------------------------------------------------------------------------- |\n| **S**tress/Safety  | _Do you feel safe in your relationship?_                                           |\n| **A**fraid/Abused  | _Have you ever been in a relationship where you were threatened, hurt, or afraid?_ |\n| **F**riend/Family  | _Are your friends aware you have been hurt?_                                       |\n| **E**mergency Plan | _Do you have a safe place to go and the resources you need in an emergency?_       |\n\n## Document\n\nConvey constructive messages:\n\n- _“Nobody deserves to be treated this way. You are not alone.”_\n- _“I am concerned about your safety and health. There is help. I’d like you to speak with an advocate/counselor.”_\n\nAssess immediate safety for patient in ED.\n\nInvolve social work. Provide list of shelters, resources, and hotline.\n\nDefine safety plan for discharge.\n\n## Resources\n\n- **National Domestic Violence Hotline:** [1-800-799-SAFE](tel:1-800-799-7233)\n- **National Sexual Assault Hotline:** [1-800-656-HOPE](tel:1-800-656-4673)\n- **National Child Abuse Hotline:** [1-800-4-A-CHILD](tel:1-800-4-2-24453) (and contact local Child Protective Services)\n\n## References\n\n- Ashur ML. Asking about domestic violence: SAFE questions. JAMA. 1993;269(18):2367. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=8479058)]\n- Moyer VA. Screening for intimate partner violence and abuse of elderly and vulnerable adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;158(6):478-86. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=23338828)]\n"
		},
		{
			"slug": "intracranial-hemorrhage",
			"title": "ED Management of Intracranial Hemorrhage",
			"authors": [
				"William Shyy, MD",
				"Debbie Yi Madhok, MD"
			],
			"created": "2017/09/04",
			"updates": null,
			"categories": [
				"Trauma",
				"Neurology"
			],
			"body": "\n\n\nRobust and comprehensive studies now support specific management guidelines for patients presenting with different intracranial hemorrhages (ICH). From the Emergency Department perspective, the primary dilemmas involve specific blood pressure goals and whether seizure prophylaxis with phenytoin is necessary. [The Brain Trauma Foundation](https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf) provides an excellent summary of the current guidelines.\n\n## Summary on the Management of Intracranial Hemorrhages\n\n### Primary ICH\n\n![Primary ICH](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/intracranial-hemorrhage/image-1.png)\n\n**Systolic BP Goal (mmHg)**: &lt; 140-180\n\n**Seizure Prophylaxis**: No\n\n**Therapy**:\n- External ventricular drain (EVD) if Glasgow Coma Scale (GCS) &lt; 9, significant intraventricular hemorrhage with obstructive hydrocephalus, or herniation\n- no platelets\n\n### Subdural ICH\n\n![Subdural ICH](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/intracranial-hemorrhage/image-2.png)\n\n**Systolic BP Goal (mmHg)**: Age-dependent blood pressure goal: SBP ≥ 100 mmHg (age 50-69 years) and SBP ≥ 110 mmHg (age >70 years)\n\n**Seizure Prophylaxis**: Phenytoin if GCS &le; 10.\n\n**Therapy**: Surgery if\n\n- Width &gt; 10 mm\n- Midline shift &gt; 5 mm\n- GCS &lt; 9 or GCS change &ge; 2\n\n### Epidural ICH\n\n![Epidural ICH](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/intracranial-hemorrhage/image-3.png)\n\n**Systolic BP Goal (mmHg)**: Age-dependent blood pressure goal: SBP ≥ 100 mmHg (age 50-69 years) and SBP ≥ 110 mmHg (age >70 years)\n\n**Seizure Prophylaxis**: Phenytoin if GCS &le; 10.\n\n**Therapy**: Surgery if\n\n- Volume &gt; 30 mL\n- GCS &lt; 9 with asymmetric pupils\n\n### Traumatic Subarachnoid Hemorrhage (SAH)\n\n![Traumatic Subarachnoid Hemorrhage](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/intracranial-hemorrhage/image-4.png)\n\n**Systolic BP Goal (mmHg)**: Age-dependent blood pressure goal: SBP &ge; 100 mmHg (age 50-69 years) and SBP &ge; 110 mmHg (age &gt; 70 years)\n\n**Seizure Prophylaxis**: Phenytoin if GCS &le; 10.\n\n**Therapy**: Supportive management\n\n### Spontaneous SAH\n\n![Spontaneous Subarachnoid Hemorrhage](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/intracranial-hemorrhage/image-5.png)\n\n**Systolic BP Goal (mmHg)**: &lt; 140-160\n\n**Seizure Prophylaxis**: No\n\n**Therapy**:\n\n- Early clipping vs coiling\n- Transfer to high-volume SAH center\n\n## Primary Intracranial Hemorrhages\n\nPrimary ICHs include both intraventricular and intraparenchymal bleeds. The majority are due to severe hypertension and are localized to the cerebellum, brainstem, and midbrain. Other etiologies include aneurysm and tumor. Up to 30% of these cases expand within the first 3 hours of onset, which is why treatment guidelines include a systolic blood pressure (SBP) goal of &lt; 140-180 mmHg. This is often achieved with an IV infusion of a vasodilator, such as nicardipine or nitroprusside. In patients with primary ICH, seizure prophylaxis and platelet transfusion may lead to worse outcomes. Indications for an external ventricular drain (EVD) include any of the following:\n\n- Confirmed ICH with a GCS &lt; 9\n- Transtentorial herniation\n- Significant intraventricular hemorrhage with hydrocephalus\n\n## Traumatic Brain Injury including Epidural, Subdural, and Subarachnoid Hemorrhages\n\nIn contrast to primary ICHs, phenytoin has been shown to be of benefit for acute traumatic brain injury (TBI). It decreases the incidence of early (≤ 7 days) post-traumatic seizures. Phenytoin is the preferred agent for a patient with a traumatic ICH and a GCS ≤ 10. However, if a patient meets any of the below criteria for seizure prophylaxis but the GCS > 10, then either phenytoin or levetiracetam is acceptable.\n\n### Indications for seizure prophylaxis in traumatic ICH 8–13\n\n- GCS &le; 10 (phenytoin is the agent of choice)\n- Depressed skull fracture\n- Subdural or epidural hematoma\n- Hemorrhagic contusion\n- Penetrating head trauma\n- Seizure within the first 24 hours\n\n### Blood pressure goals in traumatic ICH\n\n- Age 50-69 years: SBP &ge; 100 mmHg\n- Age &gt; 70 years: SBP &ge; 110 mmHg \n\n### Surgical intervention for subdural hemorrhages\n\n- Width &gt; 10 mm\n- Midline shift &gt; 5 mm\n- GCS &lt; 9 or GCS change &ge; 2 since injury\n\n### Surgical intervention for epidural hemorrhages\n\n- Hemorrhage volume &gt; 30 cm3\n- GCS &lt; 9 with asymmetric pupils\n\nSpontaneous Subarachnoid Hemorrhage (SAH)\n\nSpontaneous, atraumatic SAHs have a 5-10% chance of rebleeding in the first 72 hours. Most are due to a ruptured aneurysm and have a SBP goal < 140-160 mmHg until the aneurysm is secured. These hemorrhages should not receive seizure prophylaxis as no benefit has been shown. Early clipping or coiling of the aneurysm is imperative to survival and may require transfer to a high-volume SAH center.\n\n## References\n\n- Carney N, Totten A M, O’Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury. Brain Trauma Foundation. Published September 2016. Accessed August 10, 2017. [[Source](https://braintrauma.org/uploads/03/12/Guidelines_for_Management_of_Severe_TBI_4th_Edition.pdf)]\n- Anderson C, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23713578)]\n- Qureshi A, Palesch Y, Barsan W, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016;375(11):1033-1043. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27276234)]\n- Baharoglu M, Cordonnier C, Al-Shahi S, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605-2613. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27178479)]\n- Naidech A, Garg R, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009;40(12):3810-3815. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19797183)]\n- Messé S, Sansing L, Cucchiara B, et al. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care. 2009;11(1):38-44. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19319701)]\n- Becker K, Baxter A, Bybee H, Tirschwell D, Abouelsaad T, Cohen W. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke. 1999;30(10):2025-2032. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10512902)]\n- Torbic H, Forni A, Anger K, Degrado J, Greenwood B. Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm. 2013;70(9):759-766. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23592358)]\n- Ferguson P, Smith G, Wannamaker B, Thurman D, Pickelsimer E, Selassie A. A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. Epilepsia. 2010;51(5):891-898. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19845734)]\n- Inaba K, Menaker J, Branco B, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013;74(3):766-71; discussion 771-3. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23425733)]\n- Szaflarski J, Sangha K, Lindsell C, Shutter L. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12(2):165-172. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19898966)]\n- Bhullar I, Johnson D, Paul J, Kerwin A, Tepas J, Frykberg E. More harm than good: antiseizure prophylaxis after traumatic brain injury does not decrease seizure rates but may inhibit functional recovery. J Trauma Acute Care Surg. 2014;76(1):54-60; discussion 60-1. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24368357)]\n- Young B, Rapp R, Norton J, Haack D, Tibbs P, Bean J. Failure of prophylactically administered phenytoin to prevent late posttraumatic seizures. J Neurosurg. 1983;58(2):236-241. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/6848681)]\n- Seelig J. Increased ICP and systemic hypotension during the first 72 hours following severe head injury. In: Intracranial Pressure. Vol VI. Springer; 1986:675-679.\n- Brenner M, Stein D, Hu P, Aarabi B, Sheth K, Scalea T. Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury. J Trauma Acute Care Surg. 2012;72(5):1135-1139. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22673237)]\n- Murray G, Butcher I, McHugh G, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 2007;24(2):329-337. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17375997)]\n- Chesnut R, Marshall L, Klauber M, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34(2):216-222. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8459458)]\n- Fearnside M, Cook R, McDougall P, McNeil R. The Westmead Head Injury Project outcome in severe head injury. A comparative analysis of pre-hospital, clinical and CT variables. Br J Neurosurg. 1993;7(3):267-279. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8338647)]\n- Marmarou A, Eisenberg H M, Foulkes M A, Marshall L F, Jane J A. Impact of ICP instability and hypotension on outcome in patients with severe head trauma. JNS. 1991;75(1):59-66. [[DOI](http://thejns.org/doi/abs/10.3171/sup.1991.75.1s.0s59)]\n- Miller J, Sweet R, Narayan R, Becker D. Early insults to the injured brain. JAMA. 1978;240(5):439-442. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/660888)]\n- Miller J, Becker D. Secondary insults to the injured brain. J R Coll Surg Edinb. 1982;27(5):292-298. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7143298)]\n- Pietropaoli J, Rogers F, Shackford S, Wald S, Schmoker J, Zhuang J. The deleterious effects of intraoperative hypotension on outcome in patients with severe head injuries. J Trauma. 1992;33(3):403-407. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/1404509)]\n- Rose J, Valtonen S, Jennett B. Avoidable factors contributing to death after head injury. Br Med J. 1977;2(6087):615-618. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/409450)]\n- Berry C, Ley E, Bukur M, et al. Redefining hypotension in traumatic brain injury. Injury. 2012;43(11):1833-1837. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21939970)]\n- Panczykowski D, Pease M, Zhao Y, et al. Prophylactic Antiepileptics and Seizure Incidence Following Subarachnoid Hemorrhage: A Propensity Score-Matched Analysis. Stroke. 2016;47(7):1754-1760. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27301932)]\n"
		},
		{
			"slug": "iv-fluids-for-icu-patients",
			"title": "IV Fluid Formulations for ICU Patients",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/01/03",
			"updates": null,
			"categories": [
				"Critical Care"
			],
			"body": "\n\n\n|  Content per 1 L    | Lactated Ringer's |  Normal Saline (0.9%) | Plasma-Lyte 148 |  D5W | D5 1/2NS |     5% albumin |\n| ------------------- | ----------------: | --------------------: | --------------: | ---: | -------: | -------------: |\n| Na (mEq)            |               130 |                   154 |             140 |      |       77 |        130-160 |\n| K (mEq)             |                 4 |                       |               5 |      |          |         &lt; 1 |\n| Cl (mEq)            |               109 |                   154 |              98 |      |       77 |        130-160 |\n| Ca (mEq)            |                 3 |                       |                 |      |          |                |\n| Mg (mEq)            |                   |                       |               3 |      |          |                |\n| Lactate (mEq)       |                28 |                       |                 |      |          |                |\n| Acetate (mEq)       |                   |                       |              27 |      |          |                |\n| Gluconate (mEq)     |                   |                       |              23 |      |          |                |\n| Glucose (mg/dL)     |                   |                       |                 | 4545 |     4545 |                |\n| Osmolarity (mOsm/L) |               273 |                   308 |             294 |  252 |      406 |            309 |\n| pH                  |               6.5 |                   5.0 |             5.0 |  4.0 |      4.5 |        6.4-7.4 |\n| Other               |                   |                       |                 |      |          | 50 g/L albumin |\n\n[Yunos et al JAMA 2012 study:](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)\n\n- **Design:** Prospective open, label sequential study of 760 ICU patients (control) and 773 ICU patients (study group) at single hospital in Melbourne, Australia\n- **Control period:** Standard IVF per physician preference\n- **Study period:** Chloride-rich IVF (0.9% saline, 4% succinylated gelatin solution, 4% albumin) became restricted and required specialist approval. Standard fluids allowed were chloride-restrictive fluids (Hartmann solution – similar to Lactated Ringer’s, Plasma-Lyte 148, chloride-poor 20% albumin)\n\n|                                                                            |  Control period (Chloride-liberal) | Study period (Chloride-restricted)  |  P value  | Odds ratio for Cl-restrictive  fluid use |\n| -------------------------------------------------------------------------- | ---------------------------------: | ----------------------------------: | --------: | ---------------------------------------: |\n| Mean serum Cr increased in umol/L                                          |                  22.6 (0.26 mg/dL) |                   14.8 (0.17 mg/dL) |       0.3 |                                          |\n| Incidence of injury & failure class for \"acute kidney injury\" (RIFLE defn) |                                14% |                                8.4% | &lt;0.001 |                                     0.52 |\n| Use of renal replacement therapy (RRT)                                     |                                10% |                                6.3% |     0.005 |                                     0.52 |\n\n**Bottom line:** \n\nChloride-rich IV fluids were associated with greater acute kidney injury and need for RRT in ICU patients, compared to chloride-restrictive IV fluids. \n\n**NOTE:** There was, however, NO difference in mortality, hospital, ICU length of stay, or RRT after hospital discharge.\n\n## References\n\n- Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)]\n"
		},
		{
			"slug": "kawasaki",
			"title": "Kawasaki Disease",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/03/23",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Cardiovascular"
			],
			"body": "\n\n\n## Definition \nAcute, self-limited vasculitis of unknown etiology that occursmostly in infants and young children \n\n## Classic clinical criteria\n\n1. **Fever for &ge; 5 days**, AND\n2. At least **4** of the 5 following:\n\n- Bilateral bulbar nonexudative conjunctivitis\n- Cervical lymphadenopathy (> 1.5 cm diameter), usually unilateral\n- Changes in lips and oral cavity\n- Erythema\n  - Lip cracking\n  - Strawberry tongue\n  - Diffuse injection of oral/pharyngeal mucosae\n- Changes in extremities\n  - Acute: Erythema of palms or soles; edema of hands or feet\n  - Subacute: Periungual peeling of fingers or toes in weeks #2-3   \n- Polymorphous rash\n\n![Signs of Kawasaki Disease drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/kawasaki/image-1.png)\n\n## Complications\nCoronary artery aneurysms/ ectasis\n- Increases risk of AMI, sudden death, ischemic heart disease (15-25% if untreated, and 5% if treated)\n\n## Differential Diagnosis\n\n- Viral infections (measles, adenovirus, enterovirus, EBV)\n- Scarlet fever\n- Staphylococcal scalded skin syndrome\n- Toxic shock syndrome\n- Bacterial cervical lymphadenitis\n- Drug hypersensitivity reaction\n- Stevens-Johnson syndrome\n- Juvenile rheumatoid arthritis\n- Rocky Mountain Spotted Fever\n- Leptospirosis\n- Mercury hypersensitivity reaction \n\n## Guideline: Evaluation of suspected incomplete Kawasaki Disease\n\n2004 American Heart Association Guidelines \n\n![Kawasaki Disease clinical decision pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/kawasaki/image-2.png)\n\n**Figure Notes**\n\n2. Infants &le;6 months old on day &ge;7 of fever without other explanation should undergo lab testing and, if evidence of systemic inflammation is found, an echocardiogram, even if they have no clinical criteria\n3. Check for classic findings\n4. Supplemental lab criteria\n\n- Albumin &le;3.0 g/dL\n- Anemia for age\n- Elevation of ALT\n- Platelets after 7 d &ge;450,000/mm3\n- WBC &ge;15,000/mm3\n- Urine &ge;10 WBC/hpf\n\n5. Can treat before performing echocardiogram\n6. Echo is considered positive for purposes of this algorithm, if any of 3 conditions met: \n\n- Z score of LAD or RCA &ge;2.5\n- Coronary arteries meet Japanese Ministry of Health criteria for aneurysms \n- &ge;3 other suggestive features exist including:\n  - Perivascular brightness\n  - Lack of tapering\n  - Decreased LV function\n  - Mitral regurgitation\n  - Pericardial effusion\n  - z score of LAD or RCA is 2–2.5\n\n7. If echo is positive, treatment should be given to children within 10 days of fever onset and those beyond day 10 with clinical and lab signs of ongoing inflammation (CRP, ESR).\n8. Typical peeling begins under nail bed of fingers and then toes.\n\n## References\n\n- Newburger JW et. al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. _Circulation_. 2004 Oct 26;110(17):2747-71. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=15505111)]\n"
		},
		{
			"slug": "ketofol",
			"title": "Ketofol",
			"authors": [
				"Salim Rezaie, MD"
			],
			"created": "2013/03/20",
			"updates": null,
			"categories": [
				"Pharmacology"
			],
			"body": "\n\n\n## Take Home Points\n\n- <span class=\"drug\">Ketofol</span> is a combination of <span class=\"drug\">ketamine</span> and <span class=\"drug\">propofol</span>.\n- <span class=\"drug\">Ketamine</span> gives you a dissociative sedative, analgesic, and amnestic effect.\n- <span class=\"drug\">Propofol</span> gives you rapid sedation and antiemetic effects. \n- Overall, it appears that <span class=\"drug\">ketofol</span> could have a slightly better time to sedation, and length of sedation, but this is not statistically significant based on available evidence. However, it does appear that <span class=\"drug\">ketofol</span> does have a more steady sedation depth not requiring as many subsequent doses.  \n- More studies needed (it would be great to see a three-armed study comparing <span class=\"drug\">ketofol</span>, <span class=\"drug\">ketamine</span>, and <span class=\"drug\">propofol</span> with appropriate and clinically equivalent dosing for each). \n\n## Ketamine Basics\n\n![Ketamine basics table](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ketofol/image-1.png)\n\n<span class=\"drug\">Ketamine</span> is a dissociative anesthetic that is a phencyclidine derivative and provides sedation, analgesia, and amnesia. It works by inhibiting catecholamine uptake, which exerts a sympathomimetic effect.\n\n**Typical dose:** 1–2 mg/kg IV or 4–5 mg/kg IM\n\n- Additional doses may be required at increments of 0.5-1 mg/kg. \n\n**Major adverse outcomes:** airway obstruction, hypoxia, apnea, and laryngospasm. \n\n- In a meta-analysis, of 8,282 patients, [Green et al (2009)](http://www.ncbi.nlm.nih.gov/pubmed/19201064) stated that the total incidence of these major adverse outcomes was only 3.9%. \n- Vomiting occurs in about 7–26% of patients.\n\n### What about the elevated intraocular pressure (IOP) and intracranial pressure (ICP) that we are always hearing about?\n\n[Drayna et al (2011)](http://www.ncbi.nlm.nih.gov/pubmed/22169582) found minimal, transient elevations of IOP that were not clinically meaningful. \n\n- The largest difference from baseline IOP occurred at 15 minutes with an estimated change of only 1.09 mmHg.\n\n## Propofol Basics\n\n![Propofol basics table](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ketofol/image-2.png)\n\n<span class=\"drug\">Propofol</span> is a lipophilic, ultra short-acting hypnotic agent, which works by potentiating GABA receptors on the neuronal lipid membranes. It does not provide any analgesia, and therefore should not be used as a sole agent for sedation. Note that one of its advantages is its anti-emetic property with a very low incidence of vomiting.\n\n**Typical dosing:** 1-2 mg/kg bolus followed by either a continuous infusion at 0.05-0.1 mg/kg/min or by 0.5 mg/kg boluses every 2–3 minutes. \nThe [Pediatric Sedation Research Consortium looked at 49,836 propofol sedation cases](http://www.ncbi.nlm.nih.gov/pubmed/19201064) and found no instances of death associated with propofol. \n\n- CPR was required in 2 cases, aspiration occurred in 4 cases, oxygen desaturation (less than 90% for longer than 30 sec duration) occurred in 716 cases, and central apnea occurred in 143 cases. \n\n## HOW DO YOU MIX KETOFOL?\n\nNo standard dosing regimen established.\n\nMost studies and authors recommend a **1:1 ratio** to provide ease of administration. The medications can be mixed or given sequentially. \n\n**[Click here for full ALiEM blog post](https://www.aliem.com/2013/ketofol-game-changer-procedural-sedation/)**\n\n## References\n\n- Drayna PC, Estrada C, Wang W, Saville BR, Arnold DH. Ketamine sedation is not \nassociated with clinically meaningful elevation of intraocular pressure. _Am J\nEmerg Med_. 2012 Sep;30(7):1215-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22169582)]\n- Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH; Pediatric Sedation\nResearch Consortium.. The incidence and nature of adverse events during pediatric\nsedation/anesthesia with propofol for procedures outside the operating room: a\nreport from the Pediatric Sedation Research Consortium. _Anesth Analg_. 2009\nMar;108(3):795-804.  [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19224786)]\n- Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for\npediatric sedation. _Pediatr Emerg Care_. 2012 Dec;28(12):1391-5; quiz 1396-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23222112)]\n- Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M. A blinded,\nrandomized controlled trial to evaluate ketamine/propofol versus ketamine alone\nfor procedural sedation in children. _Ann Emerg Med_. 2011 May;57(5):425-33.e2. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20947210)]\n- Andolfatto G, Abu-Laban RB, Zed PJ, Staniforth SM, Stackhouse S, Moadebi S,\nWillman E. Ketamine-propofol combination (ketofol) versus propofol alone for\nemergency department procedural sedation and analgesia: a randomized double-blind\ntrial. _Ann Emerg Med_. 2012 Jun;59(6):504-12.e1-2. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22401952)]\n- Green SM, Roback MG, Krauss B, Brown L, McGlone RG, Agrawal D, McKee M, Weiss \nM, Pitetti RD, Hostetler MA, Wathen JE, Treston G, Garcia Pena BM, Gerber AC,\nLosek JD; Emergency Department Ketamine Meta-Analysis Study Group. Predictors of\nairway and respiratory adverse events with ketamine sedation in the emergency\ndepartment: an individual-patient data meta-analysis of 8,282 children. _Ann Emerg\nMed_. 2009 Aug;54(2):158-68.e1-4.[[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19201064)]\n"
		},
		{
			"slug": "knee-exam",
			"title": "Knee Examination",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/03/19",
			"updates": null,
			"categories": [
				"Orthopedics",
				"EBM"
			],
			"body": "\n\n\n## [Solomon et al, JAMA 2001](http://www.ncbi.nlm.nih.gov/pubmed/?term=11585485)\n\n- Meta-analysis study: The accuracy of the clinical knee exam in detecting meniscal or ligamentous injury\n\n## Anatomy of the Knee Joint\n\n- Largest articulation in body\n- Stabilized by ACL, PCL, MCL, LCL, menisci, capsule and muscle\n- ACL and PCL also aid in proprioception\n- **Medial meniscus:** Because it more immobile than the lateral meniscus, it is more commonly injured.\n\n## Anterior Cruciate Ligament (ACL) Injury\n\n**Mechanism**: Knee twist with tibia pushed anteriorlyusually with concurrent valgus stress\n\n**Symptoms**\n\n- May recall “pop” sound at injury\n- May c/o knee buckling or “giving out”\n- May notice more pronounced pain when pivoting\n\n**Exam**\n\n- Lachman test \n- Anterior drawer sign\n- **Lateral pivot shift test:** Valgus stress on knee plus internal/external rotation of knee during knee flexion\n\n![Lateral pivot shift test drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-exam/image-2.png)\n\nPivot Shift [YouTube video](http://www.youtube.com/watch?v=ZWEGB0ToXZo)\n\n## Posterior Cruciate Ligament (PCL) Injury\n\n- Knee twist with tibia pushed posteriorly\n- Composite stats for posterior drawer sign: \n  - Positive LR 21\n  - Negative LR 0.05 \n\n## Meniscus Tear\n\n- Menisci have no pain fibers and pain comesfrom traction on peripheral structures\n- 16% asymptomatic patients have meniscustear on MRI (36% if age>45)\n- Medial meniscus tear can result in knee locked in flexion (unlikely lateral meniscus because more mobile)\n- Association with “clicking” noise when walking \n- **Exam:** McMurray test - British Journal of Sports Med [YouTube video](http://www.youtube.com/watch?v=fkt1TOn1UfI)\n- **Lateral meniscus test**: Valgus stress on knee and internal/external rotation while flex/extending knee\n- **Medial meniscus test**: Varus stress on knee and internal/external rotation while flex/extending knee\n\n![McMurray Test drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-exam/image-3.png)\n\n- **Exam:** Apley compression test - British Journal of Sports Med [YouTube video](http://www.youtube.com/watch?v=w57I1cYXlCA)\n  - In a patient prone position, flex knee to 90 degrees and external/internal rotate knee while axially loading\n- **Exam:** Medial-lateral grind test: Valgus and varus stress on knee while flex/extending knee – other hand is placed at joint line to detect grinding\n- Composite stats on exam maneuvers: \n  - Positive LR 2.7, Negative LR 0.4 (Overall - not that great) \n\n## Knee Exam\n\nConduct exam first on normal knee for comparison \n\nInspection: Look for atrophy, effusion\n\n- **_Tip:_** Collateral ligament injuries often have no effusion in acute setting\n\nPalpation: Look for crepitus as sign of cartilage disruption, joint line tenderness \n\nFunction: Perform stress maneuvers\n\n## Check for Historical Clues\n\n- Typical effusion onset: Immediate = meniscus or cruciate ligament tear\n- Pop noise at time of injury = ACL tear\n- Clicking/locking sensation = Meniscus injury\n\n## Fagan Nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-exam/image-4.png)\n\n## References\n\n- Solomon DH et. al.The rational clinical examination. Does this patient have a torn meniscus or ligament of the knee? Value of the physical examination. _JAMA_. 2001 Oct 3;286(13):1610-20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=11585485)]\n"
		},
		{
			"slug": "knee-injuries",
			"title": "Knee Injuries",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/21",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## [Knee Dislocation](/cards/knee-injuries-knee-dislocation)\n\n## [Patella Fracture](/cards/knee-injuries-patella-fracture)\n\n## [Patella Dislocation](/cards/knee-injuries-patella-dislocation)\n\n* * *\n\n## References\n\n- Schwartz A. Patella Fractures Treatment & Management, Emedicine.com (June 2016) [[Source](http://emedicine.medscape.com/article/1249384-treatment)].\n\n- Hinton RY, Sharma KM. Acute and recurrent patellar instability in the young athlete. Orthop Clin North Am. 2003 Jul;34(3):385-96. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12974488)]\n\n- Ji G, et al . Surgical versus Nonsurgical Treatments of Acute Primary Patellar Dislocation with Special Emphasis on the MPFL Injury Patterns. J Knee Surg. 2016 Sep 14. Epub ahead of print. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=27626368.)]\n\n- Petri M, et al. Current Concepts for Patellar Dislocation. Arch Trauma Res. 2015 Sep 1;4(3):e29301. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=26566512)]\n\n- Medina O, et al. Vascular and nerve injury after knee dislocation: a systematic review. Clin Orthop Relat Res. 2014 Sep;472(9):2621-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=24554457)]\n"
		},
		{
			"slug": "knee-injuries-knee-dislocation",
			"title": "Knee Injuries - Knee Dislocation",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/21",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Posterior vs anterior knee dislocation drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-injuries-knee-dislocation/image-1.png)\n\n## X-ray Views\n\n### AP view\n\n- Look especially for small avulsions, such as a Segond fracture, which is a lateral tibial condyle avulsion fracture\n\n### Lateral view\n\n- Look for symmetric or irregular joint space\n\n## Acute Management\n\n**_Orthopedic vascular emergency!_**\n\n- Reduce knee and re-examine neurovascular status\n- Consult vascular surgery for hard signs of vascular injury\n\nMeasure the Ankle-Brachial index(ABIs):\n- ABI &ge; 0.9: Monitor by serial exam\n- ABI &lt; 0.9: Obtain CT angiography\n\nSplint knee in 20-30 degrees of flexion\n\n## Follow-Up Timing\n\nHospital admission required for serial neurovascular exams and consideration for surgical stabilization\n\n## Notes\n\n**Dimple sign** \n- Buttonholing of medial femoral condyle through medial capsule\n- Suggests irreducible posterolateral dislocation\n\n**Associated findings with knee dislocations**\n\n- Popliteal artery injury (18%)\n- Common peroneal nerve injury (25%) – check for foot dorsiflexion weakness and numbness to dorsal foot\n- Ligament tears\n\n## References\n\n- Schwartz A. Patella Fractures Treatment & Management, Emedicine.com (June 2016) [[Source](http://emedicine.medscape.com/article/1249384-treatment)].\n- Hinton RY, Sharma KM. Acute and recurrent patellar instability in the young athlete. Orthop Clin North Am. 2003 Jul;34(3):385-96. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12974488)]\n- Ji G, et al . Surgical versus Nonsurgical Treatments of Acute Primary Patellar Dislocation with Special Emphasis on the MPFL Injury Patterns. J Knee Surg. 2016 Sep 14. Epub ahead of print. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=27626368.)]\n- Petri M, et al. Current Concepts for Patellar Dislocation. Arch Trauma Res. 2015 Sep 1;4(3):e29301. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=26566512)]\n- Medina O, et al. Vascular and nerve injury after knee dislocation: a systematic review. Clin Orthop Relat Res. 2014 Sep;472(9):2621-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=24554457)]\n"
		},
		{
			"slug": "knee-injuries-patella-dislocation",
			"title": "Knee Injuries - Patella Dislocation",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/21",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Patella dislocation drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-injuries-patella-dislocation/image-1.png)\n\n## X-ray Views\n\n- AP knee\n- Lateral knee: Best to assess for displacement\n- Patella view: Sunrise or Merchant view\n\n## Acute Management\n\n- Closed reduction\n- Splint in above-knee plaster cast (from distal 2/3s of thigh to MTP foot joints), straight leg immobilizer, or hinged knee brace\n- Weight-bearing as tolerated with crutches\n\n## Follow-up Timing\n\n- Within 1-2 weeks\n- Consider sooner follow-up to assess for associated osteochondral fractures and medial patellofemoral ligament injury, which may require operative repair.\n\n## Notes\n\n- Most managed non-operatively\n- Complications: Recurrent dislocations\n\n## References\n\n- Schwartz A. Patella Fractures Treatment & Management, Emedicine.com (June 2016) [[Source](http://emedicine.medscape.com/article/1249384-treatment)].\n- Hinton RY, Sharma KM. Acute and recurrent patellar instability in the young athlete. Orthop Clin North Am. 2003 Jul;34(3):385-96. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12974488)]\n- Ji G, et al . Surgical versus Nonsurgical Treatments of Acute Primary Patellar Dislocation with Special Emphasis on the MPFL Injury Patterns. J Knee Surg. 2016 Sep 14. Epub ahead of print. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=27626368.)]\n- Petri M, et al. Current Concepts for Patellar Dislocation. Arch Trauma Res. 2015 Sep 1;4(3):e29301. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=26566512)]\n- Medina O, et al. Vascular and nerve injury after knee dislocation: a systematic review. Clin Orthop Relat Res. 2014 Sep;472(9):2621-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=24554457)]\n"
		},
		{
			"slug": "knee-injuries-patella-fracture",
			"title": "Knee Injuries - Patellar Fracture",
			"authors": [
				"Layla Abubshait, MD",
				"Michael Gottlieb, MD, RDMS",
				"Mary Haas, MD"
			],
			"created": "2016/11/21",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Drawing of the types of patellar fractures](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/knee-injuries-patella-fracture/image-1.png)\n\n## X-ray Views\n\n- AP knee\n- Lateral knee: Best to assess for fracture displacement\n- Patella view: Sunrise or Merchant view\n\n## Operative Indications (Outpatient)\n\n- Knee extensor function disruption\n- &gt;2 mm articular displacement\n- &gt;3 mm fracture fragment separation\n\n## Acute Management\n- Knee immobilizer with knee in full extension\n- Weight-bearing instructions as tolerated\n- **If non-operative:** Early weight bearing to minimize bone loss and muscle atrophy\n\n## Follow-Up Timing\n\nWithin 1 week\n\n**If non-operative:**\n\n- Muscle strengthening education\n- Likely conversion to long leg cast or locking knee brace\n\n## Complications\n\n- Nonunion\n- Stiffness\n- Muscle atrophy\n- Osteonecrosis\n\n## References\n\n- Schwartz A. Patella Fractures Treatment & Management, Emedicine.com (June 2016) [[Source](http://emedicine.medscape.com/article/1249384-treatment)].\n- Hinton RY, Sharma KM. Acute and recurrent patellar instability in the young athlete. Orthop Clin North Am. 2003 Jul;34(3):385-96. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12974488)]\n- Ji G, et al . Surgical versus Nonsurgical Treatments of Acute Primary Patellar Dislocation with Special Emphasis on the MPFL Injury Patterns. J Knee Surg. 2016 Sep 14. Epub ahead of print. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=27626368.)]\n- Petri M, et al. Current Concepts for Patellar Dislocation. Arch Trauma Res. 2015 Sep 1;4(3):e29301. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=26566512)]\n- Medina O, et al. Vascular and nerve injury after knee dislocation: a systematic review. Clin Orthop Relat Res. 2014 Sep;472(9):2621-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=24554457)]\n"
		},
		{
			"slug": "laceration-repair-suture-material",
			"title": "Laceration Repair and Sutures – A cheat sheet guide",
			"authors": [
				"Hyunjoo Lee, MD",
				"Layla Abubshait, MD"
			],
			"created": "2017/03/06",
			"updates": null,
			"categories": [
				"Trauma"
			],
			"body": "\n\n\n![Suture removal timing diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/laceration-repair-suture-material/image-1.png)\n\n| **SUTURE TYPE**     | **Time of Effective Tensile Strength**  |  **Time to Absorption** | **Reactivity**  |\n|---------------------|-----------------------------------------|-------------------------|-----------------|\n| Prolene             | indefinite                              | non absorbable          | low             |\n| Nylon               | gradual loss                            | non absorbable          | low             |\n| Silk                | gradual loss                            | non absorbable          | high            |\n| Fast absorbing gut  | 7 days                                  | 21-42 days              | high            |\n| Vicryl Rapide       | 5-14 days                               | 42 days                 | high            |\n| Monocryl            | 7-14 days                               | 91-119 days             | high            |\n| Vicryl              | 14-28 days                              | 56-70 days              | high            |\n| Chromic Gut         | 21-28 days                              | 90 days                 | high            |\n\n| **LOCATION**              | **CONCERN**                                                         | **TREATMENT**                                                                                                                                                                                       |\n|---------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Eyelid margin             |    Requires careful approximation                                   | Ophthalmology consult for repair                                                                                                                                                                    |\n| Medial canthus of eye     |    Lacrimal duct location                                           | Ophthalmology consult for repair                                                                                                                                                                    |\n| Vermillion border of lip  |    Requires careful approximation                                   | Consider consulting Oral Maxillofacial Surgery or Plastics                                                                                                                                          |\n| Mammalian bites           |    Risk for infection, especially of the hands: Human > Cat > Dog   | **Antibiotics:** Amoxicillin-clavulanate (Cochrane: Antibiotics not warranted for uncomplicated dog bites to non-hand areas of the body [1].) <br>Do not close wounds, especially if puncture-like. |\n\n## References\n- Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev.\n2001;(2):CD001738. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=11406003)]\n- Capella O, Hollander JE. Management of lacerations in the emergency department. Emerg Med\nClin N Am. 2003; 21:205-231. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12630738)]\n- DeBoard RH, Rondeau DF, Kang CS, Sabbaj A, McManus JG. Principles of basic wound evaluation\nand management in the emergency department. Emerg Med Clin N Am. 2007; 25:23-39. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=17400071)]\n- Lammers RL, Smith ZE. Methods of wound closure. In: Roberts and Hedges’ Clinical Procedures in\nEmergency Medicine, 6th Ed. Saunders. 2013. 644-689.\n"
		},
		{
			"slug": "legionella",
			"title": "Legionnaire's Disease",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/09/16",
			"updates": null,
			"categories": [
				"Infectious Disease",
				"Pulmonology"
			],
			"body": "\n\n\nPneumonia caused by any _Legionella_ species\n\n## Background\n\n- Outbreaks related to exposure to colonized water\n- Air travel\n- Water puddles\n- Excavation\n- Construction sites\n- Most commonly found in patients age > 50 years, smokers, immunocomprised\n- Differential diagnosis often involves other atypical pneumonia and zoonotic organisms \n- Requires reporting to your state's health department to help track for outbreaks\n\n## Clinical Presentation\n\nAcute presentation of severe community acquired pneumonia (CAP) \n\n**Classic Chest X-Ray:** Rapidly progressive asymmetrical patchy infiltrates\n\n- Besides Legionella, the differential diagnosis for such a CXR finding includes: \n  1. _Strep pneumoniae_ in patients with impaired splenic function \n  2. Zoonotic atypical pathogens (Q fever, tularemia, adenovirus)\n\nExtrapulmonary organ involvement:\n\n- **CNS:** Mental confusion, encephalopathic, headache\n- **Cardiac:** Relative bradycardia\n- **GI:** Loose stools, watery diarrhea\n- **Renal:** Microscopic hematuria, renal insufficiency \n\n| Temperature    | Appropriate HR (bpm) | Relative Bradycardia (bpm) |\n| -------------- | :------------------: | :------------------------: |\n| 102°F (38.9°C) | 110                  | &lt; 100                   |\n| 103°F (39.4°C) | 120                  | &lt; 110                   |\n| 104°F (40.0°C) | 130                  | &lt; 120                   |\n| 105°F (40.6°C) | 140                  | &lt; 130                   |\n\n![Legionella clinical pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/legionella/image-1.png)\n\n## Classic Laboratory Findings\n\n- **Na:** Low in CAP but mostly frequently associated with Legionella \n- **AST/ALT:** Mildly increased 2-5x normal\n- **Phosphate:** Decreased\n- **CK:** Increased\n- **CRP:** > 35 mg/L\n- **Ferritin:** Increased > 2x normal \n\n## Legionella Diagnostic Triad ([Cunha et al.](http://www.ncbi.nlm.nih.gov/pubmed/?term=20457348))\n\n| **Need All 3 Criteria**  | **Key Clinical Feature**                      | **Key Lab Features (Any 3)** |\n| :----------------------- | :-------------------------------------------- | :--------------------------- |\n| Signs/sx of CAP          | T >102F with unexplained relative bradycardia | Hypophophatemia              |\n| New infiltrate on CXR    |                                               | Ferritin> 2x normal          |\n| No zoonotic contact hx   |                                               | Mild transaminitis           |\n|                          |                                               | Relative lymphopenia         |\n\n## Diagnostic Test\n\n- Urine Legionella antigen: Only detects serotypes 1-6\n\n## Antibiotic Treatment\n\n- **Macrolides:** First-line agent, although a growing resistance\n- Other antibiotics: Doxycycline, fluoroquinolones \n- Duration of treatment: 2 weeks\n\n## References\n\n- Cunha BA, Mickail N, Syed U, Strollo S, Laguerre M. Rapid clinical diagnosis of Legionnaires' disease during the \"herald wave\" of the swine influenza (H1N1) pandemic: the Legionnaires' disease triad. _Heart Lung_. 2010 May-Jun;39(3):249-59. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20457348)]\n- Cunha BA. Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias. _Infect Dis Clin N Am_. 2010;24(1):73-105. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20171547)]\n"
		},
		{
			"slug": "local-anesthetic-toxicity",
			"title": "Local Anesthetic Toxicity",
			"authors": [
				"David Murphy, MD"
			],
			"created": "2014/06/13",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n## Nomogram Instructions\n\n1. Use ideal body weight (IBW). If IBW >70 kg, use 70 kg dosing.\n2. If multiple local anesthetics (LAs) are used, calculate maximum dose assuming LA with greatest toxicity is used alone.\n3. Identify administered LA under “Agent & Concentration”\n4. Draw a line between LA Agent & Concentration (left) to patient´s IBW (right).\n5. Where this line intersects “Max Volume” (center) is the maximum dose (mL) that can be safely administered to the patient.\n6. These numbers assume that the toxic levels are:\n\n- <span class=\"drug\">Bupivacaine</span> = 2 mg/kg\n- <span class=\"drug\">Lidocaine</span> = 3 mg/kg\n- <span class=\"drug\">Lidocaine</span> + “Ad”renaline (<span class=\"drug\">Epinephrine</span>) = 6 mg/kg\n\n![Nomogram for local anesthetic toxic dose limits](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/local-anesthetic-toxicity/image-1.png)\n\n## Dosing of 20% INTRAVENOUS LIPID for local anesthetic toxicity\n\n- Draw a **vertical line** downward from patient´s IBW. \n- The intersection of this line with the 3 other axes indicate weight-based initial bolus volume, infusion rate, and total maximum dose of <span class=\"drug\">intralipid (20%)</span>.\n\n![body weight to dose limit figure](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/local-anesthetic-toxicity/image-2.png)\n\n## References\n\n- Williams DJ, Walker JD. A nomogram for calculating the maximum dose of local anaesthetic. Anaesthesia. 2014;69(8):847-53. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=24820093)]\n"
		},
		{
			"slug": "lung-ultrasound",
			"title": "Ultrasound: Focused Lung Assessment",
			"authors": [
				"Anne Aspler, MD",
				"Clare Heslop, MD",
				"Mike Stone, MD"
			],
			"created": "2015/02/04",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology",
				"Pulmonology"
			],
			"body": "\n\n\n**Goals:** Evaluate for lung sliding, lung artifacts (A and B lines), consolidation, and pleural effusion\n\n**Transducer:** Performance and interpretation of lung US is not transducer-specific:\n\n- Low frequency curvilinear (or phased array) transducer allows adequate depth to assess artifacts (A lines and B lines).\n- High frequency linear transducer may be used to better visualize lung sliding at the pleura, if there is uncertainty with the low frequency curvilinear transducer.\n\n**Windows:** \n- Transducer orientation is longitudinal with directional indicator oriented towards the patient’s head. \n- The area of interest is the pleura visualized between the ribs. \n- There are many accepted scanning approaches, and two commonly used in the ED:\n\n  1. **3 views in each hemithorax:**\n\n     - **Anterior:** 2nd or 3rd interspace at the mid-clavicular line\n     - **Anterolateral:** Anterior and mid-axillary lines along the 3rd to 5th interspace\n     - **Posterolateral:** Posterior axillary line, looking into the lower thorax and upper abdominal quadrants at the level of the diaphragm\n\n  2. **8 lung zones**, or 4 sections, in each hemithorax [Volpicelli]\n\n![Transducer positions for the 8 lung zones](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lung-ultrasound/image-1.png)\n\nFigure 1: Transducer positions for the 8 lung zones\n\n## Lung Sliding\n\nThe visceral and parietal pleura appear as a single hyperechoic line deep to the internal intercostal muscle, and in healthy lungs will \"slide\" during the respiratory cycle.\n\nAbsent lung sliding is a **_pathologic finding_** found in pneumothorax, contralateral mainstem bronchus intubation or esophageal intubation (lung pulse present), pleural adhesions, stiff lungs, and pleurodesis.\n\n## A-Lines\n\n- **Horizontal** reverberation artifacts\n- Arise from the pleural line, are hyperechoic and parallel to pleural surface at equal intervals.\n- Seen with normal lung aeration and in some cases of pneumothorax\n\n![A-lines are visualized as hyperechoic, horizontal artifacts at regular intervals deep to the pleural line](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lung-ultrasound/image-2.png)\n\nFigure 2: A-lines are visualized as hyperechoic, horizontal artifacts at regular intervals deep to the pleural line. Note the ribs **(r)** in the near field.\n\n## B-Lines\n\n- **Vertical** artifacts\n- Arise from the pleural line, extend off the screen without fading, are hyperechoic and laser-like, move with respiration, and erase the normal A-line pattern.\n- More than 3 B-lines in an interspace is considered **_pathologic_**, although many experts agree that any anterior B-lines are pathologic.\n\n![B-lines are visualized as hyperechoic vertical artifacts arising from the pleural line and extending off the screen without fading, erasing the A-line pattern](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lung-ultrasound/image-3.png)\n\nFigure 3: B-lines are visualized as hyperechoic vertical artifacts arising from the pleural line and extending off the screen without fading, erasing the A-line pattern.\n\n## Comet Tails\n\n- A normal artifact\n- **Vertical** artifact that looks like B-lines, but are distinguished from them by their depth of extension. They do NOT extend to the bottom of the screen NOR erase A-Lines.\n\n## Lung Profiles\n\n- **Normal Lung:** Lung sliding present at pleural line. A-lines. B-lines may occur postero-laterally, but never more than 3 in a single interspace.\n- **Pneumothorax**: Absent lung sliding, no B-lines. A-lines are present. A lung point, representing the boundary of the pneumothorax and adjacent inflated lung, may be identified.\n- **Pneumonia:** Focal area of B-lines, asymmetric compared to contralateral lung. Consolidation with dynamic air bronchograms may be visualized (see below). Lung sliding may be absent due to inflammation causing pleural adherence, or decreased regional ventilation.\n- **Interstitial Syndromes** (pulmonary edema, ARDS, pneumonitis): Greater than three B-lines in 2 or more interspaces\n- **Pleural** **Effusion**: Subpleural collection seen in dependent regions, usually anechoic but may be hypo- or iso-echoic if exudative, and may have hyperechoic septae.\n- **Consolidation or Atelectasis:** Lung tissue appears as a subpleural tissue-like texture, without lung sliding or air artifacts.\n\n## Pleural Effusion\n\n![Pleural effusion visualized as an anechoic fluid collection](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lung-ultrasound/image-4.png)\n\nFigure 4: Pleural effusion visualized as an anechoic fluid collection located cephalad to the arrows.\n\n## Pneumonia\n\n![A lobar consolidation. The branching, hyperechoic air bronchograms define this consolidation](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lung-ultrasound/image-5.png)\n\nFigure 5: A lobar consolidation located cephalad to the diaphragm. The branching, hyperechoic air bronchograms define this consolidation.\n\n## Struggling with the Exam?\n\n- Do **_not_** move quickly. Hold the probe STILL during the respiratory cycle to see lung sliding and lung artifacts. Compare the same region of each hemithorax sequentially instead of the entire hemithorax at once.\n\n**Can’t decide if there is lung sliding?**\n\n- To optimize visualization of the pleural line, decrease the depth and decrease the overall gain.\n\n**Can’t see A-lines or B-lines?**\n\n- Turn _off_ artifact-reduction settings, or use a lung preset if available. Keep the transducer perpendicular to the patient’s chest in all zones scanned. Use a low-frequency transducer set to its lowest operating frequency.\n\n## Common Errors\n\n**Unable to identify A-lines** \n\n- Remember to turn _off_ artifact-reduction settings, or use a lung preset if available. Keep the transducer perpendicular to the patient’s chest in all zones scanned.\n\n**Quantification of B-lines** \n\n- A single B-line in dependent interspaces may be a normal finding in a healthy patient, but >3 B-lines in a single interspace indicates lung pathology.\n\n**Absence of lung sliding** is 100% sensitive for pneumothorax, but is **_not specific_** to pneumothorax. \n\n- Other possibilities may be:\n  - Failure to ventilate\n  - Contralateral mainstem intubation\n  - Dense consolidation from pneumonia\n  - Severe pulmonary fibrosis\n  - Pleural inflammatory changes\n\n## References\n\n- Blaivas M, Lyon M, Duggal S. A prospective comparison of supine chest radiography and bedside ultrasound for the diagnosis of traumatic pneumothorax. Acad Emerg Med. 2005;12(9):844-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16141018)]\n- Liteplo AS, Marill KA, Villen T, et al. Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. Acad Emerg Med. 2009;16(3):201-10. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19183402)]\n- Volpicelli G. Lung sonography. J Ultrasound Med. 2013;32(1):165-71. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23269722)]\n"
		},
		{
			"slug": "lvad-complications",
			"title": "Left Ventricular Assist Device Complications",
			"authors": [
				"Nicolas Stadlberger, MD"
			],
			"created": "2016/11/23",
			"updates": null,
			"categories": [
				"Cardiovascular",
				"Critical Care"
			],
			"body": "\n\n\n![LVAD diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lvad-complications/image-1.jpg)\n\n- These patients MAY NOT HAVE A PULSE    \n  - May need an ABG since pulse oximetry may be inaccurate without a pulse\n- Contact your hospital’s or network’s LVAD Coordinator immediately to help with management and troubleshooting.\n- Patients are usually on diuretics, and may be intravascularly depleted or have electrolyte abnormalities\n\n## LVAD Patient in Extremis: Step-Wise Diagnostic Approach\n\n### Step 1\n\n- Address airway, breathing, circulation\n- Obtain IV, O2, monitor\n- Measure blood pressure: May need manual cuff with Doppler to obtain mean arterial pressure (MAP), or use arterial line (MAP goal 70-80 mmHg)\n- Assign someone to call LVAD Coordinator\n\n### Step 2\n\n- **A** uscultate precordium. Is there a hum?\n  - Yes - LVAD is working. \n  - No - LVAD is not working.\n- **B** attery: Make sure it is plugged in.\n- **C** ontroller: Check for alarms.\n- **D** riveline: Check device type and evidence of infection or damage\n- **E** chocardiogram\n\n### Step 3\n\n- Obtain VAD variables: Flow, Power, Speed, Pulsatility Index\n\n### Step 4\n\n- Obtain ECG\n- Obtain labs:\n  - CBC\n  - Electrolytes\n  - Coagulation studies\n  - LDH\n  - Type and screen given GI bleed risk\n  - ± Blood cultures if infection concern\n  - ± ABG\n\n## Echocardiogram Findings - Causes & Management\n\n### Big right ventricle, big left ventricle\n\n**Potential Causes**\n\n- Pump failure\n- Pump thrombosis\n- Valve disorders\n\n**Management**\n\n- <span class=\"drug\">Heparin</span>\n- <span class=\"drug\">Antiplatelet agents</span>\n- <span class=\"drug\">Thrombolytics</span>\n\n### Big right ventricle, small left ventricle\n\n**Potential Causes**\n\n- Right heart failure\n- ST-elevation MI\n- Pulmonary hypertension\n- Note: If LV to outflow cannula size ratio is 1:1, then high risk for suction event\n\n**Management**\n\n- IV fluids\n- ECG\n- Consider inotropes\n\n### Small right ventricle, small left ventricle\n\n**Potential Causes**\n\n- Hypovolemia\n- Sepsis\n- GI bleed\n\n**Management**\n\n- IV fluids\n- Consider blood transfusion\n- Antibiotics\n\n## LVAD Complications\n\n### Arrhythmia\n\n- Up to 50% experience sustained VT/VF in first 4 weeks after LVAD placement\n- Difficult to determine primary vs. secondary cause:\n  - Primary: Compromised myocardium + scar tissue\n  - Secondary: Electrolyte abnormalities, hypotension, suction events\n- Management depending on the cause:\n  - IV fluid challenge is reasonable\n  - Reduce pump speed\n  - Correct electrolytes\n  - Electrical or pharmacologic: amiodarone, cardioversion\n\n### Infection\n\n- Up to 42% experience sepsis within 1 year (REMATCH Study). Most infections are in first 3 months, and 9% are fungal.\n- Treat with broad spectrum antibiotics + antifungal\n\n### Thrombus (pump thrombus, PE, stroke/TIA)\n\n- High risk despite anticoagulation. \n- Pump thrombus suggested by warm device and increased power output. \n- Lab finding: Elevated LDH\n- Treat with Heparin, thrombolytics, antiplatelet agents\n\n### Bleeding\n\n- Patients may have an acquired Von Willebrand Disease coagulopathy.\n- If life-threatening, reverse anticoagulation and transfuse as needed.\n\n### Suction Event\n\n- An underfilled LV causing suction of myocardium into LVAD\n- Can be caused by right heart failure, hypovolemia, sepsis, restrictive cardiomyopathy, arrhythmias\n- Treat with IV fluids to increase LV filling.\n\n### RV Failure\n\n- Due to acute myocardial infarction (AMI) or previous RV failure\n- Treat with IV fluids and consider inotropes. \n- Start aspirin and heparin, if AMI.\n\n### Cannula Malposition\n\n- Consider in setting of new VT, suction event, chest compressions, or trauma\n- Requires surgical exploration\n\n### Device Malfunction, Pump Failure\n\n- Suggested if no hum and mean arterial pressure (MAP) &lt;40 mmHg.\n- Treat cardiogenic shock: IV fluids, vasopressors, ACLS protocols, consider heparin for thrombosis\n\n### Cardiac Arrest\n\n- Multiple potential causes including all those listed above.\n- Follow ACLS algorithms EXCEPT:\n  - Chest compressions are controversial as they could dislodge the device.\n  - Do NOT place defibrillation pads directly over device.\n  - Assign one person to assess device placement during and after code.\n\n## Altered LVAD Patient\n\n![Altered LVAD patient clinical pathway diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/lvad-complications/image-2.png)\n\n## References\n\n- Partyka C, Taylor B. Review article: ventricular assist devices in the emergency department. _Emerg Med Australas_. 2014;26(2):104-112. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24707998)]\n- Andersen M, Videbaek R, Boesgaard S, Sander K, Hansen P, Gustafsson F. Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). _J Heart Lung Transplant_. 2009;28(7):733-735. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19560703)]\n- Greenwood J, Herr D. Mechanical circulatory support. _Emerg Med Clin North Am_. 2014;32(4):851-869. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25441039)]\n"
		},
		{
			"slug": "metacarpal-metatarsal-fractures",
			"title": "Metatarsal & Metacarpal Fractures",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2013/12/13",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Metacarpal and metatarsal drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/metacarpal-metatarsal-fractures/image-1.png)\n\n## Metatarsal Head\n\n- Typically operative, unless MCP stable and &lt; 20% articular surface involvement\n\n## Metatarsal Neck\n\n- Most are nonoperative\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td>Urgent closed reduction needed if:<br />\n</td>\n<td><ul>\n<li>&gt; 10°, 20°, 30°, 40° angulation for 2nd-5th MCs, respectively, OR<br />\n</li>\n<li>ANY rotational deformity (note scissoring with composite flexion) <br />\n</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Metacarpal Shaft\n\nMost are nonoperative, especially 3rd and 4th MC because of inter-MC ligaments\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td>Urgent closed reduction needed if<br />\n</td>\n<td><ul>\n<li>&gt; 10°, 10°, 20°, 20° angulation for 2nd-5th MCs, respectively, OR<br />\n</li>\n<li>&ge; 5 mm shortening, OR</li>\n<li>ANY rotational deformity<br />\n</li>\n</ul></td>\n</tr>\n<tr class=\"even\">\n<td>PEARL</td>\n<td><ul>\n<li>Short oblique fractures (length of fx &lt; 2x bone diameter) and displaced transverse fractures typically unstable and may need fixation. <br />\n</li>\n<li>Splint with dorsal pressure over the dorsally angulated fracture site.<br />\n</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Metacarpal Base\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td>1st MC (thumb)<br />\n</td>\n<td><em>Intraarticular:</em><br />\n\n<ul>\n<li><strong>Bennett</strong> (fx fragment on ulnar side of 1st MC) <br />\n</li>\n<li><strong>Rolando</strong> (fx fragment on ulnar &amp; radial side of 1st MC): Typically unstable and require operative repair<br />\n</li>\n</ul>\n<em>Extraarticular:</em><br />\n\n<ul>\n<li>Allow up to 30° of apex-dorsal angulation and 4 mm shortening before operative repair<br />\n</li>\n</ul></td>\n</tr>\n<tr class=\"even\">\n<td>2-4th MC<br />\n</td>\n<td>Operative repair if &ge; 2 mm articular surface displacement or significant angulation<br />\n</td>\n</tr>\n<tr class=\"odd\">\n<td>5th MC<br />\n</td>\n<td><em>Extraarticular:</em> Typically stable because of inter-MC ligaments<br />\n<em>Intraarticular</em> (high-energy injury): Unstable<br />\n\n<ul>\n<li>Fracture line between inter-MC ligaments and insertion of extensor carpi ulnaris tendon, causing base to displace proximal and dorsal</li>\n<li>Typically will need fixation<br />\n</li>\n</ul>\n<em>PEARL:</em> 4th and 5th MC base fractures are frequently fx-dislocations. Check lateral xray to ensure the carpo-MC joint is reduced.<br />\n</td>\n</tr>\n</tbody>\n</table>\n\n## Splinting\n\n| **Digit**            |  **Splint**            | **Position**                                              |\n| -------------------- | ---------------------- | --------------------------------------------------------- |\n| Thumb                | Thumb splica           | Wrist extension 20°, thumb Abduction                      |\n| Index, middle finger | Radial gutter or volar | Wrist extension in 20°, MCP flexion in 90°, keep IPs free |\n| Ring, small finger   | Ulnar gutter           | Wrist extension in 20°, MCP flexion in 90°, keep IPs free |\n\n## References\n\n- Wheeless Online. Available at: http://www.wheelessonline.com/ortho/hand_and_metacarpal_fractures. Accessed August 1, 2017.\n- Browner BD. Skeletal Trauma, Basic Science, Management, and Reconstruction. Elsevier Health Sciences; 2009.\n- Hockberger RS, Walls RM. Rosen's Emergency Medicine - Concepts and Clinical Practice, 2-Volume Set,Expert Consult Premium Edition - Enhanced Online Features and Print,7, Rosen's Emergency Medicine - Concepts and Clinical Practice, 2-Volume Set. Elsevier Health Sciences; 2009.\n- Emedicine. Available at: http://emedicine.medscape.com/article/1239721-overview. Accessed August 1, 2017\n"
		},
		{
			"slug": "methanol",
			"title": "Toxic Alcohol Ingestion - Methanol",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/06/15",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\nGeneral concepts for all 3 toxic alcohols:\n\n- Parent compounds (not metabolites) cause high osmolal gap\n- When NAD depleted, pyruvate converts to lactate - which then causes lactic acidosis\n- See metabolism of alcohols diagram below\n\n## Methanol: Factoids\n\nSolvent found in cleaning and printing solutions, adhesives, stains, paint removers, antifreeze agent in windshield wiping fluid, camp stove fuel, gasoline additive\n\n**Pharmacology**:\n\n- Peak serum concentration 30-60 minutes, elimination half-life 12-20 hours\n- Permanent blindness reported at as little as 0.1 mL/kg (6-10 mL in adults)\n- Lethal dose = 1-2 mL/kg\n- Metabolite (eg. formic acid) causes toxicity, but does NOT cause osmolal gap\n\n## Classic Presentation \n### Classic Profile\n- Altered mental status\n- Visual disturbances\n- Abdominal pain\n- High anion gap metabolic acidosis\n- High osmolal gap\n\n### Signs and Symptoms\n- **CNS:** Headache, lethargy, confusion, Parkinsonian extrapyramidal symptoms\n- **Ocular:** Blurry vision, central scotoma, impaired pupillary response, photophobia, retinal edema (permanent damage in 25-33% of patients)\n- **GI:** Vomiting, abdominal pain, pancreatitis\n\n## Stages of Presentation\n\n| **Stage**                    | **Clinical findings**                            |\n| ---------------------------- | ------------------------------------------------ |\n| Early                        | Mild euphoria, inebriation, drowsiness           |\n| Latent (lasting 6-30 hours)  | Normal sensorium but blurred vision              |\n| Late                         | Severe systemic toxicity with worsening acidosis |\n\n## Management\n\n**Goal:** Prevent further formation of formic acid (using <span class=\"drug\">fomepizole</span>) and eliminate toxic metabolites (through dialysis) \n\n- <span class=\"drug\">Folic</span> or folinic acid supplementation to enhance formate metabolism\n- **Antidote:** <span class=\"drug\">Fomipezole</span> inhibits alcohol dehydrogenase (alternative = <span class=\"drug\">ethanol</span>)\n\n| **Fomipezole**   | **Dosing**                          |\n| ---------------- | ----------------------------------- |\n| Loading dose     | 15 mg/kg IV                         |\n| Maintenance dose | 10 mg/kg IV every 12 hours x 2 days |\n\n## American Academy of Clinical Toxicology guidelines\n\n![Suspected or confirmed methanol clinical pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/methanol/image-1.png)\n\n## Metabolism of alcohols\n\n![Metabolism of alcohols diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/methanol/image-2.png)\n\n## References\n\n- Jammalamadaka D, Raissi S. Ethylene glycol, methanol and isopropyl alcohol intoxication. _Am J Med Sci_. 2010 Mar;339(3):276-81. doi: 10.1097/MAJ.0b013e3181c94601. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20090509)]\n- Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. _Clin J Am Soc Nephrol_. 2008 Jan;3(1):208-25. Epub 2007 Nov 28. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=18045860)]\n- Marraffa JM, Cohen V, Howland MA. Antidotes for toxicological emergencies: a practical review. _Am J Health Syst Pharm_. 2012 Feb 1;69(3):199-212. doi: 10.2146/ajhp110014 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22261941)]\n- Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA; American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. _J Toxicol Clin Toxicol_. 2002;40(4):415-46. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=12216995)]\n"
		},
		{
			"slug": "nih-stroke-scale",
			"title": "NIH Stroke Scale",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/02/06",
			"updates": [
				"2017/02/24"
			],
			"categories": [
				"Neurology"
			],
			"body": "\n\n\nScore\n- 0 (No stroke) \n- 1-4 (Minor stroke) \n- 5-15 (Moderate stroke)\n- 15-20 (Moderate to severe stroke)\n- 21-42 (Severe stroke) \n\n<table>\n  <tr>\n    <th colspan=\"2\">National Institute of Health Stroke Scale score </th>\n  </tr>\n  <tr>\n    <td>1a. Level of consciousness<br>\n    assessed while taking history</td><br>\n    <td>   \n      <ul>\n        <li>0 = Alert; keenly responsive</li>\n        <li>1 = Not alert, but arousable by minor stimulation</li>\n        <li>2 = Not alert; requires repeated stimulation</li>\n        <li>3 = Unresponsive or responds only with reflex</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>\n      1b. Level of consciousness questions<br>\n      What is the month?<br>\n      What is your age?<br>\n    </td>\n    <td>\n      <ul>\n        <li>0 = Answers two questions correctly</li>\n        <li>1 = Answers one question correctly</li>\n        <li>2 = Answers neither question correctly</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>\n    1c. Level of consciousness commands:<br>\n    Open and close your eyes<br>\n    Grip and release your hand</td><br>\n    <td>\n      <ul>\n        <li>0 = Performs both tasks correctly</li>\n        <li>1 = Performs one task correctly</li>\n        <li>2 = Performs neither task correctly</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>2. Best gaze</td>\n    <td>\n      <ul>\n        <li>0 = Normal </li>\n        <li>1 = Partial gaze palsy</li>\n        <li>2 = Forced deviation</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>3. Visual</td>\n    <td>\n      <ul>\n        <li>0 = No visual loss</li>\n        <li>1 = Partial hemianopia</li>\n        <li>2 = Complete hemianopia</li>\n        <li>3 = Bilateral hemianopia</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>4. Facial palsy<br> \n         Use grimmace if obtunded</td>\n    <td>\n      <ul>\n        <li>0 = Normal symmetric movements</li>\n        <li>1 = Minor paralysis</li>\n        <li>2 = Partial paralysis</li>\n        <li>3 = Complete paralysis of one or both sides</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>\n      5. Motor arm<br>\n      5a. Left arm<br>\n      5b. Right arm<br>\n    </td>\n    <td>\n      <ul>\n        <li>0 = No drift</li>\n        <li>1 = Drift</li>\n        <li>2 = Some effort against gravity</li>\n        <li>3 = No effort against gravity</li>\n        <li>4 = No movement</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>\n      6. Motor leg<br>\n      6a. Left leg<br>\n      6b. Right leg\n    </td>\n    <td>\n      <ul>\n        <li>0 = No drift</li>\n        <li>1 = Drift</li>\n        <li>2 = Some effort against gravity</li>\n        <li>3 = No effort against gravity</li>\n        <li>4 = No movement</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>7. Limb ataxia</td>\n    <td>\n      <ul>\n        <li>0 = Absent</li>\n        <li>1 = Present in one limb</li>\n        <li>2 = Present in two limbs</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>8. Sensory</td>\n    <td>\n      <ul>\n        <li>0 = Normal; no sensory loss</li>\n        <li>1 = Mild-to-moderate sensory loss</li>\n        <li>2 = Severe to total sensory loss</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>9. Best language</td>\n    <td>\n      <ul>\n        <li>0 = No aphasia; normal</li>\n        <li>1 = Mild to moderate aphasia</li>\n        <li>2 = Severe aphasia</li>\n        <li>3 = Mute, global aphasia</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>10. Dysarthria</td>\n    <td>\n      <ul>\n        <li>0 = Normal</li>\n        <li>1 = Mild to moderate dysarthria</li>\n        <li>2 = Severe dysarthria</li>\n      </ul>\n    </td>\n  </tr>\n  <tr>\n    <td>11. Extinction and inattention</td>\n    <td>\n      <ul>\n        <li>0 = No abnormality</li>\n        <li>1 = Visual, tactile, auditory, spatial, or personal inattention</li>\n        <li>2 = Profound hemi-inattention or extinction</li>\n      </ul>\n    </td>\n  </tr>\n</table>\n\n**Total score = 0-42**\n\n## References\n\n1. \"NINDS Know Stroke Campaign - NIH Stroke Scale\". Stroke.nih.gov. N.p., 2017. Web. 24 Mar. 2017. [[Source](https://stroke.nih.gov/resources/scale.htm)]\n"
		},
		{
			"slug": "nsaid-gi-bleed",
			"title": "NSAIDs and Upper GI Bleed",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/07/15",
			"updates": null,
			"categories": [
				"Gastroenterology",
				"Pharmacology"
			],
			"body": "\n\n\n- Stomach and platelets have much more COX-1 receptors than COX-2 receptors.\n- Below are statistics from a systematic review on NSAIDs and upper GI complications (bleeding, perforation)\n\n## Ketorolac \n\n- Has the highest relative risk for upper GI complication = 14.54 (see below)\n- Before giving, first check that patients do NOT have a history of a GI bleed or peptic ulcer disease.\n\n## NSAID-Induced Complications\n\n| **NSAID Medication**                      | **Estimated Relative Risk of Complication** | **[95 % CI]** |\n| ----------------------------------------- | :-----------------------------------------: | :-----------: |\n| COX-1 Inhibitors (all)                    |                     4.5                     |   [3.82-5.31] |\n|  - <span class=\"drug\">Ibuprofen</span>    |                     2.69                    |  [2.17-3.33]  |\n|  - <span class=\"drug\">Diclofenac</span>   |                     3.98                    |  [3.36-4.72]  |\n|  - <span class=\"drug\">Meloxicam</span>    |                     4.15                    |  [2.59-6.64]  |\n|  - <span class=\"drug\">Indomethacin</span> |                     5.40                    |  [4.16-7.00]  |\n|  - <span class=\"drug\">Ketoprofen</span>   |                     5.57                    |  [3.94-7.87]  |\n|  - <span class=\"drug\">Naproxen</span>     |                     5.63                    |  [3.83-8.28]  |\n|  - <span class=\"drug\">Piroxicam</span>    |                     9.94                    |  [5.99-16.50] |\n|  - <span class=\"drug\">Ketorolac</span>    |                    14.54                    |  [5.87-36.04] |\n| COX-2 Inhibitors (all)                    |                     1.88                    |  [0.96-3.71]  |\n|  - <span class=\"drug\">Celecoxib</span>    |                     1.42                    |  [0.85-2.37]  |\n|  - <span class=\"drug\">Aceclofenac</span>  |                     1.44                    |   [0.65-3.2]  |\n|  - <span class=\"drug\">Rofecoxib</span>    |                     2.12                    |  [1.59-2.84]  |\n\n## Risk Factors for Upper GI Complication\n\n1. Longer drug half-life\n2. Slow-release formulation\n3. Dual inhibition of COX-1 and COX-2 isoenzymes \n\nRelative risk is greatest when first starting medication (&lt;30 days)\n\n## References\n\n- Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20178131)]\n"
		},
		{
			"slug": "ocular-ultrasound",
			"title": "Ultrasound: Ocular Assessment",
			"authors": [
				"Sarah Elisabeth Frasure, MD",
				"Mike Stone, MD"
			],
			"created": "2015/01/28",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology",
				"Ophthalmology"
			],
			"body": "\n\n\n**Goals:** Evaluate for retinal/vitreous detachment, retinal/vitreous hemorrhage, lens dislocation, ocular foreign body, and globe rupture\n\n**Transducer:** High frequency linear transducer. If available, the _ophthalmologic, superficial_, or _small parts_ preset should be selected on the machine.\n\n**Patient Position:** With the patient’s eye closed, apply a bio-occlusive dressing (e.g. Tegaderm) over the closed eyelid to serve as a barrier. Apply a generous amount of gel over the dressing.\n\n**Windows:** Visualize the eye in 2 planes:\n\n1. **Longitudinal View**\n\n- Commence at the midline of the eye. \n- The directional indicator is oriented towards the vertex of the skull. \n- Stabilize the transducer by resting your hand against the bridge of the patient’s nose or eyebrow, taking care not to apply any more pressure to the globe than is necessary to obtain adequate contact. \n- The transducer should be ‘fanned’ from left to right to visualize the entire globe.\n\n2. **Transverse View** \n\n- Rotate the transducer 90 degrees, with the directional indicator oriented towards the patient’s right, and visualize the globe in a second plane. \n- The transducer should be ‘fanned’ up and down in order to properly visualize all structures of the eye.\n\n**Tip:** The contralateral, or ‘unaffected’ eye may be scanned in an identical manner to compare ocular anatomy.\n\n## Normal Eye\n\n![Normal eye](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ocular-ultrasound/image-1.png)\n\nFigure 1: Normal eye\n\n- **Anterior chamber** (a): Located between hyperechoic cornea anteriorly and **iris** posteriorly\n- **Lens** (L): Biconvex hyperechoic structure posterior to the anterior chamber (a).\n- **Vitreous chamber** (v): Is hypoechoic and encompasses most of the globe and the **retina** adheres to its posterior surface\n- **Optic nerve sheath** (n): Appears as a hypoechoic linear structure deep to the vitreous chamber\n\n## Ocular Pathologies\n\n## Detachments\n\n- **Retinal:** Generally remains anchored to the optic disc in most posterior section of the eye; appears as a hyperechoic membrane floating in the vitreous chamber\n- **Vitreous:** May be difficult to distinguish from a retinal detachment; may have a V-shaped appearance, similar to retinal detachment, but is generally less intensely OOhyperechoic and is better visualized with a higher gain setting.\n\n## Hemorrhage \n- Retinal vs vitreous often difficult to distinguish from each other.\n- Hemorrhages will look like echogenic opacities in the vitreous chamber.\n\n## Lens dislocation \n- Biconvex or round hyperechoic structure (lens) is displaced from its normal position. \n- With eye movement it may appear to move independently of surrounding structures.\n\n## Foreign body \n- A hyperechoic object typically located in the vitreous chamber, but may also be embedded into the retina or posterior orbit. \n- Depending on its composition, the foreign body may cause posterior acoustic shadowing, similar to gallstones.\n\n## Globe rupture \n- Very abnormal shape \n- **Clues:** Collapsed anterior chamber, irregularly shaped posterior chamber, scleral buckling, large vitreous hemorrhage\n\n## Retinal Detachment\n\n![The detached retina appears as a thick, hyperechoic band in the vitreous chamber, anchored posteriorly to the optic disc](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ocular-ultrasound/image-2.png)\n\nFigure 2: The detached **retina** appears as a thick, hyperechoic band in the vitreous chamber, anchored posteriorly to the **optic disc**.\n\n## Vitreous Hemorrhage\n\n![Vitreous hemorrhage. Area of hemorrhage is visible as faint echogenic material causing a heterogeneous appearance to the chamber](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ocular-ultrasound/image-3.png)\n\nFigure 3: Vitreous hemorrhage - area of **hemorrhage** is visible as faint echogenic material causing a heterogeneous appearance to the chamber. Note the higher gain setting used.\n\n## Lens Dislocation\n\n![Lens dislocation. The lens is seen floating en face in the vitreous chamber](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ocular-ultrasound/image-4.png)\n\nFigure 4: Lens dislocation - The **lens** is seen floating en face in the vitreous chamber.\n\n## Globe Rupture\n\n![Globe rupture. Irregular globe contour with collapsed anterior chamber. Echogenic material fills the vitreous chamber](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ocular-ultrasound/image-5.png)\n\nFigure 5: Globe rupture - irregular globe contour with collapsed anterior chamber. Echogenic material fills the vitreous chamber.\n\n## Struggling with the Exam?\n\n### Can’t visualize the eye adequately?\n\n- Increase the amount of gel on the bioocclusive dressing, as this ‘evens out’ the surface of the eye for the transducer.\n\n### Unsure if there is pathology in the vitreous chamber?\n\n- In order to adequately assess the vitreous chamber for detachment or hemorrhage, the eye should be examined with both moderate AND high gain settings. Evaluate in a fixed forward gaze AND while the patient performs extraocular movements (kinetic echography).\n\n### Is it ever unsafe to perform the exam?\n\n- Ocular ultrasound is contraindicated if there are obvious signs of open ocular trauma or globe rupture. Discontinue the examination if there are sonographic findings of globe rupture or retrobulbar hematoma.\n\n## Pearls\n\n- Apply a generous amount of conducting gel to the closed eyelid/film dressing to optimize image quality.\n- Do not miss abnormal structures in the normally anechoic vitreous chamber due to inadequate gain settings.\n\n## Limitations\n\n- Bedside ultrasound is of limited utility for the evaluation of the bony anatomy of the orbit. If fractures of the bony orbits are suspected, a maxillofacial CT is the test of choice.\n- CT imaging is more sensitive in the detection of radio-opaque foreign bodies, particularly those that have penetrated through the globe.\n\n## References\n\n- Blaivas M, Theodoro D, Sierzenski PR. A study of bedside ocular ultrasonography in the emergency department. Acad Emerg Med. 2002;9(8):791-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=12153883)]\n- Kimberly HH, Shah S, Marill K, Noble V. Correlation of optic nerve sheath diameter with direct measurement of intracranial pressure. Acad Emerg Med. 2008;15(2):201-4. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18275454)]\n"
		},
		{
			"slug": "olecranon-fracture",
			"title": "Elbow Injuries - Olecranon Fracture",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Olecranon fracture drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/olecranon-fracture/image-1.png)\n\n## Xray Views\n\n**Elbow XR:** AP and lateral\n\n## Operative indications\n\n- \\>2 mm fracture displacement\n- Absence of elbow extension\n\n## Acute Management\n\n- Adults: Long-arm posterior splint with elbow at 90° flexion\n- Children: Consider long arm cast\n\n## Follow-up Timing\n\n- **Non-operative:** 5-7 days\n- **Operative:** 2-3 days\n\n## Notes\n\n- Suspicious for osteogenesis imperfecta in kids\n- Partial closure of olecranon ossification sometimes mistaken for fracture\n- Average age of olecranon ossification closure = 15-17 years old\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/fractures_of_the_olecranon. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/trauma/1022/olecranon-fractures. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/olecranon-fractures-1. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Department of Orthopedics.\n"
		},
		{
			"slug": "open-fractures",
			"title": "Open Fractures and Antibiotics",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/01/20",
			"updates": null,
			"categories": [
				"Orthopedics",
				"Infectious Disease"
			],
			"body": "\n\n\n## Gustilo Classification for Open Fractures\n\n**Type I:** Open fracture with skin wound &lt; 1 cm and clean\n\n**Type II:** Open fracture skin laceration > 1 cm without extensive soft tissue damage, flaps, or avulsion \n\n**Type III:**  Open fracture with extensive soft tissue injury or traumatic amputation (includes gun shot wounds and farm injuries)\n\n- **IIIA:** Adequate tissue coverage\n- **IIIB:** Significant soft tissue loss with exposed bone that will require skin graft\n- **IIIC:** Associated vascular injury requiring repair for limb preservation \n\n## Level I Recommendations\n\n- Start systemic antibiotics ASAP and target gram-positive organisms (eg. first generation cephalosporins)\n- Add antibiotics for gram-negative fractures for Type III open fractures\n- Add <span class=\"drug\">high-dose penicillin</span>, if fecal or potential clostridial contamination (e.g. farm-related injuries)\n- <span class=\"drug\">Fluoroquinolones</span> provide no added benefit compared to the <span class=\"drug\">cephalosporin + aminoglycoside</span> combination. Fluoroquinolones may impair fracture healing and result in higher infection rates in type III open fractures. \n\n## Level II Recommendations\n\n- **Type III fractures**: Continue antibiotics for 72 hours post-injury, or not >24 hours after soft tissue coverage achieved\n- Once-daily aminoglycoside dosing is safe and effective for type II and III fractures \n\n## References\n\n- Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. EAST Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011 Mar;70(3):751-4. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=21610369)]\n"
		},
		{
			"slug": "ottawa-knee-ankle-foot",
			"title": "Ottawa Knee, Ankle, and Foot Rules",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/05/07",
			"updates": null,
			"categories": [
				"Orthopedics",
				"EBM"
			],
			"body": "\n\n\nPlain film x-rays are indicated if presence of traumatized extremity and ANY of the following findings:\n\n## Ottawa Knee Rules\n\n1. Patient age &ge;55 years\n2. Isolated tenderness of the patella\n3. Tenderness at the head of the fibula\n4. Inability to flex knee to 90 degrees\n5. Inability to walk 4 steps both immediately and in the ED    \n\n- Performance characteristics ([Emparanza et al, Ann Emerg Med (2001)](http://www.ncbi.nlm.nih.gov/pubmed/?term=11574791))\n  - Sensitivity 100%\n  - Reduced x-ray need by 49% \n\n## Ottawa Ankle Rules\n\nExclusion criteria: Patients &lt;18 years old\n\n1. Most distal 6 cm of fibula (lateral malleolus): Tenderness at or along posterior edge\n2. Most distal 6 cm of tibia (medial malleolus): Tenderness at or along posterior edge \n3. Inability to walk 4 steps both immediately and in the ED \n\n## Ottawa Foot Rules\n\n1. Tenderness at base of 5th metatarsal\n2. Tenderness over navicular bone\n3. Inability to walk 4 steps both immediately and in the ED \n\n## Combined Ottawa Ankle and Root Rules\n\nPerformance characteristics ([Mayer D. BMJ (2009)](http://www.ncbi.nlm.nih.gov/pubmed/?term=19666680))\n\n- Sensitivity = 97.8%\n- Specificity = 31.5%\n- Negative LR = 0.07  \n\n## Pearls\n\n**Pediatric patients:** Variable validation data for Ottawa ankle and foot rules\n\n- General rule: Ligaments are stronger than growth plates in children. \n- OK to use knee rules in pediatrics based on ([Bulloch et al. Ann Emerg Med, 2003](http://www.ncbi.nlm.nih.gov/pubmed/?term=12827123)) \n  - Mean age in study = 11.8 years +/- 3.1 years\n  - Inclusion age range = 2-16 years old\n\n## References\n\n- Mayer D. The injured ankle and foot. _BMJ_. 2009 Aug 7;339. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=19666680)]\n- Bulloch B. et al. Validation of the Ottawa Knee Rule in children: a multicenter study. _Ann Emerg Med_. 2003 Jul;42(1):48-55. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=12827123)]\n- Emparanza JI. et.al.Validation of the Ottawa Knee Rules. _Ann Emerg Med_. 2001 Oct;38(4):364-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=11574791)]\n"
		},
		{
			"slug": "pain-management",
			"title": "Initial Pain Management Options",
			"authors": [
				"Nick Koch, MD",
				"Sergey Motov, MD"
			],
			"created": "2015/10/23",
			"updates": null,
			"categories": [
				"Pharmacology"
			],
			"body": "\n\n\n## Acetaminophen and NSAIDs\n\n| Medication    | Dose                       |\n| ------------- | -------------------------- |\n| Acetaminophen | 500-1000 mg PO             |\n|               | 1000 mg IV over 15 minutes |\n|               | 650 mg PR                  |\n| Ibuprofen     | 400-600 mg PO              |\n| Naproxen      | 250-500 mg PO              |\n| Ketorolac     | 10 mg PO or 10-15 mg IV    |\n| Indomethacin  | 25-50 mg PO                |\n\n## Non-Opioids\n\n| Medication                        | Dose                                                                           |\n| --------------------------------- | ------------------------------------------------------------------------------ |\n| Lidocaine 1%                      | **Local/regional anesthetic**<br>Max: 4 mg/kg; 7 mg/kg with epinephrine        |\n|                                   | **Intra-articular**<br>5-20 mL                                                 |\n| Lidocaine 2%                      | **Local/regional anesthetic**<br>Max: 4 mg/kg; 7 mg/kg with epinephrine        |\n| Lidoderm 5% patch                 | Apply on skin                                                                  |\n| Bupivacaine 0.25-0.5%             | **Local/regional anesthetic**<br>Max dose: 2.5 mg/kg; 3 mg/kg with epinephrine |\n| Triamcinolone                     | **Intra-articular**<br>2.5-40 mg                                               |\n| Gabapentin                        | 100-300 mg PO                                                                  |\n| Pregabalin                        | 25 mg PO                                                                       |\n| Ketamine - _Subdissociative dose_ | 0.3 mg/kg IV in 100 mL NS over 10 min                                          |\n|                                   | **Continuous infusion**: 0.15 mg/kg/hr IV (100 mg in 100 mL NS)                |\n|                                   | 1 mg/kg IN (no more than 1 mL per nostril)                                     |\n\n## Opioids\n\n| Medication                                  | Dose                                                                              |\n| ------------------------------------------- | --------------------------------------------------------------------------------- |\n| Oxycodone (5 mg tablet)                     | 1-2 tabs PO                                                                       |\n| Hydrocodone (5 mg tablet)                   | 1-2 tabs PO                                                                       |\n| Oxycodone/acetaminophen (5/325 mg tablet)   | 1-2 tabs PO                                                                       |\n| Hydrocodone/acetaminophen (5/325 mg tablet) | 1-2 tabs PO                                                                       |\n| Hydrocodone/ibuprofen (2.5/200 mg tablet)   | 1-2 tabs PO                                                                       |\n| Morphine IR (15 mg tablet)                  | 1-2 tabs PO                                                                       |\n| Hydromorphone                               | **Weight-based:** 0.015 mg/kg IV titrate Q 15 min                                 |\n|                                             | **Fixed dose:** 1 mg IV titrate Q 10-15 min                                       |\n|                                             | 2-4 mg IM                                                                         |\n|                                             | 2-4 mg PO                                                                         |\n| Morphine                                    | **Weight-based:** 0.1 mg/kg IV titrate Q 20 min                                   |\n|                                             | **Fixed dose:** 5 mg IV titrate Q 10-15 min                                       |\n|                                             | **Fixed dose infusion:** 10 mg IV in 100 mL NS over 10 min titrate Q 20-30 min    |\n|                                             | 10-20 mg nebulized with 3 mL NS                                                   |\n| Fentanyl                                    | **Weight-based:** 1-1.5 mcg/kg IV in 100 mL NS over 5-10 min                      |\n|                                             | **Fixed dose:** 50-100 mcg IV in 100 mL NS over 10 min                            |\n|                                             | 1-2 mcg/kg IN (no more than 1 mL per nostril)                                     |\n|                                             | 2-4 mcg/kg nebulized                                                              |\n| Naloxone                                    | (for opioid-induced pruritus) 0.25-0.5 mcg/kg/hr IV (2 mg naloxone in 100 mL  NS) |\n\n# Pain Syndromes\n\n## Abdominal Pain (non-traumatic)\n\n| Medication     | Dose                     |\n| -------------- | ------------------------ |\n| Ketorolac      | 10-15 mg IV              |\n| Rescue Opioids | Morphine or Fentanyl IV  |\n\n## Abdominal Pain (traumatic)\n\n| Medication     | Dose                                      |\n| -------------- | ----------------------------------------- |\n| Opioids        | Morphine or Fentanyl IV                   |\n| Acetaminophen  | 1 g IV over 15 min (adjunct to opioids)   |\n\n## Back Pain (acute)\n\n| Medication    | Dose                      |\n| ------------- | ------------------------- |\n| NSAID         | Ibuprofen or naproxen     |\n| Methocarbamol | 1500 mg PO                |\n| Diazepam      | 5 mg PO                   |\n\n## Back Pain (chronic)\n\n| Medication        | Dose                            |\n| ----------------- | ------------------------------- |\n| Gabapentin        | 100-300 mg PO                   |\n| Pregabalin        | 25 mg PO                        |\n| Lidoderm 5% Patch | No more than 4 patches in 24 hr |\n\n## Dental Pain\n\n| Medication     | Dose                                                                |\n| -------------- | ------------------------------------------------------------------- |\n| NSAID          | Ibuprofen or naproxen                                               |\n| Dental Blocks  | 5 mL of Lidocaine (1-2%) **or**<br> 2 mL of Bupivacaine (0.25-0.5%) |\n\n## Headache\n\n### Oral\n\n| Medication                                            | Dose                     |\n| ----------------------------------------------------- | ------------------------ |\n| NSAID                                                 | Ibuprofen or naproxen    |\n| Butalbital/ acetaminophen/caffeine<br>(50/325/40 mg)  | 1-2 tabs PO              |\n| Metoclopramide                                        | 10 mg PO                 |\n\n### Parenteral (in preferred order)\n\n| Medication        | Dose                                      |\n| ----------------- | ----------------------------------------- |\n| Metoclopramide    | 10 mg IV (Slow drip over 10-15 min)       |\n| Diphenhydramine   | 25-50 mg IV                               |\n| Prochlorperazine  | 10 mg IV                                  |\n| Chlorpromazine    | 0.1 mg/kg IV                              |\n| Sumatriptan       | 6 mg SQ, repeat with 12 mg SQ (after 1 h) |\n| Dihydroergotamine | 0.25 mg IV, repeat with 1 mg (after 1 h)  |\n| Valproate         | 300-1000 mg IV (over 30 min)              |\n| Magnesium         | 2 gm IV (30-60 min)                       |\n| Droperidol        | 1-2.5 mg IV <br>2.5-8 mg IM               |\n| Haloperidol       | 2.5-5 mg IV                               |\n\n## Regional Nerve Blocks\n\n| Medication            | Dose                                                                 |\n| --------------------- | -------------------------------------------------------------------- |\n| Paracervical block    | 5 mL of Lidocaine (1-2%) **or**<br>2-3 mL of Bupivacaine (0.25-0.5%) |\n| Occipital nerve block | 5 mL of Lidocaine (1-2%) **or**<br>2-3 mL of Bupivacaine (0.25-0.5%) |\n\n## Musculoskeletal Pain (non-traumatic)\n\n| Medication            | Dose                                          |\n| --------------------- | --------------------------------------------- |\n| NSAID                 | Ibuprofen, naproxen, or indomethacin          |\n| Local/Regional Blocks | Lidocaine or bupivacaine ± epinephrine        |\n| Neuropathic Pain      | Gabapentin 100 mg PO<br>Pregabalin 25 mg PO   |\n| NSAID                 | Ibuprofen, naproxen, or indomethacin          |\n| Lidoderm 5% patch     | Apply on skin                                 |\n\n## Renal Colic\n\n| Medication     | Dose                     |\n| -------------- | ------------------------ |\n| Ketorolac      | 10-15 mg IV              |\n| Rescue Opioids | Morphine or Fentanyl IV  |\n\n## Sickle Cell Pain Crisis\n\n### Intravenous (IV)\n\n| Medication     | Dose                                 |\n| -------------- | ------------------------------------ |\n| Opioids        | Morphine, fentanyl, or hydromorphone |\n| Ketorolac      | 10-15 mg IV                          |\n\n### Subcutaneous (SQ)\n\n| Medication     | Dose                                                       |\n| -------------- | ---------------------------------------------------------- |\n| Morphine       | 0.1 mg/kg or 5 mg SQ fixed dose with titration Q 10-15 min |\n| Hydromorphone  | 1-1.5 mg SQ with titration Q 15 min                        |\n\n### Intranasal (IN) / Nebulized\n\n| Medication     | Dose                             |\n| -------------- | -------------------------------- |\n| Fentanyl       | 1-2 mcg/kg IN titrate Q 5-10 min |\n| Fentanyl       | 2-4 mcg/kg nebulized single dose |\n\n_Intramuscular (IM) route is DISCOURAGED!_\n\n## Trauma & Burns\n\n| Medication                         | Dose                                                                                                                                                              |\n| ---------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Local/Regional Blocks              | Lidocaine or bupivacaine ± epinephrine                                                                                                                            |\n| Opioids                            | Morphine or Fentanyl                                                                                                                                              |\n| Ketorolac                          | 10-15 mg IV                                                                                                                                                       |\n| Acetaminophen                      | 1 g IV over 15 min (adjunct to opioids/NSAIDS/ketamine)                                                                                                           |\n| Ketamine<br>_Subdissociative dose_ | 0.3 mg/kg IV in 100 mL NS over 10 min<br>**Continuous infusion**: 0.15 mg/kg/hr IV (100 mg in 100 mL NS)<br>**Intrnasal** 1 mg/kg (no more than 1 mL per nostril) |\n\n## Opiate-Tolerant Patient or Refractory/Intractable Pain\n\nConsider subdissociative dosing of ketamine.\n\n## References\n- Andolfatto G, Willman E, Joo D. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013; 20(10):1050-4. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/24127709)]\n- Bartfield JM, Flint RD, McErlean M, Broderick J. Nebulized fentanyl for relief of abdominal pain.. Acad Emerg Med. 2003; 10(3):215-8. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/12615585)]\n- Beaudoin FL, Lin C, Guan W, Merchant RC. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial.. Acad Emerg Med. 2014; 21(11):1193-202. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/25377395)]\n- Borland M, Jacobs I, King B, O'brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007;49(3):335-40. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/17067720)]\n- Chang AK, Bijur PE, Campbell CM, Murphy MK, Gallagher EJ. Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the \"1+1\" protocol. Ann Emerg Med. 2009;54(2):221-5. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/18996618)]\n- Curtis KM, Henriques HF, Fanciullo G, Reynolds CM, Suber F. A fentanyl-based pain management protocol provides early analgesia for adult trauma patients. J Trauma. 2007;63(4):819-26. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/18090011)]\n- Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008;52(4):399-406. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/18006188)]\n- Galinski M, Dolveck F, Combes X, et al. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007;25(4):385-90. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/17499654)]\n- Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010;56(1):1-6. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/20045576)]\n- Leong LB, Kelly AM. Are butyrophenones effective for the treatment of primary headache in the emergency department?. CJEM. 2011;13(2):96-104. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/21435315)]\n- Lvovschi V, Aubrun F, Bonnet P, et al. Intravenous morphine titration to treat severe pain in the ED. Am J Emerg Med. 2008;26(6):676-82. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/18606320)]\n- Miller JP, Schauer SG, Ganem VJ, Bebarta VS. Low-dose ketamine vs morphine for acute pain in the ED: a randomized controlled trial. Am J Emerg Med. 2015;33(3):402-8. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/25624076)]\n- Motov S, Rockoff B, Cohen V, et al. Intravenous Subdissociative-Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2015;66(3):222-229.e1. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/25817884)]\n- Patanwala AE, Keim SM, Erstad BL. Intravenous opioids for severe acute pain in the emergency department. Ann Pharmacother. 2010;44(11):1800-9. [[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/20978218)]\n- Thomas SH. Emergency Department Analgesia, An Evidence-Based Guide. Cambridge University Press; 2008.\n- Yeaman F, Meek R, Egerton-warburton D, Rosengarten P, Graudins A. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. Emerg Med Australas. 2014;26(3):237-42.[[Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/24712757)]\n- Strayer RJ, Motov SM, Nelson LS. Something for pain: Responsible opioid use in emergency medicine. Am J Emerg Med. 2017;35(2):337-341. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=27802876)]\n"
		},
		{
			"slug": "palliative-care-screening",
			"title": "Palliative Care Screening Tool",
			"authors": [
				"Naomi George, MD",
				"Kalie Dove-Maguire, MD"
			],
			"created": "2015/07/27",
			"updates": null,
			"categories": [
				"Palliative Care"
			],
			"body": "\n\n\n## What is Palliative Care?\n\nPalliative Care focuses on improving the care and quality of life for patients with advanced illness by decreasing suffering. It can be delivered concurrently with curative care. Early identification of patients who are likely to benefit is key.\n\n## Determine if your patient could benefit from Palliative Care consultation\n\n### STEP 1\nDetermine if your patient has at least 1 life-limiting illness:\n\n1. **Advanced Dementia or CNS Disease** (e.g. CVA, ALS, Parkinson's): Assistance needed for most self-care (e.g. ambulation, toileting) and/or minimally verbal\n2. **Advanced Cancer**: Metastatic or locally aggressive disease\n3. **End Stage Renal Disease**: On dialysis or serum creatinine >6 mg/dL\n4. **Advanced COPD**: Continuous home O2 or chronic dyspnea at rest\n5. **Advanced Heart Failure**: Chronic dyspnea, chest pain, or fatigue with minimal activity or rest\n6. **End Stage Liver Disease**: History of recurrent ascites, GI bleeding, or hepatic encephalopathy\n7. **Septic Shock**: Requires ICU admission AND has significant pre-existing comorbid illness\n8. **High Chance of Accelerated Death**: Provider discretion – e.g.: Hip fracture in age >80, major trauma in elderly (multiple rib fractures, intracranial hemorrhage), advanced AIDS\n\n### STEP 2 (Consultation)\nConsider a Palliative Care consultation if your patient has at least 1 life-limiting illness (above) AND 1 or more of the following:\n\n1. **Frequent visits**: 2 or more ED visits or hospitalizations in the past 6 months\n2. **Uncontrolled symptoms**: Visit prompted by uncontrolled symptom (e.g. pain, dyspnea, depression, fatigue)\n3. **Functional decline**: Examples - Loss of mobility, frequent falls, decreased oral intake, skin breakdown\n4. **Uncertainty/distress**: Caregiver cannot meet long-term needs; Uncertainty or distress about goals-of-care\n5. **“Surprise” question**: You wouldn’t be surprised if the patient died within 12 months\n\n## Symptom Control: Improve quality of life in the ED\n\n| **Symptom** | **Interventions to Consider**                         |\n| ----------- | ----------------------------------------------------- |\n| Agitation   | Haloperidol                                           |\n| Anxiety     | Lorazepam or diazepam                                 |\n| Dyspnea     | Supplemental O2 and/or morphine for comfort           |\n| Pain        | Standing morphine or fentanyl, or use of opioid drips |\n\n## References\n\n- George N, Barrett N, Mcpeake L, Goett R, Anderson K, Baird J. Content Validation of a Novel Screening Tool to Identify Emergency Department Patients With Significant Palliative Care Needs. Acad Emerg Med. 2015;22(7):823-37. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26171710)]\n"
		},
		{
			"slug": "paracentesis",
			"title": "Paracentesis for Ascites",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/06/25",
			"updates": null,
			"categories": [
				"Gastroenterology"
			],
			"body": "\n\n\n_[JAMA Rational Clinical Examination Series 2009](http://www.ncbi.nlm.nih.gov/pubmed/?term=18926597)_\n\n**Bottom line:** It appears safe to perform paracentesis without checking coagulation labs\n\n- 2 prospective studies\n- No instances of significant bleeding despite platelet counts &lt;50K and INR >1.5\n- 2 cases of minor bleeding\n\n**Bottom line:** Albumin likely not needed in therapeutic paracentesis\n\n- 9 prospective randomized studies\n- Pooled 806 paracentesis procedures: No difference with plasma expansion with respect to encephalopathy and death\n\n## Spontaneous Bacterial Peritonitis (SBP) Lab Findings\n\n- Ascites WBC >500 cells/mm3\n- Ascites PMN >250 cells/mm3\n- Ascites pH &lt;7.35\n- Blood-ascites pH gradient >0.1 \n\n## Ascites fluid analysis to assess for SBP (pooled data)\n\n| Lab Finding                 | # patients | (+) LR | (-) LR |\n| --------------------------- | :--------: | :----: | :----: |\n| Ascites WBC >1000 cells/mm3 |     508    |   9.1  |  0.25  |\n| Ascites WBC >500 cells/mm3  |     717    |   5.9  |  0.21  |\n| Ascites PMN >500 cells/mm3  |    1,074   |  10.6  |  0.16  |\n| Ascites PMN >250 cells/mm3  |    1,058   |   6.4  |   0.2  |\n| Ascites pH &lt;7.35         |     129    |   9.0  |  0.31  |\n| Blood-Ascites pH gradient   |     129    |   7.1  |  0.30  |\n\n## Fagan Nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/paracentesis/image-1.png)\n\n## References\n\n- Wilkerson RG, Sinert R.Evidence-based emergency medicine/rational clinical examination abstract: The use of paracentesis in the assessment of the patient with ascites. Ann Emerg Med. 2009 Sep;54(3):465-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18926597)]\n"
		},
		{
			"slug": "pe-prediction-rules",
			"title": "Pulmonary Embolism Clinical Prediction Rules",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/06/03",
			"updates": null,
			"categories": [
				"Pulmonology",
				"EBM"
			],
			"body": "\n\n\n**Note**: These rules should be used with caution, because none of these scoring protocols are perfect. For instance, in a very recent publication of the _Journal of Thrombosis and Haemostasis_, the authors found that the [PERC rule may not actually safely exclude PEs](http://www.ncbi.nlm.nih.gov/pubmed/21091866).\n\n# Pulmonary Embolism Rule-out Criteria (PERC) Rule\n[Kline et al. J Thromb Haem 2004](http://www.ncbi.nlm.nih.gov/pubmed/15304025); [Kline et al. J Thromb Haem 2008](http://www.ncbi.nlm.nih.gov/pubmed/18318689)\n- Age &lt;50 years\n- Heart rate &lt;100 bpm\n- Room air oxygen saturation &ge;95%\n- No prior DVT or PE\n- No recent trauma or surgery (4 weeks)\n- No hemoptysis\n- No exogenous estrogen\n- No clinical signs suggestive of DVT\n\nIf all 8 present: Only 1% risk for venous thromboembolism (VTE) at 45 days. \n\n# Wells' Score\n\n[Wells et al. Thromb Haemost](http://www.ncbi.nlm.nih.gov/pubmed/10744147); [Wells et al. Ann Intern Med](http://www.ncbi.nlm.nih.gov/pubmed/11453709)\n\n| Clinical Finding or Risk Factor                           | Points |\n| --------------------------------------------------------- | -----: |\n| Clinical signs and symptoms of DVT                        |     +3 |\n| PE is #1 diagnosis, or equally likely                     |     +3 |\n| Heart rate &gt; 100 bpm                                   |   +1.5 |\n| Immobilization for &ge; 3 days, or Surgery in &le; 4 wks  |   +1.5 |\n| Previous, objectively diagnosed PE or DVT                 |   +1.5 |\n| Hemoptysis                                                |     +1 |\n| Malignancy with treatment within 6 months, or palliative  |     +1 |\n\n|  Total # Wells points | Risk for PE at 3 months               |\n| :-------------------: | :-----------------------------------: |\n|                 &lt;2 |                    1.3%               |\n|                   2-6 |                   16.2%               |\n|                 &gt;6 |                   40.6%               |\n| &le;4 and neg D-Dimer |  0.5% non-fatal VTE [Van Belle, 2006] |\n\n# Simplified Geneva Score\n\n[Klok FA et al. Arch Intern Med 2008](http://www.ncbi.nlm.nih.gov/pubmed/18955643)\n\n| Clinical Finding or Risk Factor                                                              | Points |\n| -------------------------------------------------------------------------------------------- | -----: |\n| Age &gt; 65 years                                                                            |     +1 |\n| Previous DVT or PE                                                                           |     +1 |\n| Surgery (general anesthesia) or fracture (lower limbs) &le; 1 month                          |     +1 |\n| Active malignancy (solid or hematologic, 1 currently active or considered cured &lt; 1 year) |     +1 |\n| Unilateral lower-limb pain                                                                   |     +1 |\n| Hemoptysis                                                                                   |     +1 |\n| Heart rate &ge; 75 bpm                                                                       |     +1 |\n| Unilateral edema                                                                             |     +1 |\n| Pain on lower-limb deep venous palpation                                                     |     +4 |\n\n| Total # of points | Incidence of PE |\n| :---------------: | :-------------: |\n|               0-1 |            7.7% |\n|               2-4 |           29.4% |\n|               5-7 |           64.3% |\n\n## References\n\n- Klok FA et al.Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 2008 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18955643)]\n- Wells et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 2001. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11453709)]\n- Van Belle et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography.JAMA 2006 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16403929)]\n- Hugli O, Righini M, Le Gal G, Roy PM, Sanchez O, Verschuren F, Meyer G, Bounameaux H, Aujesky D.The pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary embolism.J Thromb Haemost. 2011 Feb;9(2):300-4. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21091866)]\n- Kline et al. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism.J Thromb Haem 2004. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15304025)]\n- Kline et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haem 2008. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18318689)]\n- Wells et al.Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10744147)]\n"
		},
		{
			"slug": "pediatric-assessment-triangle",
			"title": "Pediatric Assessment Triangle",
			"authors": [
				"Michelle Reina, MD",
				"Rob Bryant, MD"
			],
			"created": "2013/05/30",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Critical Care"
			],
			"body": "\n\n\n![Pediatric assessment triangle](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/pediatric-assessment-triangle/image-1.png)\n\nThe PAT functions as a rapid, initial assessment to determine “sick” or “not sick,” and should be immediately followed by/not delay the ABCDEs. It can be utilized for serial assessment of patients to track response to therapy.\n\n## Appearance: The “Tickles” (TICLS) Mnemonic\n\n|  Characteristic     | Normal features                                                                                                |\n| ------------------- | -------------------------------------------------------------------------------------------------------------- |\n| **T**one            | Move spontaneously, resists examination, sits or stands (age appropriate)                                      |\n| **I**nteractiveness | Appears alert/engaged with clinician or caregiver, interacts well with people/environment, reaches for objects |\n| **C**onsolability   | Stops crying with holding/comforting by caregiver, has differential response to caregiver vs. examiner         |\n| **L**ook/gaze       | Makes eye contact with clinician, tracks visually                                                              |\n| **S**peech/cry      | Uses age-appropriate speech                                                                                    |\n\n## Work of breathing\n\n|  Characteristic        |  Abnormal features                                                  |\n| ---------------------- | ------------------------------------------------------------------- |\n| Abnormal airway sounds | Snoring, muffled/hoarse speech, stridor, grunting, wheezing         |\n| Abnormal positioning   | Sniffing position, tripoding, prefers seated posture                |\n| Retraction             | Supraclavicular, intercostal, or substernal, head bobbing (infants) |\n| Flaring                | Flaring of the nares on inspiration                                 |\n\n## Circulation of skin\n\n| Characteristic  |  Abnormal features                                         |\n| --------------- | ---------------------------------------------------------- |\n| Pallor          | White/pale skin or mucous membranes                        |\n| Mottling        | Patchy skin discoloration due to variable vasoconstriction |\n| Cyanosis        | Bluish discoloration of skin/mucous membranes              |\n\n## Relationship of the PAT components to physiological categories and management priorities\n\n| Presentation                      | Appearance   |  Work of breathing     |  Circulation           | Management                                                                                                                                                                      |\n| --------------------------------- | ------------ | ---------------------- | ---------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Stable                            | Normal       | Normal                 | Normal                 | Specific therapy based on possible etiologies                                                                                                                                   |\n| Respiratory distress              | Normal       | **ABNORMAL**           | Normal                 | Position of comfort, O2/suction, specific therapy (e.g. albuterol, diphenhydramine, epinephrine), labs/x-rays                                                                   |\n| Respiratory failure               | **ABNORMAL** | **ABNORMAL**           | Normal or **ABNORMAL** | Position head/open airway, BVM, FB removal, advanced airway, labs/x-rays                                                                                                        |\n| Shock (compensated)               | Normal       | Normal                 | **ABNORMAL**           | O2, peripheral IV, fluid resuscitation, specific therapy based on etiology (antibiotics, surgery, antidysrhythmics), labs/x-rays                                                |\n| Shock (decompensated/hypotensive) | **ABNORMAL** | Normal or **ABNORMAL** | **ABNORMAL**           | O2, vascular access, fluid resuscitation, specific therapy based on etiology (antibiotics, vasopressors, blood products, surgery, antidysrhythmics, cardioversion), labs/x-rays |\n| CNS/Metabolic dysfunction         | **ABNORMAL** | Normal                 | Normal                 | O2, POC glucose, consider other etiologies, labs/x-rays                                                                                                                         |\n| Cardiopulmonary failure/arrest    | **ABNORMAL** | **ABNORMAL**           | **ABNORMAL**           | Position head/open airway, BMV with 100% O2, CPR, specific therapy based on etiology (defibrillation, epinephrine, amiodarone), labs/x-rays                                     |\n\n## References\n\n- Dieckmann RA, Brownstein D, Gausche-Hill M. The pediatric assessment triangle: a novel approach for the rapid evaluation of children. Pediatr Emerg Care. 2010 Apr;26(4):312-5. doi: 10.1097/PEC.0b013e3181d6db37. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20386420)]\n- ER CAST: Courtesy of Dr. Michelle Reina & Dr. Rob Bryant [[Source](http://blog.ercast.org/2010/05/the-toxic-neonate/)]\n"
		},
		{
			"slug": "pediatric-fever-neonate",
			"title": "Fever Without a Source - neonate",
			"authors": [
				"Hemal Kanzaria, MD",
				"Christine Cho, MD",
				"Andi Marmor, MD",
				"Ellen Laves, MD"
			],
			"created": "2012/02/02",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Infectious Disease"
			],
			"body": "\n\n\n- Age &le; 28 days (be more conservative for premature infants)\n- Fever defined as temperature &ge; 38°C / 100.4°F (rectal)\n- Viral URI symptoms do NOT count as a fever source in this age group.\n- **Disposition:** ADMIT all of these patients to the hospital.\n\n## Background\n\nHistory and physical are not reliable to rule-out serious bacterial infection (SBI)\n\n- 12-28% of febrile neonates have SBI, and a high rate of missed SBIs exist. [(Ishimine, EM Clin N Am 2007)](https://www.ncbi.nlm.nih.gov/pubmed/17950137)\n\n**Common causes for SBI** \n\n- UTIs 20%\n- Bacteremia 3%\n- Meningitis 1%\n\n**Other causes for SBI’s**\n\n- Bacterial gastroenteritis\n- Gonococcal keratoconjunctivitis\n- Omphalitis\n- Osteomyelitis\n- Peritonitis\n- Pneumonia\n- Septic joint \n\n**Pathogens**\n\n- More common: \n  - E. coli\n  - Group B Strep\n  - HSV \n- Less common:\n  - Listeria\n  - Salmonella\n  - Staph aureus\n\n## Workup\n\n1. CBC with differential\n2. Blood cultures\n3. Catheterized urinalysis and urine culture (or via suprapubic tap)\n4. CSF studies (cell count, glucose, protein, gram stain, culture, extra tube to hold for potential other studies)\n5. **_Consider:_** Stool culture (if diarrhea)\n6. **_Consider:_** CXR and rapid viral testing (if respiratory sx or increased work of breathing, although viral testing should not change sepsis workup)\n\n## Treatment\n\nTimely administration of IV antibiotics (<span class=\"drug\">ampicillin</span> + <span class=\"drug\">cefotaxime</span>, or <span class=\"drug\">ampicillin</span> + <span class=\"drug\">gentamicin</span>). \n- May give IM, if IV not possible\n- <span class=\"drug\">Cefotaxime</span> more consistently absorbed IM than <span class=\"drug\">gentamicin</span>.\n\nAdd **<span class=\"drug\">acyclovir</span>,** if any 1 of following:\n\n- Ill-appearing\n- Skin or mucosal lesions consistent with HSV (i.e. vesicles)\n- CSF pleocytosis\n- Seizure\n- Focal neurologic signs\n- Abnormal neuroimaging\n- Respiratory distress, apnea, or progressive pneumonitis\n- Thrombocytopenia\n- Elevated liver transaminases, viral hepatitis, or acute liver failure\n- Conjunctivitis, excessive tearing, or painful eye symptoms\n\n_Note_: Disseminated HSV and HSV encephalitis may not present with rash\n\n## References\n\n- Ishimine P, The evolving approach to the young child who has fever and no obvious source. _Emerg Med Clin North Am_. 2007 Nov;25(4):1087-115, vii. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17950137)]\n"
		},
		{
			"slug": "pediatric-fever-over-one-month",
			"title": "Pediatric Fever Without a Source - Infant",
			"authors": [
				"Hemal Kanzaria, MD",
				"Christine Cho, MD",
				"Andi Marmor, MD",
				"Ellen Laves, MD",
				"Michelle Lin, MD"
			],
			"created": "2012/02/09",
			"updates": null,
			"categories": [
				"Pediatrics"
			],
			"body": "\n\n\nFever defined as temperature **&ge; 38°C / 100.4 °F** (rectal)\n\nViral URI symptoms do NOT count as a fever source in this age group. \n\n- While RSV+ infants have a decreased serious bacterial infection risk, rate of concurrent UTI = 5.5%.\n\n## Background\n\nHistory and physical are not reliable to rule-out serious bacterial infection\n\n### Serious bacterial infections include\n\n- Urinary tract infection (up to 15%)\n- Bacteremia (1%)\n- Meningitis (0.2-0.4%)\n- Others:\n- Gastroenteritis\n- Osteomyelitis\n- Pneumonia\n- Septic joint\n- Soft tissue infection\n\n### Pathogens \n\n- More common:\n  - E. coli\n  - Group B Strep\n  - S. pneumo\n- Less common:\n  - N meningitides\n  - H flu (type B)\n  - Staph aureus\n\n### Notes\n- **Pyelonephritis:** Diagnosis made, if positive for LE or nitrites, or >10 WBC/hpf\n- **Caution:** Serum WBC does NOT predict meningitis ([Bonsu, Annals EM, 2003](http://www.annemergmed.com/article/S0196-0644(02)84932-0/abstract))\n\n## \"Low Risk Infant\" Criteria and Workup\n\n- Rochester and Philadelphia criteria apply only to the age group of 29-60 days. \n- Boston criteria applies to the age group of 29-90 days.\n\n### **Rochester Criteria**\n\nHistory\n\n- Term infant\n- No perinatal antibiotics\n- No underlying disease\n- Not hospitalized longer than mother\n\nPhysical\n\n- Well-appearing\n- No ear, soft tissue, or bone infection\n\nLabs\n\n- WBC 5K-15K\n- Absolute band count &lt;1.5K\n- Urine &le;10 WBC/hpf\n- Stool &le;5 WBC/hpf\n\n### **Philadelphia Criteria**\n\nHistory\n\n- Immunocompetent\n\nPhysical\n\n- Well-appearing\n- Unremarkable exam\n\nLabs\n\n- WBC &lt;15K\n- Band-neutrophil ratio &lt;0.2\n- Urine &lt;10 WBC/hpf\n- Urine gram stain negative\n- CSF &lt;8 WBC\n- CSF gram stain negative\n- Stool (if diarrhea): No blood, few or no WBC on smear\n\nCXR\n\n- No infiltrate\n\n### **Boston Criteria**\n\nHistory\n\n- No immunizations within last 48 hr\n- No antibiotics within last 48 hr\n- Not dehydrated\n\nPhysical\n\n- Well-appearing\n- No ear, soft tissue, or bone infection\n\nLabs\n\n- WBC &lt;20K\n- Urine &lt;10 WBC/hpf\n- CSF &lt;10 WBC/hpf\n- CXR: no infiltrate\n\n## All recommend the following minimum workup\n- CBC\n- Catheterized UA\n- Urine culture\n\n## Is further workup or antibiotics indicated?\n\n| **Criteria**  |   **Blood Culture**   |      **CXR**      |         **LP**        | **Abx** |\n| :------------ | :-------------------: | :---------------: | :-------------------: | :-----: |\n| Rochester     | If abnormal serum WBC | If respiratory sx | If abnormal serum WBC |    No   |\n| Philadelphia  |        Required       |      Required     |        Required       |    No   |\n| Boston        |        Required       | If respiratory sx |        Required       |   Yes   |\n\n## SUGGESTED WORKUP varies by provider and local practices\n\nGenerally accepted workup includes:\n\n1. CBC with differential\n2. Blood cultures\n3. Catheterized urinalysis and urine culture (or via suprapubic tap)\n4. Consider: CSF studies, if ill-appearing infant\n\n- NOTE: Strongly consider performing LP, if giving antibiotics (cell count, glucose, protein, gram stain, culture, extra tube to hold for potential other studies)\n\n5. _Consider:_ Stool culture (if diarrhea)\n6. _Consider:_ CXR and rapid viral testing (if respiratory sx or increased work of breathing)\n\n## Treatment\n\n**Low risk infant:** Must have a reliable caregiver who can return in 24 hours\n\n- Options for management:\n\n  - No antibiotics and close follow-up in 24 hrs\n  - <span class=\"drug\">Ceftriaxone</span> IV/IM after LP with close follow-up in 24 hrs\n\n**High risk infant:** Admit to hospital for **<span class=\"drug\">ceftriaxone</span> IV/IM** and closer observation\n\n## References\n\n- Ishimine P. The evolving approach to the young child who has fever and no obvious source. Emerg Med Clin North Am. 2007;25(4):1087-115, vii. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17950137)]\n"
		},
		{
			"slug": "pediatric-fever-over-three-months",
			"title": "Pediatric Fever Without a Source - 3 months to 3 years",
			"authors": [
				"Christine Cho, MD"
			],
			"created": "2012/02/09",
			"updates": null,
			"categories": [
				"Pediatrics"
			],
			"body": "\n\n\n- Fever that should prompt workup in this age group: T &ge;39.0&deg;C / 102.2&deg;F\n- Fever still defined as T &ge; 38&deg;C / 100.4&deg;F\n- Named viral infections DO count as a source, such as: HSV gingivostomatitis, Coxsackie hand-foot-mouth, RSV bronchiolitis (although UTI may present concurrently with RSV)\n- Unnamed, nonspecific viral infections MAY be considered a source for vaccinated, well-appearing child (especially with sick contacts)\n\n## Background\n\nSerious bacterial infection (SBI) includes:\n\n- **Occult bacteremia**: Most commonly Strep pneumoniae\n- **Meningitis**: &lt;0.03% risk in post-PCV7 vaccination era. Clinical exam is helpful.\n- **UTI**: 60-65% of febrile UTI patients have pyelonephritis\n- **Pneumonia**: Most common pathogens are viruses in post-PCV7 era\n- Also: Gastroenteritis, osteomyelitis, septic arthritis, soft tissue infection\n\n## Workup Guidelines (if nontoxic appearing)\n\n### Girls\n\n| Age                 | Diagnostic Testing                |\n| :-----------------: | :-------------------------------: |\n| ≤ 24 months         | Urinalysis, urine culture         |\n| > 24 months         | No urine studies                  |\n\n### Boys\n\n| Age            | Circumcised                             | Uncircumcised                           |\n| -------------- | --------------------------------------- | --------------------------------------- |\n| &le; 6 months  | _Consider_ urinalysis and urine culture | Urinalysis, urine culture               |\n| 6-12 months    | No urine studies                        | _Consider_ urinalysis and urine culture |\n| &gt; 12 months | No urine studies                        | No urine studies                        |\n\n### Urinary Tract Infection (UTI) Diagnosis\n\nAny of the following findings on UA:\n\n- Positive LE\n- Positive nitrites\n- ≥10 WBC/hpf\n\n### Additional Workup Beyond Urine Studies Based on Number of Pneumococcal Conjugate Vaccines (PCV)\n\n![Workup relative to number of pneumococcal conjugate vaccines](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/pediatric-fever-over-three-months/image-1.png)\n\n## References\n\n- Christine Cho, lecture presentation. Availabe at: http://lecture.ucsf.edu/ets/Play/b1d49de0f7f4407994c44a791b2223321d\n"
		},
		{
			"slug": "pediatric-head-injury",
			"title": "Pediatric Blunt Head Trauma (PECARN Study)",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/02/04",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Trauma"
			],
			"body": "\n\n\nRisk of CT-documented TBI in children with a GCS &lt;14 is 20% \n\n## PECARN Study\n\n- Derivation (n = 33,785) and validation (n = 8,627) of clinical decision rule for deciding who NOT to get head CTs for blunt head trauma\n- Enrolled age &lt;18 yr within 24 hrs of head trauma and GCS 14-15\n- Patients from 25 enrolling Emergency Departments\n\n**“Clinically important traumatic brain injury” (ciTBI)** predefined as:\n\n- Death from TBI\n- Intubation >24 hours duration\n- Neurosurgical intervention\n- Hospital admission &ge;2 nights\n\n## PATIENT AGE &lt;2 Years \n\n![Age less than 2 workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/pediatric-head-injury/image-1.png)\n\n**Severe Injury Mechanism**\n\n- **FALL >3 ft**\n- MVC with patient ejection, death of another passenger, or rollover\n- Pedestrian or bicyclist without helmet struck by a motorized vehicle\n- Head struck by a high-impact object\n\n## PATIENT AGE &ge;2 years\n\n![Age greater than or equal to 2 years workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/pediatric-head-injury/image-2.png)\n\n**Severe Injury Mechanism**\n\n- **FALL >5 ft**\n- MVC with patient ejection, death of another passenger, or rollover\n- Pedestrian or bicyclist without helmet struck by a motorized vehicle\n- Head struck by a high-impact object\n\n## References\n\n- Kuppermann N et al. ID of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. _Lancet_. 2009 Oct 3;374(9696):1160-70. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19758692)]\n"
		},
		{
			"slug": "pediatric-ingestion",
			"title": "Pediatric Ingestion Dose Thresholds for ED Referral",
			"authors": [
				"Bryan D. Hayes, PharmD"
			],
			"created": "2014/07/09",
			"updates": null,
			"categories": [
				"Pediatrics",
				"Toxicology"
			],
			"body": "\n\n\n_Clinical Toxicology_ has published guidelines for out-of-hospital management of 16 distinct overdoses and their dose thresholds, above which, pediatric patients should be referred to the Emergency Department for evaluation. _Clinical Toxicology_ is the official journal of the American Academy of Clinical Toxicology (AACT, [@AACTinfo](https://twitter.com/AACTinfo)), the American Association of Poison Control Centers (AAPCC, [@AAPCC](https://twitter.com/AAPCC)), and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). \n\n## There are 2 caveats to be aware of regarding these guidelines\n\n1. They were developed between 2005 and 2007. New medications have been approved since that time and there may be more recent data available.\n2. As with any poisoning, the dose is only one factor when determining disposition. Consideration should also be given to intent, underlying medical conditions, co-ingestion of other medications, presence of symptoms, and drug formulation.\n\nThis ALiEM Card summarizes the **pediatric ingestion dose thresholds** for referral to an Emergency Department.\n\n| Acronym     | Meaning                             |\n| ----------- | ----------------------------------- |\n| RSTI        | Repeated supratherapeutic ingestion |\n| IR          | Immediate release                   |\n| SR          | Sustained release                   |\n| MR          | Modified release                    |\n\n**NOTES:** \n- Whenever 2 values are noted, the lesser one should be utilized.\n- Symptomatic patients always warrant ED evaluation.\n\n# Acetaminophen\n\n**Age &lt;6 years (Acute & RSTI)**\n\n- &ge; 200 mg/kg\n- &ge; 200mg/kg over 24 hours, or\n- &ge; 150 mg/kg per 24 hours x 2 days, or\n- &ge; 100 mg/kg per 24 hours x 3 days\n\n**Age >6 years (Acute & RSTI)**\n\n- &ge; 10 g or &ge; 200 mg/kg\n- &ge; 10 g or &ge; 200 mg/kg over 24 hour, or\n- &ge; 6 g or &ge; 150 mg/kg per 24 hours x 2 days\n\n# Atypical Antipsychotics\n\n**Age &lt;12 years**\n\n| Drug        | Dose        |\n| ----------- | ----------- |\n| Ariprazole  | &gt; 15 mg  |\n| Clozapine   | &gt; 50 mg  |\n| Olanzapine  | &gt; 10 mg  |\n| Quetiapine  | &gt; 100 mg |\n| Risperidone | &gt; 1 mg   |\n| Ziprasidone | &gt; 80 mg  |\n\n**Age &gt;12 years**\n\n| Drug        | Dose         |\n| ----------- | ------------ |\n| Ariprazole  | &gt; 50 mg   |\n| Clozapine   | &gt; 62.5 mg |\n| Olanzapine  | &gt; 25 mg   |\n| Quetiapine  | &gt; 125 mg  |\n| Risperidone | &gt; 5 mg    |\n| Ziprasidone | &gt; 100 mg  |\n\n# Anticoagulant Rodenticides\n\n&ge;1 mg\n\n# Beta Blockers\n\nIngestion of any excess beta blocker in combination with a calcium channel blocker warrants referral to an ED.\n\n| Drug          | Dose            |\n| ------------- | --------------- |\n| Acebutolol    | &gt; 12 mg/kg   |\n| Atenolol      | &gt; 2 mg/kg    |\n| Carvedilol    | &gt; 0.5 mg/kg  |\n| Labetalol     | &gt; 20 mg/kg   |\n| Metoprolol IR | &gt; 2.5 mg/kg  |\n| Metoprolol SR | &gt; 5 mg/kg    |\n| Nadalol       | &gt; 2.5 mg/kg  |\n| Propanolol IR | &gt; 4 mg/kg    |\n| Propanolol SR | &gt; 5 mg/kg    |\n| Sotalol       | &gt; 4 mg/kg    |\n| Timolol       | No safe dose    |\n\n# Calcium Channel Blockers\n\nIngestion of any excess beta blocker in combination with a calcium channel blocker warrants referral to an ED.\n\n| Drug          | Dose                         |\n| ------------- | ---------------------------- |\n| Amlodipine    | &ge; 0.3 mg/kg or &ge; 30 mg |\n| Diltiazem     | &ge; 1 mg/kg                 |\n| Felodipine    | &ge; 0.3 mg/kg               |\n| Isradipine    | &ge; 0.1 mg/kg               |\n| Nifedipine IR | &ge; 1 mg/kg                 |\n| Verapamil IR  | &ge; 2.5 mg/kg               |\n\n# Camphor\n\n&gt;30 mg/kg\n\n# Dextromethorphan\n\n&gt;7.5 mg/kg\n\n# Diphenhydramine & Dimenhydrinate\n\n- Age &lt;6 years: &gt;7.5 mg/kg\n- Age &ge;6 years: &gt;7.5 mg/kg or 300 mg\n\n# Ethylene Glycol\n\nMore than witnessed taste/lick or unknown amount\n\n# Iron (Elemental)\n\n&ge;40 mg/kg of adult ferrous sulfate formulation\n\n# Mercury (Elemental)\n\n&gt;1 household fever thermometer\n\n# Methylphenidate\n\n| Drug            | Dose                  |\n| --------------- | --------------------- |\n| IR or chewed MR | &gt;2 mg/kg or 60 mg  |\n| MR (intact)     | &gt;4 mg/kg or 120 mg |\n\n# Salicylate\n\n**Aspirin equivalent**: &gt;150 mg/kg or 6.5 g\n\n**Oil of Wintergreen**:\n\n- Age &lt; 6 years: More than a taste/lick\n- Age &ge; 6 years: More than 4 mL\n\n# Selective Serotonin Reuptake Inhibitors\n\n| Drug         | Dose        |\n| ------------ | ----------- |\n| Citalopram   | &gt; 100 mg |\n| Escitalopram | &gt; 50 mg  |\n| Fluoxetine   | &gt; 100 mg |\n| Fluvoxamine  | &gt; 250 mg |\n| Paroxetine   | &gt; 100 mg |\n| Sertraline   | &gt; 250 mg |\n\n# Tricyclic Antidepressants (TCA)\n\n| Drug          | Dose           |\n| ------------- | -------------- |\n| Desipramine   | &gt; 2.5 mg/kg |\n| Nortriptyline | &gt; 2.5 mg/kg |\n| Trimipramine  | &gt; 2.5 mg/kg |\n| Protriptyline | &gt; 1 mg/kg   |\n| All Others    | &gt; 5 mg/kg   |\n\n# Valproic Acid\n\n&ge;50 mg/kg\n\n## References\n\n1. Wax P, Erdman A, Chyka P, et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(3):131-146. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15906457)]\n2. Caravati E, Erdman A, Christianson G, et al. Ethylene glycol exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(5):327-345. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16235508)]\n3. Manoguerra A, Erdman A, Booze L, et al. Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(6):553-570. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16255338)]\n4. Olson K, Erdman A, Woolf A, et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(7):797-822. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16440509)]\n5. Dart R, Erdman A, Olson K, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(1):1-18. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16496488)]\n6. Scharman E, Erdman A, Wax P, et al. Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(3):205-223. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16749537)]\n7. Manoguerra A, Erdman A, Wax P, et al. Camphor Poisoning: an evidence-based practice guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(4):357-370. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16809137)]\n8. Caravati E, Erdman A, Scharman E, et al. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(1):1-22. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17357377)]\n9. Chyka P, Erdman A, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(2):95-131. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17364628)]\n10. Woolf A, Erdman A, Nelson L, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-233. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17453872)]\n11. Nelson L, Erdman A, Booze L, et al. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(4):315-332. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17486478)]\n12. Chyka P, Erdman A, Manoguerra A, et al. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(6):662-677. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17849242)]\n13. Scharman E, Erdman A, Cobaugh D, et al. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(7):737-752. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18058301)]\n14. Cobaugh D, Erdman A, Booze L, et al. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(8):918-942. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18163235)]\n15. Caravati E, Erdman A, Christianson G, et al. Elemental mercury exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2008;46(1):1-21. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18167033)]\n16. Manoguerra A, Erdman A, Woolf A, et al. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2008;46(7):661-676. PubMed [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18608263)]\n"
		},
		{
			"slug": "penetrating-abdominal-trauma",
			"title": "Penetrating Abdominal Trauma - Observe vs Laparotomy",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/07/09",
			"updates": null,
			"categories": [
				"Trauma"
			],
			"body": "\n\n\n**Eastern Association for the Surgery Trauma (EAST) guidelines**\n\n- Diagnostic peritoneal lavage is no longer indicated, because eplaced by the use of serial abdominal exams and triple-contrast CT abd-pelvis.\n- Patients with a stab wound to flank/back should also receive a triple-contrast CT abd-pelvis.\n- A negative bedside FAST ultrasound does not replace need for triple-contrast CT in a stable patient.\n\n## Wound Management\n\n- **Gun shot wounds (GSW)** – All require laparatomy exploration because of higher incidence of intra-abdominal injuries.\n- **Stab wounds** (SW) to anterior abdomen - Can be observed vs laparotomy \n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong>Patient</strong></th>\n<th><strong>Management</strong><br />\n</th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td><p>Hemodynamically <br />\nunstable or diffuse <br />\nabdominal tenderness <br />\n</p></td>\n<td><p>Immediate laparotomy </p>\n<br />\n</td>\n</tr>\n<tr class=\"even\">\n<td><p>Unreliable clinical exam <br />\n(eg. head or c-spine injury, <br />\nintoxication, intubated) </p></td>\n<td><p>Laparotomy or imaging </p>\n<br />\n</td>\n</tr>\n<tr class=\"odd\">\n<td><p>Hemodynamically stable <br />\nand reliable clinical exam <br />\n</p></td>\n<td><ul>\n<li>“Strongly consider” triple-contrast (PO, IV, PR) abdominopelvis CT</li>\n<li><span class=\"aglmd-moreinfo ui-moreinfo\" data-iid=\"53aa2472d35d3ae92e0016b2\">Serial abdominal examinations over 24 hours</span> </li>\n<li><span class=\"aglmd-moreinfo ui-moreinfo\" data-iid=\"53aa2472d35d3ae92e0016b3\">Consider local wound exploration to determineanterior fascial integrity</span></li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Complications From Laparotomy\n\nOverall incidence of complications: 2.5-41%\n\n- Acute myocardial infarction\n- Aspiration pneumonia\n- Bowel obstruction\n- Deep venous thrombosis\n- Ileus\n- Pancreatitis\n- Pneumothorax\n- Urinary tract infection\n- Visceral injury\n- Wound infection\n- Longer hospital stay\n- Death \n\n**Goal:** Minimize number of unnecessary laparotomies\n\n## References\n\n- Como JJ et. al. Practice management guidelines for selective nonoperative management of penetrating abdominal trauma. _J Trauma_. 2010 Mar;68(3):721-33. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20220426)]\n"
		},
		{
			"slug": "pericarditis",
			"title": "Pericarditis",
			"authors": [
				"Chris Bond, MD"
			],
			"created": "2015/01/06",
			"updates": null,
			"categories": [
				"Cardiology"
			],
			"body": "\n\n\n## Diagnosis\n\n**2 of 4 Criteria Required**\n\n1. Classic chest pain history – Sharp, pleuritic, and positional (improved by sitting up and leaning forward) and pain radiating to trapezius ridge\n2. Pericardial friction rub\n3. Pericardial effusion on echocardiogram or ED bedside ultrasound\n4. Characteristic ECG changes\n\n## 3-Part Treatment\n\n1. <span class=\"drug\">NSAID</span> or <span class=\"drug\">Aspirin</span>\n- Taper dose over 3-4 weeks\n- No definite correct medication or dosing regimen has been established.\n \n2. <span class=\"drug\">Colchicine</span>\n- If >70 kg, 0.6 mg orally twice daily for 3 months \n- If <70 kg, 0.6 mg orally daily for 3 months\n- If diarrhea intractable, decrease dose to once daily for >70 kg or stop for <70 kg\n- Note: Some countries have 0.5 mg tabs only\n    \n3. <span class=\"drug\">Proton pump inhibitor</span> once daily for 3 months\n\n**Note**: _Steroids should be avoided_ in all cases except refractory cases and neoplastic/autoimmune causes. Steroids are an independent risk for increased recurrence of pericarditis. Expert consultation strongly recommended if prescribing.\n\n## Contraindications to Colchicine\n\n- Tuberculous, purulent or neoplastic pericarditis\n- Severe liver disease or aminotransferase levels ≥1.5x upper limits of normal\n- Serum creatinine >2.5 mg/dL (>221 umol/L)\n- Skeletal myopathy or CK > upper limits of normal\n- Blood dyscrasia\n- Inflammatory bowel disease\n- Life expectancy ≤18 months\n- Pregnancy or lactation\n- Women of childbearing potential not using contraception\n- Hypersensitivity to colchicine or other contraindication to its use\n\n## Cost of Colchicine per Pill\n\n- Canada/ Europe: ~ $0.50-1.00\n- USA: Up to $5 per pill\n\n## References\n\n- Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23992557)]\n- Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987-91. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=16186468)]\n- Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739-44. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=17502574)]\n"
		},
		{
			"slug": "peripheral-vertigo-vs-stroke",
			"title": "Acute Vestibular Syndrome vs Stroke",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/12/02",
			"updates": null,
			"categories": [
				"Neurology",
				"ENT",
				"EBM"
			],
			"body": "\n\n\n## Acute Vestibular Syndrome (AVS) Symptoms\n\n- Acute dizziness with nausea/vomiting\n- Unsteady gait\n- Nystagmus\n- Intolerance to head motion\n- Lasts &ge;24 hrs\n- No focal neurologic signs\n\n**Most Common Causes**\n\n- Vestibular neuritis (labyrinthitis)\n- Vertebrobasilar CVA \n\n**Central Causes**\n\n- Vertebrobasilar CVA (83%)\n- Multiple sclerosis (11%)\n- Other (6%) \n\n**Caution**\n\n- Over 50% of patients with a vertebrobasilar CVA have no focal neurologic deficit.\n\n## Which Bedside Tests Help Differentiate Peripheral from Central Causes of AVS? \n\n### NOT helpful\n\n- Differentiating characteristic of dizziness (vertigo, presyncope, unsteadiness)\n- Onset of dizziness (sudden vs gradual)\n- Provocative head movement (e.g. Hallpike-Dix)\n- Proportionality of symptoms such as severity of dizziness, vomiting, gait impairment (e.g. severe gait impairment with mild dizziness does not mean central cause)\n- Hearing loss\n- Patterns and vectors of nystagmus\n- Noncontrast head CT has sensitivity of only 16% for acute ischemic CVA\n\n### Helpful\n\n- **Multiple episodes of dizziness**: Predictive of central cause (CVA)\n- **Headache or neck pain**: Predictive of central cause (CVA, vertebral artery dissection)\n\n  - Positive LR = 3.2\n  - Absence of pain not predictive\n\n- **Any neurologic signs**, especially truncal ataxia (unable to sit upright with arms crossed) and severe gait instability \n\n  - Strongly predictive of central cause\n\n- **Horizontal head impulse test** (vestibular-ocular reflex)\n\n  - If abnormal, suggests peripheral vestibular cause\n  - If normal, predictive of central cause (positive LR 18.4, negative LR 0.16)\n\n- **Gaze-evoked nystagmus** (right-beating nystagmus on right gaze and left-beating nystagmus on left gaze)\n\n  - Means dysfunction of gaze-holding structures in brainstem and cerebellum\n  - If abnormal, predictive of central cause (specificity 92%, sensitivity 38%) \n\n- **Vertical ocular misalignment on alternate cover test**\n\n  - If abnormal skew deviation, predictive of central cause (sensitivity 30%, specificity 98%)\n\n- **Diffusion-weighted MRI**\n\n  - Good but not perfect (sensitivity 83% for ischemic CVA)\n\n## Composite HINTS Exam\n\n**HINTS** = **H**ead **I**mpulse test, **N**ystagmus, **T**est of **S**kew exam\n\nAbnormal findings summarized using **INFARCTs** acronym:\n\n- **I**mpulse **N**ormal \n- **F**ast-phase **A**lternating \n- **R**efixation on **C**over **T**est \n- If any 1 of 3 abnormal, sensitivity 100% and specificity 96% for central cause after HINT training ([Kattah et al. Stroke, 2009](https://www.ncbi.nlm.nih.gov/pubmed/?term=19762709))\n\nHINTS test seems as good as diffusion-weighted MRI to r/o CVA in AVS. \n\n## References\n\n- Kattah JC, Talkad AV, Wang DZ, Hsieh YH, Newman-Toker DE. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. _Stroke_. 2009 Nov;40(11):3504-10. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19762709)]\n- Tarnutzer AA et al. Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. _CMAJ_. 2011; 183(9): E571-592. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21576300)]\n"
		},
		{
			"slug": "pertussis",
			"title": "Pertussis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/09/03",
			"updates": null,
			"categories": [
				"Infectious Disease",
				"EBM"
			],
			"body": "\n\n\n## Background\n\n- _Bordetella pertussis_ – Gram negative coccobacillus\n- Childhood vaccination confers immunity for 5-10 years\n- Incubation period: 7-10 days \n\n## CDC Clinical Case Definition of Pertussis\n\nCough illness lasting &ge; 2 weeks without other apparent cause with 1 or more of:\n\n- Cough paroxysms\n- Posttussive emesis \n- Inspiratory whoop\n\n| **Finding**        | **Positive LR** | **Negative LR**  |\n| ------------------ | --------------- | ---------------- |\n| Paroxysmal cough   | 1.1 (1.1-1.4)   | 0.52 (0.14-0.58) |\n| Posttussive emesis | 1.8 (1.7-1.9)   | 0.58 (0.49-0.80) |\n| Inspiratory whoop  | 1.9 (1.8-2.4)   | 0.78 (0.46-0.87) |\n\n## Phases of Pertussis\n\n### Phase 1: Catarrhal (week #0-2)\n\n- Nonspecific URI symptoms\n- Afebrile or low-grade temperature\n- Excessive lacrimation, conjunctival injection \n\n### Phase 2: Paroxysmal (week #2-8)\n\n- Paroxysmal coughing spells\n- Minimal symptoms between paroxysms\n- May hear inspiratory “whoop” especially in children and infants\n- Posttussive emesis or syncope \n\n### Phase 3: Convalescent (week #8-12)\n\n- Persistent or improving cough\n\n## Diagnosis\n\n- Diagnosis is not easy\n- Dacron swab of posterior nasopharynx (cotton swab is toxic to B pertussis)\n- PCR assay (results in 1-2 days, more costly)\n- DFA is inexpensive but poorly sensitive and specific (not recommended) \n\n## Treatment\n\n- **Macrolide** (e.g. <span class=\"drug\">azithromycin</span>), or <span class=\"drug\">**trimethoprim-sulfamethoxazole**</span> (if allergic)\n- Antibiotics decrease duration of pertussis course if given in catarrhal stage (but difficult to differentiate from viral URI)\n- Antibiotics in any stage decreases transmission to others. \n\n**American Academy of Pediatrics (AAP) recommendation for patients &lt;3 months old:**\n\n- If suspect pertussis (basically a cough), swab for pertussis and start <span class=\"drug\">azithromycin</span> immediately (10 mg/kg per day in a single dose x 5 days). \n\n## Bottom Line\n\n- Positive and negative LR’s for clinical findings are not very helpful.\n- More dependent on your pretest probability of patient having pertussis.\n- Check if there is a current outbreak in your region. \n\n## Fagan Nomogram\n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/pertussis/image-1.png)\n\n## References\n\n- Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R. Does this coughing adolescent or adult patient have pertussis? _JAMA_. 2010 Aug 25;304(8):890-6. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20736473)]\n"
		},
		{
			"slug": "pesi",
			"title": "PESI Score for Pulmonary Embolism",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/11/17",
			"updates": null,
			"categories": [
				"Pulmonology",
				"Critical Care"
			],
			"body": "\n\n\n## Pulmonary Embolism Severity Index (PESI) score calculation\n\n| Finding                            | Points      |\n| ---------------------------------- | ----------- |\n| Age                                | +1 per year |\n| Male gender                        | +10         |\n| Cancer (history of or active)      | +30         |\n| Heart failure                      | +10         |\n| Chronic lung disease               | +10         |\n| Pulse &ge;110 beats per min        | +20         |\n| SBP &lt;100 mmHg                   | +30         |\n| RR &ge;30 breaths per min          | +20         |\n| Temperature &lt;36C                | +20         |\n| Altered mental status              | +60         |\n| Arterial oxygen saturation &lt;90% | +20         |\n\n| Class | Point Total |\n| ----- | ----------: |\n| I     |      &lt;66 |\n| II    |       66-85 |\n| III   |      86-105 |\n| IV    |     106-125 |\n| V     |     &gt;125 |\n\n## Outpatient Treatment of Pulmonary Embolism (OTPE) trial\n\n### Study design\n\nRandomized, prospective, non-inferiority clinical trial of 19 ED’s (n = 344 patients) in Switzerland, France, Belgium, and USA looking at morbidity/mortality of PESI class I and II patients\n\n### Exclusion criteria from study\n\n- Arterial hypoxemia (O2 saturation &lt;90% on room air, or paO2 &lt;60 mmHg)\n- SBP &lt;100 mmHg\n- Chest pain necessitating parental opioids\n- Active bleeding\n- High risk of bleeding defined as: CVA during preceding 10 days, GI bleeding in preceding 14 days, or platelets &lt;75K \n- Severe renal failure (CrCl &lt;30 mL per min)\n- Extreme obesity (body mass >150 kg)\n- History of heparin-induced thrombocytopenia or allergy to heparins\n- Therapeutic oral anticoagulation at time of PE diagnosis (INR &ge;2)\n- Any barriers to treatment adherence (current EtOH abuse, illicit drug use, psychosis, dementia, homelessness)\n- Pregnancy\n- Imprisonment\n- Diagnosis of PE &gt;23 hrs before time of screening\n\n### Results\n\n- Complication rates were calculated based on whether PE was managed as an outpatient or inpatient.\n\n| Complications                                   |   Outpatient |    Inpatient |\n| ----------------------------------------------- | -----------: | -----------: |\n| Major bleeding at &le;14 days                   | 1.2% (2/171) |   0% (0/168) |\n| Major bleeding at &le;90 days                   | 1.8% (1/171) |   0% (0/168) |\n| Recurrent venous thromboembolism at &le;90 days | 0.6% (1/171) |   0% (0/168) |\n| Death at &le;90 days                            | 0.6% (1/171) | 0.6% (1/168) |\n\n### Outpatient treatment \n\n<span class=\"drug\">Enoxaparin</span> 1 mg/kg SQ BID to bridge into PO <span class=\"drug\">warfarin</span> (target INR=2)\n\n## Conclusion\n\nPE patients with PESI class I or II seem safe to manage as outpatients.\n\n- Be aware of exclusion criteria from study\n\n## References\n\n- Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. _Lancet_. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21703676)]\n"
		},
		{
			"slug": "pneumonia-severity",
			"title": "Pneumonia Risk Stratification Tools",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/02/25",
			"updates": null,
			"categories": [
				"Pulmonology",
				"Infectious Disease",
				"EBM"
			],
			"body": "\n\n\n## Pneumonia Severity Index (PSI) \n\n[Fine et al., JAMA 1997](http://www.ncbi.nlm.nih.gov/pubmed/?term=8995086)\n- Pneumonia Patient Outcomes Research Team (PORT)\n- A large derivation and validation study with >50,000 patients\n- Best identifies low-risk/ low-mortality patients\n- Tends to miss higher-risk pneumonia in younger patients because score is based on age \n- Does not factor in immunosuppression (eg. HIV) and poor social support \n\n| Risk factors                           |         Points |\n| -------------------------------------- | -------------: |\n| Men                                    |    Age (years) |\n| Women                                  | Age (years)-10 |\n| Nursing home resident                  |            +10 |\n| History of neoplasm                    |            +30 |\n| History of liver disease               |            +20 |\n| History of heart failure               |            +10 |\n| History of stroke                      |            +10 |\n| History of renal failure               |            +10 |\n| Altered mental status                  |            +20 |\n| RR &ge; 30 breaths/ min                |            +20 |\n| SBP &lt; 90 mmHg                       |            +20 |\n| Temp &lt; 95F (35C) or &ge;104F (40C)  |            +15 |\n| HR &ge; 125 bpm                        |            +10 |\n| Arterial pH &lt; 7.35                  |            +30 |\n| BUN &gt; 30 mg/dL                      |            +20 |\n| Na &lt; 130 mmol/L                     |            +20 |\n| Glucose &ge;250 mg/dL                  |            +10 |\n| Hematocrit &lt; 30%                    |            +10 |\n| PaO2 &lt; 60 mmHg                      |            +10 |\n| Pleural effusion                       |            +10 |\n\n| PSI Class | Total Points | 30-Day Mortality | Disposition                        |\n| --------- | -----------: | ---------------: | ---------------------------------- |\n| I         |      &lt; 51 |             0.1% | Outpatient                         |\n| II        |        51-70 |             0.6% | Outpatient                         |\n| III       |        71-90 |             0.9% | Outpatient vs short-stay inpatient |\n| IV        |       91-130 |             9.3% | Inpatient                          |\n| V         |     &gt; 130 |            27.0% | Inpatient ICU                      |\n\n## CURB-65 Severity Score\n\nSupported by ([British Thoracic Society Standards of Care Committee](http://www.ncbi.nlm.nih.gov/pubmed/?term=11713364) &[ ](http://www.ncbi.nlm.nih.gov/pubmed/?term=15808136)[Aujesky et al, Am J Med, 2005](http://www.ncbi.nlm.nih.gov/pubmed/?term=15808136)) \n\n- Best identifies high-risk/ high-mortality patients\n- Tends to misclassify moderate-risk pneumonia patients (as low-risk) \n- Does not account for co-morbidities and hypoxemia\n\n|        | Risk Factor                                     | Points |\n| ------ | ----------------------------------------------- | -----: |\n| **C**  | **C**onfusion                                   |      1 |\n| **U**  | Uremia (BUN >19 mg/dL)                          |      1 |\n| **R**  | **R**R &ge; 30 breaths/min                      |      1 |\n| **B**  | **B**P low (SBP &lt;90 mmHg or DBP &lt;60 mmHg) |      1 |\n| **65** | Age &ge; **65** years                           |      1 |\n\n| Total Points | 30-Day Mortality | Disposition                        |\n| -----------: | ---------------: | ---------------------------------- |\n|            0 |             0.6% | Outpatient                         |\n|            1 |             3.2% | Outpatient                         |\n|            2 |            13.0% | Outpatient or short-stay inpatient |\n|            3 |            17.0% | Inpatient                          |\n|            4 |            41.5% | Inpatient, likely ICU              |\n|            5 |            57.0% | Inpatient ICU                      |\n\n## SMART-COP\n\nSupported by Australian CAP Study ([Charles et al., Clin Infect Dis, 2008](http://www.ncbi.nlm.nih.gov/pubmed/?term=18558884))\n\n- Tool to predict need for intensive respiratory or vasopressor support (IRVS) \n\n<table>\n<colgroup>\n<col width=\"33%\" />\n<col width=\"33%\" />\n<col width=\"33%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><br />\n</th>\n<th><strong>Risk factor</strong></th>\n<th><strong>Points</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td><strong>S</strong></td>\n<td><strong>S</strong>ystolic BP &lt; 90 mmHg</td>\n<td>2</td>\n</tr>\n<tr class=\"even\">\n<td><strong>M</strong></td>\n<td><strong>M</strong>ultilobar CXR involvement</td>\n<td>1</td>\n</tr>\n<tr class=\"odd\">\n<td><strong>A</strong></td>\n<td><strong>A</strong>lbumin &lt; 3.5 g/dL</td>\n<td>1</td>\n</tr>\n<tr class=\"even\">\n<td><strong>R</strong></td>\n<td>If age &le; 50 years: <strong>R</strong>R &ge; 25 breaths/min <br />\nIf age &gt; 50 years: <strong>R</strong>R &ge; 30 breaths min <br />\n</td>\n<td>1</td>\n</tr>\n<tr class=\"odd\">\n<td><strong>T</strong></td>\n<td><strong>T</strong>achycardia HR &ge; 125 bpm </td>\n<td>1</td>\n</tr>\n<tr class=\"even\">\n<td><strong>C</strong></td>\n<td><strong>C</strong>onfusion (new onset)</td>\n<td>1<br />\n</td>\n</tr>\n<tr class=\"odd\">\n<td><strong>O</strong></td>\n<td><strong>O</strong>xygen low<br />\n\n<p>If age &le;50 years: </p>\n<ul>\n<li>PaO2 &lt; 70 mmHg, or<br />\n</li>\n<li>O2 sat &le; 93%, or<br />\n</li>\n<li>PaO2/FiO2 &lt; 333<br />\n</li>\n</ul>\n<p>If age &gt;50 years:</p>\n<ul>\n<li>PaO2 &lt; 60 mmHg, or</li>\n<li>O2 sat &le; 90%, or </li>\n<li>PaO2/FiO2 &lt; 250 </li>\n</ul></td>\n<td>2</td>\n</tr>\n<tr class=\"even\">\n<td><strong>P</strong></td>\n<td>Arterial <strong>p</strong>H &lt; 7.35</td>\n<td>2</td>\n</tr>\n</tbody>\n</table>\n\n| Total points | Risk of needing IRVS |\n| -----------: | -------------------- |\n|          0-2 | Low                  |\n|          3-4 | Moderate (1 in 8)    |\n|          5-6 | High (1 in 3)        |\n|       &ge; 7 | Very high (2 in 3)   |\n\n## References\n\n- Aujesky D et. al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. _Am J Med_. 2005 Apr;118(4):384-92. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=15808136)]\n- Fine MJ et. al. A prediction rule to identify low-risk patients with community-acquired pneumonia. _N Engl J Med_. 1997 Jan 23;336(4):243-50. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=8995086)]\n- Charles PG et. al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. _Clin Infect Dis_. 2008 Aug 1;47(3):375-84. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18558884)]\n- British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. _Thorax_. 2001 Dec;56 Suppl 4:IV1-64. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=11713364)]\n"
		},
		{
			"slug": "procedural-sedation",
			"title": "Procedural Sedation & Analgesia",
			"authors": [
				"Demian Szyld, MD"
			],
			"created": "2010/08/06",
			"updates": null,
			"categories": [
				"Pharmacology",
				"Procedures"
			],
			"body": "\n\n\n**Airway Assessment: Predicting difficulty**\n\n<table>\n<thead>\n<tr class=\"header\">\n<th><strong>Difficult Airway (LEMON)</strong></th>\n<th><strong>Difficult Ventilation (MOANS)</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td><strong>L</strong> ook externally: syndromic, obese, gestalt</td>\n<td><strong>M</strong> ask seal (beard, trauma, prone)<br />\n</td>\n</tr>\n<tr class=\"even\">\n<td><strong>E</strong> valuate 3-3-2 rule<br />\n(mouth opening, thyromental, hyomental)</td>\n<td><strong>O</strong> besity<br />\n(redundant upper airway, OSA, poor reserve)<br />\n</td>\n</tr>\n<tr class=\"odd\">\n<td><strong>M</strong> allampati<br />\n\n<ul>\n<li>I: Uvula, tonsils, palate</li>\n<li>II: Upper uvula, tonsils</li>\n<li>III Base of uvula</li>\n<li>IV: Hard palate only<br />\n</li>\n</ul></td>\n<td><strong>A</strong> ge &gt; 55 (Loss of airway tone)</td>\n</tr>\n<tr class=\"even\">\n<td><strong>O</strong> bstruction: OSA, PTA, epiglottis, mass</td>\n<td><strong>N</strong> o teeth</td>\n</tr>\n<tr class=\"odd\">\n<td><strong>N</strong> eck mobility: Rheum. arthritis, c-collar</td>\n<td><strong>S</strong> tiffness (asthma, COPD, pregnant)</td>\n</tr>\n</tbody>\n</table>\n\n## Preparation\n\nAssemble appropriate staffing and equipment (**SOAPME**): \n\n- **S** uction\n- **O** xygen\n- **A** irway adjuncts\n- **P** ersonnel\n- **M** edications\n- **E** quipment\n\nSelect sedative AND analgesic if both are required. Match duration of procedure to duration of drug.\n\n## Medications\n\n**SEDATION medications**\n\n| **Medication / Initial IV dose**                                                  | **Advantage**                 | **Side Effects**      |\n| --------------------------------------------------------------------------------- | ----------------------------- | --------------------- |\n| <span class=\"drug\">Midazolam</span> 0.05 mg/kg                                    | Shortest benzodiazepine       |                       |\n| <span class=\"drug\">Lorazepam</span> 0.05 mg/kg                                    | Short benzodiazepine          |                       |\n| <span class=\"drug\">Diazepam</span> 0.1 mg/kg                                      | Muscle relaxation             |                       |\n| <span class=\"drug\">Etomidate</span> 0.15 mg/kg                                    | Short duration                | Myoclonus             |\n| <span class=\"drug\">Propofol</span>   1-2 mg/kg                                    | Short duration                | Transient hypotension |\n| <span class=\"drug\">Ketofol</span> 0.5 mg/kg<br>1:1 ratio of <br>ketamine:propofol | CV stable, amnesia, analgesia |                       |\n\n**ANALGESIC medications**\n\n| **Medication / Initial IV dose**                   | **Advantage**  | **Side Effects**                              |\n| -------------------------------------------------- | -------------- | --------------------------------------------- |\n| <span class=\"drug\">Fentanyl</span> 1-2 mcg/kg      | Short duration | Decreased respiratory rate                    |\n| <span class=\"drug\">Hydromorphone</span> 0.02 mg/kg |                | Decreased respiratory rate and blood pressure |\n| <span class=\"drug\">Morphine</span> 0.1-0.2 mg/kg   |                | Decreased respiratory rate and blood pressure |\n\n**DISSOCIATIVE medications**\n\n| **Medication / Initial IV dose**                                       | **Advantage**             |\n| ---------------------------------------------------------------------- | ------------------------- |\n| <span class=\"drug\">Ketamine</span> 1-2 mg/kg                           |                           |\n| <span class=\"drug\">Dexamedetomidine</span> 0.5-1 mcg/kg<br>over 10 min | No respiratory depression |\n\n## References\n\n- Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH; Pediatric Sedation Research Consortium.The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg. 2009 Mar;108(3):795-804. doi: 10.1213/ane.0b013e31818fc334. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=19224786)]\n- Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M, Rieder M .A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children. Ann Emerg Med. 2011 May;57(5):425-33.e2. doi: 10.1016/j.annemergmed.2010.08.032. Epub 2010 Oct 13. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=20947210)]\n- Andolfatto G, Abu-Laban RB, Zed PJ, Staniforth SM, Stackhouse S, Moadebi S, Willman E.,Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial.Ann Emerg Med. 2012 Jun;59(6):504-12.e1-2. doi: 10.1016/j.annemergmed.2012.01.017. Epub 2012 Mar 7. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22401952)]\n- Drayna PC, Estrada C, Wang W, Saville BR, Arnold DH, Ketamine sedation is not associated with clinically meaningful elevation of intraocular pressure. Am J Emerg Med. 2012 Sep;30(7):1215-8. doi: 10.1016/j.ajem.2011.06.001. Epub 2011 Dec 12. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=22169582)]\n- Green SM, Roback MG, Kennedy RM, Krauss B. Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update. Annals of emergency medicine. 2011 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21256625)]\n"
		},
		{
			"slug": "radial-head-fracture",
			"title": "Elbow Injuries - Radial Head Fracture",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Type 1-4 radial head fracture drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/radial-head-fracture/image-1.png)\n\n## X-ray Views\n\n**Elbow XR:** AP, lateral, +/- radiocapitellate view\n\nAssess for indirect signs of fracture or dislocation on lateral elbow view.\n\n- Sail sign or posterior fat pad\n- Radiocapitellate line misalignment\n\n### Mason Classification\n\n| Type | Description                                    |\n| ---- | ---------------------------------------------- |\n| I    | Minimally displaced fracture ≤2 mm             |\n| II   | Fracture fragment displaced >2 mm or angulated |\n| III  | Comminuted and displaced fracture              |\n| IV   | Associated elbow dislocation                   |\n\nMost common elbow fractures in adults\n\n### Operative indications\n\n- \\>3 mm displacement\n- 33% articular surface involvement\n- Angulated >30°\n- Associated elbow dislocation\n\n## Acute Management\n\n- **Type I:** Sling\n- **Type II-IV:** Long-arm posterior splint with elbow at 90° flexion (after type IV elbow dislocation reduced)\n\n## Follow-up Timing\n\n- If operative: ≤3 days\n- If non-operative: &lt;1-2 weeks with early mobilization in 48 hours to minimize elbow stiffness\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/radial_head_frx. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/trauma/1019/radial-head-fractures. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/radial-head-fractures. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Department of Orthopedics\n"
		},
		{
			"slug": "radial-head-subluxation",
			"title": "Elbow Injuries - Radial Head Subluxation (Nursemaids Elbow)",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Radial head subluxation drawing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/radial-head-subluxation/image-1.png)\n\n## Classic Presentation\n\n- Age 1-4 years\n- Occurs by pulling of extended and pronated arm\n- Patient refuses to use arm\n- Elbow in slight flexion/pronation\n- Elbow appears atraumatic\n- No focal elbow tenderness\n\n## X-ray Views\n\n- Xrays rarely indicated\n- Obtain xray if concerned for fracture, unable to reduce elbow, or inability to move arm post reduction\n\n## Acute Management\n\n- **Technique:** Closed reduction with hyperpronation or supination/flexion approach\n- If concern for supracondylar fracture, do not reduce and obtain xray first.\n\n## Follow-Up Timing\n\n- Routine follow-up with pediatrician\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/nursemaids_elbow_radial_head_subluxation. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/pediatrics/4012/nursemaids-elbow. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/radial-head-dislocation. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Department of Orthopedics\n"
		},
		{
			"slug": "rapid-sequence-intubation",
			"title": "Rapid Sequence Intubation",
			"authors": [
				"Demian Szyld, MD"
			],
			"created": "2010/07/16",
			"updates": null,
			"categories": [
				"Critical Care",
				"Procedures"
			],
			"body": "\n\n\n## Preparation\n\nPatients without a pulse do not require medications to facilitate intubation. \n\nMaximize your chances for first-pass success with:\n\n1. **Preparation**: Room, airway equipment, suction, monitor, IV access, personnel \n2. **Pre-oxygenation:** NRB mask for spontaneously breathing patient, ventilate if hypoxic \n3. **Positioning:** Ear above sternum or ramp\n4. **Plan A:** Share your laryngoscopy and intubation plan (bougie?, video?)\n5. **Plan B:** Share your rescue ventilation and rescue intubation plan (LMA?, cric kit?) \n6. **Paralysis:** Optimize laryngoscopic view with muscle relaxants\n7. **Post-intubation**: Secure and confirm tube placement, sedation and vent orders\n\nAvoid paralysis without sedation.\n\nAvoid paralysis when difficulty laryngoscopy is anticipated. Consider awake intubation strategy, alternatively.\n\n1. **Distortion** (of upper or lower airway ie: trauma, anaphylaxis) \n2. **Disproportion** (small jaw, large tongue)\n3. **Dysmobility** (neck stiffness, c-collar, rheumatoid arthritis) \n4. **Dentition** (large teeth = small mouth opening)\n\n## Medications\n\n**Pre-treatment**\n\n| Medication                          | Weight-based dose | 80 kg / 180 lbs dose | Indications |\n| ----------------------------------- | :---------------: | :------------------: | ----------- |\n| <span class=\"drug\">Lidocaine</span> |     1.5 mg/kg     |        120 mg        | Head, lung  |\n| <span class=\"drug\">Fentanyl</span>  |      3 mcg/kg     |        250 mcg       | Head, heart |\n\n**Sedation**\n\n| Medication                            | Weight-based dose | 80 kg / 180 lbs dose | Indications  |\n| ------------------------------------- | :---------------: | :------------------: | ------------ |\n| <span class=\"drug\">Etomidate</span>   |     0.3 mg/kg     |         24 mg        |              |\n| <span class=\"drug\">Propofol</span>    |     1.5 mg/kg     |        120 mg        |              |\n| <span class=\"drug\">Thiopental</span>  |      3 mg/kg      |        250 mg        |              |\n| <span class=\"drug\">Ketamine IV</span> |     1.5 mg/kg     |        120 mg        | Asthma       |\n| <span class=\"drug\">Ketamine IM</span> |     3.0 mg/kg     |        240 mg        | No IV access |\n| <span class=\"drug\">Midazolam</span>   |     0.3 mg/kg     |         24 mg        |              |\n\n**Paralytics**\n\n| Medication                                | Weight-based dose | 80 kg / 180 lbs dose | Indications |\n| ----------------------------------------- | :---------------: | :------------------: | ----------- |\n| <span class=\"drug\">Succinylcholine</span> |     1.5 mg/kg     |        120 mg        |             |\n| <span class=\"drug\">Rocuronium</span>      |     1.0 mg/kg     |         80 mg        |             |\n| <span class=\"drug\">Vecuronium</span>      |      0.2mg/kg     |         16 mg        |             |\n\n## References\n\n- Airway Cam Pocket Guide to Intubation, 2nd Edition [[Source](http://airwaycam.com)]\n- “The Airway Card”, The Airway Course [[Source](http://www.theairwaysite.com)]\n"
		},
		{
			"slug": "rash-unknown",
			"title": "An Approach to the Unknown Rash",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/08/26",
			"updates": null,
			"categories": [
				"Dermatology"
			],
			"body": "\n\n\n## How to diagnosis a rash\n\n1. Accurately describe the rash (eg. macule or nodule, vesicle, or bulla)\n2. Quickly \"profile\" the rash to see if it fits any classic pattern by patient age, rash distribution, or presence of hypotension\n3. Apply an algorithm based on the rash type\n\n## Rash Descriptors\n\n| Descriptor   | Definition                                             |\n| ------------ | ------------------------------------------------------ |\n| **Lesion**   | Single small diseased area                             |\n| **Rash**     | Eruption of skin; more than single lesion              |\n| **Macule**   | Circumscribed area of change without elevation         |\n| **Papule**   | Solid raised lesion &lt;1 cm                           |\n| **Nodule**   | Solid raised &ge;1 cm                                  |\n| **Plaque**   | Circumscribed elevated confluence of papules &ge;1 cm  |\n| **Pustule**  | Circumscribed area containing pus                      |\n| **Vesicle**  | Circumscribed fluid-filled area &lt;1 cm               |\n| **Bulla**    | Circumscribed fluid-filled area &ge;1 cm               |\n| **Petechia** | Small red/brown macule &le;1 cm that does not blanch   |\n\n## Quick Profiling of Rash\n\n### Patient Age\n\n**0-5 years**\n\n- Meningococcemia        \n- Kawasaki disease        \n- Viral exanthema  \n\n**&gt; 65 years**\n\n- Pemphigus vulgaris\n- Sepsis\n- Menigococcemia\n- Toxic epidermal necrolysis\n- Stevens Johnson syndrome\n- Toxic shock syndrome  \n\n### Rash\n\n**Diffuse Erythema**\n\n- Staph scalded skin syndrome\n- Staph/strep toxic shock syndrome\n- Necrotizing fasciitis\n\n**Mucosal Lesions**\n\n- Erythema ultiforme major\n- Toxic epidermal necrolysis/Stevens Johnson syndrome\n- Pemphigus vulgaris\n\n**Petechiae/Purpura**\n\n- Menigococcemia\n- Necrotizing fasciitis\n- Vasculitis\n- Disseminated intravascular coagulopathy \n- Rocky Mountain Spotted Fever\n\n### Symptoms\n\n**Hypotension**\n\n- Meningococcemia\n- Toxic shock syndrome\n- Rocky Mountain Spotted Fever\n- Toxic epidermal necrolysis\n- Stevens Johnson syndrome\n\n## Erythematous Rash\n\n![Erythematous rash workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/rash-unknown/image-1.png)\n\n## Maculopapular Rash\n\n![Maculopapular rash workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/rash-unknown/image-2.png)\n\n## Petechial/ Purpuric Rash\n\n![Petechial or purpuric rash workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/rash-unknown/image-3.png)\n\n## Vesiculobullous Rash\n\n![Vesiculobullous rash workup pathway](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/rash-unknown/image-4.png)\n\n## References\n\n- Murphy-Lavoie H, Le Gros TL. Emergent Diagnosis of the Unknown Rash. Emergency Medicine. 2010 March. PDF: [[Source](http://www.emedmag.com/PDF/042030006.pdf)]\n"
		},
		{
			"slug": "red-eye",
			"title": "Red Eye",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/01/22",
			"updates": null,
			"categories": [
				"Ophthalmology"
			],
			"body": "\n\n\nThere is significant overlap among conditions that cause a red, painful or red and painful eye. Here are additional cards that may help in your evaluation:\n\n- [Eye Differential Diagnoses](/cards/eye-ddx)\n- [Painful Eye](/cards/eye-painful)\n\n## Conjunctivitis\n\n![Bacterial conjunctivitis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/red-eye/image-1.png)\n\n### Allergic\n\n- IgE mediated, usually associated with itching\n- **Treatment:** Cold compresses, over-the-counter topical vasoconstrictors, histamine-blocking eyedrops\n\n### Viral\n\n- Most common form of infectious conjunctivitis (usually adenovirus)\n- Preauricular lymphadenopathy, global conjunctival injection\n- Watery discharge\n- Follicular reaction of inferior tarsal conjunctiva\n- **Treatment:** Cold compresses, artificial tears, topicaldecongestants, +/- topical antibiotics, if not able to discern from bacterial etiology\n\n### Viral: Epidemic keratoconjunctivitis\n\n![Epidemic keratoconjunctivitis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/red-eye/image-2.png)\n\n- Adenovirus\n- **Symptoms:** Eye pain, decreased visual acuity\n- **Findings:** Corneal subepithelial infiltrates (1-2 mm gray-white crumb-like defects)\n\n### Viral: HSV conjunctivitis\n\n- More prevalent in HIV patients\n- Foreign body sensation in eye (unlike typical viral conjunctivitis)\n- **Treatment**:\n  - If no skin or corneal involvement, topical antivirals (<span class=\"drug\">trifluridine</span> or <span class=\"drug\">vidarabine</span>) x 10-14 days\n  - If corneal involvement (dendrites seen), topical <span class=\"drug\">trifluridine</span> and oral <span class=\"drug\">acyclovir</span> x 7-10 days. NO STEROIDS. \n\n### Viral: HZV ophthalmicus\n\nVZV virus: Reactivation through V1 nerve \n\nFindings:\n\n- Hutchinson sign: Herpes pustules at nose tip and is predictive of ocular involvement \n- Dendrites on eye exam\n- **Treatment:** Systemic vs topical antiviral agents, +/- steroids only with ophthalmology consult\n\n### Bacterial \n\n- Often association with morning crusting \n- Injection more pronounced at fornices\n- **Contact lens wearer**: Pseudomonas risk\n  - **Treatment:** Topical fluoroquinolone, cycloplegic\n\n**Gonorrheal conjunctivitis:** \n- Sexually active patients and neonates (from birthcanal)\n- “hyperacute conjunctivitis”, abrupt onset\n- copious purulent discharge\n- **Treatment:** Topical antibiotics, usually with systemic antibitics because associated with venereal disease\n\n**Inclusion or Chlamydial conjunctivitis:** \n- Sexually active patients and neonates\n- mucopurulent discharge\n- foreign body sensation\n- Check for concurrent sexually transmitted infections (symptomatic only 1⁄2 patients).\n- **Treatment:** Topical <span class=\"drug\">erythromycin</span> and po <span class=\"drug\">azithromycin</span> x 1 \n\n## Subconjunctival Hemorrhage\n\n- In setting of trauma and large hemorrhage, consider globe rupture\n- **Treatment:** Warm compresses, lubrication drops \n\n## Episcleritis\n\n![Episcleritis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/red-eye/image-3.png)\n\n- Episclera: Thin membrane over the sclera and beneath conjunctiva\n- Benign self-limited inflammatory cond with focal area of dilated episceral vessels \n- Seen with rheumatoid arthritis, polyarteritis nodosa, lupus, inflam bowel disease, sarcoid, Wegener’s, gout, herpes zoster virus, syphilis \n- **Treatment:** Oral NSAIDs\n\n## Scleritis\n\n![Scleritis photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/red-eye/image-4.png)\n\n- **Most common immune cause:** Rheumatoid arthritis\n- **Most common vasculitis cause:** Wegener’s \n- **Symptoms:** Severe eye pain radiating to ear, scalp, face, and jaw. Dull pain. Photophobia. \n- **Exam:** Deep episcleral plexus is vascularly engorged – appears blue-violet, vessels non-blanching with vasoconstrictor, scleral edema \n- **Treatment:** \n  - Oral NSAIDs \n  - Consider oral steroids, but with ophthalmology consultation \n\n## Uveitis\n\n- Divided into anterior (iris, ciliary body) vs posterior (retinochoroiditis)\n- **Etiologies:** Inflammatory (50% assoc w/ systemic inflam disease), traumatic, infectious \n- Consider CMV in posterior uveitis in HIV patients\n- **Anterior uveitis:** Sudden, severe, painful eye; photophobia; perilimbal injection, consensual photophobia from unaffected eye\n- **Posterior uveitis:** “Floaters”, flashing light – no redness or pain\n- **Exam:** Inflammatory cells, proteinaceous flare\n- **Complications:** Cataracts, glaucoma, retinal detachment\n- **Treatment:** \n  - Mydriatic or cycloplegic drops \n  - Consider oral steroids, but with ophthalmology consult \n\n## Acute Angle Closure Glaucoma\n\n![Acute Angle Closure Glaucoma photo](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/red-eye/image-5.png)\n\n- **Symptoms:** Blurred vision, halos around lights, nausea/vomiting, headache\n- **Pearl:** Consider in all patients with “migraine HA’s” – check pupil reactivity\n- **Exam:** Corneal edema, mid-dilated NON-reactive pupil\n- Intraocular pressure >30 mmHg requires prompt treatment\n- **Treatment:** \n  - Topicals: <span class=\"drug\">Timolol</span>, <span class=\"drug\">prednisolone</span>, <span class=\"drug\">apraclonidine</span>\n  - Oral: <span class=\"drug\">Acetazolamide</span> \n\n## References\n\n- Mahmood AR, Narang AT. Diagnosis and management of the acute red eye. _Emerg Med Clin North Am_. 2008 Feb;26(1):35-55, vi. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18249256)]\n"
		},
		{
			"slug": "scaphoid-fractures",
			"title": "Scaphoid Fracture",
			"authors": [
				"Sean Kivlehan, MD MPH"
			],
			"created": "2016/02/01",
			"updates": null,
			"categories": [
				"Orthopedics",
				"EBM"
			],
			"body": "\n\n\n- **Most common** carpal fracture (70%), followed by triquetral and trapezium\n- **Initial x-ray** (full scaphoid series): **Specificity is 100%** but **Sensitivity is 80%**\n- **Pre-test probability** of scaphoid fracture in patient with scaphoid wrist pain and non-diagnostic x-rays is about 25% (17-38% across 4 studies in this meta-analysis)\n\n## Physical Exam\n\n| **Physical Exam**         | **Positive LR** [95% CI] | **Negative LR** [95% CI] |\n| ------------------------- | :----------------------: | :----------------------: |\n| Clamp Sign                |     8.6 [0.51-147.0]     |     0.40 [0.14-1.18]     |\n| Resisted Supination Pain  |     6.1 [0.04-10.86]     |     0.09 [0.00-11.9]     |\n| Thumb Compression Pain    |       2.0 [1.1-3.5]      |     0.24 [0.06-0.99]     |\n| Vibration Pain            |      1.8 [0.9-3.4]       |     0.56 [0.24-1.32]     |\n| “Clinical Examination”    |      1.8 [0.08-2.9]      |     0.22 [0.80-2.90]     |\n| Scaphoid Tubercle         |       1.7 [1.3-2.1]      |     0.23 [0.09-0.56]     |\n| Snuffbox Tenderness       |       1.5 [1.1-2.1]      |     0.15 [0.05-0.43]     |\n| Ulnar Deviation Pain      |      1.4 [0.8-2.4]       |    0.53 [0.13- &gt;1]    |\n| Swelling                  |      1.3 [0.07-2.1]      |     0.76 [0.36-1.48]     |\n| Radial Deviation Pain     |       1.0 [0.9-1.2]      |     0.97 [0.67-1.40]     |\n| Discoloration             |       0.9 [0.3-2.8]      |      1.0 [0.73-1.38]     |\n| Resisted Pronation        |      0.09 [0.6-1.3]      |     1.44 [0.54-3.87]     |\n\n- **_Clamp sign:_** Ask the patient “Exactly where does it hurt?” The patient will form a clamp with opposite thumb and index finger on both sides of the thumb\n- **_Pain with resisted supination:_** Hold the hand of the injured extremity with the patient’s forearm in neutral position. Patient attempts to supination, resulting in pain when the examiner resists.\n\n| **Imaging**                          | **Positive LR** [95% CI] | **Negative LR** [95% CI] |\n| ------------------------------------ | :----------------------: | :----------------------: |\n| Xray fat pad on initial xray         |       2.7 [1.4-5.2]      |     0.24 [0.07-0.79]     |\n| Fat pad on 10-14 day follow up x-ray |      4.7 [1.6-14.4]      |     0.67 [0.50-0.89]     |\n| Bone scan                            |      6.6 [3.9-11.1]      |     0.11 [0.05-0.23]     |\n| Ultrasound (radiologist performed)   |      5.6 [3.0-10.5]      |     0.27 [0.13-0.56]     |\n| CT                                   |     15.4 [8.8-27.0]      |     0.23 [0.16-0.34]     |\n| MRI                                  |     22.0 [11.9-40.1]     |     0.09 [0.04-0.19]     |\n\n**NOTE:** There is limited usefulness for LR’s with wide CIs.\n\n## Management Plan Based on XRay Findings\n\n- Displaced (>1 mm) or proximal pole frature: Orthopedic/Hand consult in ED\n- Non- or minimally displaced fracture: Splint and Ortho/Hand clinic follow up in 5-7 days\n- Suspected fracture but non-diagnostics xrays: \n  - Thumb spica splint\n  - Follow up with primary care physician or Ortho/Hand clinic for repeat exam and potentially repeat x-rays within 10-14 days\n\n## Pearls\n\n- The clinical exam has **high sensitivity** but **low specificity**\n- MRI is the most sensitive and specific imaging modality, but cost-benefit must be balanced with patient’s economic loss from being splinted or a missed fracture.\n- Avascular necrosis and nonunion can occur leading to carpal instability and osteoarthritis\n  - Those at greatest risk: Displaced or initially missed scaphoid fractures\n\n## References\n\nCarpenter C, Pines J, Schuur J, Muir M, Calfee R, Raja A. Adult scaphoid fracture. _Acad Emerg Med_. 2014;21(2):101-121. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24673666)]\n"
		},
		{
			"slug": "sepsis-definitions",
			"title": "Sepsis Definitions",
			"authors": [
				"Jeremy Voros, MD"
			],
			"created": "2017/12/01",
			"updates": null,
			"categories": [
				"Critical Care"
			],
			"body": "\n\n\nIn 2015 the Centers for Medicare and Medicaid Services (CMS) adopted the Sepsis Bundle Project, which is a quality improvement project aimed at reducing sepsis mortality by increasing compliance with national guidelines. But the CMS definitions of sepsis, differ from those is prominent trials (ProCESS, ARISE, ProMISE), and have since diverged from the Surviving Sepsis Campaign definitions, which may be different from your hospital guidelines! This card will help you keep it all straight.\n\n## CMS Definitions\n\nThese are the definitions tied to reimbursement, and likely the measures used to establish your hospital guidelines.\n\n| CMS Term                                              | Definition                                                                                                                        |\n|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|\n| Sepsis                                                | 2 SIRS criteria _plus_ suspected infection                                                                                        |\n| <span style=\"white-space:nowrap\">Severe Sepsis</span> | Sepsis _plus_ 1 or more signs of organ dysfunction                                                                                |\n| <span style=\"white-space:nowrap\">Septic Shock</span>  | Severe sepsis _plus either_: sepsis-induced hypoperfusion persisting despite adequate fluid resuscitation _or_ lactate > 4 mmol/L | |\n\n### SIRS Criteria\n- Temp >38°C (100.4°F) or < 36°C (96.8°F)\n- Heart rate > 90\n- Respiratory rate > 20 or PaCO₂ < 32 mm Hg\n- WBC > 12,000/mm³, < 4,000/mm³, or > 10% bands\n\n### Organ Dysfunction Criteria\n- SBP < 90 mmHg, or MAP < 65 mmHg, or SBP decrease of > 40 mmHg from known baseline\n- Creatinine > 2.0 mg/dL, or urine output < 0.5 mL/kg/hour for 2 hours   \n- Bilirubin > 2 mg/dL (34.2 mmol/L)                                      \n- Platelet count < 100,000                                               \n- INR > 1.5 or aPTT > 60 sec                                             \n- Lactate > 2 mmol/L (18.0 mg/dL)                                        \n\n### Sepsis-induced Hypoperfusion Criteria\nAny one of:\n- SBP < 90 mmHg\n- MAP < 70 mmHg\n- SBP decrease of > 40 mmHg or > 2 standard deviations from normal for age or known baseline\n\n## Study Definitions\n\nThe 3 most recent and most prominent studies investigating resuscitation in septic shock were ProCESS, ARISE and ProMISE. They all share a common definition of septic shock, but do not directly address what CMS calls \"severe sepsis.\"\n\nTheir definition differs from CMS on the MAP cutoff for hypoperfusion. CMS sets a MAP cutoff of < 70 mmHg, while these studies use a MAP < 65 mmHg.\n\n| Study Term                                            | Definition                                                                                                                                                                                                                            |\n|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Sepsis                                                | _not defined_                                                                                                                                                                                                                         |\n| <span style=\"white-space:nowrap\">Severe Sepsis</span> | _not defined_                                                                                                                                                                                                                         |\n| <span style=\"white-space:nowrap\">Septic Shock</span>  | 2 SIRS criteria _plus either_: refractory hypotension (SBP <90 mmHg or MAP <65 mmHg, despite resuscitation with at least 1 liter of intravenous fluids within 60 minutes) or hyperlactatemia (blood lactate level, ≥ 4 mmol per liter |\n\n## Surviving Sepsis Campaign (SSC) and Sepsis-3\n\nThe latest 2016 guidelines from the prominent international working group are based on previously established definitions of sepsis, i.e. the CMS definitions. \n\nHowever also in 2016, the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) were published in the Journal of the American Medical Association. SSC has indicated their guidelines will begin transitioning to these new definitions.\n\nNotably, the **Sepsis-3** definitions do away with the term \"severe sepsis\".\n\n| <span style=\"white-space:nowrap\">Sepsis-3 Term</span> | Definition                                                                                                                                                      |\n|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Sepsis                                                | Life-threatening organ dysfunction caused by a dysregulated host response to infection                                                                          |\n| <span style=\"white-space:nowrap\">Severe Sepsis</span> | _No longer defined_                                                                                                                                             |\n| <span style=\"white-space:nowrap\">Septic Shock</span>  | Sepsis with persistent hypotension requiring vasopressors to maintain MAP ≥ 65 mm Hg and a serum lactate level > 2 mmol/L despite adequate volume resuscitation |\n\nOrgan dysfunction can be identified as an acute change in Sequential Organ Failure Assessment (SOFA) score ≥ 2 points due to the infection.\n\nPatients with suspected infection who are likely to have a prolonged ICU stay or to die in the hospital can be promptly identified at the bedside with qSOFA (quick SOFA).\n\n### qSOFA Criteria\nAny one of:\n- GCS < 14\n- SBP < 100 mmHg\n- Respiratory rate > 21\n\n## SOFA Score\n\nThe total Sequential Organ Failure Assessment (SOFA) score is the sum of scores for each organ system. A nice calculator can be found at [MDCalc](https://www.mdcalc.com/sequential-organ-failure-assessment-sofa-score).\n\n## References\n\n- Severe Sepsis and Septic Shock: Management Bundle. National Quality Forum website https://www.qualityforum.org/Projects/i-m/Infectious_Disease_Endorsement_Maintenance_2012/0500.aspx. Updated October 5, 2012. Accessed November 29, 2017.\n- Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-93. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24635773)]\n- Peake SL, Delaney A, Bailey M, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-506. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25272316)]\n- Mouncey PR, Osborn TM, Power GS, et al; ProMISe Trial Investigators: Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 372:1301–1311 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=25776532)]\n- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26903338)]\n"
		},
		{
			"slug": "septic-arthritis",
			"title": "Septic Arthritis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/06/11",
			"updates": null,
			"categories": [
				"Orthopedics",
				"Infectious Disease",
				"EBM"
			],
			"body": "\n\n\n## Nongonococcal Septic Arthritis\n\n- Destroys cartilage within days\n- Staph and strep are most likely isolates\n- 50% cases involve knee joint\n- No history or exam finding can rule out nongonococcal septic arthritis \n\n## Risk Factors\n\n| Factor                                    | Sensitivity % | Specificity % |          (+) LR |           (-) LR |\n| ----------------------------------------- | ------------: | ------------: | --------------: | ---------------: |\n| Age >&gt;0                                |            19 |            95 |   3.5 (1.8-7.0) | 0.86 (0.83-1.00) |\n| Diabetes Mellitus                         |            12 |            96 |   2.7 (1.0-6.9) | 0.93 (0.83-1.00) |\n| Rheumatoid arthritis                      |            68 |            73 |   2.5 (2.0-3.1) | 0.45 (0.32-0.72) |\n| Recent joint surgery                      |            24 |            96 |  6.9 (3.8-12.0) | 0.78 (0.64-0.94) |\n| Hip or knee prosthesis                    |            35 |            89 |   3.1 (2.0-4.9) | 0.73 (0.57-0.93) |\n| Skin infection                            |            32 |            88 |   2.8 (1.7-4.5) | 0.76 (0.60-0.96) |\n| Hip or knee prosthesis and skin infection |            24 |            98 | 15.0 (8.1-28.0) | 0.77 (0.64-0.93) |\n| HIV-1 infection                           |            79 |            50 |   1.7 (1.0-2.8) | 0.47 (0.25-0.90) |\n\n## Physical Exam\n\n| Factor | Sensitivity % | Specificity % |           (+) LR |        (-) LR |\n| ------ | ------------: | ------------: | ---------------: | ------------: |\n| Fever  |            46 |            31 | 0.67 (0.43-1.00) | 1.7 (1.0-3.0) |\n\n## Serum Laboratory Values\n\n| Factor                       | Sensitivity % | Specificity % |        (+) LR |           (-) LR |\n| ---------------------------- | ------------: | ------------: | ------------: | ---------------: |\n| Elevated WBC (&gt; 10 k/mcL) |            90 |            36 | 1.4 (1.1-1.8) | 0.28 (0.07-1.10) |\n| Elevated ESR (&gt; 30 mm/h)  |            95 |            29 | 1.3 (1.1-1.8) | 0.17 (0.20-1.30) |\n| Elevated CRP (&gt; 100 mg/L) |            77 |            53 | 1.6 (1.1-2.5) | 0.44 (0.24-0.82) |\n\n## Synovial Fluid Laboratory Values\n\n| Factor              | Sensitivity % | Specificity % |           (+) LR |           (-) LR |\n| ------------------- | ------------: | ------------: | ---------------: | ---------------: |\n| WBC &gt;100,000/hpf |            29 |            99 | 28.0 (12.0-66.0) | 0.71 (0.64-0.79) |\n| WBC &gt;50,000/hpf  |            62 |            92 |   7.7 (5.7-11.0) | 0.42 (0.34-0.51) |\n| WBC &gt;25,000/hpf  |            77 |            73 |    2.9 (2.5-3.4) | 0.32 (0.23-0.43) |\n| PMN &ge;90%         |            73 |            79 |    3.4 (2.8-4.2) | 0.34 (0.25-0.47) |\n\n## Fagan Nomogram\n\nLikelihood ratios\n\n- Positive LR = How strongly a positive result increase the odds of disease\n- Negative LR = How well a negative result decreases the odds of disease \n\n![Fagan nomogram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/septic-arthritis/image-1.png)\n\n## References\n\n- Carpenter CR, Schuur JD, Everett WW, Pines JM.Evidence-based diagnostics: adult septic arthritis. _Acad Emerg Med_. 2011 Aug;18(8):781-96. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=21843213)]\n- Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? _JAMA_. 2007 Apr 4;297(13):1478-88. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=17405973)]\n"
		},
		{
			"slug": "serotonin-syndrome",
			"title": "Serotonin Syndrome",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/01/06",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n## Classic triad of findings \n\n- Altered mental status\n- Autonomic instability\n- Neuromuscular hyperactivity\n\n## Medications contributing to serotonin syndrome\n\n**Amphetamines and derivatives**\n\n**Analgesics**\n\n- <span class=\"drug\">Cyclobenzaprine</span>\n- <span class=\"drug\">Fentanyl</span>\n- <span class=\"drug\">Meperidine</span>\n- <span class=\"drug\">Tramadol</span>\n\n**Antidepressants/ mood stabilizers**\n\n- <span class=\"drug\">Buspirone</span>\n- <span class=\"drug\">Lithium</span>\n- <span class=\"drug\">MOA-I</span>\n- <span class=\"drug\">SSRIs</span>\n- <span class=\"drug\">SNRIs </span>\n- <span class=\"drug\">Serotonin 2A-R blockers</span>\n- <span class=\"drug\">St. John’s wort</span>\n- <span class=\"drug\">Tricyclic antidepressants</span>\n\n**Antiemetics**\n\n- <span class=\"drug\">Metoclopramide </span>\n- <span class=\"drug\">Ondansetron</span>\n\n**Antimigraine medications**\n\n- <span class=\"drug\">Carbamazepine </span>\n- <span class=\"drug\">Ergots </span>\n- <span class=\"drug\">Triptans</span>\n- <span class=\"drug\">Valproic acid</span>\n\n**Miscellaneous**\n\n- <span class=\"drug\">Cocaine</span>\n- <span class=\"drug\">Dextromethorphan</span>\n- <span class=\"drug\">Linezolid</span>\n- <span class=\"drug\">L-tryptophan</span>\n- <span class=\"drug\">5-hydroxytryptophan</span>\n\n**Tip:** Be especially aware of adding drug that inhibits cytochrome P450 2D6 +/- 3A4 (eg. erythromycin) to someone on SSRI.\n\n## Hunter's Decision Rule \n\nSensitivity 84%, Specificity 97%\n\n![Hunter's decision Rule diagram](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/serotonin-syndrome/image-1.png)\n\n## Sternbach's criteria\n\nNeed 3 of 10 symptoms: (Sensitivity 75%, specificity 96%)\n\n- Agitation or restlessness\n- Diaphoresis\n- Diarrhea\n- Hyperreflexia\n- Incoordination or ataxia\n- Confusion\n- Hypomania\n- Myoclonus\n- Shivering\n- Tremor \n\n## Differential Diagnosis\n\n- Anticholinergic syndrome\n- Neuroleptic malignant syndrome\n- Malignant hyperthermia \n\n![Sternbach's criteria table](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/serotonin-syndrome/image-2.png)\n\nTable adapted from [Boyer EW, Shannon M. NEJM 2005](http://www.ncbi.nlm.nih.gov/pubmed/15784664)\n\n## Treatment \n\nUsually supportive (benzodiazepines), although can give <span class=\"drug\">cyproheptadine</span> (serotonin 2A antagonist) \n\n## References\n\n- Boyer EW, Shannon M. The serotonin syndrome. _N Engl J Med_. 2005 Mar 17;352(11):1112-20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15784664)]\n- Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. _Am Fam Physician_. 2010 May 1;81(9):1139-42. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20433130)]\n"
		},
		{
			"slug": "shock-rush-exams",
			"title": "Causes of Elevated Lactate",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2009/12/22",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology"
			],
			"body": "\n\n\n## High lactate levels associated with worse prognosis in medical and trauma patients\n\n- Level >2 mmol/L is abnormal\n- Level >4 mmol/L suggests tissue hypoperfusion\n\n## Causes for elevation in lactate that is NOT related to shock\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong> Pathology</strong></th>\n<th><strong>Causes</strong> </th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td><br />\nInadequate <br />\nO<sub>2</sub> delivery</td>\n<td><ul>\n<li>Severe dehydration</li>\n<li>Blood loss</li>\n<li>Severe anemia</li>\n<li>Hypoxemia</li>\n<li>CO prolonged exposure</li>\n<li>Trauma</li>\n</ul></td>\n</tr>\n<tr class=\"even\">\n<td><br />\nDisproportionate<br />\nO<sub>2</sub> demand<br />\n</td>\n<td><ul>\n<li>Hyperthermia</li>\n<li>Shivering</li>\n<li>Seizure</li>\n<li>Strenuous exercise<br />\n</li>\n</ul></td>\n</tr>\n<tr class=\"odd\">\n<td><br />\nInadequate<br />\nO2 use<br />\n</td>\n<td>SIRS<br />\n<li>DM</li>\n<li>TPN</li>\n<li>HIV infection</li>\n<li><b>Medications:</b></li>\n<ul>\n<li>Metformin</li>\n<li>Salicyclate</li>\n<li>Antiretrovirals</li>\n<li>INH</li>\n<li>Propofol</li>\n<li>Cyanide</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## References\n\n- Strehlow MC.Early identification of shock in critically ill patients. Emerg Med Clin North Am. 2010 Feb;28(1):57-66, vii. doi: 10.1016/j.emc.2009.09.006. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19945598)]\n- Perera P et al. Rapid Ultrasound in SHock in the Evaluation of the Critically lll. EMCNA 2010; 28: 29-56. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19945597)]\n"
		},
		{
			"slug": "shoulder-exam",
			"title": "Shoulder Exam Provocative Testing",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/01/28",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n## Supraspinatus muscle injury\n\n### Jobe's Test (\"Empty Can\" Test)\n\n1. Position arm in scapular plane and point thumb down as if emptying out can.\n2. Examiner pushes down on arm.\n\n![Jobe's Test (\"Empty Can\" Test)](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-1.png)\n\n### Hawkin's Test\n1. Position arm in throwing position and flex forward 30 degrees.\n2. Examiner internally rotates humerus.\n\n![Hawkin's Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-2.png)      \n\n### Drop Arm Test\n\n1. Position patient's arm fully abducted so hand is over the head.\n2. Ask patient to slowly adduct arm to their side.\n3. If supraspinatus muscle is torn, at &lt; 90 degrees the arm will suddenly drop.\n\n![Drop Arm Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-3.png)\n\n## Infraspinatus muscle injury\n\n90% of shoulder external rotation uses infraspinatus muscle. \n\n### Infraspinatus scapular rotation test\n\nPatient has pain when externally rotates shoulder against resistance (with elbow in 90 degree flexion)\n\n![Infraspinatus scapular rotation test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-4.png)\n\n## Subscapularis muscle injury\n\n### Lift-off test\n\n1. Position patient's hand behind the back of waist level with palm facing out\n2. Ask patient to move arm away from body against examiner resistance\n\n## Rotator cuff subacrominal impingement\n\n### Neer Test\n\n1. With the arm fully pronated, the examiner raises the arm above the patient's head in forward flexion movement\n2. Stabilize the scapula to prevent scapulothoracic motion\n\n![Neer Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-5.png)\n\n## Labral tear\n\n### Crank Test\n\n1. Position patient's arm in 90 degree abduction and elbow flexion\n2. Examiner pushes humerus into glenohumeral joint while internally and externally rotating arm\n\n![Crank Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-6.png) \n\n### O'Brien Test\n\n1. Position patient's shoulder in 90 degree flexion, elbow extended, and 14 degrees adducted (medial to sagittal plane)\n2. Point thumb down\n3. Examiner stand behind pateint and applies downward force\n4. Repeat with arm supinated (thumb up)\n5. If pain is elicited in first maneuver only, then suggests labral tear (if pain \"inside\" shoulder) or AC joint abnormality (if pain \"on top\" of shoulder)\n\n![O'Brien Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-7.png)\n\n## Bicep muscle injury\n\n### Yergason Test\n\n1. Position patient's elbow at 90 degrees with thumb up\n2. Have the patient supinate and flex elbow against examiner's resistance (holding at wrist)\n\n![Yergason Test](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/shoulder-exam/image-8.png)\n\n## References\n\n- Levine W. Shoulder Exam. Orthobullets. Available at: http://www.orthobullets.com/sports/3037/shoulder-exam. Accessed August 1, 2017.\n"
		},
		{
			"slug": "skin-soft-tissue-ultrasound",
			"title": "Skin and Soft Tissue Ultrasound",
			"authors": [
				"Alissa Genthon, MD",
				"Patricia Henwood, MD",
				"Mike Stone, MD"
			],
			"created": "2015/01/07",
			"updates": null,
			"categories": [
				"Ultrasound",
				"Radiology"
			],
			"body": "\n\n\n**Goals:** Use ultrasound to evaluate the skin or soft tissue to identify and differentiate various types of pathology.\n\n**Transducer:** High frequency linear transducer. Consider low frequency curvilinear transducer for deeper structures. Use a “superficial” or similar preset.\n\n**Windows:** Image the area of interest in both longitudinal and transverse planes.\nScan completely through the affected area to define borders.\nUse an adjacent or contralateral (unaffected) area as a comparison.\n\n## Normal Skin and Soft Tissue\n\n**Hypodermis:** Varying thickness, less echogenic (epidermis/dermis can be difficult to distinguish)\n\n**Muscle:** Hypoechoic with hyperechoic fibro-fatty septae and surrounding fascia\n\n**Lymph nodes**: Hypoechoic oval/kidney bean shape cortex with fatty echogenic hilum (vascular)\n\n**Subcutaneous fat**: Hypoechoic with thin echogenic septations\n\n**Fascia:** Hyperechoic linear stripes\n\n**Bone**: Hyperechoic linear structure parallel to skin surface with posterior shadowing\n\n## Abscess\n\n- Can vary in appearance but typically hypo- or anechoic areas with a regular or irregular border.\n- Contents may be seen to \"swirl” or “squish” when purulent material moves with compression by the transducer.\n- If anechoic and regular circular border, may be difficult to distinguish from a cyst.\n\n![Subcutaneous abscess characterized by a mixed echogenicity fluid collection with irregular borders](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/skin-soft-tissue-ultrasound/image-1.png)\n\nFigure 1: Subcutaneous abscess characterized by a mixed echogenicity **fluid collection with irregular borders** (yellow arrows)\n\n## Cellulitis\n\nAppears as \"cobblestoning,\" caused by interstitial edema separating adipose tissue.\n\n![Cellulitis](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/skin-soft-tissue-ultrasound/image-2.png)\n\nFigure 2: Cellulitis\n\n## Foreign Body\n\n- Will vary in appearance based on composition\n- May exhibit the \"halo sign\" which appears as hypoechoic ring surrounding a hyperechoic foreign body (generally only present in foreign bodies of >24 hours)\n\n![A subcutaneous wooden foreign body (red arrows) is identified with deep shadowing](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/skin-soft-tissue-ultrasound/image-3.png)\n\nFigure 3: A subcutaneous **wooden foreign body** (red arrows) is identified with **deep shadowing** (yellow arrows)\n\n## Struggling with the Exam?\n\n### Is your preset set correctly?\n\n- Make sure you are using a “superficial” preset. A vascular or vascular access preset has a very high contrast (low dynamic range) & can make it difficult to identify subtle skin and soft tissue findings.\n\n### Looking for abscess?\n\n- Other structures may be mistaken for abscess including lymph nodes, solid masses, hematoma, deep venous thrombosis, or cyst. Be sure to slide all the way through the structure in 2 planes to define its borders.\n\n### Looking for foreign body?\n\n- Other hyperechoic structures may be mistaken for a foreign body including tendons, fascia, etc.\n\n### Is the area is too painful to apply a probe?\n\n- Try a water bath or heap up a generous pile of ultrasound gel to improve image acquisition and decrease the discomfort of the exam.\n\n## Common Errors\n\nBe sure to familiarize yourself with normal anatomy when performing exams to avoid mistaking artifacts and normal structures for pathology.\n\nFine movements and control of probe is necessary for accuracy and to avoid slipping off the area of interest when performing with soft tissue ultrasound. Consider resting the ulnar aspect of your hand or your 5th digit on the patient adjacent to the area of interest in order to maintain appropriate transducer position.\n\n## References\n\n- Tayal VS, Hasan N, Norton HJ, Tomaszewski CA. The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. Acad Emerg Med. 2006;13(4):384-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16531602)]\n"
		},
		{
			"slug": "spinal-epidural-abscess",
			"title": "Spinal Epidural Abscess",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/08/05",
			"updates": null,
			"categories": [
				"Infectious Disease",
				"EBM"
			],
			"body": "\n\n\n**Classic triad** (back pain + fever + neuro deficits) found in only 2-13% of SEA pts. [1](https://www.ncbi.nlm.nih.gov/pubmed/?term=15028325),[3](https://www.ncbi.nlm.nih.gov/pubmed/?term=21417700)\n\n## ESR test\n\n- If ESR >20, sensitivity=90% [1](https://www.ncbi.nlm.nih.gov/pubmed/?term=15028325).\n- If ESR >30, sensitivity=81% [2].\n\n## Diagnostic Guideline\n\n![Spinal epidural abscess guideline flowchart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/spinal-epidural-abscess/image-1.png)\nImage adapted from ([Davis et al., 2011](https://www.ncbi.nlm.nih.gov/pubmed/?term=21417700))\n\n## Study design\n\n- Prospective cohort analysis of clinical decision guidelines to diagnose SEA \n- n = 86 patients (55 in 9-year control group, 31 in 5-year study group)\n\n## Outcome measures\n\n1. Diagnostic delays (multiple ED visits or admission to nonsurgical service without diagnosis of SEA\n2. Presence of motor deficits at time of diagnosis\n\n## Risk factors for SEA used in this study\n\n- Diabetes\n- IVDU history\n- Chronic liver or kidney disease\n- Recent spine procedure\n- Indwelling spinal hardware\n- Recent spine fracture\n- Indwelling vascular catheter\n- Immunocompromised\n- Other site of infection\n\n## Limitation\n\n1/3 of physicians did NOT follow guidelines with &ge;1 risk factor esp in setting of trauma and non-midline spine pain\n\n## Results \n\n- **Diagnostic delays:** 84% without guidelines, 10% with guidelines (OR = 48)\n- **Motor deficits at diagnosis:** 82% without guidelines, 19% with guidelines (OR = 19)\n- **ESR:** Sensitivity = 100% and specificity = 67% if &ge;1 SEA risk factor\n- **ROC curve** better with ESR (0.96) than CRP (0.81)\n\n## References\n\n- Sidman RD, Delorie RC, Spitalnic SJ, Sucov A: Screening tests for spinal epidural abscess lack the sensitivity required to rule it out, Acad Emerg Med (abstract), 9(5):413-4, 2002.\n- Davis DP, Salazar A, Chan TC, Vilke GM. Prospective evaluation of a clinical decision guideline to diagnose spinal epidural abscess in patients who present to the emergency department with spine pain J Neurosurg Spine. 2011 Jun;14(6):765-70. doi: 10.3171/2011.1.SPINE1091. Epub 2011 Mar 18. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21417700)]\n- Davis DP, Wold RM, Patel RJ, Tran AJ, Tokhi RN, Chan TC, Vilke GM. The clinical presentation and impact of diagnostic delays on emergency department patients with spinal epidural abscess. J Emerg Med. 2004 Apr;26(3):285-91. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=15028325)]\n"
		},
		{
			"slug": "strep-pharyngitis",
			"title": "Streptococcal Pharyngitis",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/07/30",
			"updates": null,
			"categories": [
				"ENT",
				"Infectious Disease",
				"EBM"
			],
			"body": "\n\n\n- **Most cases of pharyngitis:** Viral\n- **Most cases of bacterial pharyngitis:** Group A beta-hemolytic streptococcus\n- **Incidence:** 15-30% (children) and 5-20% (adults) \n- **Peak season:**  late winter/ early spring\n- **Transmission:** respiratory secretions\n- **Incubation period:**  24-72 hours\n- Antibiotics shorten symptoms by 16 hours\n\n## Modified Centor Scoring\n\n| Criteria                          | Points |\n| --------------------------------- | -----: |\n| Absence of cough                  |      1 |\n| Swollen and tender cervical nodes |      1 |\n| Temp &gt;100.4F (38C)             |      1 |\n| Tonsillar exudates or swelling    |      1 |\n| Patient age:                      |        |\n| 3-14 yr                           |      1 |\n| 15-44 yr                          |      0 |\n| &ge; 45 yr                        |     -1 |\n\n| Score | Incidence of GABHS | Plan                            |\n| ----: | -----------------: | ------------------------------- |\n| &le;0 |             1-2.5% | No testing, no antibiotics      |\n|     1 |              5-10% | No testing, no antibiotics      |\n|     2 |             11-17% | Do rapid antigen test           |\n|     3 |             28-35% | Do rapid antigen test           |\n| &ge;4 |             51-53% | No testing, empiric antibiotics |\n\n## National Organization Guidelines\n\n### How to screen for strep pharyngitis\n\n| Group            | Recommendations                                                                           |\n| ---------------- | ----------------------------------------------------------------------------------------- |\n| **ACP/CDC/AAFP** | Use Centor criteria to decide testing and antibiotics                                     |\n| **AAP**          | Use clinical & epidemiological findings to assess risk for GABHS (includes Centor scores) |\n| **IDSA**         | Use clinical & epidemiological findings to assess risk for GABHS (includes Centor scores) |\n\n### Diagnostic Test\n\n| Group            | Recommendations                                               |\n| ---------------- | ------------------------------------------------------------- |\n| **ACP/CDC/AAFP** | Rapid antigen test only for Centor scores of 2 or 3 only      |\n| **AAP**          | Rapid antigen test or throat culture for ALL patients at risk |\n| **IDSA**         | Rapid antigen test or throat culture for ALL patients at risk |\n\n### Backup culture needed if rapid Ag test is negative?\n\n| Group            | Recommendations              |\n| ---------------- | ---------------------------- |\n| **ACP/CDC/AAFP** | Adults: No; Pediatrics: Yes  |\n| **AAP**          | Adults: N/A; Pediatrics: Yes |\n| **IDSA**         | Adults: No; Pediatrics: Yes  |\n\n### Who gets antibiotics?\n\n| Group            | Recommendations                                                                          |\n| ---------------- | ---------------------------------------------------------------------------------------- |\n| **ACP/CDC/AAFP** | Empiric abx for Centor score of &ge; 4, or those with positive rapid antigen test result |\n| **AAP**          | Positive rapid antigen test or throat culture                                            |\n| **IDSA**         | Positive rapid antigen test or throat culture                                            |\n\n### Which antibiotic?\n\n| Group            | Recommendations                                                                                                                                  |\n| ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------ |\n| **ACP/CDC/AAFP** | Oral <span class=\"drug\">penicillin</span> V, IM <span class=\"drug\">penicillin</span> G benzathine, or oral <span class=\"drug\">amoxacillin</span> |\n| **AAP**          | Oral <span class=\"drug\">penicillin</span> V, IM <span class=\"drug\">penicillin</span> G benzathine, or oral <span class=\"drug\">amoxacillin</span> |\n| **IDSA**         | Oral <span class=\"drug\">penicillin</span> V, IM <span class=\"drug\">penicillin</span> G benzathine, or oral <span class=\"drug\">amoxacillin</span> |\n\n### Which antibiotic for PCN allergy?\n\n| Group            | Recommendations                                                         |\n| ---------------- | ----------------------------------------------------------------------- |\n| **ACP/CDC/AAFP** | Oral <span class=\"drug\">erythromycin</span>, or first-gen cephalosporin |\n| **AAP**          | Oral <span class=\"drug\">erythromycin</span>, or first-gen cephalosporin |\n| **IDSA**         | Oral <span class=\"drug\">erythromycin</span>, or first-gen cephalosporin |\n\n- ACP = American College of Physicians\n- CDC = Center for Disease Control\n- AAFP = American Academy of Family Physicians\n- AAP = American Academy of Pediatrics\n- IDSA = Infectious Disease Society of America \n\n## References\n\n- Choby BA.Diagnosis and treatment of streptococcal pharyngitis.Am Fam Physician. 2009 Mar 1;79(5):383-90. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=19275067)]\n"
		},
		{
			"slug": "subarachnoid-hemorrhage",
			"title": "Management of Aneurysmal Subarachnoid Hemorrhage",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/12/17",
			"updates": null,
			"categories": [
				"Neurology"
			],
			"body": "\n\n\n1. Control rebleeding: 4% incidence in first 24 hrs of bleed\n2. Blood pressure (BP) control:\n\n- No evidence for a target BP\n\n3. “Triple H therapy” to treat vasospasm: Hypervolemia, hypertension, hemodilution\n4. Ventriculostomy, if hydrocephalus (occurs in 33-50% of SAH patients) \n5. <span class=\"drug\">Nimodipine</span>: Vasospasm and delayed cerebral ischemia: Usually occurs 7-10 days after bleed. \n6. Definitive treatment: Microvascular aneurysm clipping or endovascular coil embolization\n\n## Grading Scales\n\n**Hunt-Hess Scale** (subjective and poor inter-rater variability) \n\n|  **Grade**  | **Description**                                                         |\n| :---------: | ----------------------------------------------------------------------- |\n|      0      | Unruptured                                                              |\n|      1      | Asymptomatic, or mild H/A and slight nuchal rigidity                    |\n|      1a     | Acute meningeal/brain reaction, but with fixed neuro deficit            |\n|      2      | Cranial nerve palsy, moderate to severe headache, or nuchal rigidity    |\n|      3      | Mild focal deficit, lethargy, or confusion                              |\n|      4      | Stupor, moderate to severe hemiparesis, or clearly decerebrate rigidity |\n|      5      | Deep coma, decerebrate rigidity, moribund appearance                    |\n\nIncrease by 1 grade for serious system disease, or severe vasospasm on arteriography\n\n**World Federation of Neurosurgical Societies** (WFNS) \n\n|  **WFNS Grade** | **Glasgow Coma Score**  |  **Major Focal Deficit** |\n| :-------------: | :---------------------: | :----------------------: |\n|  0 (unruptured) |          -----          |          ------          |\n|        1        |            15           |          Absent          |\n|        2        |          13-14          |          Absent          |\n|        3        |          13-14          |          Present         |\n|        4        |           7-12          |      Present/absent      |\n|        5        |           3-6           |      Present/absent      |\n\n## References\n\n- Edlow JA, Malek AM, Ogilvy CS. Aneurysmal subarachnoid hemorrhage: update for emergency physicians. J Emerg Med. 2008 Apr;34(3):237-51. Epub 2007 Dec 26. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=18155383)]\n"
		},
		{
			"slug": "supracondylar-fracture-extension",
			"title": "Elbow Injuries - Supracondylar Fractures Extension",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Type 1 through 3 supracondylar extension fractures](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/supracondylar-fracture-extension/image-1.png)\n\n## X-ray views\n\n- **Elbow:** AP and lateral.\n- **Forearm:** AP and lateral.\n\nAssess for indirect signs of fx on lateral elbow view:\n- Sail sign or posterior fat pad.\n- Anterior humeral line no longer intersects middle third of capitellum.\n\n## Acute Management\n\nLong arm posterior splint in position of comfort.\n\n## Follow Up Timing\n\n**Non-displaced fracture:** Urgent orthopedic follow-up in &le;2 days.\n**Displaced fracture:** Hospital admission for serial neurovascular exams and operative stabilization.\n\n## Notes\n\n### Classifications\n\n- **Type I:** Non-displaced/\n- **Type II:** Displaced with intact posterior cortex.\n- **Type III:** Complete displacement (both anterior and posterior cortex).\n\n### Complications\n\n- Median (anterior interosseous nerve branch), ulnar, or radial nerve injury.\n- Malunion causing deformity, Volkmann contracture.\n\nExtension more common in children.\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/pediatric_supracondylar_fractures_of_the_humerus. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/pediatrics/4007/supracondylar-fracture--pediatric. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/supracondylar-fracture. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Dept of Orthopedics.\n"
		},
		{
			"slug": "supracondylar-fracture-flexion",
			"title": "Elbow Injuries - Supracondylar Fracture Flexion",
			"authors": [
				"Melody Glenn, MD",
				"Andrew Little, DO",
				"Mary Haas, MD"
			],
			"created": "2016/12/12",
			"updates": null,
			"categories": [
				"Orthopedics"
			],
			"body": "\n\n\n![Types 1 through 3 supracondylar flexion fractures](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/supracondylar-fracture-flexion/image-1.png)\n\n## X-ray Views\n\n**Elbow:** AP and lateral.\n**Forearm:** AP and lateral.\n\n## Acute Management\n\nLong arm posterior splint in position of comfort.\n\n## Follow-up Timing\n\n**Type I:** Orthopedic follow up in &le;7 days\n**Displaced fracture:** Consult orthopedicsurgeon to discuss, because no evidence on best treatment plan for adults and children (closed reduction plus immobilization vs operative).\n\n## Notes\n\n### Classifications\n- **Type I:** Non-displaced.\n- **Type II:** Displaced with intact anterior cortex.\n- **Type III:** Complete displacement (both anterior and posterior cortex).\n\nFlexion type (compared to extension) more likely to need operative repair in children.\n\n**Complications:** Ulnar nerve entrapment and injury.\n\nLess common overall, more common in adults.\n\n## References\n\n- Wheeless’ Textbook of Orthopaedics. Available at: http://www.wheelessonline.com/ortho/pediatric_supracondylar_fractures_of_the_humerus. Accessed August 1, 2017.\n- Orthobullets. Available at: http://www.orthobullets.com/pediatrics/4007/supracondylar-fracture--pediatric. Accessed August 1, 2017.\n- Radiopaedia. Available at: http://radiopaedia.org/articles/supracondylar-fracture. Accessed August 1, 2017.\n- General Guidelines For Management for Orthopedic Injuries card by the Nationwide Children’s Hospital, Dept of Orthopedics.\n"
		},
		{
			"slug": "supratherapeutic-INR",
			"title": "Supratherapeutic INR",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2012/08/10",
			"updates": null,
			"categories": [
				"Hematology and Oncology"
			],
			"body": "\n\n\n**ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)**\n\n|         INR | Therapeutic Intervention                                                                                                                                                                                                                      |\n| ----------: | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n|      &le;10 | **_If no bleeding:_** Hold <span class=\"drug\">coumadin</span>. Restart when INR is therapeutic                                                                                                                                                |\n|      &gt;10 | **_If no bleeding:_** Hold <span class=\"drug\">coumadin</span>. Give oral <span class=\"drug\">vitamin K</span> (2.5 mg)                                                                                                                         |\n| Major bleed | Hold <span class=\"drug\">coumadin</span>. Give <span class=\"drug\">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class=\"drug\">PCC</span> (<span class=\"drug\">FFP</span> not of added benefit with 4-factor <span class=\"drug\">PCC</span>) |\n\n**Higher bleeding risk associated with coumadin**\n\n- NSAIDS: non-selective and COX-2 selective\n- Antiplatelet agents: <span class=\"drug\">aspirin</span>, <span class=\"drug\">clopidogrel</span>\n- <span class=\"drug\">Clotrimoxazole</span>\n- Antibiotics (especially <span class=\"drug\">fluoroquinolones</span>)\n\n**Pearl**\n\n- Risk of intracranial hemorrhage doubles for every 1-point increase in INR\n\n## Causes for supratherapeutic INR >6\n\n[Hylek et al. JAMA 1998 study](https://www.ncbi.nlm.nih.gov/pubmed/9496982)\n\n- Retrospective case-control study of patients with INR >6\n- Enrolled 93 cases, 196 controls\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong>Risk Factor / Explanation</strong></th>\n<th><strong>Odds Ratio</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td>Advanced malignancy</td>\n<td>16.4</td>\n</tr>\n<tr class=\"even\">\n<td><strong></strong>\n<p><span class=\"drug\">Acetaminophen intake</span><br/> • 4.5-9.1 g/wk<br />\n• &gt; 9.1 g/wk</p></td>\n<td>6.8<br />\n10<br /></td>\n</tr>\n<tr class=\"odd\">\n<td>New medication</td>\n<td>8.5</td>\n</tr>\n<tr class=\"even\">\n<td>Excess <span class=\"drug\">coumadin</span> intake</td>\n<td>8.1</td>\n</tr>\n<tr class=\"odd\">\n<td>Decreased oral intake</td>\n<td>3.6</td>\n</tr>\n<tr class=\"even\">\n<td>Acute diarrheal illness</td>\n<td>3.5</td>\n</tr>\n<tr class=\"odd\">\n<td>Vitamin K intake</td>\n<td>0.7</td>\n</tr>\n<tr class=\"even\">\n<td>Alcohol use<br />\n(1 drink QOD-2 drinks daily)</td>\n<td>0.2</td>\n</tr>\n</tbody>\n</table>\n\n## References\n\n- Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9496982)]\n- Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22315259)]\n"
		},
		{
			"slug": "suture-materials",
			"title": "Suture Materials",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/01/07",
			"updates": null,
			"categories": [
				"Surgery"
			],
			"body": "\n\n\nUndesired tissue reactivity is greater with:\n\n- Multifilament (compared to monofilament)\n- Larger suture gauge\n- Natural material (compared to synthetic) \n\n## Absorbable Sutures\n\n| **Type**           | **Effective Support** | **Complete Absorption** | **Comments**                                                                |\n| ------------------ | :-------------------: | :---------------------: | --------------------------------------------------------------------------- |\n| Surgical Gut       |        8-9 days       |         30 days         | Rarely used; high tissue reactivity                                         |\n| Chromic Gut        |       10-21 days      |        > 90 days        | Gut treated with chromium to decrease tissue reactivity and slow absorption |\n| Fast Absorbing Gut |        5-7 days       |        14-28 days       | Gut treated with heat to speed absorption                                   |\n| Polyglac (Vicryl)  |        21 days        |         90 days         | Less reactive than gut; synthetic                                           |\n| Vicryl Rapide      |        10 days        |         42 days         | Gamma-irradiated to speed absorption                                        |\n\n## Non-Absorbable Sutures\n\n| **Type**                | **Tensile Strength** | **Tissue Reactivity** | **Comments**                                                                      |\n| ----------------------- | :------------------: | :-------------------: | --------------------------------------------------------------------------------- |\n| Silk                    |          Low         |          High         | Multifilament, pliable                                                            |\n| Nylon (Ethilon)         |         High         |          Low          | Monofilament, stiff                                                               |\n| Polypropylene (Prolene) |       Moderate       |        Very low       | Monofilament, less knot security because slippery (may need  extra throw in knot) |\n\n## Suture Removal Timeframes\n\n| **Body Part**            | **# of Days After Suturing** |\n| ------------------------ | :--------------------------: |\n| Face                     |              3-5             |\n| Scalp                    |               7              |\n| Chest, extremities       |             7-10             |\n| High tension areas, back |             10-14            |\n\n## References\n\n- Taylor B et al. Basic plastic surgery techniques and principles: Choosing the right suture material. Student BMJ, 11: 2003. [[Source](http://www.docstoc.com/docs/81946959/Basic-plastic-surgery-techniques-and-principles-Choosing-the)]\n- Tajirian AL, Goldberg DJ.A review of sutures and other skin closure materials. J Cosmet Laser Ther. 2010 Dec;12(6):296-302 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=21142740)]\n"
		},
		{
			"slug": "testicular-ultrasound",
			"title": "Testicular Ultrasound Assessment",
			"authors": [
				"Matthew Dawson, MD",
				"Mike Stone, MD"
			],
			"created": "2015/01/21",
			"updates": null,
			"categories": [
				"Genitourinary",
				"Radiology",
				"Ultrasound"
			],
			"body": "\n\n\n**Goals:** Evaluate for testicular torsion, orchitis, and epididymitis\n\n**Transducer:** High-frequency linear transducer\n\n**Pt Position:**    Frog-leg position with sling of towels underneath scrotum\n\n**Windows:**\n\n1. **Transverse** **survey** of each testicle: Directional indicator oriented to patient’s right\n2. **Longitudinal** **survey** of each testicle: Directional indicator oriented to patient’s head. The epididymis will be located posterolaterally to the testicle\n3. **Doppler**: Color flow or Power Doppler of each testicle looking for flow and comparing each side. Begin with the unaffected testicle and adjust color gain to have a small but visible amount of flow. Then move to the affected testicle and compare flow with the same settings. Comparison of both sides is critical.\n4. **Single midline view** of both testicles side by side if possible, both with and without color for comparison.\n\n## Color and Flow Comparison\n\n- Always compare flow relative to unaffected testicle.\n- Decreased or absent flow in the affected testicle suggests **torsion**\n\n![Left testicular torsion - midline transverse view demonstrating absent flow](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/testicular-ultrasound/image-1.png)\n\nFigure 1: Left testicular torsion - midline transverse view demonstrating absent flow\n\n## Color and Flow Comparison (cont’d)\n\n- Increased flow in the affected testicle or epididymis suggests orchitis and/or epididymitis (or a recently detorsed testicle if clinically consistent). \n- Isolated orchitis is rare, **epididymitis** most common diagnosis.\n\n![Acute epididymitis. Longitudinal view demonstrating increased color flow in the body of the epididymis](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/testicular-ultrasound/image-2.png)\n\nFigure 2: Acute epididymitis - longitudinal view demonstrating increased color flow in the body of the epididymis\n\n## Advanced Assessment\n\nIf unclear, consider pulse wave Doppler to identify both arterial and venous flow as early torsion will have arterial flow but absent venous flow.\n\nTorsion cannot be excluded with ultrasound, although a normal comprehensive spectral Doppler assessment makes torsion very unlikely. Normal testicular resistive indices range from 0.5 to 0.8.\n\n## References\n\n- Blaivas M, Sierzenski P. Emergency ultrasonography in the evaluation of the acute scrotum. Acad Emerg Med. 2001;8(1):85-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11136158)]\n- Blaivas M, Sierzenski P, Lambert M. Emergency evaluation of patients presenting with acute scrotum using bedside ultrasonography. Acad Emerg Med. 2001;8(1):90-3. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11136159)]\n"
		},
		{
			"slug": "toxidrome-vitals",
			"title": "Toxidromes by Vital Signs",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/11/19",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n## Bradycardia\n\n**PACED**\n\n- **P**ropranolol/ beta-blockers, **P**oppies (opiates), **P**ropoxyphene,**P**hysostigmine \n- **A**nticholinesterases, **A**ntiarrhythmics\n- **C**lonidine, **C**alcium channel blockers \n- **E**thanol or other alcohols\n- **D**igoxin, digitalis\n\n## Tachycardia\n\n**FAST**\n\n- **F**ree base or other cocaine forms, **F**reon \n- **A**nticholinergics, **A**ntihistamine, **A**ntipsychotic, **A**mphetamines, **A**lcohol withdrawal\n- **S**ympathomimentics, **S**olvent use, **S**trychnine \n- **T**heophylline, **T**CAs, **T**hyroid hormones\n\n## Hypothermia\n\n**COOLS**\n\n- **C**arbon monoxide\n- **O**pioids\n- **O**ral hypoglycemics and insulin\n- **L**iquor (alcohol)\n- **S**edative-hypnotics \n\n## Hyperthermia\n\n**NASA**\n\n- **N**euroleptic malignant syndrome, **N**icotine\n- **A**ntihistamine, **A**lcohol withdrawal\n- **S**alicylates, **S**ympathomimetics, **S**erotonin syndrome\n- **A**nticholinergics, **A**ntidepressants, **A**ntipsychotics \n\n## Hypotension\n\n**CRASH**\n\n- **C**lonidine, **C**alcium channel blockers\n- **R**odenticides (has arsenic, cyanide)\n- **A**ntidepressants, **A**minophylline, **A**ntihypertensives\n- **S**edative-hypnotics\n- **H**eroin or other opiate \n\n## Hypertension\n\n**CT SCAN**\n\n- **C**ocaine\n- **T**hyroid supplements\n- **S**ympathomimetics\n- **C**affeine\n- **A**nticholinergics, **A**mphetamines\n- **N**icotine \n\n## Tachypnea\n\n**PANT**\n\n- **P**CP, **P**araquat, **P**neumonitis (chemical), **P**hosgene \n- **A**SA and other salicylates\n- **N**oncardiogenic pulmonary edema, **N**erve agents \n- **T**oxin-mediated metabolic acidosis \n\n## Bradypnea\n\n**SLOW**\n\n- **S**edative-hypnotics\n- **L**iquor (alcohols)\n- **O**pioids\n- **W**eed (marijuana) \n\n## References\n\n- Erickson TB, Thompson TM, Lu JJ.The approach to the patient with an unknown overdose. Emerg Med Clin North Am. 2007 May;25(2):249-81 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=17482020)]\n"
		},
		{
			"slug": "tpa-code-dose",
			"title": "TPA Code Dose",
			"authors": [
				"Bryan D. Hayes, PharmD"
			],
			"created": "2013/05/14",
			"updates": null,
			"categories": [
				"Critical Care"
			],
			"body": "\n\n\n**Clinical Question:** In the rare situation where fibrinolytics may be indicated in cardiac arrest from PE or Acute Myocardial Infarction (AMI), what’s the dose?\n\n**Take Home Points**\n\n- The dose of <span class=\"drug\">tPA</span> in cardiac arrest is somewhere between **50-100 mg** given as a bolus +/- infusion.\n- According to the [2010 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care](http://circ.ahajournals.org/content/122/18_suppl_3/S729.full), “Ongoing CPR is not an absolute contraindication for fibrinolysis.”\n- Some studies suggest allowing 15 minutes of CPR for drug to work.\n- Evidence is ‘best’ for PE; data does not support for undifferentiated cardiac arrest.\n- Anticoagulants, such as heparin, were used in most studies along with the fibrinolytic.\n\n![Table describing various study designs](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/tpa-code-dose/image-1.png)\n\n## References\n\n- Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.Circulation. 2010 Nov 2;122(18 Suppl 3):S729-67 [[Source](http://circ.ahajournals.org/content/122/18_suppl_3/S729.full)]\n\nClick here [[Source](https://www.aliem.com/2013/whats-code-dose-of-tpa/)] for full ALiEM blog post\n"
		},
		{
			"slug": "tpa-contraindications",
			"title": "2013 AHA Guidelines: Contraindications for Thrombolytics",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/09/10",
			"updates": [
				"2013/05/13"
			],
			"categories": [
				"Neurology"
			],
			"body": "\n\n\n## Inclusion Criteria\n\n1. Diagnosis of ischemic stroke causing measurable neurologic deficit\n2. Age &ge;18 years\n\n## Exclusion Criteria\n\n### 0-3 hours from symptom onset\n\n#### Absolute Exclusion Criteria\n\n- Significant head trauma or prior stroke in previous 3 months\n- Symptoms suggest subarachnoid hemorrhage\n- Arterial puncture at noncompressible site in previous 7 days\n- History of previous intracranial hemorrhage\n- Intracranial neoplasm, AV malformation, or aneurysm\n- Recent intracranial or intraspinal surgery\n- Elevated BP (SBP >185 mmHg or DBP >110 mmHg)\n- Active internal bleeding\n- Acute bleeding diathesis (Platelet count &lt;100,000/mm3; Heparin received within 48 hours, resulting in aPTT above upper limit of normal)\n- Current use of anticoagulant with INR >1.7 or PT > 15 sec     \n- Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive lab tests (such as aPTT, INR, platelet, and ecarin clotting time; TT; or appropriate factor Xa activity assays)\n- Blood glucose &lt;50 mg/dL (2.7 mmol/L)\n- CT shows multilobar infarct (hypodensity >1/3 cerebral hemisphere)\n\n#### Relative Exclusion Criteria\n\n- Only minor or rapidly improvement stroke symptoms (clearing spontaneously)\n- Pregnancy\n- Seizure at onset with postictal residual neurologic impairments\n- Major surgery or serious trauma within previous 14 days\n- Recent GI or urinary tract hemorrhage within previous 21 days\n- Recent acute MI within previous 3 months\n\n### 3-4.5 hours from symptom onset\n\n#### Absolute Exclusion Criteria\n\n> **_List is same as for 0-3 hour time frame above PLUS any of the following_**:\n\n- Age >80 years\n- Severe stroke (NIHSS >25)\n- Taking oral anticoagulant regardless of INR\n- History of both diabetes mellitus AND prior ischemic stroke\n\n## References\n\n- Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. PMID: 23370205. [[Source](http://stroke.ahajournals.org/content/44/3/870.full.pdf)]\n- NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7. [[Source](http://www.nejm.org/doi/full/10.1056/NEJM199512143332401)]\n"
		},
		{
			"slug": "ultrasound-measurements",
			"title": "Ultrasound Measurement Cheat Sheet",
			"authors": [
				"Maria Beylin, MD",
				"Scott Fischette, MD",
				"Nate Teismann, MD"
			],
			"created": "2015/10/15",
			"updates": null,
			"categories": [
				"Radiology",
				"Ultrasound"
			],
			"body": "\n\n\n## Aorta\n\n| Item                         | Normal                    |\n| ---------------------------- | ------------------------- |\n| Diameter                     | &lt;3 cm (outer-to-outer) |\n| Common iliac artery diameter | &le;6 mm                  |\n\n## Bladder\n\n| Item               | Normal         |\n| ------------------ | -------------- |\n| Post-void residual | &le;100-150 mL |\n\n## Cardiac\n\n| Item                                                        | Normal        |\n| ----------------------------------------------------------- | ------------- |\n| E-point septal separation (EPSS) impaired systolic funciton | &le;7 mm      |\n| Aortic root diameter                                        | &le;3.9 cm    |\n\n## DVT\n\n### Areas for compression\n\n1. CFV above SFJ\n2. SFV at SJF\n3. CFV just below SJF\n4. Proximal SFV\n5. Mid SFV\n6. Distal SFV (if possible)\n7. Popliteal Fossa\n\n_CFV: Common femoral vein, SFJ: Saphenofemoral junction, SFV: Superficial femoral vein_\n\n## Gallbladder\n\n| Item                                 | Normal                                                       |\n| ------------------------------------ | ------------------------------------------------------------ |\n| Wall thickness                       | &le;3-4 mm                                                   |\n| CBD diameter                         | &le;4-7 mm (up to 8-9 mm if elderly or post-cholecystectomy) |\n| Gallbladder dimensions on short axis | &lt;4 x 10 cm                                                |\n\n## Inferior Vena Cava\n\n| Central Venous Pressure     | Normal                                                               |\n| --------------------------- | -------------------------------------------------------------------- |\n| 0-5 mmHg                    | &le;2.1 cm with &gt;50% collapse with patient sniffing               |\n| 6-10 mmHg                   | &le;2.1 cm with &lt;50% collapse or &gt;2.1 cm with &gt;50% collapse |\n| 11-20 mmHg                  | &gt;2.1 cm with &lt;50% collapse                                     |\n\n## Intrauterine Pregnancy - endocavitary probe\n\n| Item                         | Normal                                               |\n| ---------------------------- | ---------------------------------------------------- |\n| Gestational sac              | Present at 4-5 weeks estimated gestational age (EGA) |\n| Yolk sac                     | Present at ~5.5 weeks EGA                            |\n| Fetal pole, cardiac activity | Present at ~6 weeks EGA                              |\n\n## Criteria for nonviable intrauterine pregnancy\n\n| Item                          | Ultrasound Finding         |\n| ----------------------------- | -------------------------- |\n| Crown rump length             | &ge;7 mm and no heart beat |\n| Mean gestational sac diameter | &ge;25 mm and no embryo    |\n\n**_Structures should be measured by assessing the luminal diameter of the structure, which is inner-to-inner wall except for:_**\n\n1. **Aorta** - which requires taking any thrombus or plaque into account\n2. **Biparietal diameter of fetus** - which is measured outer to inner wall of the skull\n\n## References\n"
		},
		{
			"slug": "upper-gi-bleed",
			"title": "Does Your Patient have a Severe Upper GI Bleed (UGIB)?",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2011/06/17",
			"updates": null,
			"categories": [
				"Gastroenterology",
				"EBM"
			],
			"body": "\n\n\n[JAMA Rational Clinical Examination Series (2012)](http://www.ncbi.nlm.nih.gov/pubmed/?term=22416103)\n\n## Signs\n\n| Finding                                |           (+) LR |           (-) LR |\n| -------------------------------------- | ---------------: | ---------------: |\n| Melena on exam                         |       25 (4-174) | 0.52 (0.42-0.64) |\n| NG lavage with blood or coffee grounds |       9.6 (4-23) | 0.58 (.049-0.70) |\n| Clots in stool                         | 0.05 (0.01-0.38) |    1.2 (1.1-1.2) |\n\n### Labs\n\n| Finding             |       (+) LR |           (-) LR |\n| ------------------- | -----------: | ---------------: |\n| BUN/Cr ratio &gt;30 | 7.5 (2.8-12) | 0.53 (0.28-0.78) |\n\n## Likelihood of Severe Bleeding Requiring intervention\n\n### History\n\n| Finding                    |           (+) LR |           (-) LR |\n| -------------------------- | ---------------: | ---------------: |\n| Cirrhosis or malignancy hx |    3.7 (1.6-8.8) | 0.83 (0.72-0.97) |\n| Syncope                    |    3.0 (1.7-5.4) | 0.95 (0.91-0.98) |\n| Using analgesics           |    2.6 (1.3-5.2) | 0.92 (0.84-0.99) |\n| Coffee ground emesis       | 0.41 (0.26-0.64) |    1.1 (1.1-1.2) |\n\n### Signs\n\n| Finding                                    |        (+) LR |           (-) LR |\n| ------------------------------------------ | ------------: | ---------------: |\n| Pulse &gt;100/min                          | 4.9 (3.2-7.6) | 0.34 (0.22-0.53) |\n| NG lavage with red blood                   |  3.1 (1.2-14) | 0.32 (0.17-0.57) |\n| NG lavage with red blood or coffee grounds | 2.0 (1.0-4.0) | 0.40 (0.20-0.81) |\n| Hypotension                                |       1.2-4.8 |        0.51-0.78 |\n\n### Labs\n\n| Finding           |        (+) LR |           (-) LR |\n| ----------------- | ------------: | ---------------: |\n| HgB &lt;8 g/dL    |       4.5-6.2 |        0.36-0.41 |\n| BUN &gt;90 mg/dL  | 3.6 (2.4-5.5) | 0.45 (0.31-0.65) |\n| WBC &gt;12        | 3.4 (2.2-5.1) | 0.48 (0.34-0.68) |\n\n## Blatchford Score\n\nValidated decision tool to identify UGIB patients who DON'T need urgent intervention\n\n**Serum BUN (mg/dL)**\n\n|   Finding | Score |\n| --------: | ----: |\n|  &lt;18.2 |     0 |\n|   18-22.4 |     2 |\n| 22.4-28.0 |     3 |\n|   28-70.0 |     4 |\n|  &ge;70.0 |     6 |\n\n**Hemoglobin (men, g/dL)**\n\n| Finding | Score |\n| ------: | ----: |\n|  &gt;13 |     0 |\n| 12-12.9 |     1 |\n| 10-11.9 |     3 |\n|  &lt;10 |     6 |\n\n**Hemoglobin (women, d/gL)**\n\n|   Finding | Score |\n| --------: | ----: |\n|    &gt;12 |     0 |\n| 10 - 11.9 |     1 |\n|    &lt;10 |     6 |\n\n**SBP (mmHg)**\n\n| Finding | Score |\n| ------: | ----: |\n| &gt;109 |     0 |\n| 100-109 |     1 |\n|   90-99 |     2 |\n|  &lt;90 |     3 |\n\n**Others**\n\n| Finding            | Score |\n| ------------------ | ----: |\n| Pulse &gt;100/min  |     1 |\n| Melena on Exam     |     1 |\n| Syncope            |     2 |\n| Hepatic disease    |     2 |\n| Heart failure      |     2 |\n\n### Likelihood Ratio of Need for Urgent Evaluation by Score\n\n| Blatchford Score |        (+) LR |           (-) LR |\n| ---------------: | ------------: | ---------------: |\n|                0 | 1.2 (1.0-1.3) |     0.2 (0-0.05) |\n|            &le;2 | 1.4 (1.1-1.8) | 0.08 (0.01-0.41) |\n\n## References\n\n- Kumar R, Mills AM. GI Bleeding. EM Clin N Am. 2011; 29:239-52. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=21515178)]\n- Srygley FD et al. Does this patient have a severe UGIB? JAMA. Mar 14, 2012; 307(10):1072-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=22416103)]\n"
		},
		{
			"slug": "urine-tox-screen",
			"title": "Urine Toxicology Screen",
			"authors": [
				"Michelle Lin, MD"
			],
			"created": "2010/07/22",
			"updates": [
				"2017/02/14"
			],
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n| Drug                             | Causes False (+) Test                                                                                                                                                                                                                                               | Duration of detectability                                                                                                       |\n| -------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------- |\n| Amphetamines                     | Amantadine, Buproprion, Chlorpromazine, Desipramine, Fluoxetine, L-methamphetamine in nasal decongestant, Labetalol, Methylphenidate (Ritalin), Phentermine, Phenylephrine, Phenylpropanolamine, Promethazine, Pseudoephedrine, Ranitidine, Thioridazine, Trazodone | **2-3 days**                                                                                                                    |\n| Benzodiazepines                  | Oxaprozin, Sertraline                                                                                                                                                                                                                                               | **3 days** for short acting (e.g. lorazepam) and up to **30 days** for long acting (e.g. diazepam)                              |\n| Cocaine                          | Topical anesthetics which have cocaine                                                                                                                                                                                                                              | **2-3 days** (occasional user), up to **8 days** (heavy user)                                                                   |\n| Opiates                          | Dextromethorphan, Diphenhydramine, Fluoroquinolones, Poppy seed, Quinine, Rifampin, Verapamil                                                                                                                                                                       | **1-3 days**                                                                                                                    |\n| Phenycyclidine                   | Dextromethorphan, Diphenhydramine, Ibuprofen, Imipramine, Ketamine, Lamotrigine, Meperidine, Thioridazine, Tramadol, Venlafaxine                                                                                                                                    | **7-14 days**                                                                                                                   |\n| Marijuana (tetrahydrocannabinol) | Dronabinol, NSAID, Pantoprazole and other proton pump inhibitors                                                                                                                                                                                                    | **3-5 days** with 1x use, **5-7 days** with 4x/wk use, **10-15 days** with daily use, **>30 days** with long term and heavy use |\n\n**Pearl**:  MDMA (Ecstacy) may not be positive on amphetamine drug screen, unless specifically screen for MDMA. \n\n## Benzodiazepines\n\nBenzodiazepines are popular. In the U.S., **alprazolam**, **clonazepam**, **lorazepam**, and **diazepam** are among the most commonly prescribed medications in the outpatient setting.\n\nImportant points on benzodiazepine urine toxicology test:\n\n1. Most benzodiazepines screens look for **oxazepam**, because **diazepam** and **chlordiazepoxide** both are metabolized to **oxazepam**.\n2. The test does not specifically look for **alprazolam**, **clonazepam**, **lorazepam** (or many others). Therefore, a negative result does not necessarily rule out use of these agents.\n3. Benzodiazepines vary in reactivity and potency and can trigger a positive result due to cross-reactivity.\n\n### Bottom Line\n\nA negative result doesn't rule out benzodiazepine ingestion, and a positive result only guarantees that **oxazepam**, **diazepam**, or **chlordiazepoxide** is present.\n\n## Opioid vs Opiate\n\nThese two terms are often used interchangeably and really shouldn't be.\n\n- **Opioid:** Broad category name which encompasses opiates, semi-synthetic, and synthetic agents\n- **Opiate:** Refers to only naturally occurring opioids\n\n| Opiates  | Semi-Synthetic | Synthetic |\n| -------- | -------------- | --------- |\n| Opium    | Heroin         | Fentanyl  |\n| Morphine | Hydrocodone    | Methadone |\n| Codeine  | Hydromorphone  | Tramadol  |\n|          | Oxycodone      |           |\n|          | Oxymorphone    |           |\n|          | Buprenorphine  |           |\n\n- **Oxycodone**, a semi-synthetic, is similar to **morphine**.\n- **Methadone**, a synthetic, has a completely unrelated structure.\n\n**LEARNING POINTS**\n\n1. Notice the name of the urine drug screen next time you order one. It is opiates (not opioids).\n2. The test was designed to look for heroin (technically a semi-synthetic) via its metabolite, **6-monacetyl morphine**. It also picks up **morphine** and **codeine**.\n3. The test does not specifically look for **oxycodone**, **hydromorphone**, **hydrocodone**, etc. They can trigger a positive result due to their structural similarities, but not in every case. Therefore, a negative result doesn't rule out use of these common drugs of abuse.\n4. Synthetics will never cross-react with the opiate urine drug screen. They are too structurally dissimilar. That's why there is a separate test for methadone.\n\n### Bottom Line\n\nA negative result doesn't rule out opioid ingestion, and a positive result only guarantees that **heroin, morphine, or codeine** is present.\n\n## References\n\n- Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010 Mar 1;81(5):635-40. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20187600)]\n- Geraci, M.J., Peele, J., McCoy, S.L. et al. Int J Emerg Med. 2010 Nov 3: 327. doi:10.1007/s12245-010-0235-3\n"
		},
		{
			"slug": "vasopressors-in-hypotension",
			"title": "Vasopressors in Hypotension",
			"authors": [
				"Todd A. Seigel, MD"
			],
			"created": "2013/08/20",
			"updates": null,
			"categories": [
				"Critical Care",
				"Cardiovascular"
			],
			"body": "\n\n\n## Table of Vasopressor Effects, Side Effects, and Prototypical Clinical Scenario\n\nSide effects of vasoactive medications are related both to the direct mechanism of action of the agent, as well as the compensatory mechanisms precipitated by them. Concerning side effects of inotropes include dysrhythmias and increased myocardial oxygen demand, whereas vasopressors can cause undesired limitations in blood flow to the gut and kidneys.\n\n| **Agent**            |                     **Primary Receptor**                     | **Primary Impact**                | **Potential Side Effect**                             | **Prototypical Clinical Scenario**              |\n| -------------------- | :----------------------------------------------------------: | --------------------------------- | ----------------------------------------------------- | ----------------------------------------------- |\n| Phenylephrine        |                         α<sub>1</sub>                        | Increased SVR                     | Reflexive decreased HR                                | Neurogenic shock                                |\n| Vasopressin          |                               V                              | Increased SVR                     | Decreased splanchnic flow                             | Adjunct for septic shock                        |\n| Dobutamine           |                β<sub>1</sub>, β<sub>2 </sub>                 | Increased inotropy                | Transient decreases in SVR (β<sub>2 </sub>agonsim)    | Cardiogenic shock from late-stage heart failure |\n| Dopamine (low-dose)  |                       D, β<sub>1</sub>                       | Increased inotropy and heart rate | Tachydysrhythmias                                     | Cardiogenic shock, particularly if bradycardic  |\n| Epinephrine          | α<sub>1</sub>, α<sub>2, </sub>β<sub>1</sub>, β<sub>2 </sub>  | Increased SVR and inotropy        | Tachydysrhythmias and decreased splanchnic flow       | Anaphylaxis                                     |\n| Norepinephrine       |                       α1, α2, β1>> β2                        | Increased SVR and inotropy        | Decreased splanchnic and renal flow                   | Septic shock                                    |\n| Dopamine (high-dose) |                        D, α1, β1>> β2                        | Increased SVR and inotropy        | Tachydysrhythmias and decreased splanchnic/renal flow | Bradycardic cardiovascular collapse             |\n\n## References\n\n- Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 2012;27:172-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21436167)]\n- Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-84. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=17720019)]\n- Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008;34:2226-34. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18654759)]\n- Ellender TJ, Skinner JC. The use of vasopressors and inotropes in the emergency medical treatment of shock. Emerg Med Clin North Am 2008;26:759-86, ix. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18655944)]\n- De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012;40:725-30. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22036860)]\n\nClick here [[Source](https://www.aliem.com/2013/choosing-the-right-vasopressor-agent-in-hypotension/)] for full ALiEM blog post\n"
		},
		{
			"slug": "ventilator-settings",
			"title": "Ventilator Setting for Lung Protection",
			"authors": [
				"Jenny Wilson, MD"
			],
			"created": "2011/10/14",
			"updates": null,
			"categories": [
				"Pulmonology",
				"Critical Care"
			],
			"body": "\n\n\n**Lung protection:** Strategy for patients with lung injury and those prone to lung injury. This applies to every intubated patient **except** those with acute asthma/COPD.\n\nInitial ventilator setting for patient with predicted body wt = 70 kg (5'9\" male; 5'11\" female)\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td><ul>\n<li>Mode = Volume Assist Control (AC)<br />\n</li>\n<li>Tidal volume = 350-560 mL<br />\n</li>\n<li>Inspiratory flow rate = 60 L/min<br />\n</li>\n<li>Respiratory rate = 16<br />\n</li>\n</ul></td>\n<td><ul>\n<li>FiO2 = 100%<br />\n</li>\n<li>PEEP = 5<br />\n</li>\n<li>Goal plateau P &lt;30 cmH2O<br />\n</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Ventilator Mode\n\nVolume Assist Control (AC)\n\n## Tidal Volume (Vt)\n\n6-8 mL/kg (LUNG PROTECTION)\n\n- Based on predicted body weight (kg)\n- If acute lung injury (ALI) or ARDS present, goal is to bring down to 6 mL/kg\n- Do NOT alter to fix ventilation, but may need to alter if plateau pressure is > 30 cmH2O, see below). Only protects lung by preventing barotrauma.\n\n## Inspiratory Flow Rate (IFR)\n\n60-80 L/min (PATIENT COMFORT)\n\n- Increase IFR and ensure adequate sedation if patient uncomfortable or sucking on tube\n\n## Respiratory rate (RR)\n\nStart at 16-18, then adjust based on pCO2 (VENTILATION)\n\n- Goal pH = 7.30 - 7.45\n- Goal pCO2 = mild hypercarbia\n\n## FiO2 & PEEP\n\nStart at FiO2 100% and PEEP 5 (OXYGENATION)\n\n- Goal PaO2=55-80 or SpO2=88-95%\n- Wait 5-15 min, then draw an ABG\n- If ABG and SpO2 show adequate oxygenation, drop FiO2 to 30-40% and begin titrating FiO2 and PEEP per the chart below to achieve oxygenation goal.\n\n![FiO2 and PEEP chart](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ventilator-settings/image-1.png)\n\n[EMCrit.org](http://www.EMCrit.org)\n\n## Plateau Pressure (Pplt)\n\n- Goal Pplt &lt;30 cmH2O\n- Check after initial settings, and at regular intervals thereafter\n- Technique: Press inspiratory hold button for 0.5 sec and look at pressure gauge\n- If Pplt >30 cmH2O, lower Vt until you acheive your goal\n- May need to go as low as 4 mL/kg of predicted body weight\n\n## References\n\n- NHLBI ARDS Network, \"Ventilator Protocol Card\" [[Source](http://www.ardsnet.org/node/77791)]\n- Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000 May 4;342(18):1301-8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10793162)]\n"
		},
		{
			"slug": "ventilator-settings-obstruction",
			"title": "Ventilator Setting for Obstructive Lung Disease",
			"authors": [
				"Jenny Wilson, MD"
			],
			"created": "2011/10/21",
			"updates": null,
			"categories": [
				"Pulmonology",
				"Critical Care"
			],
			"body": "\n\n\n## Goal in obstruction (asthma/COPD)\n\nGive the patient time to exhale\n\nInitial vent settings for patient with predicted Ideal Body Weight (IBW) = 70 kg (5'9\" male; 5'11\" female)\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<tbody>\n<tr class=\"odd\">\n<td><ul>\n<li>Mode = Volume Assist Control (AC)</li>\n<li>Tidal volume = 560 mL</li>\n<li>Inspiratory flow rate = 80 L/min</li>\n<li>Respiratory rate = 10</li>\n</ul></td>\n<td><ul>\n<li>FiO2 = 100%</li>\n<li>PEEP = 0-5</li>\n<li>Goal Pplt &lt; 30 cmH2O</li>\n</ul></td>\n</tr>\n</tbody>\n</table>\n\n## Ventilator Mode\n\nVolume Assist Control (AC)\n\n## Tidal Volume (Vt)\n\n8 mL/kg Based on ideal body weight (kg)\n\n## Inspiratory Flow Rate (IFR)\n\n80-100 L/min\n\n- Increase IFR and ensure adequate sedation if patient uncomfortable or sucking on tube\n\n## Respiratory rate (RR)\n\nStart at 10, then adjust to give time to exhale **(IMPORTANT)**\n\n- Goal I:E of 1:4 or 1:5\n- Permissive hypercapnea, as long as pH stays above 7.2\n- Prevents air-trapping/auto PEEP\n\n## FiO2 & PEEP\n\nStart at FiO2 100% and PEEP 0-5\n\n- Goal SpO2 = 92-95%\n- Can usually quickly titrate down the FiO2\n\n## Plateau Pressure (Pplt)\n\n- Goal Pplt &lt;30 cm H2O\n- Check after initial settings and at regular intervals thereafter\n- Technique: Press inspiratory hold button for 0.5 sec and look at pressure gauge \n- If Pplt >30 cm H2O, investigate possible air trapping\n\n## Air-Trapping (Auto-PEEP)\n\n- Air trapping (auto-PEEP) = gas trapped in alveoli at end-expiration\n- Suspect auto-PEEP if P(plat) >30 cm H2O, or if hypotension develops\n- First step is to disconnect vent and allow trapped air to escape\n- Prevent further air trapping by decreasing RR and increasing expiratory time\n\n![Diagram of auto-PEEP ventilator flow waveform](https://raw.githubusercontent.com/aliemteam/aliemcards_cards/master/cards/ventilator-settings-obstruction/image-1.png)\n\n_[EMcrit.org](http://emcrit.org/podcasts/vent-part-2/)_\n\n## References\n\n- EMCrit. Available at: http://emcrit.org/podcasts/vent-part-2/ Accessed August 1, 2017.\n- Brenner B, Corbridge T, Kazzi A. Intubation and mechanical ventilation of the asthmatic patient in respiratory failure. J Emerg Med. 2009 Aug;37(2 Suppl):S23-34. doi: 10.1016/j.jemermed.2009.06.108. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19683662/)]\n"
		},
		{
			"slug": "when-avoid-tramadol",
			"title": "When to Avoid Tramadol",
			"authors": [
				"Jill Logan, PharmD"
			],
			"created": "2014/01/06",
			"updates": null,
			"categories": [
				"Toxicology"
			],
			"body": "\n\n\n## Take Home Points\n\nAvoid tramadol in:\n\n- Seizure patients\n- Renal patients\n- Patients taking antidepressants\n- Patients taking warfarin\n\nTramadol is a popular agent for the treatment of pain and offers an alternative to opioid therapy. Tramadol exerts its analgesic effects through weak stimulation of the mu opioid receptor as well as inhibiting the reuptake of serotonin and norepinephrine similar to some antidepressant medications. While tramadol may be an effective option for mild to moderate pain in otherwise healthy individuals, the following patients may benefit from an alternative analgesic selection:\n\n| **Patient Population**                    | **Tramadol Effect**                                                                                                                                                                                                                                                                                                                                                              |     |\n| ----------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --- |\n| **Seizure patients**                      | Tramadol may lower the seizure threshold thereby potentially increasing seizure frequency in patients at risk or treated for seizures.                                                                                                                                                                                                                                           |     |\n| **Renal patients**                        | Tramadol requires renal dose adjustment to a frequency of Q 12 hours in patients with CrCl &lt;30 mL/min.                                                                                                                                                                                                                                                                        |     |\n| **Patients treated with antidepressants** | As tramadol exerts serotonin and norepinephrine reuptake inhibition, this may put patients exposed to serotonergic agents at higher risk for serotonin syndrome. While the use of antidepressants and tramadol may be safely used concomitantly, use particular caution with MAO inhibitors and have suspicion for this interaction in patients in potential overdose situations |     |\n| **Warfarin patients**                     | Tramadol will likely lead to an increased INR due to its serotonergic effects as well as other unknown mechanisms.                                                                                                                                                                                                                                                               |     |\n\n_NOTE: Linezolid and some Parkinson’s medications fall into the class of MAO inhibiters (although the MAO type B inhibitors may pose less of a risk)_\n\n## References\n\n- Gardner JS, et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy 2000;20(12)1423-31. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11130214)]\n- Park SH, et al. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract. 2013 Oct 23. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24153222)]\n- Tramadol: Drug Information. Lexi-Comp OnlineTM , Lexi-DrugsTM, Hudson, Ohio: Lexi-Comp, Inc.; December 17, 2013.\n- Nelson LS, Olsen D. Chapter 38. Opioids. In: Nelson LS, Olsen D, eds. Goldfrank’s Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011. Accessed December 17, 2013.\n"
		}
	]
}